PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
18519842-0	2008	Erythropoietin increases endothelial biosynthesis of tetrahydrobiopterin by activation of protein kinase B alpha/Akt1.	sapropterin	53-72	erythropoietin	Mus musculus	0-14
18519842-7	2008	Treatment with a selective phosphatidylinositol 3-kinase inhibitor wortmannin significantly reduced BH(4) biosynthesis stimulated by EPO.	Wortmannin	67-77	erythropoietin	Mus musculus	133-136
18519842-7	2008	Treatment with a selective phosphatidylinositol 3-kinase inhibitor wortmannin significantly reduced BH(4) biosynthesis stimulated by EPO.	sapropterin	100-105	erythropoietin	Mus musculus	133-136
18359468-8	2008	We showed that the artesunate-erythropoietin drug combination led to clinical recovery 24 h earlier for surviving mice, and to increase in the global survival rate compared to artesunate monotherapy (p<0.01).	Artesunate	19-29	erythropoietin	Mus musculus	30-44
18350568-8	2008	A 6-fold decrease in the number of prominent endothelial cells--suspected to be indicative of cellular activation and inflammatory response--was observed in lung sections derived from mice treated with bleomycin and EPO compared to animals injected with bleomycin alone (p < 0.008).	Bleomycin	254-263	erythropoietin	Mus musculus	216-219
18350568-10	2008	Alveolar mononuclear phagocytic hyperplasia was reduced by as much as 100% in animals treated with bleomycin and EPO compared to animals treated with bleomycin alone (p < 0.03).	Bleomycin	150-159	erythropoietin	Mus musculus	113-116
18359468-8	2008	We showed that the artesunate-erythropoietin drug combination led to clinical recovery 24 h earlier for surviving mice, and to increase in the global survival rate compared to artesunate monotherapy (p<0.01).	Artesunate	176-186	erythropoietin	Mus musculus	30-44
18204093-0	2008	Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.	dimethylarginine	59-75	erythropoietin	Mus musculus	18-32
18204093-13	2008	Systolic blood pressure and serum concentrations of ADMA were significantly elevated in EPO-treated mice.	N,N-dimethylarginine	52-56	erythropoietin	Mus musculus	88-91
18276585-1	2008	Erythropoietin (Epo) stimulates a significant increase in the intracellular calcium concentration ([Ca(2+)](i)) through activation of the murine transient receptor potential channel TRPC2, but TRPC2 is a pseudogene in humans.	Calcium	76-83	erythropoietin	Mus musculus	0-14
18276585-1	2008	Erythropoietin (Epo) stimulates a significant increase in the intracellular calcium concentration ([Ca(2+)](i)) through activation of the murine transient receptor potential channel TRPC2, but TRPC2 is a pseudogene in humans.	Calcium	76-83	erythropoietin	Mus musculus	16-19
18341422-3	2008	We have examined a new approach of delivering plasmid encoding mouse EPO cDNA into mouse skeletal muscle, using an amphiphilic block copolymer.	copolymer	133-142	erythropoietin	Mus musculus	69-72
18423190-3	2008	(2008) use conditional knockout mice to demonstrate that sensing of O2 by keratinocytes in the epidermis leads to alterations in cutaneous blood flow that affect the production of the hormone erythropoietin, thereby modulating red blood cell production and the O2-carrying capacity of blood.	Oxygen	68-70	erythropoietin	Mus musculus	192-206
18423190-3	2008	(2008) use conditional knockout mice to demonstrate that sensing of O2 by keratinocytes in the epidermis leads to alterations in cutaneous blood flow that affect the production of the hormone erythropoietin, thereby modulating red blood cell production and the O2-carrying capacity of blood.	Oxygen	261-263	erythropoietin	Mus musculus	192-206
18423195-5	2008	We show that nitric oxide release induced by the HIF pathway acts on cutaneous vascular flow to increase systemic erythropoietin expression.	Nitric Oxide	13-25	erythropoietin	Mus musculus	114-128
18259195-2	2008	Here, we show a dissociation of the intracellular pathway mediating the protective effect of EPO against glutamate toxicity from that needed for its neurotrophic activity using hippocampal neuronal cultures from Stat5a/b-knockout (Stat5(-/-)) mouse fetuses.	Glutamic Acid	105-114	erythropoietin	Mus musculus	93-96
18259195-3	2008	Both pretreatment and post-treatment with EPO counteracted glutamate-induced cell death in Stat5(+/+) and Stat5(-/-) neurons.	Glutamic Acid	59-68	erythropoietin	Mus musculus	42-45
18413601-7	2008	Also, EPO- and VEGF-induced neuroprotection against GD, oxygen-glucose deprivation, and NMDA excitotoxicity depended significantly on TNFRI presence.	oxygen-glucose	56-70	erythropoietin	Mus musculus	6-9
18413601-7	2008	Also, EPO- and VEGF-induced neuroprotection against GD, oxygen-glucose deprivation, and NMDA excitotoxicity depended significantly on TNFRI presence.	N-Methylaspartate	88-92	erythropoietin	Mus musculus	6-9
18413601-8	2008	Finally, EPO prevented neuronal damage induced by kainic acid in WT but not TNFRI KO mice.	Kainic Acid	50-61	erythropoietin	Mus musculus	9-12
17969148-7	2008	We observed a significant synergistic effect of EPO and SCF on the net generation of benzidine positive (erythroid) colony-forming cells, CD71++ (early erythroblasts) cells and TER-119+ (late erythroblasts and reticulocytes) cells in culture.	benzidine	85-94	erythropoietin	Mus musculus	48-51
18341422-6	2008	We conclude that repeated injections of low doses of block copolymer-DNA formulations that do not induce (1) inflammation at the injection site, (2) overexpression of EPO, or (3) the production of anti-EPO neutralizing auto-antibodies hold promise for in vivo expression of therapeutic proteins, in particular for systemic delivery.	copolymer	59-68	erythropoietin	Mus musculus	202-205
18219388-2	2008	In this issue of the JCI, Chen, Smith, and colleagues demonstrate that the temporal expression of Epo is critical for determining whether physiological or pathological repair occurs following neurovascular retinal injury in the oxygen-induced retinopathy neonatal mouse model (see the related article beginning on page 526).	Oxygen	228-234	erythropoietin	Mus musculus	98-101
17712792-7	2008	The number of benzidine-positive colonies in the co-culture system with EPO (86.6+/-17.86) was significantly different compared to the simple culture system with EPO (43.6+/-4.77; P <or= 0.05).	benzidine	14-23	erythropoietin	Mus musculus	72-75
17928571-0	2008	Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway.	Doxorubicin	32-43	erythropoietin	Mus musculus	0-14
17967455-0	2008	Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice.	Streptozocin	120-123	erythropoietin	Mus musculus	0-14
17928571-3	2008	The purpose of this study was to assess whether EPO protects the heart against cardiotoxicity induced by DOX.	Doxorubicin	105-108	erythropoietin	Mus musculus	48-51
17928571-4	2008	We found that DOX-induced apoptosis and impaired heart function in mice were largely prevented by EPO administration.	Doxorubicin	14-17	erythropoietin	Mus musculus	98-101
17928571-6	2008	EPO protected against DOX-induced cardiomyocyte death (by approximately 50%) and apoptosis assessed by annexin-V labeling, DNA fragmentation, and caspase-3 activity.	Doxorubicin	22-25	erythropoietin	Mus musculus	0-3
17928571-7	2008	DOX-mediated increases in reactive oxygen species, which trigger cardiotoxicity, were also reversed by preconditioning with EPO.	Doxorubicin	0-3	erythropoietin	Mus musculus	124-127
17928571-7	2008	DOX-mediated increases in reactive oxygen species, which trigger cardiotoxicity, were also reversed by preconditioning with EPO.	Reactive Oxygen Species	26-49	erythropoietin	Mus musculus	124-127
17928571-10	2008	Thus, pretreatment with therapeutic levels of EPO can protect the myocardium against DOX-induced impaired heart function and cardiomyocyte apoptosis by activating PI3K-Akt cell survival pathways.	Doxorubicin	85-88	erythropoietin	Mus musculus	46-49
17950726-8	2007	Consequently, the autocrine Epo-EpoR signaling pathway was activated, as evidenced by higher p-Tyr JAK2, p-Tyr EpoR and p-Tyr STAT5B in the ANKH transfectants.	p-tyr	93-98	erythropoietin	Mus musculus	28-31
17950726-8	2007	Consequently, the autocrine Epo-EpoR signaling pathway was activated, as evidenced by higher p-Tyr JAK2, p-Tyr EpoR and p-Tyr STAT5B in the ANKH transfectants.	p-tyr	105-110	erythropoietin	Mus musculus	28-31
17950726-8	2007	Consequently, the autocrine Epo-EpoR signaling pathway was activated, as evidenced by higher p-Tyr JAK2, p-Tyr EpoR and p-Tyr STAT5B in the ANKH transfectants.	Tyrosine	95-98	erythropoietin	Mus musculus	28-31
17855480-1	2007	Previous studies have yielded conflicting results as to whether extracellular adenosine generation and signaling contributes to hypoxia-induced increases in renal erythropoietin (EPO) secretion.	Adenosine	78-87	erythropoietin	Mus musculus	163-177
17855480-1	2007	Previous studies have yielded conflicting results as to whether extracellular adenosine generation and signaling contributes to hypoxia-induced increases in renal erythropoietin (EPO) secretion.	Adenosine	78-87	erythropoietin	Mus musculus	179-182
17855480-2	2007	In this study, we combined pharmacological and genetic approaches to elucidate a potential contribution of extracellular adenosine to renal EPO release in mice.	Adenosine	121-130	erythropoietin	Mus musculus	140-143
17855480-8	2007	Together, these studies combine genetic and pharmacological in vivo evidence that increases of EPO secretion during limited oxygen availability are not affected by extracellular adenosine generation or signaling.	Oxygen	124-130	erythropoietin	Mus musculus	95-98
17724331-3	2007	Led by the intriguing observation that most of the mouse EPO-R (mEPO-R) is retained in the endoplasmic reticulum (ER), we hypothesized that sEPO-R is expressed at higher levels on the cell surface, thus maximizing the response to elevated EPO, which has been reported in this species.	sepo-r	140-146	erythropoietin	Mus musculus	57-60
17652365-1	2007	Apart from enhancing red blood cell production, erythropoietin (Epo) has been shown to modulate the ventilatory response to reduced oxygen supply.	Oxygen	132-138	erythropoietin	Mus musculus	48-62
17652365-1	2007	Apart from enhancing red blood cell production, erythropoietin (Epo) has been shown to modulate the ventilatory response to reduced oxygen supply.	Oxygen	132-138	erythropoietin	Mus musculus	64-67
17898652-6	2007	Oligonucleotides of peptide nucleic acid (PNA) type capable of antisense binding to unique murine Epo-mRNA sequences were synthesized by solid phase methods, and elongated at the N-terminus with the HIV Tat (48-60) cell penetrating peptide.	Oligonucleotides	0-16	erythropoietin	Mus musculus	98-101
17898652-8	2007	Downregulation of newly expressed erythropoietin protein in such cells additionally confirmed the penetration and hybridizing properties of the selected labeled oligonucleotide.	Oligonucleotides	161-176	erythropoietin	Mus musculus	34-48
17898652-9	2007	I-labeled Tat-PNAs were intravenously injected into mice that had previously received the Epo gene into the right tibialis muscle by DNA electrotransfer.	Iodine	0-1	erythropoietin	Mus musculus	90-93
17724331-6	2007	To map these domains of the sEPO-R that augment receptor maturation, we generated EPO-R derivatives in which parts of the extracellular region of mEPO-R were replaced with the corresponding fragments of sEPO-R.	r	33-34	erythropoietin	Mus musculus	29-32
17394573-8	2007	RESULTS: Systemic treatment of mice with the PHD inhibitor, EDHB, leads to elevated levels of HIF-1alpha in liver and HIF-inducible EPO in serum, indicating activation of the cellular oxygen-sensing pathway.	ethyl protocatechuate	60-64	erythropoietin	Mus musculus	132-135
17347485-3	2007	METHODS AND RESULTS: Here we show in C57BL/6J mice that 4-week treatment with the long-lasting EPO analogue darbepoetin-alpha (DPO) at a dose of 10 microg/kg/week induces a reduction of platelet reactivity using flow cytometry and Western blot analysis of tyrosine-specific platelet phosphorylation.	darbepoetin-alpha	108-125	erythropoietin	Mus musculus	95-98
17347485-3	2007	METHODS AND RESULTS: Here we show in C57BL/6J mice that 4-week treatment with the long-lasting EPO analogue darbepoetin-alpha (DPO) at a dose of 10 microg/kg/week induces a reduction of platelet reactivity using flow cytometry and Western blot analysis of tyrosine-specific platelet phosphorylation.	dpo	127-130	erythropoietin	Mus musculus	95-98
17347485-3	2007	METHODS AND RESULTS: Here we show in C57BL/6J mice that 4-week treatment with the long-lasting EPO analogue darbepoetin-alpha (DPO) at a dose of 10 microg/kg/week induces a reduction of platelet reactivity using flow cytometry and Western blot analysis of tyrosine-specific platelet phosphorylation.	Tyrosine	256-264	erythropoietin	Mus musculus	95-98
17713435-8	2007	At 24 hr after I/R, the Cr (mg/dL) levels in Sham, Vehicle, EPO, and asialoEPO were 0.13+/-0.01, 1.24+/-0.70, 0.24+/-0.08, and 0.25+/-0.13, respectively (P<0.05).	Creatinine	24-26	erythropoietin	Mus musculus	60-63
17584830-2	2007	Here we demonstrate that sEpoR, a negative regulator of Epo"s binding to the EpoR, is present in the mouse brain and is down-regulated by 62% after exposure to normobaric chronic hypoxia (10% O2 for 3 days).	Oxygen	192-194	erythropoietin	Mus musculus	26-29
17584830-4	2007	These observations imply that hypoxic downregulation of sEpoR is required for adequate ventilatory acclimatization to hypoxia, thereby underlying the function of Epo as a key factor regulating oxygen delivery not only by its classical activity on red blood cell production, but also by regulating ventilation.	Oxygen	193-199	erythropoietin	Mus musculus	57-60
17395782-1	2007	Adaptive mechanisms to hematocrit levels of 0.9 in our erythropoietin-overexpressing mice (tg6) include increased plasma nitric oxide levels and erythrocyte flexibility.	Nitric Oxide	121-133	erythropoietin	Mus musculus	55-69
17254689-0	2007	EPO receptor, Bax and Bcl-x(L) expressions in murine erythropoiesis after cyclophosphamide treatment.	Cyclophosphamide	74-90	erythropoietin	Mus musculus	0-3
17372034-8	2007	EPO upregulated expression of phosphorylated Ser1177-eNOS and normalized the vasodilator response to acetylcholine (P<0.05).	Acetylcholine	101-114	erythropoietin	Mus musculus	0-3
17174578-0	2007	Antioxidant N-acetyl-L-cysteine inhibits erythropoietin-induced differentiation of erythroid progenitors derived from mouse fetal liver.	Acetylcysteine	12-31	erythropoietin	Mus musculus	41-55
17174578-6	2007	These results suggest that reactive oxygen species are involved in Epo-mediated erythroid differentiation.	Reactive Oxygen Species	27-50	erythropoietin	Mus musculus	67-70
17157835-9	2007	EPO reduced PI uptake by 33+/-5 and 15+/-8%, respectively, in the OGD and NMDA exposed cultures.	N-Methylaspartate	74-78	erythropoietin	Mus musculus	0-3
16804549-9	2007	Cerebral glucose metabolic rate may also be increased by a direct effect of Epo in the brain (tg-21 mice).	Glucose	9-16	erythropoietin	Mus musculus	76-79
16804549-9	2007	Cerebral glucose metabolic rate may also be increased by a direct effect of Epo in the brain (tg-21 mice).	Thioguanine	94-96	erythropoietin	Mus musculus	76-79
17365666-1	2007	OBJECTIVE: Acclimatization to reduced environmental oxygen includes erythropoietin-regulated increase in erythrocytes enhancing the blood"s oxygen content.	Oxygen	52-58	erythropoietin	Mus musculus	68-82
17068014-7	2007	In DTZ pre-treated irradiated animals, a significant increase in pro- and normoblasts, erythrocytes, leukocytes, differential leukocyte count, haematocrit and haemoglobin values, and a significant decrease in erythropoietin values, were observed compared with control.	Diltiazem	3-6	erythropoietin	Mus musculus	209-223
17068014-9	2007	Similarly, pre-treatment of DTZ caused a significant increase in erythropoietin and glutathione levels in serum in comparison with irradiated animals.	Diltiazem	28-31	erythropoietin	Mus musculus	65-79
17365666-1	2007	OBJECTIVE: Acclimatization to reduced environmental oxygen includes erythropoietin-regulated increase in erythrocytes enhancing the blood"s oxygen content.	Oxygen	140-146	erythropoietin	Mus musculus	68-82
17365666-3	2007	To assess this oxygen supply to the skin, the authors used erythropoietin overexpressing transgenic mice (tg6) that develop excessive erythrocytosis in an oxygen-independent manner.	Oxygen	155-161	erythropoietin	Mus musculus	59-73
17046564-4	2006	To study the effect of CpG-ODN on erythroid cell maturation in vitro, we obtained primary EPO-responsive cells by treating mice with thiamphenicol (15 mg/g body weight).	Thiamphenicol	133-146	erythropoietin	Mus musculus	90-93
16949343-0	2006	HSV-mediated delivery of erythropoietin restores dopaminergic function in MPTP-treated mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	74-78	erythropoietin	Mus musculus	25-39
16880289-9	2006	In mice bearing Hep3B hepatoma, curcumin retarded tumor growth and suppressed ARNT, erythropoietin, and vascular endothelial growth factor in tumors.	Curcumin	32-40	erythropoietin	Mus musculus	84-98
16959492-2	2006	When administered 1 h following intracerebral injection of 10 microg ibotenic acid at day 5 of life, both a single injection of EPO (5000 IU/kg bw) and repetitive administrations of EPO reduced white and gray matter lesion size.	Ibotenic Acid	69-82	erythropoietin	Mus musculus	128-131
16959492-2	2006	When administered 1 h following intracerebral injection of 10 microg ibotenic acid at day 5 of life, both a single injection of EPO (5000 IU/kg bw) and repetitive administrations of EPO reduced white and gray matter lesion size.	Ibotenic Acid	69-82	erythropoietin	Mus musculus	182-185
17081643-5	2006	The present paper investigates the long-term functionality and biocompatibility of murine erythropoietin (EPO) secreting C2C12 cells entrapped in microcapsules elaborated with alginates with different properties (purity, composition and viscosity).	Alginates	176-185	erythropoietin	Mus musculus	90-104
17081643-5	2006	The present paper investigates the long-term functionality and biocompatibility of murine erythropoietin (EPO) secreting C2C12 cells entrapped in microcapsules elaborated with alginates with different properties (purity, composition and viscosity).	Alginates	176-185	erythropoietin	Mus musculus	106-109
17081643-8	2006	Although EPO delivery may be limited by the formation of a fibrotic layer around non-biomedical grade alginate microcapsules, the high EPO secretion of the encapsulated cells together with the pharmacodynamic behaviour and the angiogenic and immune-modulatory properties of EPO result in no direct correlation between the biocompatibility of the alginate and the therapeutic response obtained.	Alginates	102-110	erythropoietin	Mus musculus	9-12
17081643-8	2006	Although EPO delivery may be limited by the formation of a fibrotic layer around non-biomedical grade alginate microcapsules, the high EPO secretion of the encapsulated cells together with the pharmacodynamic behaviour and the angiogenic and immune-modulatory properties of EPO result in no direct correlation between the biocompatibility of the alginate and the therapeutic response obtained.	Alginates	346-354	erythropoietin	Mus musculus	9-12
16904088-4	2006	Treatment with EPO significantly reduced apoptosis induced by norepinephrine (NE) in the wild-type cardiomyocytes.	Norepinephrine	62-76	erythropoietin	Mus musculus	15-18
16904088-6	2006	However, the anti-apoptotic effects of EPO were significantly decreased in wild-type cardiomyocytes treated with L-NAME, which inhibits nitric oxide synthase activity.	NG-Nitroarginine Methyl Ester	113-119	erythropoietin	Mus musculus	39-42
16865060-9	2006	RESULTS: The results of this study suggest that blockade of chemokine receptors significantly potentiated erythropoietin- and quercetin-induced inhibition of carbachol-induced bronchoconstriction (P<0.05) compared with the control group.	Carbachol	158-167	erythropoietin	Mus musculus	106-120
17426839-1	2006	We compared the capacity of superlow-dose of antibodies to erythropoietin (Poetam) and recombinant erythropoietin (Recormon) to stimulate the recovery of adriamycin-suppressed erythropoiesis in mice.	Doxorubicin	154-164	erythropoietin	Mus musculus	99-113
16330260-2	2006	Thus, the objective of our study was to determine if anemic Epo-TAg(h) mice could survive in hypoxia despite low oxygen carrying capacity.	Oxygen	113-119	erythropoietin	Mus musculus	60-63
16330260-7	2006	The difference was mainly due to a higher tidal volume that could explain a higher arterial PO2 in Epo-TAg(h) mice.	PO-2	92-95	erythropoietin	Mus musculus	99-102
17088947-2	2006	ASIALO-EPO and CEPO, like the parent compound EPO, protected primary motoneuron cultures from kainate-induced death in vitro.	Kainic Acid	94-101	erythropoietin	Mus musculus	7-10
16928320-0	2006	[An iron regulator hepcidin is affected by EPO].	Iron	4-8	erythropoietin	Mus musculus	43-46
17088947-2	2006	ASIALO-EPO and CEPO, like the parent compound EPO, protected primary motoneuron cultures from kainate-induced death in vitro.	Kainic Acid	94-101	erythropoietin	Mus musculus	16-19
15982852-1	2006	Hematopoietic cytokines, including interleukin (IL)-3 and erythropoietin (Epo), regulate hematopoiesis by stimulating their receptors coupled with the Jak2 tyrosine kinase to induce receptor tyrosine phosphorylation and activate mainly the STAT5, PI3K/Akt, and Ras/MEK/ERK signaling pathways.	Tyrosine	156-164	erythropoietin	Mus musculus	58-72
16882545-1	2006	Erythropoietin (EPO) loaded microneedles were prepared using thread-forming polymer as a base for the percutaneous administration of EPO.	Polymers	76-83	erythropoietin	Mus musculus	0-14
16882545-1	2006	Erythropoietin (EPO) loaded microneedles were prepared using thread-forming polymer as a base for the percutaneous administration of EPO.	Polymers	76-83	erythropoietin	Mus musculus	16-19
16882545-1	2006	Erythropoietin (EPO) loaded microneedles were prepared using thread-forming polymer as a base for the percutaneous administration of EPO.	Polymers	76-83	erythropoietin	Mus musculus	133-136
16882545-3	2006	Under room temperature, EPO solution was added to high concentration of polymer solution and microneedles were prepared by forming thread with polypropylene tips.	Polymers	72-79	erythropoietin	Mus musculus	24-27
16882545-3	2006	Under room temperature, EPO solution was added to high concentration of polymer solution and microneedles were prepared by forming thread with polypropylene tips.	Polypropylenes	143-156	erythropoietin	Mus musculus	24-27
16882545-7	2006	Dextrin EPO microneedles were administered both pc and subcutaneously (sc) to mice.	Dextrins	0-7	erythropoietin	Mus musculus	8-11
16882545-11	2006	When chondroitin sulfate and albumin were used as the microneedle base, the serum EPO levels vs. time profiles showed almost the same pattern.	Chondroitin Sulfates	5-24	erythropoietin	Mus musculus	82-85
16414957-0	2006	Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains.	Cysteine	63-71	erythropoietin	Mus musculus	27-41
16288465-8	2006	Epo administration 24 h before exposure to paraquat significantly improved the survivability of the SOD2(-/+) astrocytes.	Paraquat	43-51	erythropoietin	Mus musculus	0-3
16288465-10	2006	Our study demonstrates an important role for Epo in the protection of astrocytes from reactive oxygen species.	Reactive Oxygen Species	86-109	erythropoietin	Mus musculus	45-48
16817792-8	2006	Polyamines inhibited the activity of EPO, but they did not have any direct effect on colony formation of the fetal mouse liver cells.	Polyamines	0-10	erythropoietin	Mus musculus	37-40
16484922-0	2006	Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice.	Zymosan	69-76	erythropoietin	Mus musculus	0-14
16484922-2	2006	In the present study, we investigated the effects of erythropoietin (1000 IU/kg subcutaneously) on the development of nonseptic shock caused by zymosan.	Zymosan	144-151	erythropoietin	Mus musculus	53-67
16484922-7	2006	Erythropoietin was administered at the dose of 1000 IU/kg subcutaneously, 1 and 6 hrs after zymosan administration.	Zymosan	92-99	erythropoietin	Mus musculus	0-14
16484922-9	2006	MEASUREMENTS AND MAIN RESULTS: Treatment of mice with erythropoietin (1000 IU/kg subcutaneously, 1 and 6 hrs after zymosan administration) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan.	Zymosan	115-122	erythropoietin	Mus musculus	54-68
16484922-9	2006	MEASUREMENTS AND MAIN RESULTS: Treatment of mice with erythropoietin (1000 IU/kg subcutaneously, 1 and 6 hrs after zymosan administration) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan.	Zymosan	230-237	erythropoietin	Mus musculus	54-68
16484922-10	2006	Erythropoietin also attenuated the lung, liver, and pancreatic injury and renal dysfunction caused by zymosan as well as the increase in myeloperoxidase activity caused by zymosan in the lung and intestine.	Zymosan	102-109	erythropoietin	Mus musculus	0-14
16484922-10	2006	Erythropoietin also attenuated the lung, liver, and pancreatic injury and renal dysfunction caused by zymosan as well as the increase in myeloperoxidase activity caused by zymosan in the lung and intestine.	Zymosan	172-179	erythropoietin	Mus musculus	0-14
16484922-12	2006	The degree of staining for nitrotyrosine and poly(ADP-ribose) was markedly reduced in tissue sections obtained from zymosan-treated mice, which received erythropoietin.	3-nitrotyrosine	27-40	erythropoietin	Mus musculus	153-167
16484922-12	2006	The degree of staining for nitrotyrosine and poly(ADP-ribose) was markedly reduced in tissue sections obtained from zymosan-treated mice, which received erythropoietin.	Poly Adenosine Diphosphate Ribose	45-61	erythropoietin	Mus musculus	153-167
16484922-12	2006	The degree of staining for nitrotyrosine and poly(ADP-ribose) was markedly reduced in tissue sections obtained from zymosan-treated mice, which received erythropoietin.	Zymosan	116-123	erythropoietin	Mus musculus	153-167
16484922-14	2006	Treatment with erythropoietin significantly reduced the development of systemic toxicity, the loss in body weight, and the mortality caused by zymosan.	Zymosan	143-150	erythropoietin	Mus musculus	15-29
16484922-15	2006	CONCLUSIONS: This study provides evidence, for the first time, that erythropoietin attenuates the degree of zymosan-induced nonseptic shock in mice.	Zymosan	108-115	erythropoietin	Mus musculus	68-82
16414957-7	2006	These data suggest that activation of dimeric EpoR by Epo binding is achieved by reorienting the EpoR transmembrane and the connected cytosolic domains and that certain disulfide-bonded dimers represent the activated dimeric conformation of the EpoR, constitutively activating downstream signaling.	Disulfides	169-178	erythropoietin	Mus musculus	46-49
15982852-1	2006	Hematopoietic cytokines, including interleukin (IL)-3 and erythropoietin (Epo), regulate hematopoiesis by stimulating their receptors coupled with the Jak2 tyrosine kinase to induce receptor tyrosine phosphorylation and activate mainly the STAT5, PI3K/Akt, and Ras/MEK/ERK signaling pathways.	Tyrosine	156-164	erythropoietin	Mus musculus	74-77
15982852-2	2006	Here we demonstrate that IL-3 or Epo induces a rapid and transient (peaking at 30 min) as well as late progressive increase in reactive oxygen species (ROS) in a hematopoietic progenitor model cell line, 32Dcl3, and its subclone expressing the Epo receptor (EpoR), 32D/EpoR-Wt.	Reactive Oxygen Species	127-150	erythropoietin	Mus musculus	33-36
15982852-2	2006	Here we demonstrate that IL-3 or Epo induces a rapid and transient (peaking at 30 min) as well as late progressive increase in reactive oxygen species (ROS) in a hematopoietic progenitor model cell line, 32Dcl3, and its subclone expressing the Epo receptor (EpoR), 32D/EpoR-Wt.	Reactive Oxygen Species	152-155	erythropoietin	Mus musculus	33-36
15878311-5	2006	HVR was higher in Epo-TAg(h) mice at every FIO2 suggesting a higher chemosensitivity.	fio2	43-47	erythropoietin	Mus musculus	18-21
16449733-0	2006	Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy.	Doxorubicin	62-73	erythropoietin	Mus musculus	21-35
16449733-6	2006	Erythropoietin also protected hearts against doxorubicin-induced cardiomyocyte atrophy and degeneration, myocardial fibrosis, inflammatory cell infiltration, and downregulation of expression of GATA-4 and 3 sarcomeric proteins, myosin heavy chain, troponin I, and desmin.	Doxorubicin	45-56	erythropoietin	Mus musculus	0-14
16449733-7	2006	Cyclooxygenase-2 expression was upregulated in doxorubicin-treated hearts, and that, too, was attenuated by erythropoietin.	Doxorubicin	47-58	erythropoietin	Mus musculus	108-122
16449733-9	2006	Antiatrophic and GATA-4 restoring effects of erythropoietin were demonstrated in the in vitro experiments with cultured cardiomyocytes exposed to doxorubicin, which indicated the direct cardioprotective effects of erythropoietin beyond erythropoiesis.	Doxorubicin	146-157	erythropoietin	Mus musculus	45-59
16449733-9	2006	Antiatrophic and GATA-4 restoring effects of erythropoietin were demonstrated in the in vitro experiments with cultured cardiomyocytes exposed to doxorubicin, which indicated the direct cardioprotective effects of erythropoietin beyond erythropoiesis.	Doxorubicin	146-157	erythropoietin	Mus musculus	214-228
16449733-10	2006	Cardiac erythropoietin receptor expression was downregulated in doxorubicin-induced cardiomyopathy but was restored by erythropoietin.	Doxorubicin	64-75	erythropoietin	Mus musculus	8-22
16449733-11	2006	Among the downstream mediators of erythropoietin receptor signaling, activation of extracellular signal-regulated kinase was reduced by doxorubicin but restored by erythropoietin.	Doxorubicin	136-147	erythropoietin	Mus musculus	34-48
16449733-13	2006	CONCLUSIONS: The present study indicates a protective effect of erythropoietin against doxorubicin-induced cardiomyopathy.	Doxorubicin	87-98	erythropoietin	Mus musculus	64-78
16336625-8	2006	When erythropoietin was administered to mice unilaterally lesioned with 6-hydroxydopamine, it prevented the loss of nigral dopaminergic neurons and maintained striatal catecholamine levels for at least 8 weeks.	Catecholamines	168-181	erythropoietin	Mus musculus	5-19
16758646-2	2005	It was found that in animals with different behavior subjected to experimental neuroses the regulatory effects of CNS monoamines on proliferation and differentiation are mediated via adrenergic and erythropoietin-sensitive structures on erythroid stem cells.	monoamines	118-128	erythropoietin	Mus musculus	198-212
16141447-8	2005	RA or EPO maintained mean alveolar volume, alveolar surface area, and endothelial cell volume density in the SU1498-treated animals.	SU 1498	109-115	erythropoietin	Mus musculus	6-9
16336625-0	2006	Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death.	Oxidopamine	32-49	erythropoietin	Mus musculus	0-14
16336625-3	2006	Using both the dopaminergic cell line, MN9D, and primary dopamine neurons, we show that erythropoietin (1-3 U/mL) is neuroprotective against the dopaminergic neurotoxin, 6-hydroxydopamine.	Dopamine	15-23	erythropoietin	Mus musculus	88-102
16336625-3	2006	Using both the dopaminergic cell line, MN9D, and primary dopamine neurons, we show that erythropoietin (1-3 U/mL) is neuroprotective against the dopaminergic neurotoxin, 6-hydroxydopamine.	Oxidopamine	170-187	erythropoietin	Mus musculus	88-102
16336625-8	2006	When erythropoietin was administered to mice unilaterally lesioned with 6-hydroxydopamine, it prevented the loss of nigral dopaminergic neurons and maintained striatal catecholamine levels for at least 8 weeks.	Oxidopamine	72-89	erythropoietin	Mus musculus	5-19
16203826-5	2006	Using two different Epo-responsive cell lines, we found that depletion of mevalonate and its isoprenoid derivatives using the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor lovastatin impairs Epo signaling as assessed by phosphorylation of cellular substrates and inhibition of apoptosis.	Mevalonic Acid	74-84	erythropoietin	Mus musculus	20-23
16203826-5	2006	Using two different Epo-responsive cell lines, we found that depletion of mevalonate and its isoprenoid derivatives using the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor lovastatin impairs Epo signaling as assessed by phosphorylation of cellular substrates and inhibition of apoptosis.	Mevalonic Acid	74-84	erythropoietin	Mus musculus	202-205
16203826-5	2006	Using two different Epo-responsive cell lines, we found that depletion of mevalonate and its isoprenoid derivatives using the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor lovastatin impairs Epo signaling as assessed by phosphorylation of cellular substrates and inhibition of apoptosis.	Terpenes	93-103	erythropoietin	Mus musculus	20-23
16203826-5	2006	Using two different Epo-responsive cell lines, we found that depletion of mevalonate and its isoprenoid derivatives using the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor lovastatin impairs Epo signaling as assessed by phosphorylation of cellular substrates and inhibition of apoptosis.	Lovastatin	183-193	erythropoietin	Mus musculus	20-23
16236368-0	2005	Protective effects of erythropoietin against ethanol-induced apoptotic neurodegenaration and oxidative stress in the developing C57BL/6 mouse brain.	Ethanol	45-52	erythropoietin	Mus musculus	22-36
16236368-5	2005	In the present study, we investigated the effect of EPO against ethanol-induced neurodegeneration and oxidative stress in the developing C57BL/6 mouse brain.	Ethanol	64-71	erythropoietin	Mus musculus	52-55
16236368-13	2005	Regarding the wide use of erythropoietin in premature newborns, this agent may be potentially beneficial in treating ethanol-induced brain injury in the perinatal period.	Ethanol	117-124	erythropoietin	Mus musculus	26-40
15899920-1	2005	The long form of B-cell lymphoma-x (Bcl-x(L)), an outer mitochondrial membrane protein, has been proposed to mediate the antiapoptotic action of erythropoietin on erythroid progenitor cells and to be necessary for heme synthesis in erythroblasts.	Heme	214-218	erythropoietin	Mus musculus	145-159
16098677-4	2005	The recombinant erythropoietin derived from mouse milk showed a different migration and distribution after SDS-PAGE electrophoresis as well as a low in vivo hematopoietic activity.	Sodium Dodecyl Sulfate	107-110	erythropoietin	Mus musculus	16-30
16579393-5	2005	Heparin potentiated the loss of skeletal muscle tone induced by mefenamic acid and carbenoxolone while urokinase & erythropoietin significantly enhanced the skeletal muscle tone as evaluated by all or one of the tests.	Adenosine Monophosphate	114-117	erythropoietin	Mus musculus	119-133
16282054-10	2005	The RBC, Hb concentration, HCT, plasma EPO level and the relative values of EPO mRNA in renal tissue and pallium of mice were significantly higher in the flavones-treated group than those in the untreated group.	Flavones	154-162	erythropoietin	Mus musculus	39-42
16282054-10	2005	The RBC, Hb concentration, HCT, plasma EPO level and the relative values of EPO mRNA in renal tissue and pallium of mice were significantly higher in the flavones-treated group than those in the untreated group.	Flavones	154-162	erythropoietin	Mus musculus	76-79
16282054-11	2005	CONCLUSION: The anti-hypoxia ingredients extracted from Portulaca oleracea are flavones and the anti-hypoxia effects may be obtained by improving the expression level of EPO and accelerating the generations of erythrocyte and Hb.	Flavones	79-87	erythropoietin	Mus musculus	170-173
15953601-5	2005	PLCgamma1 is rapidly tyrosine phosphorylated upon EPO stimulation and associates with EPO-R in an SH2-domain-dependent manner.	Tyrosine	21-29	erythropoietin	Mus musculus	50-53
15772935-9	2005	Nonetheless, regulation of mouse EPO secretion was maintained during the entire experimental period, both when the vector dosage was reduced and when the tet-dependent transcription factors were put under the control of a muscle-specific promoter.	Tetracycline	154-157	erythropoietin	Mus musculus	33-36
16210801-6	2005	Hypoxia (7% O2) induced low oxygen tension in proximal tubular epithelial cells of renal cortex, and increased the expression of EPO mRNA and the number of EPO-producing cells in both ICR and ICGN mice.	Oxygen	12-14	erythropoietin	Mus musculus	129-132
16210801-6	2005	Hypoxia (7% O2) induced low oxygen tension in proximal tubular epithelial cells of renal cortex, and increased the expression of EPO mRNA and the number of EPO-producing cells in both ICR and ICGN mice.	Oxygen	12-14	erythropoietin	Mus musculus	156-159
15772935-0	2005	Immune responses against tetracycline-dependent transactivators affect long-term expression of mouse erythropoietin delivered by a helper-dependent adenoviral vector.	Tetracycline	25-37	erythropoietin	Mus musculus	101-115
15626745-2	2005	Erythropoietin gene expression increases under conditions associated with lowered oxygen content such as anemia and hypoxia.	Oxygen	82-88	erythropoietin	Mus musculus	0-14
15935736-2	2005	Polymer microcapsules (0.5 ml) loaded with EPO-secreting C(2)C(12) myoblasts and releasing 15,490 +/- 600 IU EPO/24 h were implanted in the peritoneum and subcutaneous tissue of syngeneic and allogeneic mice.	Polymers	0-7	erythropoietin	Mus musculus	43-46
15935736-2	2005	Polymer microcapsules (0.5 ml) loaded with EPO-secreting C(2)C(12) myoblasts and releasing 15,490 +/- 600 IU EPO/24 h were implanted in the peritoneum and subcutaneous tissue of syngeneic and allogeneic mice.	Polymers	0-7	erythropoietin	Mus musculus	109-112
15705783-11	2005	Furthermore, wild-type Lnk, but not the Lnk SH2 mutant, becomes tyrosine-phosphorylated following Epo administration and inhibits EpoR phosphorylation and JAK2 activation.	Tyrosine	64-72	erythropoietin	Mus musculus	98-101
15890996-11	2005	CONCLUSIONS: Hypoxic preconditioning induces ROS, which may downregulate the threshold for production of HIF-1alpha and Epo expression during subsequent lethal hypoxia, thus exerting neuroprotection through the Jak2-Stat5 and NF-kappaB pathways.	Reactive Oxygen Species	45-48	erythropoietin	Mus musculus	120-123
15674326-3	2005	Here we report that erythropoietin or IL-3 promotes G2/M arrest and prevents apoptosis induced by the topoisomerase II inhibitor etoposide in murine hematopoietic 32D cells and human leukemic UT7 cells.	Etoposide	129-138	erythropoietin	Mus musculus	20-34
15766748-0	2005	Retinoic acid, hypoxia, and GATA factors cooperatively control the onset of fetal liver erythropoietin expression and erythropoietic differentiation.	Tretinoin	0-13	erythropoietin	Mus musculus	88-102
15766748-3	2005	Our previous work demonstrated that the Epo gene is a direct target of retinoic acid action, via a retinoic acid receptor binding site in the Epo gene enhancer.	Tretinoin	71-84	erythropoietin	Mus musculus	40-43
15766748-3	2005	Our previous work demonstrated that the Epo gene is a direct target of retinoic acid action, via a retinoic acid receptor binding site in the Epo gene enhancer.	Tretinoin	71-84	erythropoietin	Mus musculus	142-145
15751086-14	2005	The degree of oxidative and nitrosative damage was significantly reduced in EPO-treated mice as indicated by decreased nitrotyrosine formation and poly(ADP-ribose) polymerase activation.	3-nitrotyrosine	119-132	erythropoietin	Mus musculus	76-79
15671158-6	2005	In agreement with the cardioprotective effect observed in vivo, staurosporine-induced apoptosis of adult rat or mouse cardiomyocytes in vitro was also significantly attenuated ( approximately 35%) by CEPO, which is comparable with the effect of EPO.	Staurosporine	64-77	erythropoietin	Mus musculus	201-204
15664399-6	2005	Pretreatment of the myocytes with EPO prevented the A/R-induced proinflammatory effects.	r	54-55	erythropoietin	Mus musculus	34-37
15078939-6	2004	Mutational analysis of sf-Stk indicated that a functional kinase domain and 8 of its 12 tyrosine residues are required for the induction of Epo-independent colonies.	Tyrosine	88-96	erythropoietin	Mus musculus	140-143
15329338-0	2004	Erythropoietin-modulated calcium influx through TRPC2 is mediated by phospholipase Cgamma and IP3R.	Calcium	25-32	erythropoietin	Mus musculus	0-14
15329338-2	2004	Erythroblasts were isolated from the spleens of phenylhydrazine-treated mice, and Epo stimulation resulted in a significant and dose-dependent increase in intracellular calcium concentration ([Ca(2+)](i)).	phenylhydrazine	48-63	erythropoietin	Mus musculus	82-85
15329338-2	2004	Erythroblasts were isolated from the spleens of phenylhydrazine-treated mice, and Epo stimulation resulted in a significant and dose-dependent increase in intracellular calcium concentration ([Ca(2+)](i)).	Calcium	169-176	erythropoietin	Mus musculus	82-85
15329338-3	2004	This increase in [Ca(2+)](i) was inhibited by pretreatment with the phospholipase C (PLC) inhibitor U-73122 but not by the inactive analog U-73343, demonstrating the requirement for PLC activity in Epo-modulated Ca(2+) influx in primary erythroid cells.	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	100-107	erythropoietin	Mus musculus	198-201
15329338-6	2004	Epo-induced Ca(2+) influx through TRPC2 was inhibited by pretreatment with U-73122 or by downregulation of PLCgamma1 by RNA interference.	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	75-82	erythropoietin	Mus musculus	0-3
15302898-5	2004	When compared with DNBS-treated mice, EPO (1000 IU/kg day s.c.)-treated mice subjected to DNBS-induced colitis experienced significantly lower rates in the extent and severity of the histological signs of colon injury.	dinitrobenzenesulfonic acid	19-23	erythropoietin	Mus musculus	38-41
15302898-5	2004	When compared with DNBS-treated mice, EPO (1000 IU/kg day s.c.)-treated mice subjected to DNBS-induced colitis experienced significantly lower rates in the extent and severity of the histological signs of colon injury.	dinitrobenzenesulfonic acid	90-94	erythropoietin	Mus musculus	38-41
15302898-10	2004	On the contrary, the treatment of DNBS-treated mice with EPO significantly reduced the degree of diarrhea and weight loss caused by administration of DNBS.	dinitrobenzenesulfonic acid	34-38	erythropoietin	Mus musculus	57-60
15302898-10	2004	On the contrary, the treatment of DNBS-treated mice with EPO significantly reduced the degree of diarrhea and weight loss caused by administration of DNBS.	dinitrobenzenesulfonic acid	150-154	erythropoietin	Mus musculus	57-60
15302898-11	2004	EPO also caused a substantial reduction of the degree of colon injury, the rise in myeloperoxidase activity (mucosa), and the increase in staining (immunohistochemistry) for nitrotyrosine as well as the up-regulation of ICAM-1 caused by DNBS in the colon.	3-nitrotyrosine	174-187	erythropoietin	Mus musculus	0-3
15302898-11	2004	EPO also caused a substantial reduction of the degree of colon injury, the rise in myeloperoxidase activity (mucosa), and the increase in staining (immunohistochemistry) for nitrotyrosine as well as the up-regulation of ICAM-1 caused by DNBS in the colon.	dinitrobenzenesulfonic acid	237-241	erythropoietin	Mus musculus	0-3
15631710-22	2004	The bone marrow stromal cell differentiation system combining with VEGF, SCF, IL-3, IL-6 and EPO was an optimal system for the generation of HSC with CD(34)(+)/Sca-1(+) surface marker from ESC differentiated in vitro.	Cadmium	150-152	erythropoietin	Mus musculus	93-96
15363543-11	2004	When EPO and mitomycin C were injected together, tumor mass was further reduced by 14% compared to that seen in mice treated with mitomycin C alone.	Mitomycin	130-141	erythropoietin	Mus musculus	5-8
15379762-9	2004	Co2+ induced erythropoietin expression.	Cobalt(2+)	0-4	erythropoietin	Mus musculus	13-27
15059850-4	2004	Treatment with the JNK inhibitor SP600125 inhibited JNK activity and EPO-dependent proliferation of HCD57 cells and the human EPO-dependent cell lines TF-1 and UT7-EPO.	pyrazolanthrone	33-41	erythropoietin	Mus musculus	69-72
15059850-4	2004	Treatment with the JNK inhibitor SP600125 inhibited JNK activity and EPO-dependent proliferation of HCD57 cells and the human EPO-dependent cell lines TF-1 and UT7-EPO.	pyrazolanthrone	33-41	erythropoietin	Mus musculus	126-129
15375030-2	2005	Here we report that extracellular superoxide dismutase (EC-SOD) plays a major role in regulating the magnitude of hypoxia-induced erythropoietin (Epo) gene expression, thus implicating superoxide as an intermediary signal transduction molecule critical to this process.	Superoxides	34-44	erythropoietin	Mus musculus	130-144
15375030-2	2005	Here we report that extracellular superoxide dismutase (EC-SOD) plays a major role in regulating the magnitude of hypoxia-induced erythropoietin (Epo) gene expression, thus implicating superoxide as an intermediary signal transduction molecule critical to this process.	Superoxides	34-44	erythropoietin	Mus musculus	146-149
15375030-8	2005	We conclude that EC-SOD functions as a major repressor of hypoxia-induced Epo gene expression, which implicates superoxide as a signaling intermediate whose downstream effects, at least in part, may be mediated by HIF-1alpha.	Superoxides	112-122	erythropoietin	Mus musculus	74-77
15468192-3	2005	METHODS: Plasmids encoding either constitutive human secreted alkaline phosphatase or murine erythropoietin inducible via a Tet-on system were formulated with PE6400 and intramuscularly injected into the mouse tibial anterior muscle.	tetramethylenedisulfotetramine	124-127	erythropoietin	Mus musculus	93-107
15468192-5	2005	In the presence of doxycycline, a single injection of 10 microg plasmid encoding inducible murine erythropoietin formulated with PE6400 significantly increased the hematocrit, whereas the same amount of DNA in the absence of PE6400 had no effect.	Doxycycline	19-30	erythropoietin	Mus musculus	98-112
15242770-7	2004	BAF3 cells expressing a mutant EPOR with no cytoplasmic tyrosine residues were capable of triggering EPO-dependent TNF-alpha synthesis and secretion, indicating that tyrosine-docking sites in the EPOR were not required for EPO-dependent TNF-alpha secretion.	Tyrosine	166-174	erythropoietin	Mus musculus	31-34
15242770-7	2004	BAF3 cells expressing a mutant EPOR with no cytoplasmic tyrosine residues were capable of triggering EPO-dependent TNF-alpha synthesis and secretion, indicating that tyrosine-docking sites in the EPOR were not required for EPO-dependent TNF-alpha secretion.	Tyrosine	166-174	erythropoietin	Mus musculus	101-104
15026317-3	2004	We now show that EPO induces phosphorylation of Raf-1 at serine 338 and within the carboxy-terminal domain, resulting in an electrophoretic mobility change (hyperphosphorylation).	Serine	57-63	erythropoietin	Mus musculus	17-20
14699131-3	2004	Erythroblasts were isolated from the spleens of phenylhydrazine-treated mice, and Epo stimulation resulted in a significant and dose-dependent increase in [Ca](i).	phenylhydrazine	48-63	erythropoietin	Mus musculus	82-85
15133284-5	2004	DTZ maintained the higher erythropoietin level in blood, which acted on bone marrow and spleen colony forming unit for erythroblast (CFU-E), and stimulated such cells to produce RBCs.	Diltiazem	0-3	erythropoietin	Mus musculus	26-40
15133284-6	2004	These results confirm that DTZ has the potency to alter anaemic condition favorably through the protection of bone marrow stem cells, and subsequently it maintains the higher number of pro- and normoblasts in bone marrow, RBC counts, hemoglobin (Hb), hematocrit (Hct) percentage, and erythropoietin level in blood and the lower myeloid/erythroid ratio in bone marrow.	Diltiazem	27-30	erythropoietin	Mus musculus	284-298
14732207-0	2004	Norepinephrine-induced acute heart failure in transgenic mice overexpressing erythropoietin.	Norepinephrine	0-14	erythropoietin	Mus musculus	77-91
14732207-11	2004	The NE-induced reduction in myocardial adenosin-triphosphate (ATP) content was more pronounced in Epo-tg6 mice after 10 min of continuous NE infusion (50 ng/min per mouse).	Adenosine Triphosphate	62-65	erythropoietin	Mus musculus	98-101
14661182-7	2003	Following implantation of microencapsulated CHO-K1 cell derivatives transgenic for macrolide-controlled bidirectional expression of erythropoietin (EPO) and the human secreted alkaline phosphatase (SEAP) intraperitoneally into mice, serum EPO and SEAP levels could be coadjusted to desired levels by administration of different erythromycin doses.	Macrolides	83-92	erythropoietin	Mus musculus	239-242
14668002-5	2003	We have designed a plasmid-based, muscle-specific GeneSwitch system that is delivered to skeletal muscle by electroporation and provides regulated erythropoietin (EPO) expression in mice and rats in a manner that is dependent on orally administered mifepristone (MFP).	Mifepristone	249-261	erythropoietin	Mus musculus	147-161
12869513-0	2003	Attenuated signaling by a phosphotyrosine-null Epo receptor form in primary erythroid progenitor cells.	Phosphotyrosine	26-41	erythropoietin	Mus musculus	47-50
14668002-5	2003	We have designed a plasmid-based, muscle-specific GeneSwitch system that is delivered to skeletal muscle by electroporation and provides regulated erythropoietin (EPO) expression in mice and rats in a manner that is dependent on orally administered mifepristone (MFP).	Mifepristone	249-261	erythropoietin	Mus musculus	163-166
12753297-12	2003	In vitro studies showed EPO secretion from modified HPMC over 6 months.	hydroxypropylmethylcellulose-lactose matrix	52-56	erythropoietin	Mus musculus	24-27
12753297-14	2003	EPO, in MPMC transplanted mice, was detected up to 3 weeks (peak at 13 +/- 1 mIU/mL), and anemia of uremic mice was corrected (35.3 +/- 0.9 mIU/mL to 41.9 +/- 1.1 mIU/mL).	Xylylcarb	8-12	erythropoietin	Mus musculus	0-3
12615719-2	2003	In the present study, we assessed the effect that erythropoietin and interleukin-3 have on cisplatin-treated hematopoietic cells.	Cisplatin	91-100	erythropoietin	Mus musculus	50-64
12713714-1	2003	Current evidence suggests that a modulatory action on O(2)-dependent EPO secretion is exerted by the erythroid/precursor cell population in the erythropoietic organs through a negative feedback system.	o(2)	54-58	erythropoietin	Mus musculus	69-72
12713714-3	2003	Since erythropoietic depression was elicited by cyclophosphamide administration, which could have altered EPO production directly, the aim of the present investigation was to estimate hypoxia-stimulated EPO secretion in a mouse model of functional depressed erythropoiesis induced by exposure to normobaric hyperoxia.	Cyclophosphamide	48-64	erythropoietin	Mus musculus	106-109
12713714-12	2003	Data support the concept that the rate of erythropoiesis, perhaps through the number of the erythroid progenitor/precursor cell population, modulates O(2)-dependent EPO secretion.	o(2)	150-154	erythropoietin	Mus musculus	165-168
12727112-6	2003	Specifically, expression of Epo was dependent on the presence of a chimeric transcription factor that is activated by the orally available small molecule drug rapamycin.	Sirolimus	159-168	erythropoietin	Mus musculus	28-31
12727112-7	2003	beta-thalassemic mice injected with vectors containing the regulated Epo gene failed to show any effect until they were administered a regimen of rapamycin, which led to the production of Epo and an increase in hematocrit values.	Sirolimus	146-155	erythropoietin	Mus musculus	188-191
12706120-4	2003	However, after being treated with 5-AzaC, 32D Ro cells acquired the ability to generate EPO-dependent clones (1 clone/10(4) cells) which gave rise to EPO-dependent cell lines.	Azacitidine	34-40	erythropoietin	Mus musculus	88-91
12706120-4	2003	However, after being treated with 5-AzaC, 32D Ro cells acquired the ability to generate EPO-dependent clones (1 clone/10(4) cells) which gave rise to EPO-dependent cell lines.	Azacitidine	34-40	erythropoietin	Mus musculus	150-153
12706120-5	2003	All the 10 EPO-responsive cell lines independently isolated from 5-AzaC-treated 32D Ro cells had erythroid morphology and expressed high levels of alpha- and beta-globin.	Azacitidine	65-71	erythropoietin	Mus musculus	11-14
12706120-7	2003	Therefore, 5-AzaC treatment reactivates the potential of the myeloid-restricted 32D Ro cells to generate EPO-responsive erythroid clones suggesting that gene methylation played an important role in the G-CSF-mediated restriction/activation of the differentiation potential of these cells.	Azacitidine	11-17	erythropoietin	Mus musculus	105-108
12490547-6	2003	Compared with their wild-type littermates, aortic rings of Epo transgenic animals exhibited a marked reduction in vascular reactivity to ET-1 and big ET-1, but this effect was abrogated upon preincubation with the NO synthase inhibitor N-nitro-L-arginine methyl ester (L-NAME).	n-nitro-l-arginine methyl ester	236-267	erythropoietin	Mus musculus	59-62
12490547-6	2003	Compared with their wild-type littermates, aortic rings of Epo transgenic animals exhibited a marked reduction in vascular reactivity to ET-1 and big ET-1, but this effect was abrogated upon preincubation with the NO synthase inhibitor N-nitro-L-arginine methyl ester (L-NAME).	NG-Nitroarginine Methyl Ester	269-275	erythropoietin	Mus musculus	59-62
12393728-5	2002	NU-L(PAN) also inhibited MS-5-induced or EPO-induced erythroid differentiation of CD34(+) cells.	nu-l	0-4	erythropoietin	Mus musculus	41-44
12498775-0	2002	Mechanisms leading to sustained reversion of beta-thalassemia in mice by doxycycline-controlled Epo delivery from muscles.	Doxycycline	73-84	erythropoietin	Mus musculus	96-99
12498775-5	2002	beta-Thalassemic mice were rendered steadily normocythemic by the intramuscular injection of a tetracycline-inducible AAV vector encoding mouse Epo.	Tetracycline	95-107	erythropoietin	Mus musculus	144-147
12440938-0	2002	Erythropoietin and interleukin-1beta modulate nitrite production in a Swiss 3T3 cell model of rheumatoid synovial fibroblasts.	Nitrites	46-53	erythropoietin	Mus musculus	0-14
12239150-5	2002	Here we describe an oxygen-regulated gene therapy approach to treating homozygous erythropoietin-SV40 T antigen (Epo-TAg(h)) mice with relative erythropoietin deficiency.	Oxygen	20-26	erythropoietin	Mus musculus	82-96
12239150-5	2002	Here we describe an oxygen-regulated gene therapy approach to treating homozygous erythropoietin-SV40 T antigen (Epo-TAg(h)) mice with relative erythropoietin deficiency.	Oxygen	20-26	erythropoietin	Mus musculus	113-116
12239150-5	2002	Here we describe an oxygen-regulated gene therapy approach to treating homozygous erythropoietin-SV40 T antigen (Epo-TAg(h)) mice with relative erythropoietin deficiency.	Oxygen	20-26	erythropoietin	Mus musculus	144-158
12135708-1	2002	Erythropoietin (Epo)-induced glycosylphosphatidylinositol (GPI) hydrolysis was previously described to be correlated with phospholipase C-gamma 2 (PLC-gamma2) activation.	Glycosylphosphatidylinositols	29-57	erythropoietin	Mus musculus	16-19
12135708-4	2002	Wortmannin, another PtdIns 3-kinase inhibitor, also suppressed Epo-induced PLC-gamma2 tyrosine phosphorylation.	Wortmannin	0-10	erythropoietin	Mus musculus	63-66
12135708-1	2002	Erythropoietin (Epo)-induced glycosylphosphatidylinositol (GPI) hydrolysis was previously described to be correlated with phospholipase C-gamma 2 (PLC-gamma2) activation.	Glycosylphosphatidylinositols	59-62	erythropoietin	Mus musculus	16-19
12135708-4	2002	Wortmannin, another PtdIns 3-kinase inhibitor, also suppressed Epo-induced PLC-gamma2 tyrosine phosphorylation.	Tyrosine	86-94	erythropoietin	Mus musculus	63-66
12135708-2	2002	Here, we analyzed the involvement of phosphatidylinositol (PtdIns) 3-kinase in GPI hydrolysis through PLC-gamma2 tyrosine phosphorylation in response to Epo in FDC-P1 cells transfected with a wild type (WT) erythropoietin-receptor (Epo-R).	Phosphatidylinositols	37-57	erythropoietin	Mus musculus	153-156
12135708-2	2002	Here, we analyzed the involvement of phosphatidylinositol (PtdIns) 3-kinase in GPI hydrolysis through PLC-gamma2 tyrosine phosphorylation in response to Epo in FDC-P1 cells transfected with a wild type (WT) erythropoietin-receptor (Epo-R).	Tyrosine	113-121	erythropoietin	Mus musculus	153-156
12135708-5	2002	We also present evidence that PLC-gamma2 translocation to the membrane fraction on Epo stimulation is completely inhibited by LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	126-134	erythropoietin	Mus musculus	83-86
12135708-6	2002	Upon Epo stimulation, the tyrosine-phosphorylated PLC-gamma2 was found to be associated with the tyrosine-phosphorylated Grb2-associated binder (GAB)2, SHC and SHP2 proteins.	Tyrosine	26-34	erythropoietin	Mus musculus	5-8
12135708-3	2002	We showed that phosphatidylinositol 3-kinase (PtdIns 3-kinase) inhibitor LY294002 inhibits Epo-induced hydrolysis of endogenous GPI and Epo-induced PLC-gamma2 tyrosine phosphorylation in a dose-dependent manner.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	73-81	erythropoietin	Mus musculus	91-94
12135708-6	2002	Upon Epo stimulation, the tyrosine-phosphorylated PLC-gamma2 was found to be associated with the tyrosine-phosphorylated Grb2-associated binder (GAB)2, SHC and SHP2 proteins.	Tyrosine	97-105	erythropoietin	Mus musculus	5-8
12135708-3	2002	We showed that phosphatidylinositol 3-kinase (PtdIns 3-kinase) inhibitor LY294002 inhibits Epo-induced hydrolysis of endogenous GPI and Epo-induced PLC-gamma2 tyrosine phosphorylation in a dose-dependent manner.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	73-81	erythropoietin	Mus musculus	136-139
12135708-3	2002	We showed that phosphatidylinositol 3-kinase (PtdIns 3-kinase) inhibitor LY294002 inhibits Epo-induced hydrolysis of endogenous GPI and Epo-induced PLC-gamma2 tyrosine phosphorylation in a dose-dependent manner.	Tyrosine	159-167	erythropoietin	Mus musculus	91-94
12135708-3	2002	We showed that phosphatidylinositol 3-kinase (PtdIns 3-kinase) inhibitor LY294002 inhibits Epo-induced hydrolysis of endogenous GPI and Epo-induced PLC-gamma2 tyrosine phosphorylation in a dose-dependent manner.	Tyrosine	159-167	erythropoietin	Mus musculus	136-139
11877405-3	2002	However, since the discovery that myeloperoxidase (MPO) and eosinophil peroxidase (EPO) can generate nitrotyrosine via oxidation of nitrite (NO(2)(-)), several questions have arisen.	3-nitrotyrosine	101-114	erythropoietin	Mus musculus	83-86
12235036-11	2002	O(2) sensing in EPO-producing cells of the kidney appears to be independent of the gp91(phox) and p47(phox) components of the phagocytic NADPH oxidase.	Oxygen	0-4	erythropoietin	Mus musculus	16-19
12149239-0	2002	Short-term granulocyte colony-stimulating factor and erythropoietin treatment enhances hematopoiesis and survival in the mitomycin C-conditioned Fancc(-/-) mouse model, while long-term treatment is ineffective.	Mitomycin	121-132	erythropoietin	Mus musculus	53-67
12149239-3	2002	Fancc(-/-) mice injected with granulocyte colony-stimulating factor, erythropoietin, or both cytokines showed a delay in mitomycin C (MMC)-induced bone marrow (BM) failure compared to untreated mice.	Mitomycin	121-132	erythropoietin	Mus musculus	69-83
12149239-3	2002	Fancc(-/-) mice injected with granulocyte colony-stimulating factor, erythropoietin, or both cytokines showed a delay in mitomycin C (MMC)-induced bone marrow (BM) failure compared to untreated mice.	Mitomycin	134-137	erythropoietin	Mus musculus	69-83
12084393-5	2002	Erythropoietin (Epo) therapy has been used for reversal of AZT induced erythroid toxicity.	Zidovudine	59-62	erythropoietin	Mus musculus	0-14
12084393-5	2002	Erythropoietin (Epo) therapy has been used for reversal of AZT induced erythroid toxicity.	Zidovudine	59-62	erythropoietin	Mus musculus	16-19
12084393-5	2002	Erythropoietin (Epo) therapy has been used for reversal of AZT induced erythroid toxicity.	erythroid	71-80	erythropoietin	Mus musculus	0-14
12084393-5	2002	Erythropoietin (Epo) therapy has been used for reversal of AZT induced erythroid toxicity.	erythroid	71-80	erythropoietin	Mus musculus	16-19
12365000-7	2002	The poly-L-glutamate formulation was effective in two different muscle groups in mice at various plasmid doses for several transgenes, including an erythropoietin (EPO) gene, for which expression was elevated four- to 12-fold in comparison to animals that received EPO plasmid in saline.	Polyglutamic Acid	4-20	erythropoietin	Mus musculus	148-162
12365000-7	2002	The poly-L-glutamate formulation was effective in two different muscle groups in mice at various plasmid doses for several transgenes, including an erythropoietin (EPO) gene, for which expression was elevated four- to 12-fold in comparison to animals that received EPO plasmid in saline.	Polyglutamic Acid	4-20	erythropoietin	Mus musculus	164-167
12365000-7	2002	The poly-L-glutamate formulation was effective in two different muscle groups in mice at various plasmid doses for several transgenes, including an erythropoietin (EPO) gene, for which expression was elevated four- to 12-fold in comparison to animals that received EPO plasmid in saline.	Polyglutamic Acid	4-20	erythropoietin	Mus musculus	265-268
12167663-0	2002	Erythropoietin modulates calcium influx through TRPC2.	Calcium	25-32	erythropoietin	Mus musculus	0-14
12167663-2	2002	Erythropoietin (Epo) stimulates a rise in intracellular calcium ([Ca](i)) via activation of voltage-independent calcium channel(s) in erythroid cells.	Calcium	56-63	erythropoietin	Mus musculus	0-14
12167663-2	2002	Erythropoietin (Epo) stimulates a rise in intracellular calcium ([Ca](i)) via activation of voltage-independent calcium channel(s) in erythroid cells.	Calcium	56-63	erythropoietin	Mus musculus	16-19
12167663-11	2002	These results identify a calcium-permeable channel, TRPC2, in erythroid cells and demonstrate modulation of calcium influx through this channel by erythropoietin.	Calcium	25-32	erythropoietin	Mus musculus	147-161
12161181-0	2002	Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts.	Doxycycline	10-21	erythropoietin	Mus musculus	45-59
12161181-2	2002	We investigated doxycycline-based regulation of gene expression to modulate the secretion of erythropoietin (EPO) from encapsulated myoblasts in a mouse model.	Doxycycline	16-27	erythropoietin	Mus musculus	93-107
12161181-2	2002	We investigated doxycycline-based regulation of gene expression to modulate the secretion of erythropoietin (EPO) from encapsulated myoblasts in a mouse model.	Doxycycline	16-27	erythropoietin	Mus musculus	109-112
11877405-3	2002	However, since the discovery that myeloperoxidase (MPO) and eosinophil peroxidase (EPO) can generate nitrotyrosine via oxidation of nitrite (NO(2)(-)), several questions have arisen.	Nitrites	132-139	erythropoietin	Mus musculus	83-86
11877405-6	2002	Using multiple distinct models of acute inflammation with EPO- and MPO-knockout mice, we now demonstrate that leukocyte peroxidases participate in nitrotyrosine formation in vivo.	3-nitrotyrosine	147-160	erythropoietin	Mus musculus	58-61
11877405-7	2002	In some models, MPO and EPO played a dominant role, accounting for the majority of nitrotyrosine formed.	3-nitrotyrosine	83-96	erythropoietin	Mus musculus	24-27
11877405-11	2002	Collectively, our results demonstrate that: 1) MPO and EPO contribute to tyrosine nitration in vivo; 2) the major reactive nitrogen species formed by leukocyte peroxidase-catalyzed oxidation of NO(2)(-) is the one-electron oxidation product, (*)NO(2); 3) as a minor reaction, peroxidases may also catalyze the two-electron oxidation of NO(2)(-), producing a ONOO(-)-like product.	Tyrosine	73-81	erythropoietin	Mus musculus	55-58
11877405-11	2002	Collectively, our results demonstrate that: 1) MPO and EPO contribute to tyrosine nitration in vivo; 2) the major reactive nitrogen species formed by leukocyte peroxidase-catalyzed oxidation of NO(2)(-) is the one-electron oxidation product, (*)NO(2); 3) as a minor reaction, peroxidases may also catalyze the two-electron oxidation of NO(2)(-), producing a ONOO(-)-like product.	Nitrogen	123-131	erythropoietin	Mus musculus	55-58
12090760-0	2002	Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.	Zidovudine	65-79	erythropoietin	Mus musculus	37-51
11977113-1	2002	Formulations containing maltodextrin (2% w/v) were identified to facilitate intramuscular (im) delivery of plasmid DNA in mice using the reporter genes luciferase and chloramphenicol acetyltransferase (CAT) and the therapeutic gene of erythropoietin (EPO) as monitors of transfection efficiency.	maltodextrin	24-36	erythropoietin	Mus musculus	235-249
11977113-1	2002	Formulations containing maltodextrin (2% w/v) were identified to facilitate intramuscular (im) delivery of plasmid DNA in mice using the reporter genes luciferase and chloramphenicol acetyltransferase (CAT) and the therapeutic gene of erythropoietin (EPO) as monitors of transfection efficiency.	maltodextrin	24-36	erythropoietin	Mus musculus	251-254
11977113-3	2002	In a therapeutically significant experiment, a single im injection of an EPO plasmid formulation containing 2% (w/v) maltodextrin resulted in a significant and prolonged elevation of the hematocrit levels of mice compared with control DNA in saline.	maltodextrin	117-129	erythropoietin	Mus musculus	73-76
11977113-3	2002	In a therapeutically significant experiment, a single im injection of an EPO plasmid formulation containing 2% (w/v) maltodextrin resulted in a significant and prolonged elevation of the hematocrit levels of mice compared with control DNA in saline.	Sodium Chloride	242-248	erythropoietin	Mus musculus	73-76
12090760-2	2002	Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.	Zidovudine	167-170	erythropoietin	Mus musculus	34-48
12090760-2	2002	Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.	Zidovudine	167-170	erythropoietin	Mus musculus	50-53
12090760-2	2002	Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.	Zidovudine	167-170	erythropoietin	Mus musculus	160-163
12090760-2	2002	Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.	Zidovudine	167-170	erythropoietin	Mus musculus	160-163
12090760-2	2002	Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.	Zidovudine	167-170	erythropoietin	Mus musculus	160-163
12090760-5	2002	There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre-treated with IGF-IL-3 and EPO.	Thymidine	37-46	erythropoietin	Mus musculus	145-148
12090760-6	2002	Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.	Thymidine	150-159	erythropoietin	Mus musculus	115-118
12090760-6	2002	Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.	Thymidine	150-159	erythropoietin	Mus musculus	277-280
11812277-7	2002	Moreover, a stringent control of mEpo gene expression and Hct levels in the absence of any background activity was maintained over a 10-month period by injecting as little as 1 microg of a single plasmid containing the rtTA2(S)-S2 expression cassette and the Tet-responsive mEpo cDNA.	Tetracycline	259-262	erythropoietin	Mus musculus	33-37
11872260-5	2002	Further, Epo stimulated astroglial GSHPx production in neonatal murine astroglial cell culture suggesting that the possible cell source for the stimulation of GSHPx activity by Epo in the MPTP-induced neurotoxicity model are astroglia.	gshpx	159-164	erythropoietin	Mus musculus	177-180
11872260-5	2002	Further, Epo stimulated astroglial GSHPx production in neonatal murine astroglial cell culture suggesting that the possible cell source for the stimulation of GSHPx activity by Epo in the MPTP-induced neurotoxicity model are astroglia.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	188-192	erythropoietin	Mus musculus	9-12
11872260-5	2002	Further, Epo stimulated astroglial GSHPx production in neonatal murine astroglial cell culture suggesting that the possible cell source for the stimulation of GSHPx activity by Epo in the MPTP-induced neurotoxicity model are astroglia.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	188-192	erythropoietin	Mus musculus	177-180
11872260-6	2002	In conclusion, modulation of the astroglial antioxidant defense system might be one of the mechanisms by which Epo exerts a beneficial effect in MPTP-induced Parkinsonism.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	145-149	erythropoietin	Mus musculus	111-114
11872260-0	2002	Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	59-103	erythropoietin	Mus musculus	0-14
11872260-1	2002	Recently, we have reported that erythropoietin (Epo) provides neuroprotection in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced neurotoxicity in vivo.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	81-125	erythropoietin	Mus musculus	32-46
11872260-1	2002	Recently, we have reported that erythropoietin (Epo) provides neuroprotection in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced neurotoxicity in vivo.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	81-125	erythropoietin	Mus musculus	48-51
11872260-1	2002	Recently, we have reported that erythropoietin (Epo) provides neuroprotection in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced neurotoxicity in vivo.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	127-131	erythropoietin	Mus musculus	32-46
11872260-1	2002	Recently, we have reported that erythropoietin (Epo) provides neuroprotection in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced neurotoxicity in vivo.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	127-131	erythropoietin	Mus musculus	48-51
11872260-3	2002	We found that MPTP treatment decreased GSHPx activity in both substantia nigra and striatum, and Epo restores nigral GSHPx activity decreased by MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	145-149	erythropoietin	Mus musculus	97-100
11872260-5	2002	Further, Epo stimulated astroglial GSHPx production in neonatal murine astroglial cell culture suggesting that the possible cell source for the stimulation of GSHPx activity by Epo in the MPTP-induced neurotoxicity model are astroglia.	gshpx	35-40	erythropoietin	Mus musculus	9-12
11872260-5	2002	Further, Epo stimulated astroglial GSHPx production in neonatal murine astroglial cell culture suggesting that the possible cell source for the stimulation of GSHPx activity by Epo in the MPTP-induced neurotoxicity model are astroglia.	gshpx	159-164	erythropoietin	Mus musculus	9-12
11806992-3	2002	Previous studies have shown that an EPO receptor form containing Jak2-binding domains plus a single phosphotyrosine(343) (PY(343))-STAT5-binding site provides all signals needed for erythroid cell development.	Phosphotyrosine	100-115	erythropoietin	Mus musculus	36-39
11849379-12	2002	The results of an in vivo mouse assay revealed that L-NAME inhibited the expression of Epo, but this inhibition of Epo expression by L-NAME was rescued by pretreatment with L-arginine.	NG-Nitroarginine Methyl Ester	52-58	erythropoietin	Mus musculus	87-90
11849379-12	2002	The results of an in vivo mouse assay revealed that L-NAME inhibited the expression of Epo, but this inhibition of Epo expression by L-NAME was rescued by pretreatment with L-arginine.	NG-Nitroarginine Methyl Ester	133-139	erythropoietin	Mus musculus	115-118
11849379-12	2002	The results of an in vivo mouse assay revealed that L-NAME inhibited the expression of Epo, but this inhibition of Epo expression by L-NAME was rescued by pretreatment with L-arginine.	Arginine	173-183	erythropoietin	Mus musculus	87-90
11849379-12	2002	The results of an in vivo mouse assay revealed that L-NAME inhibited the expression of Epo, but this inhibition of Epo expression by L-NAME was rescued by pretreatment with L-arginine.	Arginine	173-183	erythropoietin	Mus musculus	115-118
11443118-1	2001	The erythropoietin (Epo) receptor transduces its signals by activating physically associated tyrosine kinases, mainly Jak2 and Lyn, and thereby inducing tyrosine phosphorylation of various substrates including the Epo receptor (EpoR) itself.	Tyrosine	93-101	erythropoietin	Mus musculus	4-18
11716471-0	2001	Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells.	Tyrosine	32-40	erythropoietin	Mus musculus	0-14
11716471-6	2001	Therefore, it was concluded that Lyn may be the kinase responsible for tyrosine phosphorylating Raf-1 and increasing its exokinase activity in response to erythropoietin.	Tyrosine	71-79	erythropoietin	Mus musculus	155-169
11592940-5	2001	Enprofylline, a selective adenosine A(2B) receptor antagonist, significantly inhibited the increase in plasma levels of Epo in normal mice exposed to hypoxia.	enprofylline	0-12	erythropoietin	Mus musculus	120-123
11592940-6	2001	Chelerythrine chloride, an antagonist of protein kinase C activation, significantly inhibited hypoxia-induced increases in serum levels of Epo in normal mice.	chelerythrine	0-22	erythropoietin	Mus musculus	139-142
11601763-5	2001	CONCLUSIONS: This multiple-control system is of interest for spatially restricting transgene expression into hypoxic tumors, and for finely adjusting the expression level of a therapeutic protein to the oxygen supply in medical applications such as neoangiogenesis or the erythropoietin-mediated treatment of anemia.	Oxygen	203-209	erythropoietin	Mus musculus	272-286
12678228-4	2002	Evaluation of 14 batches of EPO has shown that the new assay is highly sensitive and able to reveal subtle changes in N-linked carbohydrates.	n-linked carbohydrates	118-140	erythropoietin	Mus musculus	28-31
11443118-1	2001	The erythropoietin (Epo) receptor transduces its signals by activating physically associated tyrosine kinases, mainly Jak2 and Lyn, and thereby inducing tyrosine phosphorylation of various substrates including the Epo receptor (EpoR) itself.	Tyrosine	93-101	erythropoietin	Mus musculus	20-23
11443118-2	2001	We previously demonstrated that, in Epo-stimulated cells, an adapter protein, CrkL, becomes tyrosine-phosphorylated, physically associates with Shc, SHP-2, and Cbl, and plays a role in activation of the Ras/Erk signaling pathway.	Tyrosine	92-100	erythropoietin	Mus musculus	36-39
11443118-8	2001	Together, the present study suggests that, upon Epo stimulation, CrkL is recruited to the EpoR through interaction between the CrkL SH2 domain and phosphorylated Tyr(460) in the EpoR cytoplasmic domain and undergoes tyrosine phosphorylation by receptor-associated Lyn to activate the downstream signaling pathway leading to the activation of Erk and Elk-1.	Tyrosine	162-165	erythropoietin	Mus musculus	48-51
11443118-8	2001	Together, the present study suggests that, upon Epo stimulation, CrkL is recruited to the EpoR through interaction between the CrkL SH2 domain and phosphorylated Tyr(460) in the EpoR cytoplasmic domain and undergoes tyrosine phosphorylation by receptor-associated Lyn to activate the downstream signaling pathway leading to the activation of Erk and Elk-1.	Tyrosine	216-224	erythropoietin	Mus musculus	48-51
11297512-2	2001	We have found that the Epo gene is a direct transcriptional target gene of retinoic acid signaling during early erythropoiesis (prior to embryonic day E12.5) in the fetal liver.	Tretinoin	75-88	erythropoietin	Mus musculus	23-26
11389016-6	2001	Controlled secretion of dimeric erythropoietin was achieved in beta-thalassemic mice by in vivo intramuscular electrotransfer of a mouse Epo-Epo plasmid containing the tetO element and of a plasmid encoding the tetracycline controlled transactivator tTA.	Tetracycline	211-223	erythropoietin	Mus musculus	32-46
11389016-8	2001	On tetracycline withdrawal, expression of the Epo-Epo dimer resumed, thereby resulting in a large and sustained hematocrit increase in beta-thalassemic mice.	Tetracycline	3-15	erythropoietin	Mus musculus	46-49
11389016-8	2001	On tetracycline withdrawal, expression of the Epo-Epo dimer resumed, thereby resulting in a large and sustained hematocrit increase in beta-thalassemic mice.	Tetracycline	3-15	erythropoietin	Mus musculus	50-53
11676223-15	2001	Splenic cultures showed a linear dose-response to rh Epo at day 5 post-paclitaxel administration (p < 0.05 with 125 mU/ml).	Paclitaxel	71-81	erythropoietin	Mus musculus	53-56
11676223-16	2001	Medullar and splenic total progenitor colony-forming units (CFU) scorings with and without rh Epo revealed a notable enhancement at 5 days post-paclitaxel treatment.	Paclitaxel	144-154	erythropoietin	Mus musculus	94-97
11676223-17	2001	Data from this study suggest that paclitaxel causes deep injury in the erythropoietic compartment, including temporary variations of Epo sensitivity in late bone marrow erythroid progenitors, early multilineage hematopoietic explosion and terminal erythroid precursors depletion as a result of a complex microenvironmental restitutive regulation.	Paclitaxel	34-44	erythropoietin	Mus musculus	133-136
11406592-0	2001	The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis.	Tyrosine	31-40	erythropoietin	Mus musculus	48-51
11297512-8	2001	We propose that Epo expression is regulated during the E9.5--E11.5 phase of fetal liver erythropoiesis by RXR alpha and retinoic acid, and that expression then becomes dominated by HNF4 activity from E11.5 onward.	Tretinoin	120-133	erythropoietin	Mus musculus	16-19
10880228-1	2000	Recent studies of erythropoietin (Epo) receptor signalling suggest that signals for mitogenesis, survival and differentiation are relayed efficiently by receptor forms lacking at least seven of eight cytoplasmic (phospho)tyrosine [(P)Y] sites for effector recruitment.	Tyrosine	221-229	erythropoietin	Mus musculus	34-37
11298601-1	2001	Gene expression profiles during erythropoietin (Epo)-induced differentiation of erythroid progenitor cells derived from the Friend virus anaemia (FVA) and phenylhydrazine (PHZ) murine models have been examined using differential display polymerase chain reaction (PCR).	phenylhydrazine	155-170	erythropoietin	Mus musculus	32-46
11298601-1	2001	Gene expression profiles during erythropoietin (Epo)-induced differentiation of erythroid progenitor cells derived from the Friend virus anaemia (FVA) and phenylhydrazine (PHZ) murine models have been examined using differential display polymerase chain reaction (PCR).	phenylhydrazine	155-170	erythropoietin	Mus musculus	48-51
11298601-1	2001	Gene expression profiles during erythropoietin (Epo)-induced differentiation of erythroid progenitor cells derived from the Friend virus anaemia (FVA) and phenylhydrazine (PHZ) murine models have been examined using differential display polymerase chain reaction (PCR).	phenylhydrazine	172-175	erythropoietin	Mus musculus	48-51
10960479-6	2000	In T-ER transformants expressing JAK2 (T-JER), EPO induced tyrosine phosphorylation of the EPOR, JAK2, and STAT5, and consequently STAT5-responsive genes including bcl-X and cis1 were normally induced.	Tyrosine	59-67	erythropoietin	Mus musculus	47-50
10985958-1	2000	We investigated the ability of an improved mifepristone-dependent GeneSwitch system to regulate the expression of genes for two therapeutic proteins: vascular endothelial growth factor (VEGF) and erythropoietin.	Mifepristone	43-55	erythropoietin	Mus musculus	196-210
10907637-3	2000	We tested the effects of iron overload or depletion on the expression of the mouse erythropoietin transgene (cDNA), driven by the hypoxia-regulated phosphoglycerate kinase 1 promoter.	Iron	25-29	erythropoietin	Mus musculus	83-97
10918485-5	2000	When the DNA encoded mouse erythropoietin, sodium phosphate vehicle increased hematocrits by two-fold compared with DNA injected in saline.	sodium phosphate	43-59	erythropoietin	Mus musculus	27-41
11163297-0	2001	Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	41-85	erythropoietin	Mus musculus	0-14
11163297-0	2001	Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production.	Nitric Oxide	121-133	erythropoietin	Mus musculus	0-14
11163297-4	2001	Our findings suggest that EPO has protective and treating effect in MPTP-induced neurotoxicity in this mouse model of Parkinson"s Disease via increasing nitric oxide production.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	68-72	erythropoietin	Mus musculus	26-29
11163297-4	2001	Our findings suggest that EPO has protective and treating effect in MPTP-induced neurotoxicity in this mouse model of Parkinson"s Disease via increasing nitric oxide production.	Nitric Oxide	153-165	erythropoietin	Mus musculus	26-29
10995753-5	2000	We also observed that Epo stimulation activates Jak2/Stat5 signal transduction and increases cytoplasmic calcium, which is dependent on tyrosine phosphorylation.	Calcium	105-112	erythropoietin	Mus musculus	22-25
10995753-5	2000	We also observed that Epo stimulation activates Jak2/Stat5 signal transduction and increases cytoplasmic calcium, which is dependent on tyrosine phosphorylation.	Tyrosine	136-144	erythropoietin	Mus musculus	22-25
11027359-0	2000	Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin.	Nitric Oxide	0-12	erythropoietin	Mus musculus	105-119
11037966-7	2000	EPO mRNA was expressed in kidney but not in liver or spleen of phlebotomized mice injected with CL2MDP-liposome, and the serum EPO concentration in these mice was higher than that in phlebotomized mice.	Clodronic Acid	96-102	erythropoietin	Mus musculus	0-3
11037966-7	2000	EPO mRNA was expressed in kidney but not in liver or spleen of phlebotomized mice injected with CL2MDP-liposome, and the serum EPO concentration in these mice was higher than that in phlebotomized mice.	Clodronic Acid	96-102	erythropoietin	Mus musculus	127-130
10979952-2	2000	Treatment of the EPO-dependent HCD57 murine cell line with 70 micromol/L orthovanadate, a tyrosine phosphatase inhibitor, resulted in both increased tyrosine protein phosphorylation and prevention of apoptosis in the absence of EPO without promoting proliferation.	Vanadates	73-86	erythropoietin	Mus musculus	17-20
10979952-2	2000	Treatment of the EPO-dependent HCD57 murine cell line with 70 micromol/L orthovanadate, a tyrosine phosphatase inhibitor, resulted in both increased tyrosine protein phosphorylation and prevention of apoptosis in the absence of EPO without promoting proliferation.	Vanadates	73-86	erythropoietin	Mus musculus	228-231
10979952-2	2000	Treatment of the EPO-dependent HCD57 murine cell line with 70 micromol/L orthovanadate, a tyrosine phosphatase inhibitor, resulted in both increased tyrosine protein phosphorylation and prevention of apoptosis in the absence of EPO without promoting proliferation.	Tyrosine	90-98	erythropoietin	Mus musculus	17-20
10961869-4	2000	L-NAME (analogue of L-NMMA) also inhibited Epo production in anemic mice.	NG-Nitroarginine Methyl Ester	0-6	erythropoietin	Mus musculus	43-46
10961869-4	2000	L-NAME (analogue of L-NMMA) also inhibited Epo production in anemic mice.	omega-N-Methylarginine	20-26	erythropoietin	Mus musculus	43-46
10678740-0	2000	Endogenous nitric oxide attenuates erythropoietin gene expression in vivo.	Nitric Oxide	11-23	erythropoietin	Mus musculus	35-49
10756076-0	2000	Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain.	Oxygen	41-47	erythropoietin	Mus musculus	31-34
10756076-4	2000	Both the astrocytic and neuronal expression of Epo mRNA are induced not only by hypoxia, but also by desferrioxamine (DFX) and cobalt chloride (CoCl(2)), two agents known to mimic the hypoxic induction of Epo in hepatoma cells.	Deferoxamine	101-116	erythropoietin	Mus musculus	47-50
10756076-4	2000	Both the astrocytic and neuronal expression of Epo mRNA are induced not only by hypoxia, but also by desferrioxamine (DFX) and cobalt chloride (CoCl(2)), two agents known to mimic the hypoxic induction of Epo in hepatoma cells.	Deferoxamine	101-116	erythropoietin	Mus musculus	205-208
10756076-4	2000	Both the astrocytic and neuronal expression of Epo mRNA are induced not only by hypoxia, but also by desferrioxamine (DFX) and cobalt chloride (CoCl(2)), two agents known to mimic the hypoxic induction of Epo in hepatoma cells.	Deferoxamine	118-121	erythropoietin	Mus musculus	47-50
10756076-4	2000	Both the astrocytic and neuronal expression of Epo mRNA are induced not only by hypoxia, but also by desferrioxamine (DFX) and cobalt chloride (CoCl(2)), two agents known to mimic the hypoxic induction of Epo in hepatoma cells.	Deferoxamine	118-121	erythropoietin	Mus musculus	205-208
10756076-4	2000	Both the astrocytic and neuronal expression of Epo mRNA are induced not only by hypoxia, but also by desferrioxamine (DFX) and cobalt chloride (CoCl(2)), two agents known to mimic the hypoxic induction of Epo in hepatoma cells.	cobaltous chloride	127-142	erythropoietin	Mus musculus	47-50
10756076-4	2000	Both the astrocytic and neuronal expression of Epo mRNA are induced not only by hypoxia, but also by desferrioxamine (DFX) and cobalt chloride (CoCl(2)), two agents known to mimic the hypoxic induction of Epo in hepatoma cells.	cobaltous chloride	127-142	erythropoietin	Mus musculus	205-208
10756076-4	2000	Both the astrocytic and neuronal expression of Epo mRNA are induced not only by hypoxia, but also by desferrioxamine (DFX) and cobalt chloride (CoCl(2)), two agents known to mimic the hypoxic induction of Epo in hepatoma cells.	cobaltous chloride	144-151	erythropoietin	Mus musculus	47-50
10756076-4	2000	Both the astrocytic and neuronal expression of Epo mRNA are induced not only by hypoxia, but also by desferrioxamine (DFX) and cobalt chloride (CoCl(2)), two agents known to mimic the hypoxic induction of Epo in hepatoma cells.	cobaltous chloride	144-151	erythropoietin	Mus musculus	205-208
10756076-6	2000	Furthermore, the addition of H(2)O(2) decreases the hypoxia-induced Epo mRNA levels.	Hydrogen Peroxide	29-37	erythropoietin	Mus musculus	68-71
10756076-7	2000	These data indicate that, following hypoxia, a common oxygen sensing and signaling pathway leads to increased Epo gene expression in both nervous and hepatoma cells; this pathway would be dependent on the redox-state of the brain.	Oxygen	54-60	erythropoietin	Mus musculus	110-113
10756076-8	2000	Furthermore, we show that the in vivo administration of CoCl(2) and DFX to mice induces an increased Epo mRNA level in the neocortex.	cobaltous chloride	56-63	erythropoietin	Mus musculus	101-104
10756076-8	2000	Furthermore, we show that the in vivo administration of CoCl(2) and DFX to mice induces an increased Epo mRNA level in the neocortex.	Deferoxamine	68-71	erythropoietin	Mus musculus	101-104
10756076-9	2000	As Epo protects the brain against ischemia, our in vivo experiments suggest that the use of molecules such as CoCl(2) or DFX, that provoke an increased Epo gene expression in the brain, could be useful in the development of potential therapeutic strategies for the treatment of hypoxic or ischemic brain injury.	cobaltous chloride	110-117	erythropoietin	Mus musculus	3-6
10756076-9	2000	As Epo protects the brain against ischemia, our in vivo experiments suggest that the use of molecules such as CoCl(2) or DFX, that provoke an increased Epo gene expression in the brain, could be useful in the development of potential therapeutic strategies for the treatment of hypoxic or ischemic brain injury.	cobaltous chloride	110-117	erythropoietin	Mus musculus	152-155
10756076-9	2000	As Epo protects the brain against ischemia, our in vivo experiments suggest that the use of molecules such as CoCl(2) or DFX, that provoke an increased Epo gene expression in the brain, could be useful in the development of potential therapeutic strategies for the treatment of hypoxic or ischemic brain injury.	Deferoxamine	121-124	erythropoietin	Mus musculus	3-6
10756076-9	2000	As Epo protects the brain against ischemia, our in vivo experiments suggest that the use of molecules such as CoCl(2) or DFX, that provoke an increased Epo gene expression in the brain, could be useful in the development of potential therapeutic strategies for the treatment of hypoxic or ischemic brain injury.	Deferoxamine	121-124	erythropoietin	Mus musculus	152-155
10827006-0	2000	The oviduct produces erythropoietin in an estrogen- and oxygen-dependent manner.	Oxygen	56-62	erythropoietin	Mus musculus	21-35
10678740-1	2000	This study aimed to investigate the role of endogenous nitric oxide (NO) in erythropoietin (EPO) gene expression in mice in vivo.	Nitric Oxide	55-67	erythropoietin	Mus musculus	76-90
10678740-1	2000	This study aimed to investigate the role of endogenous nitric oxide (NO) in erythropoietin (EPO) gene expression in mice in vivo.	Nitric Oxide	55-67	erythropoietin	Mus musculus	92-95
10678740-3	2000	EPO gene expression was stimulated by normobaric hypoxia (8% O2) or by 0.1% carbon monoxide (CO) inhalation for 4 h each, or by intraperitoneal injection of 60 mg/kg cobaltous chloride (CoCl2) for 6 h. Renal EPO mRNA in wt increased 12-, 40-, and 13-fold over normoxic levels in response to hypoxia, CO and CoCl2 respectively.	Oxygen	61-63	erythropoietin	Mus musculus	0-3
10678740-3	2000	EPO gene expression was stimulated by normobaric hypoxia (8% O2) or by 0.1% carbon monoxide (CO) inhalation for 4 h each, or by intraperitoneal injection of 60 mg/kg cobaltous chloride (CoCl2) for 6 h. Renal EPO mRNA in wt increased 12-, 40-, and 13-fold over normoxic levels in response to hypoxia, CO and CoCl2 respectively.	Carbon Monoxide	76-91	erythropoietin	Mus musculus	0-3
10678740-3	2000	EPO gene expression was stimulated by normobaric hypoxia (8% O2) or by 0.1% carbon monoxide (CO) inhalation for 4 h each, or by intraperitoneal injection of 60 mg/kg cobaltous chloride (CoCl2) for 6 h. Renal EPO mRNA in wt increased 12-, 40-, and 13-fold over normoxic levels in response to hypoxia, CO and CoCl2 respectively.	Carbon Monoxide	93-95	erythropoietin	Mus musculus	0-3
10678740-3	2000	EPO gene expression was stimulated by normobaric hypoxia (8% O2) or by 0.1% carbon monoxide (CO) inhalation for 4 h each, or by intraperitoneal injection of 60 mg/kg cobaltous chloride (CoCl2) for 6 h. Renal EPO mRNA in wt increased 12-, 40-, and 13-fold over normoxic levels in response to hypoxia, CO and CoCl2 respectively.	cobaltous chloride	166-184	erythropoietin	Mus musculus	0-3
10678740-3	2000	EPO gene expression was stimulated by normobaric hypoxia (8% O2) or by 0.1% carbon monoxide (CO) inhalation for 4 h each, or by intraperitoneal injection of 60 mg/kg cobaltous chloride (CoCl2) for 6 h. Renal EPO mRNA in wt increased 12-, 40-, and 13-fold over normoxic levels in response to hypoxia, CO and CoCl2 respectively.	cobaltous chloride	186-191	erythropoietin	Mus musculus	0-3
10678740-3	2000	EPO gene expression was stimulated by normobaric hypoxia (8% O2) or by 0.1% carbon monoxide (CO) inhalation for 4 h each, or by intraperitoneal injection of 60 mg/kg cobaltous chloride (CoCl2) for 6 h. Renal EPO mRNA in wt increased 12-, 40-, and 13-fold over normoxic levels in response to hypoxia, CO and CoCl2 respectively.	Carbon Monoxide	300-302	erythropoietin	Mus musculus	0-3
10678740-3	2000	EPO gene expression was stimulated by normobaric hypoxia (8% O2) or by 0.1% carbon monoxide (CO) inhalation for 4 h each, or by intraperitoneal injection of 60 mg/kg cobaltous chloride (CoCl2) for 6 h. Renal EPO mRNA in wt increased 12-, 40-, and 13-fold over normoxic levels in response to hypoxia, CO and CoCl2 respectively.	cobaltous chloride	307-312	erythropoietin	Mus musculus	0-3
10678740-5	2000	Renal and hepatic EPO gene expression in wt+L-NAME appeared moderately increased relative to wt with a maximal 2.5-fold enhancement after CO exposure.	NG-Nitroarginine Methyl Ester	44-50	erythropoietin	Mus musculus	18-21
10678740-6	2000	EPO mRNA levels in eNOS-/- mirrored those of wt+L-NAME, but the effects were less prominent.	NG-Nitroarginine Methyl Ester	48-54	erythropoietin	Mus musculus	0-3
10567359-6	1999	Results obtained on FDC-P1 cells transfected with erythropoietin receptor mutated on tyrosine residues suggest that tyrosines 343, 401, 464, and/or 479 are involved in erythropoietin-induced GPI hydrolysis and tyrosine phosphorylation of PLC-gamma(2), whereas tyrosines 429 and/or 431 seem to be involved in an inhibition of both effects.	Tyrosine	85-93	erythropoietin	Mus musculus	50-64
10590051-5	1999	Phorbol 12-myristate 13-acetate, which activated ERKs by a different mechanism, also suppressed the activation of JNKs and significantly retarded apoptosis of the cells caused by withdrawal of EPO.	Tetradecanoylphorbol Acetate	0-31	erythropoietin	Mus musculus	193-196
10590051-6	1999	Furthermore, MEK inhibitor PD98059, which inhibited activation of ERKs, caused activation of JNKs, whereas suppression of JNK expression by antisense oligonucleotides and inhibition of p38 MAP kinase by SB203580 caused attenuation of the apoptosis that occurs upon withdrawal of EPO.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	27-34	erythropoietin	Mus musculus	279-282
11920199-0	2000	Enhancement of erythropoietin-stimulated cell proliferation by Anandamide correlates with increased activation of the mitogen-activated protein kinases ERK1 and ERK2.	anandamide	63-73	erythropoietin	Mus musculus	15-29
10567359-0	1999	Erythropoietin induces glycosylphosphatidylinositol hydrolysis.	Glycosylphosphatidylinositols	23-51	erythropoietin	Mus musculus	0-14
10567359-6	1999	Results obtained on FDC-P1 cells transfected with erythropoietin receptor mutated on tyrosine residues suggest that tyrosines 343, 401, 464, and/or 479 are involved in erythropoietin-induced GPI hydrolysis and tyrosine phosphorylation of PLC-gamma(2), whereas tyrosines 429 and/or 431 seem to be involved in an inhibition of both effects.	Tyrosine	85-93	erythropoietin	Mus musculus	168-182
10567359-2	1999	We showed that erythropoietin induced rapid glycosylphosphatidylinositol (GPI) hydrolysis and tyrosine phosphorylation of phospholipase C (PLC)-gamma(2) in FDC-P1 cells transfected with the wild-type erythropoietin-receptor.	Glycosylphosphatidylinositols	44-72	erythropoietin	Mus musculus	15-29
10567359-2	1999	We showed that erythropoietin induced rapid glycosylphosphatidylinositol (GPI) hydrolysis and tyrosine phosphorylation of phospholipase C (PLC)-gamma(2) in FDC-P1 cells transfected with the wild-type erythropoietin-receptor.	Glycosylphosphatidylinositols	74-77	erythropoietin	Mus musculus	15-29
10567359-6	1999	Results obtained on FDC-P1 cells transfected with erythropoietin receptor mutated on tyrosine residues suggest that tyrosines 343, 401, 464, and/or 479 are involved in erythropoietin-induced GPI hydrolysis and tyrosine phosphorylation of PLC-gamma(2), whereas tyrosines 429 and/or 431 seem to be involved in an inhibition of both effects.	Tyrosine	116-125	erythropoietin	Mus musculus	50-64
10567359-2	1999	We showed that erythropoietin induced rapid glycosylphosphatidylinositol (GPI) hydrolysis and tyrosine phosphorylation of phospholipase C (PLC)-gamma(2) in FDC-P1 cells transfected with the wild-type erythropoietin-receptor.	Tyrosine	94-102	erythropoietin	Mus musculus	15-29
10567359-6	1999	Results obtained on FDC-P1 cells transfected with erythropoietin receptor mutated on tyrosine residues suggest that tyrosines 343, 401, 464, and/or 479 are involved in erythropoietin-induced GPI hydrolysis and tyrosine phosphorylation of PLC-gamma(2), whereas tyrosines 429 and/or 431 seem to be involved in an inhibition of both effects.	Tyrosine	116-125	erythropoietin	Mus musculus	168-182
10567359-3	1999	Erythropoietin-induced tyrosine phosphorylation of PLC-gamma(2) was time- and dose-dependent.	Tyrosine	23-31	erythropoietin	Mus musculus	0-14
10567359-6	1999	Results obtained on FDC-P1 cells transfected with erythropoietin receptor mutated on tyrosine residues suggest that tyrosines 343, 401, 464, and/or 479 are involved in erythropoietin-induced GPI hydrolysis and tyrosine phosphorylation of PLC-gamma(2), whereas tyrosines 429 and/or 431 seem to be involved in an inhibition of both effects.	Tyrosine	116-124	erythropoietin	Mus musculus	50-64
10567359-4	1999	By using FDC-P1 cells transfected with an erythropoietin receptor devoid of tyrosine residues, we showed that both effects required the tyrosine residues of intracellular domain on the erythropoietin receptor.	Tyrosine	76-84	erythropoietin	Mus musculus	42-56
10567359-4	1999	By using FDC-P1 cells transfected with an erythropoietin receptor devoid of tyrosine residues, we showed that both effects required the tyrosine residues of intracellular domain on the erythropoietin receptor.	Tyrosine	136-144	erythropoietin	Mus musculus	42-56
10567359-6	1999	Results obtained on FDC-P1 cells transfected with erythropoietin receptor mutated on tyrosine residues suggest that tyrosines 343, 401, 464, and/or 479 are involved in erythropoietin-induced GPI hydrolysis and tyrosine phosphorylation of PLC-gamma(2), whereas tyrosines 429 and/or 431 seem to be involved in an inhibition of both effects.	Tyrosine	116-124	erythropoietin	Mus musculus	168-182
10567359-6	1999	Results obtained on FDC-P1 cells transfected with erythropoietin receptor mutated on tyrosine residues suggest that tyrosines 343, 401, 464, and/or 479 are involved in erythropoietin-induced GPI hydrolysis and tyrosine phosphorylation of PLC-gamma(2), whereas tyrosines 429 and/or 431 seem to be involved in an inhibition of both effects.	Tyrosine	260-269	erythropoietin	Mus musculus	50-64
10567359-6	1999	Results obtained on FDC-P1 cells transfected with erythropoietin receptor mutated on tyrosine residues suggest that tyrosines 343, 401, 464, and/or 479 are involved in erythropoietin-induced GPI hydrolysis and tyrosine phosphorylation of PLC-gamma(2), whereas tyrosines 429 and/or 431 seem to be involved in an inhibition of both effects.	Tyrosine	260-269	erythropoietin	Mus musculus	168-182
10567359-7	1999	Thus, our results suggest that erythropoietin regulates GPI hydrolysis via tyrosine phosphorylation of its receptor and PLC-gamma(2) activation.	Glycosylphosphatidylinositols	56-59	erythropoietin	Mus musculus	31-45
10567359-7	1999	Thus, our results suggest that erythropoietin regulates GPI hydrolysis via tyrosine phosphorylation of its receptor and PLC-gamma(2) activation.	Tyrosine	75-83	erythropoietin	Mus musculus	31-45
10581608-3	1999	It was shown that erythropoietin, embedded in this polymer, induces formation of erythropoietic foci on acetate-cellulose membranes in the peritoneal cavity of mice.	Acetates	104-111	erythropoietin	Mus musculus	18-32
10527940-4	1999	Erythropoietin was found to stimulate nuclear mitogen-activated protein kinase activity in addition to TAL1 protein phosphorylation, both of which were quantitatively inhibited by the mitogen-activated protein kinase kinase inhibitor PD 098059 and the phosphatidylinositol 3-kinase inhibitor wortmannin.	Wortmannin	292-302	erythropoietin	Mus musculus	0-14
10527940-5	1999	Tryptic phosphopeptide analysis of radiolabelled TAL1 immunoprecipitated from nuclear extracts of Friend virus-induced proerythroblasts revealed that phosphorylation of Ser(122), shown previously to be a substrate for the mitogen-activated protein kinase ERK1 (extracellular signal-regulated protein kinase) in vitro, was specifically, although not exclusively, increased by erythropoietin and inhibited by wortmannin and PD 098059.	Serine	169-172	erythropoietin	Mus musculus	375-389
10586424-2	1999	Mice with hemolytic anemia followed by phenylhydorazine (PHZ) injection for 3 days showed a decrease in the hematocrit (25.4%) and an increase in serum Epo by 14-fold of the control on day 3 after the treatment.	phenylhydorazine	39-55	erythropoietin	Mus musculus	152-155
10586424-2	1999	Mice with hemolytic anemia followed by phenylhydorazine (PHZ) injection for 3 days showed a decrease in the hematocrit (25.4%) and an increase in serum Epo by 14-fold of the control on day 3 after the treatment.	phz	57-60	erythropoietin	Mus musculus	152-155
10586424-5	1999	Additionally, bone marrow suppressive anemia induced by 5-fluorouracil resulted in enhanced CPA the same as for PHZ mice, but in contrast, anemia with suppression of Epo-production due to nephrotoxicity induced by cisplatin caused a decrease in CPA.	Cisplatin	214-223	erythropoietin	Mus musculus	166-169
10514505-0	1999	CrkL mediates Ras-dependent activation of the Raf/ERK pathway through the guanine nucleotide exchange factor C3G in hematopoietic cells stimulated with erythropoietin or interleukin-3.	Guanine Nucleotides	74-92	erythropoietin	Mus musculus	152-166
10581608-3	1999	It was shown that erythropoietin, embedded in this polymer, induces formation of erythropoietic foci on acetate-cellulose membranes in the peritoneal cavity of mice.	Cellulose	112-121	erythropoietin	Mus musculus	18-32
10397175-5	1999	In spite of this, we demonstrated in this paper that in ELM-I-1 cells the Epo-induced down-regulation of c-myb expression and hemoglobin production can be effectively enhanced by the simultaneously added [Ca2+]i-increasing agent, cyclopiazonic acid (CPA).	cyclopiazonic acid	230-248	erythropoietin	Mus musculus	74-77
10515662-5	1999	Injection of 19-ND into young and old mice markedly enhanced the erythropoietin levels but not IL3 and GM-CSF levels in the serum of both groups.	19-nd	13-18	erythropoietin	Mus musculus	65-79
10397175-5	1999	In spite of this, we demonstrated in this paper that in ELM-I-1 cells the Epo-induced down-regulation of c-myb expression and hemoglobin production can be effectively enhanced by the simultaneously added [Ca2+]i-increasing agent, cyclopiazonic acid (CPA).	cyclopiazonic acid	250-253	erythropoietin	Mus musculus	74-77
10329047-14	1999	Among mice bearing small sq tumors, a significant improvement in tumor regression was achieved in the Epo + cisplatin group compared to the cisplatin group (P < 0.05).	Cisplatin	108-117	erythropoietin	Mus musculus	102-105
10340394-4	1999	When maintained in IL-3, about 3% of N-Fms cells formed large hemoglobinized colonies in semisolid cultures supplemented with erythropoietin (EPO).	Nitrogen	37-38	erythropoietin	Mus musculus	126-140
10340394-4	1999	When maintained in IL-3, about 3% of N-Fms cells formed large hemoglobinized colonies in semisolid cultures supplemented with erythropoietin (EPO).	Nitrogen	37-38	erythropoietin	Mus musculus	142-145
10329047-14	1999	Among mice bearing small sq tumors, a significant improvement in tumor regression was achieved in the Epo + cisplatin group compared to the cisplatin group (P < 0.05).	Cisplatin	140-149	erythropoietin	Mus musculus	102-105
10329047-16	1999	Epo resulted in a 25-35% increase in the hematocrit in both the Epo group and the Epo + cisplatin group (P < 0.01).	Cisplatin	88-97	erythropoietin	Mus musculus	0-3
10329047-19	1999	CONCLUSIONS: The data demonstrate a cisplatin-sensitizing effect on human ovarian cancer in SCID mice induced by the pretreatment elevation and maintenance of the hematocrit using Epo.	Cisplatin	36-45	erythropoietin	Mus musculus	180-183
10210776-7	1999	In cells treated with vanadate, a protein tyrosine phosphatase (PTP) inhibitor, Epo induces prolonged STAT5 activation and strongly stimulates IL-2Ralpha expression.	Vanadates	22-30	erythropoietin	Mus musculus	80-83
10082121-6	1999	Inhibition of this induction with antisense oligodeoxynucleotides increased Epo-induced hemoglobinization 2.5-fold.	Oligodeoxyribonucleotides	44-65	erythropoietin	Mus musculus	76-79
10048390-0	1999	Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells.	Doxycycline	39-50	erythropoietin	Mus musculus	11-25
10051313-6	1999	The predicted gene order around Jsr was determined to be cen-(Epo, Pdgfa, D5Mit31, D5Mit374)-(Jsr, Nfe2u, D5Mit99, D5Mit247, D5Mit284, D5Mit292, D5Mit327)-D5Mit328-tel.	Glutaryl-7-aca	57-60	erythropoietin	Mus musculus	62-65
10048390-0	1999	Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells.	Mifepristone	54-66	erythropoietin	Mus musculus	11-25
10048390-3	1999	We generated populations of immortalized murine NIH 3T3 fibroblasts that secrete mouse erythropoietin (Epo) in response to stimulation by doxycycline or mifepristone.	Doxycycline	138-149	erythropoietin	Mus musculus	87-101
10048390-3	1999	We generated populations of immortalized murine NIH 3T3 fibroblasts that secrete mouse erythropoietin (Epo) in response to stimulation by doxycycline or mifepristone.	Doxycycline	138-149	erythropoietin	Mus musculus	103-106
10048390-3	1999	We generated populations of immortalized murine NIH 3T3 fibroblasts that secrete mouse erythropoietin (Epo) in response to stimulation by doxycycline or mifepristone.	Mifepristone	153-165	erythropoietin	Mus musculus	87-101
10048390-3	1999	We generated populations of immortalized murine NIH 3T3 fibroblasts that secrete mouse erythropoietin (Epo) in response to stimulation by doxycycline or mifepristone.	Mifepristone	153-165	erythropoietin	Mus musculus	103-106
10048390-5	1999	Animals receiving doxycycline or mifepristone showed stable polyhemia and increased serum Epo concentrations over a 6-month observation period, whereas animals not receiving the inducer drug had normal hematocrits.	Doxycycline	18-29	erythropoietin	Mus musculus	90-93
10048390-5	1999	Animals receiving doxycycline or mifepristone showed stable polyhemia and increased serum Epo concentrations over a 6-month observation period, whereas animals not receiving the inducer drug had normal hematocrits.	Mifepristone	33-45	erythropoietin	Mus musculus	90-93
10048390-6	1999	Epo secretion could be switched on and off, depending on the presence of doxycycline in the drinking water.	Doxycycline	73-84	erythropoietin	Mus musculus	0-3
9872748-4	1999	Administration of rapamycin resulted in 200-fold induction of plasma Epo.	Sirolimus	18-27	erythropoietin	Mus musculus	69-72
9488432-4	1998	While the Janus protein tyrosine kinase JAK2 and the transcription factor STAT5 became tyrosine phosphorylated with the EPO stimulation in EPO-responsive erythroblastoid cells from anemic mice, JAK1 and STAT5 were constitutively tyrosine phosphorylated in all of these FVp gp55-induced erythroblastoid or erythroleukemic cells.	Tyrosine	24-32	erythropoietin	Mus musculus	120-123
9824435-2	1998	Oxygen tension in the venous blood normally determine EPO elaboration, and, therefore, oxygen consumption in the kidney appears to be an essential part of the oxygen-sensing physiological mechanism.	Oxygen	0-6	erythropoietin	Mus musculus	54-57
9824435-3	1998	As renal oxygen consumption is closely linked to urine production, we have compared responsiveness of the EPO gene to diminished oxygen supply in the normal kidney with that of the hydronephrotic kidney, resulting from ureter ligation.	Oxygen	129-135	erythropoietin	Mus musculus	106-109
9716577-0	1998	Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector.	Doxycycline	38-49	erythropoietin	Mus musculus	11-25
9716577-4	1998	Because this method is potentially applicable clinically, we constructed an AAV vector in which the expression of the mouse erythropoietin (Epo) cDNA is modulated in response to doxycycline.	Doxycycline	178-189	erythropoietin	Mus musculus	124-138
9716577-4	1998	Because this method is potentially applicable clinically, we constructed an AAV vector in which the expression of the mouse erythropoietin (Epo) cDNA is modulated in response to doxycycline.	Doxycycline	178-189	erythropoietin	Mus musculus	140-143
9716577-6	1998	We observed that hematocrit and serum Epo concentrations could be modulated over a 29-week period in response to the presence or absence of doxycycline in the drinking water of these animals.	Doxycycline	140-151	erythropoietin	Mus musculus	38-41
9722929-5	1998	Analysis of the degree of Epo-dependent differentiation of the transfectants, based on the steady-state levels of beta major-globin mRNA, showed that the carboxyl terminal 133 amino acids and tyrosyl residues located at positions 429/431 and 460/464 were not necessary for the induction of differentiation.	cyclo(tyrosyl-tyrosyl)	192-199	erythropoietin	Mus musculus	26-29
9741839-7	1998	EPO, pEPO, marrow responsiveness, or red cell volume were altered by either injections of rh-EPO, 5-fluorouracil, or phenylhydrazine, or by bleeding, or red cell transfusion.	Fluorouracil	98-112	erythropoietin	Mus musculus	0-3
9741839-7	1998	EPO, pEPO, marrow responsiveness, or red cell volume were altered by either injections of rh-EPO, 5-fluorouracil, or phenylhydrazine, or by bleeding, or red cell transfusion.	phenylhydrazine	117-132	erythropoietin	Mus musculus	0-3
10028828-10	1998	Values of 1 alpha, 25(OH)2D3 and EPO were significantly high increased in the ethanol groups relative to the control.	Ethanol	78-85	erythropoietin	Mus musculus	33-36
9735323-4	1998	AZT-induced reduction in colony-forming unit-erythroid (CFU-E) and colony-forming unit-granulocyte monocyte (CFU-GM) were also reversed by the combined treatment of AZT and PA. PA treatment showed an increased level of erythropoietin in the blood plasma, and cellularity of spleen, thymus, and bonemarrow was also increased in the group receiving combined treatment (PA+AZT), higher than that in the AZT group.	Zidovudine	0-3	erythropoietin	Mus musculus	219-233
9735323-4	1998	AZT-induced reduction in colony-forming unit-erythroid (CFU-E) and colony-forming unit-granulocyte monocyte (CFU-GM) were also reversed by the combined treatment of AZT and PA. PA treatment showed an increased level of erythropoietin in the blood plasma, and cellularity of spleen, thymus, and bonemarrow was also increased in the group receiving combined treatment (PA+AZT), higher than that in the AZT group.	Zidovudine	165-168	erythropoietin	Mus musculus	219-233
9735323-4	1998	AZT-induced reduction in colony-forming unit-erythroid (CFU-E) and colony-forming unit-granulocyte monocyte (CFU-GM) were also reversed by the combined treatment of AZT and PA. PA treatment showed an increased level of erythropoietin in the blood plasma, and cellularity of spleen, thymus, and bonemarrow was also increased in the group receiving combined treatment (PA+AZT), higher than that in the AZT group.	Zidovudine	165-168	erythropoietin	Mus musculus	219-233
9735323-4	1998	AZT-induced reduction in colony-forming unit-erythroid (CFU-E) and colony-forming unit-granulocyte monocyte (CFU-GM) were also reversed by the combined treatment of AZT and PA. PA treatment showed an increased level of erythropoietin in the blood plasma, and cellularity of spleen, thymus, and bonemarrow was also increased in the group receiving combined treatment (PA+AZT), higher than that in the AZT group.	Zidovudine	165-168	erythropoietin	Mus musculus	219-233
9657741-4	1998	In fact, long-term proliferation studies performed in the absence of serum show that even at saturating concentrations of Epo, Ba/F3 cells expressing these truncated receptors die via apoptosis, while cells bearing WT EpoRs do not, and this programmed cell death correlates with an inability of Epo-stimulated Ba/F3 cells expressing truncated EpoRs to induce the tyrosine phosphorylation of MAPK and the activation of p70(S6K).	Tyrosine	363-371	erythropoietin	Mus musculus	122-125
9558407-1	1998	Hypoxic induction of erythropoietin (Epo) and other oxygen-dependent genes is mediated by the hypoxia-inducible factor-1 (HIF-1), a heterodimeric transactivator consisting of an alpha and a beta subunit.	Oxygen	52-58	erythropoietin	Mus musculus	21-35
9558407-1	1998	Hypoxic induction of erythropoietin (Epo) and other oxygen-dependent genes is mediated by the hypoxia-inducible factor-1 (HIF-1), a heterodimeric transactivator consisting of an alpha and a beta subunit.	Oxygen	52-58	erythropoietin	Mus musculus	37-40
9488432-4	1998	While the Janus protein tyrosine kinase JAK2 and the transcription factor STAT5 became tyrosine phosphorylated with the EPO stimulation in EPO-responsive erythroblastoid cells from anemic mice, JAK1 and STAT5 were constitutively tyrosine phosphorylated in all of these FVp gp55-induced erythroblastoid or erythroleukemic cells.	Tyrosine	24-32	erythropoietin	Mus musculus	139-142
9488432-4	1998	While the Janus protein tyrosine kinase JAK2 and the transcription factor STAT5 became tyrosine phosphorylated with the EPO stimulation in EPO-responsive erythroblastoid cells from anemic mice, JAK1 and STAT5 were constitutively tyrosine phosphorylated in all of these FVp gp55-induced erythroblastoid or erythroleukemic cells.	Tyrosine	87-95	erythropoietin	Mus musculus	120-123
9488432-4	1998	While the Janus protein tyrosine kinase JAK2 and the transcription factor STAT5 became tyrosine phosphorylated with the EPO stimulation in EPO-responsive erythroblastoid cells from anemic mice, JAK1 and STAT5 were constitutively tyrosine phosphorylated in all of these FVp gp55-induced erythroblastoid or erythroleukemic cells.	Tyrosine	87-95	erythropoietin	Mus musculus	139-142
9454745-6	1998	However, only gp55-P induces erythroid bursts from burst-forming unit-erythroid progenitors and only gp55-P induces Epo independence in Epo-dependent cell lines.	gp55-p	101-107	erythropoietin	Mus musculus	116-119
9454745-6	1998	However, only gp55-P induces erythroid bursts from burst-forming unit-erythroid progenitors and only gp55-P induces Epo independence in Epo-dependent cell lines.	gp55-p	101-107	erythropoietin	Mus musculus	136-139
9450795-4	1998	Epoetin beta also contained slightly more than epoetin alfa of EPO binding to Lycopersicon esculentum agglutinin (which binds N-glycans containing repeating Gal beta1-4GlcNAc sequences), to the leucoagglutinin of Phaseolus vulgaris (which binds tetraantennary and 2,6-branched triantennary N-glycans) and to Agaricus bisporus agglutinin (which binds Gal beta1-3GalNAc containing O-glycans).	n-glycans	126-135	erythropoietin	Mus musculus	63-66
9597146-2	1998	His early work on the quest for the cell that produces erythropoietin (Epo) to his current work on oxygen sensing and signal transduction pathways involved in erythropoietin gene expression are reported.	Oxygen	99-105	erythropoietin	Mus musculus	55-69
9597146-2	1998	His early work on the quest for the cell that produces erythropoietin (Epo) to his current work on oxygen sensing and signal transduction pathways involved in erythropoietin gene expression are reported.	Oxygen	99-105	erythropoietin	Mus musculus	159-173
9450795-4	1998	Epoetin beta also contained slightly more than epoetin alfa of EPO binding to Lycopersicon esculentum agglutinin (which binds N-glycans containing repeating Gal beta1-4GlcNAc sequences), to the leucoagglutinin of Phaseolus vulgaris (which binds tetraantennary and 2,6-branched triantennary N-glycans) and to Agaricus bisporus agglutinin (which binds Gal beta1-3GalNAc containing O-glycans).	gal beta1-4glcnac	157-174	erythropoietin	Mus musculus	63-66
9450795-4	1998	Epoetin beta also contained slightly more than epoetin alfa of EPO binding to Lycopersicon esculentum agglutinin (which binds N-glycans containing repeating Gal beta1-4GlcNAc sequences), to the leucoagglutinin of Phaseolus vulgaris (which binds tetraantennary and 2,6-branched triantennary N-glycans) and to Agaricus bisporus agglutinin (which binds Gal beta1-3GalNAc containing O-glycans).	n-glycans	290-299	erythropoietin	Mus musculus	63-66
9450795-4	1998	Epoetin beta also contained slightly more than epoetin alfa of EPO binding to Lycopersicon esculentum agglutinin (which binds N-glycans containing repeating Gal beta1-4GlcNAc sequences), to the leucoagglutinin of Phaseolus vulgaris (which binds tetraantennary and 2,6-branched triantennary N-glycans) and to Agaricus bisporus agglutinin (which binds Gal beta1-3GalNAc containing O-glycans).	o-glycans	379-388	erythropoietin	Mus musculus	63-66
9382954-0	1997	A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension.	Oxygen	81-87	erythropoietin	Mus musculus	49-63
9778688-0	1998	Role of gp55 in restoring the sensitivity of Friend murine erythroleukemia cells to erythropoietin by exposure to dimethyl sulfoxide.	Dimethyl Sulfoxide	114-132	erythropoietin	Mus musculus	84-98
9778688-3	1998	Dimethyl sulfoxide (DMSO) induced the differentiation of MEL cells and partially restored responsiveness to Epo, with both increased proliferation and further hemoglobin synthesis.	Dimethyl Sulfoxide	0-18	erythropoietin	Mus musculus	108-111
9778688-3	1998	Dimethyl sulfoxide (DMSO) induced the differentiation of MEL cells and partially restored responsiveness to Epo, with both increased proliferation and further hemoglobin synthesis.	Dimethyl Sulfoxide	20-24	erythropoietin	Mus musculus	108-111
9778688-4	1998	Treatment of MEL cells with DMSO caused a decrease in the cellular content of gp55 as measured by Western analysis and an increase in the level of the EpoR as measured by [125I]Epo binding.	Dimethyl Sulfoxide	28-32	erythropoietin	Mus musculus	151-154
9778688-7	1998	An increase in the level of gp55 interfered with the ability of DMSO to restore sensitivity to Epo, whereas a decrease in the level of gp55 increased the Epo-sensitizing effects of DMSO.	Dimethyl Sulfoxide	64-68	erythropoietin	Mus musculus	95-98
9778688-7	1998	An increase in the level of gp55 interfered with the ability of DMSO to restore sensitivity to Epo, whereas a decrease in the level of gp55 increased the Epo-sensitizing effects of DMSO.	Dimethyl Sulfoxide	181-185	erythropoietin	Mus musculus	154-157
9778688-9	1998	DMSO treatment caused an increase in the level of [125I]Epo cross-linking.	Dimethyl Sulfoxide	0-4	erythropoietin	Mus musculus	56-59
9778688-11	1998	The finding of a decrease in the cellular content of gp55, an increase in the level of the EpoR, and an increase in the formation of the Epo/EpoR complex is consistent with the acquisition of sensitivity to Epo by MEL cells following treatment with DMSO.	Dimethyl Sulfoxide	249-253	erythropoietin	Mus musculus	91-94
9778688-11	1998	The finding of a decrease in the cellular content of gp55, an increase in the level of the EpoR, and an increase in the formation of the Epo/EpoR complex is consistent with the acquisition of sensitivity to Epo by MEL cells following treatment with DMSO.	Dimethyl Sulfoxide	249-253	erythropoietin	Mus musculus	137-140
9419812-3	1997	It mediates tyrosine phosphorylation through its association with nonreceptor tyrosine kinases such as JAK2 and initiates a cascade of signalling events in response to erythropoietin.	Tyrosine	12-20	erythropoietin	Mus musculus	168-182
9428699-2	1997	Uptake of transferrin and iron doubled 24 h after exposure to erythropoietin, due to a twofold rise in surface transferrin receptors.	Iron	26-30	erythropoietin	Mus musculus	62-76
9428699-3	1997	In addition, a tenfold increase in iron incorporation into haem was observed after erythropoietin stimulation, as iron taken up from transferrin was directed towards haem biosynthesis and away from storage in ferritin.	Iron	35-39	erythropoietin	Mus musculus	83-97
9428699-3	1997	In addition, a tenfold increase in iron incorporation into haem was observed after erythropoietin stimulation, as iron taken up from transferrin was directed towards haem biosynthesis and away from storage in ferritin.	Iron	114-118	erythropoietin	Mus musculus	83-97
9428699-6	1997	We have shown previously that amiloride blocks erythropoietin-enhanced proliferation of J2E cells, but potentiates maturation [Callus, B.	Amiloride	30-39	erythropoietin	Mus musculus	47-61
9524923-0	1997	Erythropoietin stimulates nuclear localization of diacylglycerol and protein kinase C beta II in B6SUt.EP cells.	Diglycerides	50-64	erythropoietin	Mus musculus	0-14
9524923-2	1997	Although the membrane-bound receptor for EPO has no intrinsic kinase activity, it triggers the activation of protein kinases via phospholipases A2, C, and D. A cascade of serine and threonine kinases, including Raf-1, MAP kinase and protein kinase C (PKC) is activated following tyrosine phosphorylation.	Serine	171-177	erythropoietin	Mus musculus	41-44
9524923-2	1997	Although the membrane-bound receptor for EPO has no intrinsic kinase activity, it triggers the activation of protein kinases via phospholipases A2, C, and D. A cascade of serine and threonine kinases, including Raf-1, MAP kinase and protein kinase C (PKC) is activated following tyrosine phosphorylation.	Tyrosine	279-287	erythropoietin	Mus musculus	41-44
9524923-3	1997	In this study, we have examined whether changes in nuclear PKC and 1,2-diacylglycerol (DAG) are induced following EPO treatment of the murine target cell line, B6SUt.EP.	1,2-diacylglycerol	67-85	erythropoietin	Mus musculus	114-117
9524923-3	1997	In this study, we have examined whether changes in nuclear PKC and 1,2-diacylglycerol (DAG) are induced following EPO treatment of the murine target cell line, B6SUt.EP.	1,2-diacylglycerol	87-90	erythropoietin	Mus musculus	114-117
9524923-6	1997	These rapid increases in nuclear DAG and PKC beta II expression suggest a mechanism for EPO-induced changes in gene expression necessary for cell proliferation.	1,2-diacylglycerol	33-36	erythropoietin	Mus musculus	88-91
9359406-0	1997	Phosphorylation of erythropoietin receptors in the endoplasmic reticulum by pervanadate-mediated inhibition of tyrosine phosphatases.	pervanadate	76-87	erythropoietin	Mus musculus	19-33
9344843-0	1997	Erythropoietin and IL-3 induce tyrosine phosphorylation of CrkL and its association with Shc, SHP-2, and Cbl in hematopoietic cells.	Tyrosine	31-39	erythropoietin	Mus musculus	0-14
9344843-1	1997	The present study demonstrates that erythropoietin (Epo) and IL-3 induce tyrosine phosphorylation of the SH2/SH3-containing adapter protein CrkL and its transient association with tyrosine-phosphorylated SHP-2, Shc, and Cbl in a murine IL-3-dependent cell line, 32D, expressing the Epo receptor (EpoR).	Tyrosine	73-81	erythropoietin	Mus musculus	36-50
9344843-1	1997	The present study demonstrates that erythropoietin (Epo) and IL-3 induce tyrosine phosphorylation of the SH2/SH3-containing adapter protein CrkL and its transient association with tyrosine-phosphorylated SHP-2, Shc, and Cbl in a murine IL-3-dependent cell line, 32D, expressing the Epo receptor (EpoR).	Tyrosine	73-81	erythropoietin	Mus musculus	52-55
9344843-1	1997	The present study demonstrates that erythropoietin (Epo) and IL-3 induce tyrosine phosphorylation of the SH2/SH3-containing adapter protein CrkL and its transient association with tyrosine-phosphorylated SHP-2, Shc, and Cbl in a murine IL-3-dependent cell line, 32D, expressing the Epo receptor (EpoR).	Tyrosine	180-188	erythropoietin	Mus musculus	36-50
9344843-1	1997	The present study demonstrates that erythropoietin (Epo) and IL-3 induce tyrosine phosphorylation of the SH2/SH3-containing adapter protein CrkL and its transient association with tyrosine-phosphorylated SHP-2, Shc, and Cbl in a murine IL-3-dependent cell line, 32D, expressing the Epo receptor (EpoR).	Tyrosine	180-188	erythropoietin	Mus musculus	52-55
9344843-3	1997	Studies using cells expressing mutant EpoRs showed that the Epo-induced tyrosine phosphorylation of CrkL is dependent on the membrane-proximal EpoR cytoplasmic region involved in the activation of Jak2 as well as the C-terminal 145 amino acid region which is required for tyrosine phosphorylation of SHP-2 and Shc.	Tyrosine	72-80	erythropoietin	Mus musculus	38-41
9359406-5	1997	PV-mediated Tyr phosphorylation of EPO-R occurred at several intracellular sites including the endoplasmic reticulum (ER), because both endoglycosidase H (endo H)-resistant EPO-R and the ER-retained EPO-R mutant (DeltaWS1 EPO-R) were Tyr phosphorylated in response to PV.	Tyrosine	12-15	erythropoietin	Mus musculus	35-38
9359406-5	1997	PV-mediated Tyr phosphorylation of EPO-R occurred at several intracellular sites including the endoplasmic reticulum (ER), because both endoglycosidase H (endo H)-resistant EPO-R and the ER-retained EPO-R mutant (DeltaWS1 EPO-R) were Tyr phosphorylated in response to PV.	Tyrosine	12-15	erythropoietin	Mus musculus	173-176
9359406-5	1997	PV-mediated Tyr phosphorylation of EPO-R occurred at several intracellular sites including the endoplasmic reticulum (ER), because both endoglycosidase H (endo H)-resistant EPO-R and the ER-retained EPO-R mutant (DeltaWS1 EPO-R) were Tyr phosphorylated in response to PV.	Tyrosine	234-237	erythropoietin	Mus musculus	35-38
9129019-0	1997	Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins.	Tyrosine	42-50	erythropoietin	Mus musculus	0-14
9192787-3	1997	Our previous studies showed that, after 20 to 32 hours of culture in folate-deficient medium with 4 U/mL of erythropoietin, the folate-deficient proerythroblasts underwent apoptosis, whereas control erythroblasts survived and differentiated into reticulocytes over a period of 48 hours.	Folic Acid	69-75	erythropoietin	Mus musculus	108-122
9192789-4	1997	Hypersensitivity to Epo of erythroid progenitors from an affected individual was observed in in vitro methylcellulose cultures, as indicated by more numerous and larger colonies compared with those of a control subject.	Methylcellulose	102-117	erythropoietin	Mus musculus	20-23
9168989-3	1997	Here, we describe the roles of Stat5 and of these tyrosine residues in the EPOR in the erythroid differentiation of murine hematopoietic cell line SKT6 which produces hemoglobin in response to EPO.	Tyrosine	50-58	erythropoietin	Mus musculus	75-78
9310478-5	1997	Phosphorylation of tyrosyl residues of the EpoR, Stat5, and JAK2 occurred upon Epo stimulation in clones representing each category.	cyclo(tyrosyl-tyrosyl)	19-26	erythropoietin	Mus musculus	43-46
9364843-0	1997	[Establishment and characterization of a renal carcinoma cell line producing erythropoietin (effects of cyclic AMP on erythropoietin production in vitro)].	Cyclic AMP	104-114	erythropoietin	Mus musculus	77-91
9364843-0	1997	[Establishment and characterization of a renal carcinoma cell line producing erythropoietin (effects of cyclic AMP on erythropoietin production in vitro)].	Cyclic AMP	104-114	erythropoietin	Mus musculus	118-132
9192755-0	1997	Erythropoietin induces tyrosine phosphorylation of the interleukin-3 receptor beta subunit (betaIL3) and recruitment of Stat5 to possible Stat5-docking sites in betaIL3.	Tyrosine	23-31	erythropoietin	Mus musculus	0-14
9192755-3	1997	In the present study, we demonstrate that Epo stimulation induces unidirectional cross-phosphorylation of the IL-3 receptor beta subunit (betaIL3) on tyrosines and its rapid and transient association with Stat5 in murine IL-3-dependent cell lines engineered to express the Epo receptor (EpoR).	Tyrosine	150-159	erythropoietin	Mus musculus	42-45
9192755-4	1997	Using cell lines expressing various EpoR mutants, it was demonstrated that the Epo-induced tyrosine phosphorylation of betaIL3 is dependent on the membrane-proximal EpoR cytoplasmic region involved in the activation of Jak2, but not on the extracellular and transmembrane regions or on the carboxy-terminal 145 amino acid region containing all the intracellular tyrosine residues.	Tyrosine	91-99	erythropoietin	Mus musculus	36-39
9129019-4	1997	Erythropoietin (EPO) and interleukin-3 induced a dose and time-dependent tyrosine phosphorylation of Cbl in both EPO-dependent Ba/F3 and DA-3 transfectants, and the erythroid cell line HCD-57.	Tyrosine	73-81	erythropoietin	Mus musculus	0-14
9129019-4	1997	Erythropoietin (EPO) and interleukin-3 induced a dose and time-dependent tyrosine phosphorylation of Cbl in both EPO-dependent Ba/F3 and DA-3 transfectants, and the erythroid cell line HCD-57.	Tyrosine	73-81	erythropoietin	Mus musculus	16-19
9129019-4	1997	Erythropoietin (EPO) and interleukin-3 induced a dose and time-dependent tyrosine phosphorylation of Cbl in both EPO-dependent Ba/F3 and DA-3 transfectants, and the erythroid cell line HCD-57.	Tyrosine	73-81	erythropoietin	Mus musculus	113-116
9209412-0	1997	The role of erythropoietin receptor tyrosine phosphorylation in erythropoietin-induced proliferation.	Tyrosine	36-44	erythropoietin	Mus musculus	12-26
9130706-3	1997	We have shown previously that intracellular signalling is disrupted in the J2E-NR cell line and that tyrosine phosphorylation is dramatically reduced after erythropoietin stimulation.	Tyrosine	101-109	erythropoietin	Mus musculus	156-170
9130706-8	1997	Conversely, the ability of J2E cells to differentiate in response to epo was severely curtailed when antisense lyn oligonucleotides or a dominant negative lyn were introduced into the cells.	Oligonucleotides	115-131	erythropoietin	Mus musculus	69-72
9209412-0	1997	The role of erythropoietin receptor tyrosine phosphorylation in erythropoietin-induced proliferation.	Tyrosine	36-44	erythropoietin	Mus musculus	64-78
9209412-1	1997	Although studies with truncated erythropoietin receptors (EpoRs) have suggested the tyrosine phosphorylation (Yphos) of the EpoR may not play a significant role in Epo-induced proliferation, we found, using a full length EpoR mutant designed Null, in which all 8 of the intracellular tyrosines (Ys) were substituted with phenylalanines (Fs), that Null cells required 5-10 fold more Epo than wild type (WT) EpoR containing cells in order to proliferate as well.	Tyrosine	84-92	erythropoietin	Mus musculus	124-127
8977232-0	1996	Physical and functional interactions between Stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3.	Tyrosine	59-67	erythropoietin	Mus musculus	97-111
9096338-2	1997	Tyrosine phosphorylation of the EPO-R creates "docking sites" for SH2 domain(s) in signaling molecules such as the protein tyrosine phosphatases SH-PTP1 and SH-PTP2, phosphoinositide 3-kinase (PI3 kinase), and STAT5.	Tyrosine	0-8	erythropoietin	Mus musculus	32-35
9113417-2	1997	Here we present evidence that p70S6k is activated through both phosphatidylinositol (PI) 3-kinase-dependent and independent pathways: whereas the early phase of EPO-dependent stimulation of p70S6k activity was strongly suppressed by the potent PI 3-kinase inhibitor wortmannin, late phase was much less affected.	Phosphatidylinositols	63-83	erythropoietin	Mus musculus	161-164
9113417-2	1997	Here we present evidence that p70S6k is activated through both phosphatidylinositol (PI) 3-kinase-dependent and independent pathways: whereas the early phase of EPO-dependent stimulation of p70S6k activity was strongly suppressed by the potent PI 3-kinase inhibitor wortmannin, late phase was much less affected.	Wortmannin	266-276	erythropoietin	Mus musculus	161-164
9113417-3	1997	The dose-dependent inhibition of cell growth by wortmannin indicates an important role of PI 3-kinase in the mediation of EPO-induced cell proliferation.	Wortmannin	48-58	erythropoietin	Mus musculus	122-125
9017423-9	1997	Myotubes differentiation induced tTA expression, leading to a 28-fold increase of Epo mRNAs, which was suppressed by tetracycline.	Tetracycline	117-129	erythropoietin	Mus musculus	82-85
9017423-10	1997	Basal Epo secretion in myoblasts increased 23- to 41-fold during the formation of multinucleated myotubes, and turned back close to myoblast level when tetracycline was added.	Tetracycline	152-164	erythropoietin	Mus musculus	6-9
9055857-0	1997	Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts.	Doxycycline	49-60	erythropoietin	Mus musculus	21-35
9055857-4	1997	After transplantation of transduced cells into mouse skeletal muscles, Epo secretion could be iteratively switched on and off over a five-month period, depending on the presence or the absence of doxycycline in the drinking water.	Doxycycline	196-207	erythropoietin	Mus musculus	71-74
9029007-0	1997	Iron metabolism in transgenic mice with hypoplastic anaemia due to incomplete deficiency of erythropoietin.	Iron	0-4	erythropoietin	Mus musculus	92-106
9027714-1	1997	Although a great deal of evidence supports the hypothesis that plasma erythropoietin (EPO) levels of mammals are related to the oxygen supply to the tissues relative to their oxygen needs, several observation millitate against its inherent simplicity.	Oxygen	128-134	erythropoietin	Mus musculus	70-84
9027714-1	1997	Although a great deal of evidence supports the hypothesis that plasma erythropoietin (EPO) levels of mammals are related to the oxygen supply to the tissues relative to their oxygen needs, several observation millitate against its inherent simplicity.	Oxygen	128-134	erythropoietin	Mus musculus	86-89
9027714-1	1997	Although a great deal of evidence supports the hypothesis that plasma erythropoietin (EPO) levels of mammals are related to the oxygen supply to the tissues relative to their oxygen needs, several observation millitate against its inherent simplicity.	Oxygen	175-181	erythropoietin	Mus musculus	70-84
9027714-1	1997	Although a great deal of evidence supports the hypothesis that plasma erythropoietin (EPO) levels of mammals are related to the oxygen supply to the tissues relative to their oxygen needs, several observation millitate against its inherent simplicity.	Oxygen	175-181	erythropoietin	Mus musculus	86-89
9002972-4	1997	We show that, in human (K562) and murine erythroleukemic cells (MEL), Epo enhances the binding affinity of iron-regulatory protein (IRP)-1, the central regulator of cellular iron metabolism, to specific RNA stem-loop structures, known as iron-responsive elements (IREs).	Iron	107-111	erythropoietin	Mus musculus	70-73
9002972-4	1997	We show that, in human (K562) and murine erythroleukemic cells (MEL), Epo enhances the binding affinity of iron-regulatory protein (IRP)-1, the central regulator of cellular iron metabolism, to specific RNA stem-loop structures, known as iron-responsive elements (IREs).	Iron	174-178	erythropoietin	Mus musculus	70-73
9253112-4	1997	A strong correlation between the number of CFU-Mk and HPP-CFC formation from 5-fluorouracil bone marrow cells was observed when these cells were stimulated with EPO in the presence of SCF and IL-3.	Fluorouracil	77-91	erythropoietin	Mus musculus	161-164
8977232-1	1996	Erythropoietin (Epo) and interleukin-3 (IL-3) stimulate activation of the Jak2 tyrosine kinase and induce tyrosine phosphorylation and activation of Stat5.	Tyrosine	79-87	erythropoietin	Mus musculus	0-14
8977232-1	1996	Erythropoietin (Epo) and interleukin-3 (IL-3) stimulate activation of the Jak2 tyrosine kinase and induce tyrosine phosphorylation and activation of Stat5.	Tyrosine	79-87	erythropoietin	Mus musculus	16-19
8977232-2	1996	In the present study, we have shown that Epo or IL-3 stimulation induces binding of Stat5 to the tyrosine-phosphorylated Epo receptor (EpoR) or IL-3 receptor beta subunit (betaIL3), respectively, in IL-3-dependent 32D cells expressing the EpoR.	Tyrosine	97-105	erythropoietin	Mus musculus	41-44
8977232-2	1996	In the present study, we have shown that Epo or IL-3 stimulation induces binding of Stat5 to the tyrosine-phosphorylated Epo receptor (EpoR) or IL-3 receptor beta subunit (betaIL3), respectively, in IL-3-dependent 32D cells expressing the EpoR.	Tyrosine	97-105	erythropoietin	Mus musculus	121-124
8977240-7	1996	Tpo added to SCF + erythropoietin (Epo)-supplemented methylcellulose cultures potently enhanced the formation of multilineage colonies containing granulocytes, macrophages, erythrocytes, and Mks.	Methylcellulose	53-68	erythropoietin	Mus musculus	19-33
8977240-7	1996	Tpo added to SCF + erythropoietin (Epo)-supplemented methylcellulose cultures potently enhanced the formation of multilineage colonies containing granulocytes, macrophages, erythrocytes, and Mks.	Methylcellulose	53-68	erythropoietin	Mus musculus	35-38
8790155-0	1996	Parenteral iron increases serum erythropoietin concentration during the "early anaemia" of 10-20-day-old mice.	Iron	11-15	erythropoietin	Mus musculus	32-46
8943308-4	1996	We found that the 78-kDa erythropoietin receptor (EPOR), a highly modified form of the 66-kDa receptor which is abundant in HCD57 cells, was phosphorylated on serine residues without EPO stimulation.	Serine	159-165	erythropoietin	Mus musculus	50-53
8943308-8	1996	These data suggest that phosphorylation of either serine or tyrosine residues of the EPOR can enhance the association of the receptor with JAK2, possibly increasing the sensitivity to EPO.	Serine	50-56	erythropoietin	Mus musculus	85-88
8943308-8	1996	These data suggest that phosphorylation of either serine or tyrosine residues of the EPOR can enhance the association of the receptor with JAK2, possibly increasing the sensitivity to EPO.	Tyrosine	60-68	erythropoietin	Mus musculus	85-88
8943354-9	1996	Interestingly, association of the SH2n domain of SHP-1 with the tyrosine phosphorylated erythropoietin receptor modestly potentiated but was not essential for SHP-1-mediated dephosphorylation of Jak2 and had no effect on c-fes phosphorylation.	Tyrosine	64-72	erythropoietin	Mus musculus	88-102
8906421-0	1996	Erythropoietin in mouse avascular yolk sacs is increased by retinoic acid.	Tretinoin	60-73	erythropoietin	Mus musculus	0-14
8906421-14	1996	EPO and EPR appear to be synthesized in the endodermal cells of the VYSs that are likely to respond to the circumstances induced by RA.	Tretinoin	132-134	erythropoietin	Mus musculus	0-3
8790155-2	1996	In the present study we examined the effect of parenteral iron upon serum immunoreactive erythropoietin (siEpo) concentration in young mice (age 6-24d) and in adult iron-deficient mice.	Iron	58-62	erythropoietin	Mus musculus	89-103
8695792-2	1996	An arginine to cysteine (R129C) mutation of the extracytoplasmic domain of the murine EpoR leads to Epo-independent growth in transduced cells (cEpoR).	Arginine	3-11	erythropoietin	Mus musculus	86-89
8695792-2	1996	An arginine to cysteine (R129C) mutation of the extracytoplasmic domain of the murine EpoR leads to Epo-independent growth in transduced cells (cEpoR).	Cysteine	15-23	erythropoietin	Mus musculus	86-89
8695792-7	1996	Furthermore, the functional hybrid receptors showed Epo-dependent (nE beta) or constitutive (cE alpha and cE beta) tyrosine phosphorylation of the cytoplasmic kinases JAK1 and JAK2.	Tyrosine	115-123	erythropoietin	Mus musculus	52-55
8662717-7	1996	The erythropoietin-induced down-regulation of c-myb mRNA levels could be demonstrated also in the presence of EGTA and was resistant to calmodulin antagonists and cyclosporin A.	Egtazic Acid	110-114	erythropoietin	Mus musculus	4-18
8774484-0	1996	Localization of erythropoietin gene expression in proximal renal tubular cells detected by digoxigenin-labelled oligonucleotide probes.	Digoxigenin	91-102	erythropoietin	Mus musculus	16-30
8774484-0	1996	Localization of erythropoietin gene expression in proximal renal tubular cells detected by digoxigenin-labelled oligonucleotide probes.	Oligonucleotides	112-127	erythropoietin	Mus musculus	16-30
8774484-7	1996	Six digoxigenin-labelled oligonucleotide probes complementary to EPO exon sequences were utilized for in situ hybridization for EPO messenger RNA.	Digoxigenin	4-15	erythropoietin	Mus musculus	128-131
8774484-7	1996	Six digoxigenin-labelled oligonucleotide probes complementary to EPO exon sequences were utilized for in situ hybridization for EPO messenger RNA.	Oligonucleotides	25-40	erythropoietin	Mus musculus	128-131
8756083-1	1996	Injection of bacterial endotoxin or granulocyte/macrophage colony-stimulating factor (GM-CSF) into exhypoxic polycythemic mice simultaneously with erythropoietin (EPO) suppressed erythroid cell formation, as monitored by 59Fe incorporation into circulating red blood cells.	Iron-59	221-225	erythropoietin	Mus musculus	163-166
8662717-7	1996	The erythropoietin-induced down-regulation of c-myb mRNA levels could be demonstrated also in the presence of EGTA and was resistant to calmodulin antagonists and cyclosporin A.	Cyclosporine	163-176	erythropoietin	Mus musculus	4-18
9081618-5	1996	Exposure to a low level of oxygen led to elevated erythropoietin mRNA levels in the monkey brain, as did anaemia in the mouse brain.	Oxygen	27-33	erythropoietin	Mus musculus	50-64
8645341-2	1996	Here, we show that the immunosuppressant rapamycin inhibited basal- as well as erythropoietin-stimulated proliferation of the erythroid cell line J2E.	Sirolimus	41-50	erythropoietin	Mus musculus	79-93
8660378-1	1996	The heterodimeric hypoxia-inducible transcription factor HIF-1 is involved in the oxygen-regulated transcription of several genes including erythropoietin.	Oxygen	82-88	erythropoietin	Mus musculus	140-154
8639815-0	1996	Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis.	Tyrosine	0-8	erythropoietin	Mus musculus	34-48
8639815-0	1996	Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis.	Tyrosine	113-121	erythropoietin	Mus musculus	34-48
8639815-1	1996	Erythropoietin (Epo), the primary in vivo stimulator of erythroid proliferation and differentiation, acts, in part, by altering the tyrosine phosphorylation levels of various intracellular signaling molecules.	Tyrosine	132-140	erythropoietin	Mus musculus	0-14
8639815-1	1996	Erythropoietin (Epo), the primary in vivo stimulator of erythroid proliferation and differentiation, acts, in part, by altering the tyrosine phosphorylation levels of various intracellular signaling molecules.	Tyrosine	132-140	erythropoietin	Mus musculus	16-19
8639815-7	1996	Moreover, Y425 in the EpoR reduces the Epo requirement for Syp tyrosine phosphorylation and promotes proliferation.	y425	10-14	erythropoietin	Mus musculus	22-25
8639815-7	1996	Moreover, Y425 in the EpoR reduces the Epo requirement for Syp tyrosine phosphorylation and promotes proliferation.	Tyrosine	63-71	erythropoietin	Mus musculus	22-25
8665851-0	1996	Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation.	Tyrosine	18-26	erythropoietin	Mus musculus	75-89
8665851-4	1996	Erythropoietin-induced activation of STAT5 was strongly reduced in cells expressing mutated variants of the erythropoietin receptors in which tyrosine residues in their intracellular domain have been eliminated.	Tyrosine	142-150	erythropoietin	Mus musculus	0-14
8665851-4	1996	Erythropoietin-induced activation of STAT5 was strongly reduced in cells expressing mutated variants of the erythropoietin receptors in which tyrosine residues in their intracellular domain have been eliminated.	Tyrosine	142-150	erythropoietin	Mus musculus	108-122
8665851-5	1996	We determined that the erythropoietin receptor tyrosine residues 343 and 401 are independently necessary for STAT5 activation.	Tyrosine	47-55	erythropoietin	Mus musculus	23-37
8665851-8	1996	We propose that these two tyrosine residues of the erythropoietin receptor constitute docking sites for the STAT5 SH2 domain.	Tyrosine	26-34	erythropoietin	Mus musculus	51-65
9081618-8	1996	When incubated at 1% oxygen, astrocytes showed >100-fold time-dependent erythropoietin mRNA accumulation, as measured with the quantitative reverse transcription-polymerase chain reaction.	Oxygen	21-27	erythropoietin	Mus musculus	75-89
8615780-1	1996	A murine haematopoietic stem-cell line, B6SUt.EP, responsive to erythropoietin (EPO), has been found to exhibit both early and late changes in diacylglycerol (DAG) and phosphatidic acid (PA) as measured by HPLC and TLC.	Diglycerides	143-157	erythropoietin	Mus musculus	64-78
8615780-1	1996	A murine haematopoietic stem-cell line, B6SUt.EP, responsive to erythropoietin (EPO), has been found to exhibit both early and late changes in diacylglycerol (DAG) and phosphatidic acid (PA) as measured by HPLC and TLC.	Diglycerides	143-157	erythropoietin	Mus musculus	80-83
8615780-1	1996	A murine haematopoietic stem-cell line, B6SUt.EP, responsive to erythropoietin (EPO), has been found to exhibit both early and late changes in diacylglycerol (DAG) and phosphatidic acid (PA) as measured by HPLC and TLC.	Diglycerides	159-162	erythropoietin	Mus musculus	64-78
8615780-1	1996	A murine haematopoietic stem-cell line, B6SUt.EP, responsive to erythropoietin (EPO), has been found to exhibit both early and late changes in diacylglycerol (DAG) and phosphatidic acid (PA) as measured by HPLC and TLC.	Diglycerides	159-162	erythropoietin	Mus musculus	80-83
8615780-1	1996	A murine haematopoietic stem-cell line, B6SUt.EP, responsive to erythropoietin (EPO), has been found to exhibit both early and late changes in diacylglycerol (DAG) and phosphatidic acid (PA) as measured by HPLC and TLC.	Phosphatidic Acids	168-185	erythropoietin	Mus musculus	64-78
8615780-1	1996	A murine haematopoietic stem-cell line, B6SUt.EP, responsive to erythropoietin (EPO), has been found to exhibit both early and late changes in diacylglycerol (DAG) and phosphatidic acid (PA) as measured by HPLC and TLC.	Phosphatidic Acids	187-189	erythropoietin	Mus musculus	64-78
8615780-7	1996	In the presence of EPO and GTP[S], PA levels increased to 64.8 micrograms.	Phosphatidic Acids	35-37	erythropoietin	Mus musculus	19-22
8615780-8	1996	An antagonist of G-proteins, guanosine 5"[beta-thio]diphosphate (GDP[S]), had no effect on control levels of PA (5.9 micrograms/10(6) cells) but blocked the effect of EPO on PA (30.6 micrograms/10(6) cells).	6-thioguanosine 5'-diphosphate	29-63	erythropoietin	Mus musculus	167-170
8615780-8	1996	An antagonist of G-proteins, guanosine 5"[beta-thio]diphosphate (GDP[S]), had no effect on control levels of PA (5.9 micrograms/10(6) cells) but blocked the effect of EPO on PA (30.6 micrograms/10(6) cells).	Phosphatidic Acids	174-176	erythropoietin	Mus musculus	167-170
8615780-9	1996	Thus, EPO stimulated both lipid second messengers, DAG and PA.	Diglycerides	51-54	erythropoietin	Mus musculus	6-9
8615780-9	1996	Thus, EPO stimulated both lipid second messengers, DAG and PA.	Phosphatidic Acids	59-61	erythropoietin	Mus musculus	6-9
8615780-10	1996	Our results demonstrate DAG kinetics to be biphasic, as observed with a high concentration of EPO, or monophasic, as observed with low concentrations of EPO.	Diglycerides	24-27	erythropoietin	Mus musculus	94-97
8615780-10	1996	Our results demonstrate DAG kinetics to be biphasic, as observed with a high concentration of EPO, or monophasic, as observed with low concentrations of EPO.	Diglycerides	24-27	erythropoietin	Mus musculus	153-156
8615780-13	1996	In addition, phospholipase D (PLD) activation was demonstrated with a maximal increase in phosphatidylethanol at 5 min, suggesting the EPO increases PA via a guanine nucleotide-binding protein coupled to PLD.	phosphatidylethanol	90-109	erythropoietin	Mus musculus	135-138
8615780-13	1996	In addition, phospholipase D (PLD) activation was demonstrated with a maximal increase in phosphatidylethanol at 5 min, suggesting the EPO increases PA via a guanine nucleotide-binding protein coupled to PLD.	Phosphatidic Acids	149-151	erythropoietin	Mus musculus	135-138
8615781-0	1996	Molecular species of phospholipids in a murine stem-cell line responsive to erythropoietin.	Phospholipids	21-34	erythropoietin	Mus musculus	76-90
8615781-1	1996	The generation of the lipid signalling molecules, diacylglycerol (DAG) and phosphatidic acid (PA), has been implicated in the transduction events essential for proliferation of murine B6SUt.EP stem cells responsive to erythropoietin (EPO).	Diglycerides	50-64	erythropoietin	Mus musculus	218-232
8615781-1	1996	The generation of the lipid signalling molecules, diacylglycerol (DAG) and phosphatidic acid (PA), has been implicated in the transduction events essential for proliferation of murine B6SUt.EP stem cells responsive to erythropoietin (EPO).	Diglycerides	50-64	erythropoietin	Mus musculus	234-237
8615781-1	1996	The generation of the lipid signalling molecules, diacylglycerol (DAG) and phosphatidic acid (PA), has been implicated in the transduction events essential for proliferation of murine B6SUt.EP stem cells responsive to erythropoietin (EPO).	Phosphatidic Acids	75-92	erythropoietin	Mus musculus	218-232
8615781-1	1996	The generation of the lipid signalling molecules, diacylglycerol (DAG) and phosphatidic acid (PA), has been implicated in the transduction events essential for proliferation of murine B6SUt.EP stem cells responsive to erythropoietin (EPO).	Phosphatidic Acids	75-92	erythropoietin	Mus musculus	234-237
8615781-1	1996	The generation of the lipid signalling molecules, diacylglycerol (DAG) and phosphatidic acid (PA), has been implicated in the transduction events essential for proliferation of murine B6SUt.EP stem cells responsive to erythropoietin (EPO).	Phosphatidic Acids	94-96	erythropoietin	Mus musculus	218-232
8615781-1	1996	The generation of the lipid signalling molecules, diacylglycerol (DAG) and phosphatidic acid (PA), has been implicated in the transduction events essential for proliferation of murine B6SUt.EP stem cells responsive to erythropoietin (EPO).	Phosphatidic Acids	94-96	erythropoietin	Mus musculus	234-237
8615781-3	1996	In an attempt to better understand the biphasic nature of DAG and PA appearance in response to EPO, an analysis of the molecular species of DAG, phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and PA in control and EPO-treated B6SUt.EP cells was made by HPLC and TLC.	Diglycerides	58-61	erythropoietin	Mus musculus	95-98
8615781-3	1996	In an attempt to better understand the biphasic nature of DAG and PA appearance in response to EPO, an analysis of the molecular species of DAG, phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and PA in control and EPO-treated B6SUt.EP cells was made by HPLC and TLC.	Phosphatidic Acids	66-68	erythropoietin	Mus musculus	95-98
8615781-7	1996	Comparison of the increase in DAG species caused by EPO with the molecular species present in PC and PI showed both PI and PC as the source of the fast DAG accumulation and only PC as the source of the slow DAG accumulation.	Diglycerides	30-33	erythropoietin	Mus musculus	52-55
8615781-10	1996	In addition, changes in molecular species of PA in response to EPO suggest that PI cannot account for the mass of PA formed during the first 30 s incubation with EPO, nor for PA formed during 30 min with EPO.	Phosphatidic Acids	45-47	erythropoietin	Mus musculus	63-66
8729004-10	1996	66-70 kDa, but immunoprecipitation of [35S]methionine/cysteine labelled cell lysates with an antibody to the amino-terminus of the erythropoietin receptor identified a truncated 37 kDa protein in F4N cells.	Sulfur-35	39-42	erythropoietin	Mus musculus	131-145
9052992-4	1996	The importance of JAK2 to J2E cell maturation was demonstrated by inhibiting JAK2 protein synthesis with antisense oligonucleotides; not only was erythropoietin-stimulated mitogenesis inhibited by this procedure, but differentiation was also suppressed.	Oligonucleotides	115-131	erythropoietin	Mus musculus	146-160
8599970-5	1996	Furthermore, when lentinan administration was followed by administration of erythropoietin (Epo) in 5-FU-treated mice, increases in femoral marrow and splenic CFU-E formation and augmentation of reticulocyte counts were observed beyond the level observed in mice treated with Epo alone.	Lentinan	18-26	erythropoietin	Mus musculus	76-90
8599970-5	1996	Furthermore, when lentinan administration was followed by administration of erythropoietin (Epo) in 5-FU-treated mice, increases in femoral marrow and splenic CFU-E formation and augmentation of reticulocyte counts were observed beyond the level observed in mice treated with Epo alone.	Lentinan	18-26	erythropoietin	Mus musculus	92-95
8599970-5	1996	Furthermore, when lentinan administration was followed by administration of erythropoietin (Epo) in 5-FU-treated mice, increases in femoral marrow and splenic CFU-E formation and augmentation of reticulocyte counts were observed beyond the level observed in mice treated with Epo alone.	Lentinan	18-26	erythropoietin	Mus musculus	276-279
8599970-5	1996	Furthermore, when lentinan administration was followed by administration of erythropoietin (Epo) in 5-FU-treated mice, increases in femoral marrow and splenic CFU-E formation and augmentation of reticulocyte counts were observed beyond the level observed in mice treated with Epo alone.	Fluorouracil	100-104	erythropoietin	Mus musculus	76-90
8599970-5	1996	Furthermore, when lentinan administration was followed by administration of erythropoietin (Epo) in 5-FU-treated mice, increases in femoral marrow and splenic CFU-E formation and augmentation of reticulocyte counts were observed beyond the level observed in mice treated with Epo alone.	Fluorouracil	100-104	erythropoietin	Mus musculus	92-95
8599970-5	1996	Furthermore, when lentinan administration was followed by administration of erythropoietin (Epo) in 5-FU-treated mice, increases in femoral marrow and splenic CFU-E formation and augmentation of reticulocyte counts were observed beyond the level observed in mice treated with Epo alone.	Fluorouracil	100-104	erythropoietin	Mus musculus	276-279
8599971-4	1996	Phosphoamino acid analysis and tryptic phosphopeptide map analysis of eIF-4E isolated from both control and erythropoietin-treated cells identified a predominant phosphopeptide containing phosphoserine.	Phosphoserine	188-201	erythropoietin	Mus musculus	108-122
8729004-10	1996	66-70 kDa, but immunoprecipitation of [35S]methionine/cysteine labelled cell lysates with an antibody to the amino-terminus of the erythropoietin receptor identified a truncated 37 kDa protein in F4N cells.	Methionine	43-53	erythropoietin	Mus musculus	131-145
8729004-10	1996	66-70 kDa, but immunoprecipitation of [35S]methionine/cysteine labelled cell lysates with an antibody to the amino-terminus of the erythropoietin receptor identified a truncated 37 kDa protein in F4N cells.	Cysteine	54-62	erythropoietin	Mus musculus	131-145
8570210-2	1996	A drug-selectable retrovirus expressing p135Gag-Myb-Ets induced an erythropoietin(Epo)-responsive phenotype in the cell lines FDC-P2, BaF3 and 32Dc123.	fdc-p2	126-132	erythropoietin	Mus musculus	67-81
8570210-2	1996	A drug-selectable retrovirus expressing p135Gag-Myb-Ets induced an erythropoietin(Epo)-responsive phenotype in the cell lines FDC-P2, BaF3 and 32Dc123.	fdc-p2	126-132	erythropoietin	Mus musculus	82-85
8537396-0	1995	Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells.	Tyrosine	27-35	erythropoietin	Mus musculus	0-14
27406619-2	1996	The present study was thus designed to investigate EPO production during acute hypoxemia in a mouse model in which the oxygen-carrying capacity of blood, the plasma EPO level, and the plasma EPO half-life were within normal values in spite of a marked depression of the red cell production rate (RCPR) induced by cyclophosphamide (CP) administration.	Oxygen	119-125	erythropoietin	Mus musculus	51-54
27406619-2	1996	The present study was thus designed to investigate EPO production during acute hypoxemia in a mouse model in which the oxygen-carrying capacity of blood, the plasma EPO level, and the plasma EPO half-life were within normal values in spite of a marked depression of the red cell production rate (RCPR) induced by cyclophosphamide (CP) administration.	Cyclophosphamide	313-329	erythropoietin	Mus musculus	51-54
27406619-5	1996	The results support the hypothesis that the EPO production rate in mammals is not only related to the oxygen supply to the tissues relative to their oxygen needs (main stimulus) but also to the erythroid activity of the marrow (modulatory action).	Oxygen	102-108	erythropoietin	Mus musculus	44-47
27406619-5	1996	The results support the hypothesis that the EPO production rate in mammals is not only related to the oxygen supply to the tissues relative to their oxygen needs (main stimulus) but also to the erythroid activity of the marrow (modulatory action).	Oxygen	149-155	erythropoietin	Mus musculus	44-47
9085366-0	1996	Products of red blood cell degradation inhibit responsiveness of the erythropoietin oxygen sensor.	Oxygen	84-90	erythropoietin	Mus musculus	69-83
8788116-3	1995	In normal mice receiving AZT, an increase in only plasma erythropoietin and not GM-CSF, Meg-CSF or TNF-alpha has been reported.	Zidovudine	25-28	erythropoietin	Mus musculus	57-71
8647512-3	1995	The present study was thus designed to investigate EPO production during acute hypoxemia in a mouse model in which the oxygen-carrying capacity of blood, the plasma EPO level, the blood viscosity and the plasma EPO half-life are within normal values in spite of an intense stimulation of erythropoiesis.	Oxygen	119-125	erythropoietin	Mus musculus	51-54
8647512-10	1995	injection of the hormone and sampling by cardiac puncture every hour for 6 h. RESULTS: Administration of rhEPO to mice increased splenic 59Fe uptake significantly without affecting the hematocrit, the plasma EPO level or the plasma disappearance of radiolabeled EPO.	Iron-59	137-141	erythropoietin	Mus musculus	107-110
8521814-4	1995	This domain appears to be functionally conserved in the erythropoietin (EPO) receptor because substitution of cysteines for residues in the analogous region causes EPO-independent receptor activation via disulfide-linked homodimerization.	Cysteine	110-119	erythropoietin	Mus musculus	56-70
8521814-4	1995	This domain appears to be functionally conserved in the erythropoietin (EPO) receptor because substitution of cysteines for residues in the analogous region causes EPO-independent receptor activation via disulfide-linked homodimerization.	Cysteine	110-119	erythropoietin	Mus musculus	72-75
8521814-4	1995	This domain appears to be functionally conserved in the erythropoietin (EPO) receptor because substitution of cysteines for residues in the analogous region causes EPO-independent receptor activation via disulfide-linked homodimerization.	Cysteine	110-119	erythropoietin	Mus musculus	164-167
8521814-4	1995	This domain appears to be functionally conserved in the erythropoietin (EPO) receptor because substitution of cysteines for residues in the analogous region causes EPO-independent receptor activation via disulfide-linked homodimerization.	Disulfides	204-213	erythropoietin	Mus musculus	56-70
8521814-4	1995	This domain appears to be functionally conserved in the erythropoietin (EPO) receptor because substitution of cysteines for residues in the analogous region causes EPO-independent receptor activation via disulfide-linked homodimerization.	Disulfides	204-213	erythropoietin	Mus musculus	72-75
8521814-4	1995	This domain appears to be functionally conserved in the erythropoietin (EPO) receptor because substitution of cysteines for residues in the analogous region causes EPO-independent receptor activation via disulfide-linked homodimerization.	Disulfides	204-213	erythropoietin	Mus musculus	164-167
8746957-2	1995	The bioactivity of EPO was measured in the assay by its stimulatory effect on 125I-deoxyuridine incorporation in spleen cells from phenylhydrazine-treated mice.	125i-deoxyuridine	78-95	erythropoietin	Mus musculus	19-22
7559499-6	1995	A comparison of erythropoietin-induced tyrosine phosphorylations and proliferation of wild-type and Y503F EpR-infected DA-3 cells revealed no differences.	Tyrosine	39-47	erythropoietin	Mus musculus	16-30
8746957-2	1995	The bioactivity of EPO was measured in the assay by its stimulatory effect on 125I-deoxyuridine incorporation in spleen cells from phenylhydrazine-treated mice.	phenylhydrazine	131-146	erythropoietin	Mus musculus	19-22
7559499-7	1995	However, the PI-3 kinase inhibitor, wortmannin, markedly inhibited the erythropoietin-induced proliferation of both cell types, suggesting that PI 3-kinase is activated in Y503F EpR expressing cells.	Wortmannin	36-46	erythropoietin	Mus musculus	71-85
7559499-8	1995	This was confirmed by carrying out PI 3-kinase assays with anti-phosphotyrosine immunoprecipitates from erythropoietin-stimulated Y503F EpR-infected DA-3 cells and suggested that PI 3-kinase has a role in regulating erythropoietin-induced proliferation, but at a site distinct from the EpR.	Phosphotyrosine	64-79	erythropoietin	Mus musculus	104-118
7559499-8	1995	This was confirmed by carrying out PI 3-kinase assays with anti-phosphotyrosine immunoprecipitates from erythropoietin-stimulated Y503F EpR-infected DA-3 cells and suggested that PI 3-kinase has a role in regulating erythropoietin-induced proliferation, but at a site distinct from the EpR.	Phosphotyrosine	64-79	erythropoietin	Mus musculus	216-230
7673128-2	1995	The oxygen-regulated control system responsible for the induction of erythropoietin (Epo) by hypoxia is present in most (if not all) cells and operates on other genes, including those involved in energy metabolism.	Oxygen	4-10	erythropoietin	Mus musculus	69-83
7545788-6	1995	In HCD57 cells, SCF rapidly induces tyrosine phosphorylation of the EPO receptor, and KIT physically associates with the extended box 2 region in the cytoplasmic domain of the EPO receptor.	Tyrosine	36-44	erythropoietin	Mus musculus	68-71
7545788-7	1995	Our results indicate that KIT may activate the EPO receptor by tyrosine phosphorylation to induce further proliferation and maturation of CFU-Es.	Tyrosine	63-71	erythropoietin	Mus musculus	47-50
7570600-10	1995	When erythropoietin was injected into the polyemia mice prior to CdCl2, the concentration of Cd-MT in spleen increased about sixfold.	Cadmium Chloride	65-70	erythropoietin	Mus musculus	5-19
7570600-10	1995	When erythropoietin was injected into the polyemia mice prior to CdCl2, the concentration of Cd-MT in spleen increased about sixfold.	D-4-chloro-17 beta-hydroxy-3-oxo-17 alpha-methylandrosta-1,4-diene	93-98	erythropoietin	Mus musculus	5-19
7673128-2	1995	The oxygen-regulated control system responsible for the induction of erythropoietin (Epo) by hypoxia is present in most (if not all) cells and operates on other genes, including those involved in energy metabolism.	Oxygen	4-10	erythropoietin	Mus musculus	85-88
7665979-2	1995	Intravenous injections of CGS-21680 (100 to 500 nmol/kg mouse/day) and DPMA (50 to 500 nmol/kg mouse/day) for 4 days produced significant increases in serum levels of EPO in exhypoxic polycythemic mice.	cysteinylglycine	26-29	erythropoietin	Mus musculus	167-170
7665979-2	1995	Intravenous injections of CGS-21680 (100 to 500 nmol/kg mouse/day) and DPMA (50 to 500 nmol/kg mouse/day) for 4 days produced significant increases in serum levels of EPO in exhypoxic polycythemic mice.	CGS 24012	71-75	erythropoietin	Mus musculus	167-170
7646543-5	1995	AZT caused a concentration-dependent inhibition in the levels of the mRNA of Epo receptors and c-fos, whereas the level of c-myc mRNA was unaffected.	Zidovudine	0-3	erythropoietin	Mus musculus	77-80
7646543-7	1995	Simultaneous addition of Epo or interleukin-3 (IL-3) partially reversed the inhibitory effects of AZT on the levels of the mRNAs and on PKC activity; however, a combination of Epo and IL-3 was significantly more effective.	Zidovudine	98-101	erythropoietin	Mus musculus	25-28
7646543-8	1995	These studies demonstrate that (i) AZT-induced down-regulation of Epo receptors and c-fos expression coupled with inhibition of Epo receptor-mediated signal transduction through PKC are significant contributory factors to AZT-induced erythroid toxicity, and (ii) these inhibitory effects can be overcome by treatment with a combination of Epo and IL-3.	Zidovudine	35-38	erythropoietin	Mus musculus	66-69
7646543-8	1995	These studies demonstrate that (i) AZT-induced down-regulation of Epo receptors and c-fos expression coupled with inhibition of Epo receptor-mediated signal transduction through PKC are significant contributory factors to AZT-induced erythroid toxicity, and (ii) these inhibitory effects can be overcome by treatment with a combination of Epo and IL-3.	Zidovudine	35-38	erythropoietin	Mus musculus	128-131
7646543-8	1995	These studies demonstrate that (i) AZT-induced down-regulation of Epo receptors and c-fos expression coupled with inhibition of Epo receptor-mediated signal transduction through PKC are significant contributory factors to AZT-induced erythroid toxicity, and (ii) these inhibitory effects can be overcome by treatment with a combination of Epo and IL-3.	Zidovudine	35-38	erythropoietin	Mus musculus	128-131
7646543-8	1995	These studies demonstrate that (i) AZT-induced down-regulation of Epo receptors and c-fos expression coupled with inhibition of Epo receptor-mediated signal transduction through PKC are significant contributory factors to AZT-induced erythroid toxicity, and (ii) these inhibitory effects can be overcome by treatment with a combination of Epo and IL-3.	Zidovudine	222-225	erythropoietin	Mus musculus	66-69
7646543-8	1995	These studies demonstrate that (i) AZT-induced down-regulation of Epo receptors and c-fos expression coupled with inhibition of Epo receptor-mediated signal transduction through PKC are significant contributory factors to AZT-induced erythroid toxicity, and (ii) these inhibitory effects can be overcome by treatment with a combination of Epo and IL-3.	Zidovudine	222-225	erythropoietin	Mus musculus	128-131
7646543-8	1995	These studies demonstrate that (i) AZT-induced down-regulation of Epo receptors and c-fos expression coupled with inhibition of Epo receptor-mediated signal transduction through PKC are significant contributory factors to AZT-induced erythroid toxicity, and (ii) these inhibitory effects can be overcome by treatment with a combination of Epo and IL-3.	Zidovudine	222-225	erythropoietin	Mus musculus	128-131
7731971-5	1995	Exposure to 0.1% carbon monoxide, a procedure that causes functional anemia, resulted in a 20-fold increase of EPO mRNA in mouse brain as quantified by competitive reverse transcription-PCR, whereas the EPO-R mRNA level was not influenced by hypoxia.	Carbon Monoxide	17-32	erythropoietin	Mus musculus	111-114
20650109-6	1995	DAF-positive cells appeared at day 5-6 of differentiation, whereas EPO mRNA was found in undifferentiated ES cells and in EBs at all stages of differentiation.	Einsteinium	106-108	erythropoietin	Mus musculus	67-70
7601257-4	1995	Similarly, murine post-5 fluorouracil (5-FU) bone marrow cells or fetal liver cells, induced to express EpoR and stimulated by Epo, displayed a significant enhancement of megakaryocyte colony formation, particularly of the BFU-megakaryocyte (BFU-Mk) colony type.	Fluorouracil	25-37	erythropoietin	Mus musculus	104-107
7601257-4	1995	Similarly, murine post-5 fluorouracil (5-FU) bone marrow cells or fetal liver cells, induced to express EpoR and stimulated by Epo, displayed a significant enhancement of megakaryocyte colony formation, particularly of the BFU-megakaryocyte (BFU-Mk) colony type.	Fluorouracil	39-43	erythropoietin	Mus musculus	104-107
7541671-0	1995	Tyrosine phosphorylation of the erythropoietin receptor: role for differentiation and mitogenic signal transduction.	Tyrosine	0-8	erythropoietin	Mus musculus	32-46
7541671-3	1995	We and others have shown that Epo induces the tyrosine phosphorylation of its cognate receptor as well as phosphorylation of other proteins.	Tyrosine	46-54	erythropoietin	Mus musculus	30-33
7541671-5	1995	Eight tyrosine residues are located within the intracellular domain of the murine Epo receptor.	Tyrosine	6-14	erythropoietin	Mus musculus	82-85
7541671-12	1995	The mutated receptors all induced the tyrosine phosphorylation of several cellular proteins after Epo stimulation.	Tyrosine	38-46	erythropoietin	Mus musculus	98-101
7543055-0	1995	Amiloride suppresses erythropoietin-induced proliferation and MAP kinase, but potentiates differentiation of J2E cells.	Amiloride	0-9	erythropoietin	Mus musculus	21-35
7543055-5	1995	In marked contrast, epo-initiated differentiation was potentiated when J2E cells were cultured with the drug: the number of benzidine-positive cells increased, hemoglobin content per cell rose, and more morphologically mature cells were produced.	benzidine	124-133	erythropoietin	Mus musculus	20-23
7543055-6	1995	Immunoblotting with anti-phosphotyrosine antibodies revealed that amiloride reduced the number of phosphorylated proteins in epo-stimulated cells.	Phosphotyrosine	25-40	erythropoietin	Mus musculus	125-128
7543055-6	1995	Immunoblotting with anti-phosphotyrosine antibodies revealed that amiloride reduced the number of phosphorylated proteins in epo-stimulated cells.	Amiloride	66-75	erythropoietin	Mus musculus	125-128
7543055-8	1995	These data indicate that amiloride may interfere with epo-induced signaling cascades within J2E cells which result in restricted cell division and promotion of maturation.	Amiloride	25-34	erythropoietin	Mus musculus	54-57
7781605-3	1995	Here we demonstrate that interleukin 2 (IL-2) as well as erythropoietin (EPO) stimulate STAT5 and induce tyrosine phosphorylation of STAT5.	Tyrosine	105-113	erythropoietin	Mus musculus	57-71
7781605-3	1995	Here we demonstrate that interleukin 2 (IL-2) as well as erythropoietin (EPO) stimulate STAT5 and induce tyrosine phosphorylation of STAT5.	Tyrosine	105-113	erythropoietin	Mus musculus	73-76
7538110-0	1995	Erythropoietin-induced recruitment of Shc via a receptor phosphotyrosine-independent, Jak2-associated pathway.	Phosphotyrosine	57-72	erythropoietin	Mus musculus	0-14
7538110-2	1995	FDC-P1 cells stably expressing the wild type murine EPOR supported the EPO-induced association of Shc with Jak2 and its rapid tyrosine phosphorylation.	Tyrosine	126-134	erythropoietin	Mus musculus	52-55
7794810-7	1995	We concluded, therefore, that hemoglobin synthesis in epo-induced J2E cells normally results from the coordinate stimulation of heme and globin synthesis.	Heme	128-132	erythropoietin	Mus musculus	54-57
7895784-4	1995	Results from in vitro cultures of purified splenic colony-forming units-erythroid (CFU-E), with and without erythropoietin (Epo), and in vivo Epo treatments of thiamphenicol (TAP)-pretreated mice showed neither reduction in cycle times nor addition of extra cell divisions in the differentiating erythroid lineage.	Thiamphenicol	160-173	erythropoietin	Mus musculus	142-145
7893759-7	1995	Soluble GST-EPO fusion proteins were affinity purified on immobilised glutathione.	Glutathione	70-81	erythropoietin	Mus musculus	12-15
7893759-9	1995	The pGEX expression system was evaluated as a means of analysing the structure-function relationships of EPO by in vitro mutagenesis.	pgex	4-8	erythropoietin	Mus musculus	105-108
7819073-3	1994	Furthermore, fraxiparin was found to potentiate the stimulating activity of aplastic anaemia serum (AAS) but not stem cell factor (SCF), interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (Epo), on MK colony growth in vitro, and to neutralize the inhibitory effect of platelet factor 4 (PF4) in vitro and in vivo.	Nadroparin	13-23	erythropoietin	Mus musculus	221-235
7528577-0	1995	Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites.	Tyrosine	104-112	erythropoietin	Mus musculus	47-61
7528577-0	1995	Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites.	Tyrosine	104-112	erythropoietin	Mus musculus	63-66
7528577-0	1995	Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites.	Tyrosine	104-112	erythropoietin	Mus musculus	83-86
7528577-1	1995	Erythropoietin (Epo) binding to its receptor (EpoR) induces tyrosine phosphorylation in responsive cells and this ability is required for a mitogenic response.	Tyrosine	60-68	erythropoietin	Mus musculus	0-14
7528577-1	1995	Erythropoietin (Epo) binding to its receptor (EpoR) induces tyrosine phosphorylation in responsive cells and this ability is required for a mitogenic response.	Tyrosine	60-68	erythropoietin	Mus musculus	16-19
7528577-5	1995	In the studies presented here, we show that HCP binds the tyrosine phosphorylated Epo receptor through the amino-terminal src-homology 2 (SH2) domain of HCP.	Tyrosine	58-66	erythropoietin	Mus musculus	82-85
7542230-0	1995	Diaminofluorene is more sensitive than benzidine for detecting hemoglobin in erythropoietin responsive J2E cells.	Diaminofluorene	0-15	erythropoietin	Mus musculus	77-91
7542230-0	1995	Diaminofluorene is more sensitive than benzidine for detecting hemoglobin in erythropoietin responsive J2E cells.	benzidine	39-48	erythropoietin	Mus musculus	77-91
7542230-1	1995	We have used the diaminofluorene stain to detect hemoglobin production in J2E cells following erythropoietin-induced differentiation.	Diaminofluorene	17-32	erythropoietin	Mus musculus	94-108
7669952-6	1995	The response to EPO was evaluated in terms of 3H-thymidine uptake.	3h-thymidine	46-58	erythropoietin	Mus musculus	16-19
7923208-2	1994	Concentrations of vitaletheine modulators from 1 femtograms/ml to 100 picograms/ml medium regulate RBC production from progenitors initially deprived of erythropoietin.	vitaletheine	18-30	erythropoietin	Mus musculus	153-167
7819073-3	1994	Furthermore, fraxiparin was found to potentiate the stimulating activity of aplastic anaemia serum (AAS) but not stem cell factor (SCF), interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (Epo), on MK colony growth in vitro, and to neutralize the inhibitory effect of platelet factor 4 (PF4) in vitro and in vivo.	Nadroparin	13-23	erythropoietin	Mus musculus	237-240
7929424-1	1994	Using murine myeloid factor-dependent FDC-P1/ER cells, we demonstrate that the hematopoietic growth factors interleukin-3 and erythropoietin and bryostatin-1, a macrocyclic lactone natural product and potent activator of protein kinase C (PKC), suppress apoptosis and induce the rapid serine phosphorylation of Bc12 alpha.	Serine	285-291	erythropoietin	Mus musculus	126-140
7957803-2	1994	Since it was shown in a mouse model that alpha-D-tocopherol (vitamin E derivative) antagonizes the inhibitory influence of AZT on the growth of burst-forming units-erythrocyte (BFU-E), it was the aim of this study to investigate whether alpha-D-tocopherol and high dosages of erythropoietin (EPO) increase the hematopoietic colony-forming capacity of bone marrow cells from patients with progressive HIV disease and especially if they reverse the inhibitory effects of AZT.	alpha-Tocopherol	41-59	erythropoietin	Mus musculus	276-290
7957803-2	1994	Since it was shown in a mouse model that alpha-D-tocopherol (vitamin E derivative) antagonizes the inhibitory influence of AZT on the growth of burst-forming units-erythrocyte (BFU-E), it was the aim of this study to investigate whether alpha-D-tocopherol and high dosages of erythropoietin (EPO) increase the hematopoietic colony-forming capacity of bone marrow cells from patients with progressive HIV disease and especially if they reverse the inhibitory effects of AZT.	alpha-Tocopherol	41-59	erythropoietin	Mus musculus	292-295
7957803-2	1994	Since it was shown in a mouse model that alpha-D-tocopherol (vitamin E derivative) antagonizes the inhibitory influence of AZT on the growth of burst-forming units-erythrocyte (BFU-E), it was the aim of this study to investigate whether alpha-D-tocopherol and high dosages of erythropoietin (EPO) increase the hematopoietic colony-forming capacity of bone marrow cells from patients with progressive HIV disease and especially if they reverse the inhibitory effects of AZT.	Vitamin E	61-70	erythropoietin	Mus musculus	276-290
7957803-2	1994	Since it was shown in a mouse model that alpha-D-tocopherol (vitamin E derivative) antagonizes the inhibitory influence of AZT on the growth of burst-forming units-erythrocyte (BFU-E), it was the aim of this study to investigate whether alpha-D-tocopherol and high dosages of erythropoietin (EPO) increase the hematopoietic colony-forming capacity of bone marrow cells from patients with progressive HIV disease and especially if they reverse the inhibitory effects of AZT.	Vitamin E	61-70	erythropoietin	Mus musculus	292-295
7957803-2	1994	Since it was shown in a mouse model that alpha-D-tocopherol (vitamin E derivative) antagonizes the inhibitory influence of AZT on the growth of burst-forming units-erythrocyte (BFU-E), it was the aim of this study to investigate whether alpha-D-tocopherol and high dosages of erythropoietin (EPO) increase the hematopoietic colony-forming capacity of bone marrow cells from patients with progressive HIV disease and especially if they reverse the inhibitory effects of AZT.	Zidovudine	123-126	erythropoietin	Mus musculus	276-290
7957803-2	1994	Since it was shown in a mouse model that alpha-D-tocopherol (vitamin E derivative) antagonizes the inhibitory influence of AZT on the growth of burst-forming units-erythrocyte (BFU-E), it was the aim of this study to investigate whether alpha-D-tocopherol and high dosages of erythropoietin (EPO) increase the hematopoietic colony-forming capacity of bone marrow cells from patients with progressive HIV disease and especially if they reverse the inhibitory effects of AZT.	Zidovudine	123-126	erythropoietin	Mus musculus	292-295
7926812-2	1994	32D GM cells were previously shown to express significant levels of the Epo receptor mRNA and protein which was retained intracellularly and did not appear on the cell surface.	gm	4-6	erythropoietin	Mus musculus	72-75
7522324-0	1994	Activated Ki-Ras complements erythropoietin signaling in CTLL-2 cells, inducing tyrosine phosphorylation of a 160-kDa protein.	Tyrosine	80-88	erythropoietin	Mus musculus	29-43
8043864-0	1994	Effects of butyrate on the erythropoietin receptor of cell line IW201.	Butyrates	11-19	erythropoietin	Mus musculus	27-41
7828414-3	1994	However the addition of IL-1 alpha, IL1-beta and gamma IFN (3.3 x 10(-8) gl-1) caused a significant (P < 0.01) inhibition of EPO stimulated thymidine incorporation.	Thymidine	143-152	erythropoietin	Mus musculus	128-131
8043864-6	1994	These data indicate that an accessory protein induced by sodium butyrate is responsible for high-affinity binding of erythropoietin.	Butyric Acid	57-72	erythropoietin	Mus musculus	117-131
8148375-0	1994	Characterisation of functional domains within the mouse erythropoietin 3" enhancer conveying oxygen-regulated responses in different cell lines.	Oxygen	93-99	erythropoietin	Mus musculus	56-70
8185227-11	1994	The ratio of bioactivity to enzyme activity for the Arg 163-->Glu mutant was approximately one third of the value obtained for each of the other fusion proteins, indicating that arginine at 163 is functionally important for EPO activity.	Arginine	52-55	erythropoietin	Mus musculus	227-230
8185227-11	1994	The ratio of bioactivity to enzyme activity for the Arg 163-->Glu mutant was approximately one third of the value obtained for each of the other fusion proteins, indicating that arginine at 163 is functionally important for EPO activity.	Glutamic Acid	65-68	erythropoietin	Mus musculus	227-230
8185227-11	1994	The ratio of bioactivity to enzyme activity for the Arg 163-->Glu mutant was approximately one third of the value obtained for each of the other fusion proteins, indicating that arginine at 163 is functionally important for EPO activity.	Arginine	181-189	erythropoietin	Mus musculus	227-230
8034573-2	1994	Binding of EPO to its transmembrane receptor leads to the rapid tyrosine phosphorylation of several cellular targets including Shc, Raf-1, Gap120, the cloned EPO receptor (EPOR), pp100/97, and a M(r) 130,000 EPO-activated receptor-associated Janus protein tyrosine kinase, Jak2.	Tyrosine	64-72	erythropoietin	Mus musculus	11-14
8148375-1	1994	We have analysed sequences within the mouse erythropoietin enhancer which are required for oxygen regulated operation in the erythropoietin producing cell line, HepG2, and in two non-erythropoietin producing cell lines; the lung fibroblastoid cell line a23, and mouse erythroleukaemia (MEL) cells.	Oxygen	91-97	erythropoietin	Mus musculus	44-58
8148375-1	1994	We have analysed sequences within the mouse erythropoietin enhancer which are required for oxygen regulated operation in the erythropoietin producing cell line, HepG2, and in two non-erythropoietin producing cell lines; the lung fibroblastoid cell line a23, and mouse erythroleukaemia (MEL) cells.	Oxygen	91-97	erythropoietin	Mus musculus	125-139
8148375-1	1994	We have analysed sequences within the mouse erythropoietin enhancer which are required for oxygen regulated operation in the erythropoietin producing cell line, HepG2, and in two non-erythropoietin producing cell lines; the lung fibroblastoid cell line a23, and mouse erythroleukaemia (MEL) cells.	Oxygen	91-97	erythropoietin	Mus musculus	125-139
8148375-6	1994	Though operation of this 3" sequence differed according to the cell type, oxygen regulated operation was dependent on the same two critical sites in the 5" region in both erythropoietin producing and non-erythropoietin producing cells.	Oxygen	74-80	erythropoietin	Mus musculus	171-185
8148375-6	1994	Though operation of this 3" sequence differed according to the cell type, oxygen regulated operation was dependent on the same two critical sites in the 5" region in both erythropoietin producing and non-erythropoietin producing cells.	Oxygen	74-80	erythropoietin	Mus musculus	204-218
8139531-6	1994	EPO-R(T) inhibited the EPO-dependent tyrosine phosphorylation of wild-type EPO-R, the tyrosine kinase (JAK2), and the SH2 adaptor protein (Shc).	Tyrosine	37-45	erythropoietin	Mus musculus	0-3
8005230-5	1994	On the other hand, the tyrosine kinase inhibitors erbstatin and herbimycin suppressed the effect of EPO.	herbimycin	64-74	erythropoietin	Mus musculus	100-103
8005230-7	1994	The PKC activator phorbol myristate acetate (PMA) not only induced luciferase activity by itself but enhanced the action of Epo.	Tetradecanoylphorbol Acetate	18-43	erythropoietin	Mus musculus	124-127
8005230-7	1994	The PKC activator phorbol myristate acetate (PMA) not only induced luciferase activity by itself but enhanced the action of Epo.	Tetradecanoylphorbol Acetate	45-48	erythropoietin	Mus musculus	124-127
8005230-8	1994	On the other hand, the PKC inhibitor 1-(5-isoquinolynyl-sulfonyl)-2-methylpiperazine (H7) suppressed the effect of Epo and PMA, whereas a nonspecific protein kinase inhibitor, N-(2-Guanidinoethyl)-5-Isoquinolinesulfornamine (HA1004) inhibited the action of neither Epo nor PMA.	1-(5-isoquinolynyl-sulfonyl)-2-methylpiperazine	37-84	erythropoietin	Mus musculus	115-118
8005230-8	1994	On the other hand, the PKC inhibitor 1-(5-isoquinolynyl-sulfonyl)-2-methylpiperazine (H7) suppressed the effect of Epo and PMA, whereas a nonspecific protein kinase inhibitor, N-(2-Guanidinoethyl)-5-Isoquinolinesulfornamine (HA1004) inhibited the action of neither Epo nor PMA.	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine	86-88	erythropoietin	Mus musculus	115-118
8005230-8	1994	On the other hand, the PKC inhibitor 1-(5-isoquinolynyl-sulfonyl)-2-methylpiperazine (H7) suppressed the effect of Epo and PMA, whereas a nonspecific protein kinase inhibitor, N-(2-Guanidinoethyl)-5-Isoquinolinesulfornamine (HA1004) inhibited the action of neither Epo nor PMA.	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine	86-88	erythropoietin	Mus musculus	265-268
8005230-8	1994	On the other hand, the PKC inhibitor 1-(5-isoquinolynyl-sulfonyl)-2-methylpiperazine (H7) suppressed the effect of Epo and PMA, whereas a nonspecific protein kinase inhibitor, N-(2-Guanidinoethyl)-5-Isoquinolinesulfornamine (HA1004) inhibited the action of neither Epo nor PMA.	Tetradecanoylphorbol Acetate	123-126	erythropoietin	Mus musculus	265-268
8005230-8	1994	On the other hand, the PKC inhibitor 1-(5-isoquinolynyl-sulfonyl)-2-methylpiperazine (H7) suppressed the effect of Epo and PMA, whereas a nonspecific protein kinase inhibitor, N-(2-Guanidinoethyl)-5-Isoquinolinesulfornamine (HA1004) inhibited the action of neither Epo nor PMA.	n-(2-guanidinoethyl)-5-isoquinolinesulfornamine	176-223	erythropoietin	Mus musculus	115-118
8005230-8	1994	On the other hand, the PKC inhibitor 1-(5-isoquinolynyl-sulfonyl)-2-methylpiperazine (H7) suppressed the effect of Epo and PMA, whereas a nonspecific protein kinase inhibitor, N-(2-Guanidinoethyl)-5-Isoquinolinesulfornamine (HA1004) inhibited the action of neither Epo nor PMA.	N-(2-guanidinoethyl)-5-isoquinolinesulfonamide	225-231	erythropoietin	Mus musculus	115-118
8005230-8	1994	On the other hand, the PKC inhibitor 1-(5-isoquinolynyl-sulfonyl)-2-methylpiperazine (H7) suppressed the effect of Epo and PMA, whereas a nonspecific protein kinase inhibitor, N-(2-Guanidinoethyl)-5-Isoquinolinesulfornamine (HA1004) inhibited the action of neither Epo nor PMA.	Tetradecanoylphorbol Acetate	273-276	erythropoietin	Mus musculus	115-118
8005230-9	1994	Another known PKC inhibitor staurosporine (STSP) did not inhibit but rather enhanced the effect of Epo.	Staurosporine	28-41	erythropoietin	Mus musculus	99-102
8005230-9	1994	Another known PKC inhibitor staurosporine (STSP) did not inhibit but rather enhanced the effect of Epo.	Staurosporine	43-47	erythropoietin	Mus musculus	99-102
8005230-11	1994	These results suggest that the EPO-mediated early signal transduction pathway leading to c-fos expression involves protein-tyrosine phosphorylation, is modulated by tyrosine phosphatase activity and is positively regulated by PKC.	Tyrosine	123-131	erythropoietin	Mus musculus	31-34
8005230-4	1994	The tyrosine phosphatase inhibitor orthovanadate not only induced luciferase activity by itself but enhanced the action of EPO.	Vanadates	35-48	erythropoietin	Mus musculus	123-126
8005230-5	1994	On the other hand, the tyrosine kinase inhibitors erbstatin and herbimycin suppressed the effect of EPO.	erbstatin	50-59	erythropoietin	Mus musculus	100-103
8139531-6	1994	EPO-R(T) inhibited the EPO-dependent tyrosine phosphorylation of wild-type EPO-R, the tyrosine kinase (JAK2), and the SH2 adaptor protein (Shc).	Tyrosine	37-45	erythropoietin	Mus musculus	23-26
8260696-2	1993	Exposure of mice to AZT for 5 weeks produced marked anemia, thrombocytopenia, neutropenia, and weight loss, whereas mice that received Epo and heme for 3 subsequent weeks showed significant alleviation of AZT cytotoxicity.	Zidovudine	205-208	erythropoietin	Mus musculus	135-138
7994062-6	1994	One of the substrates of tyrosine phosphorylation is the receptor and, in the case of the receptor for Epo, the membrane distal region of the cytoplasmic domain is phosphorylated.	Tyrosine	25-33	erythropoietin	Mus musculus	103-106
7894046-3	1994	The drug also inhibited the oxygen-dependent secretion of erythropoietin (estimated by the plasma immunoreactive hormone concentration) in hypoxemic mice when injected between 0 and 2 h after initiation of the hypoxic stimulation.	Oxygen	28-34	erythropoietin	Mus musculus	58-72
7816003-0	1994	The inhibitory action of aluminum on mouse bone marrow cell growth: evidence for an erythropoietin- and transferrin-mediated mechanism.	Aluminum	25-33	erythropoietin	Mus musculus	84-98
7816003-3	1994	Mouse bone marrow cells were stimulated in vitro with erythropoietin (Epo) in the presence of Al3+ ion and erythroid colony-forming units were then determined.	ALUMINUM ION	94-98	erythropoietin	Mus musculus	54-68
7816003-3	1994	Mouse bone marrow cells were stimulated in vitro with erythropoietin (Epo) in the presence of Al3+ ion and erythroid colony-forming units were then determined.	ALUMINUM ION	94-98	erythropoietin	Mus musculus	70-73
8260696-0	1993	Additive effect of erythropoietin and heme on murine hematopoietic recovery after azidothymidine treatment.	Zidovudine	82-96	erythropoietin	Mus musculus	19-33
8178735-5	1994	The oral administration of bropirimine against RCC heterotransplanted in nude mice (JRC 901: an erythropoietin-producing strain) tended to inhibit tumor growth dose-dependently, but not significantly (mean tumor weight ratio: T/C ratio: over 43%, degeneration degree of tumor: incomplete).	bropirimine	27-38	erythropoietin	Mus musculus	96-110
7597990-0	1994	Computerized histographic characterization of changes in tissue pO2 induced by erythropoietin.	PO-2	64-67	erythropoietin	Mus musculus	79-93
7597990-10	1994	These data lend support to the value of EPO in reversing the anemia associated with malignancy and suggest a role of pO2 histography in monitoring the beneficial effects of EPO therapy.	PO-2	117-120	erythropoietin	Mus musculus	173-176
8190019-0	1994	Effect of combination interleukin-1 and erythropoietin in ameliorating the hematopoietic toxicity associated with the use of zidovudine administered to normal mice.	Zidovudine	125-135	erythropoietin	Mus musculus	40-54
8190019-3	1994	We report results describing the effect of combination interleukin-1 (IL-1) and erythropoietin (Epo) in their ability to modulate the hematopoietic toxicity associated with dose-escalation zidovudine administered in normal mice.	Zidovudine	189-199	erythropoietin	Mus musculus	80-94
8190019-3	1994	We report results describing the effect of combination interleukin-1 (IL-1) and erythropoietin (Epo) in their ability to modulate the hematopoietic toxicity associated with dose-escalation zidovudine administered in normal mice.	Zidovudine	189-199	erythropoietin	Mus musculus	96-99
8190019-4	1994	When administered over a six-week period, IL-1 and Epo raised the packed red cell volume, white blood cell and platelet counts in control mice and mice receiving dose-escalation zidovudine.	Zidovudine	178-188	erythropoietin	Mus musculus	51-54
8190019-6	1994	These results indicate that use of combined IL-1 and Epo may be efficacious in ameliorating the hematopoietic toxicity associated with the use of zidovudine.	Zidovudine	146-156	erythropoietin	Mus musculus	53-56
7854499-0	1994	Enhanced erythropoietin and suppression of gamma-glutamyl transpeptidase (GGT) activity in murine lymphoma following administration of vanadium.	Vanadium	135-143	erythropoietin	Mus musculus	9-23
8260696-3	1993	Treatment with Epo (10 U for 5 times/week) stimulated hematopoietic recovery in the AZT-treated animals and reduced the severe anemia and thrombocytopenia by 3 weeks.	Zidovudine	84-87	erythropoietin	Mus musculus	15-18
8260696-4	1993	Administration of a lower Epo dose (1 U Epo) resulted in only a modest retardation of AZT-induced anemia, although, when combined with heme, there was a great improvement in recovery of erythropoiesis.	Zidovudine	86-89	erythropoietin	Mus musculus	26-29
8260696-5	1993	The combination of heme with Epo (10 U) produced the optimum response, resulting in almost normal recovery of bone marrow cellularity as well as recovery of burst-forming units-erythroid (BFU-E) and splenic hematopoietic progenitor content (colony-forming unit-spleen [CFU-S]) by the end of 3 weeks of post-AZT treatment.	Zidovudine	307-310	erythropoietin	Mus musculus	29-32
8260696-7	1993	Long-term bone marrow cultures (LTBMCs) established from mice exposed to AZT for 8 weeks showed a marked reduction in cellularity and this was completely alleviated when mice received heme and Epo (10 U) for 3 weeks after 5 weeks of AZT administration.	Zidovudine	73-76	erythropoietin	Mus musculus	193-196
8260696-8	1993	The additive effect of heme and Epo was seen in BFU-E production, as well as in CFU-S production, in LTBMCs.	cfu-s	80-85	erythropoietin	Mus musculus	32-35
8260699-7	1993	DFX administration to mice transiently increased EPO RNA levels in the kidney.	Deferoxamine	0-3	erythropoietin	Mus musculus	49-52
7505116-2	1993	Coimmunoprecipitation of p85 with epitope-tagged EPO receptors was observed initially in FDC-HER cells labeled metabolically with [32P]orthophosphate, and association of these factors was confirmed by Western analyses of receptor immunoprecipitates using p85 antiserum.	Phosphorus-32	131-134	erythropoietin	Mus musculus	49-52
7505116-2	1993	Coimmunoprecipitation of p85 with epitope-tagged EPO receptors was observed initially in FDC-HER cells labeled metabolically with [32P]orthophosphate, and association of these factors was confirmed by Western analyses of receptor immunoprecipitates using p85 antiserum.	Phosphates	135-149	erythropoietin	Mus musculus	49-52
7505116-4	1993	However, EPO was observed to stimulated the rapid formation of phosphatidylinositol 32P-phosphate in FDC-HER and FDC-ER cells.	phosphatidylinositol 32p-phosphate	63-97	erythropoietin	Mus musculus	9-12
7505116-4	1993	However, EPO was observed to stimulated the rapid formation of phosphatidylinositol 32P-phosphate in FDC-HER and FDC-ER cells.	fdc-her	101-108	erythropoietin	Mus musculus	9-12
8330646-0	1993	Hemin or butyrate increases constitutive erythropoietin formation by mouse erythroleukemia cell lines.	Butyrates	9-17	erythropoietin	Mus musculus	41-55
8397229-2	1993	Serum levels of EPO in ex-hypoxic polycythemic mice were significantly increased after injections of 200 micrograms/kg sodium nitroprusside for 4 d. One injection of NG-nitro-L-arginine methyl ester (L-NAME) produced a significant dose-related decrease in serum levels of EPO in ex-hypoxic polycythemic mice in response to hypoxia.	Nitroprusside	119-139	erythropoietin	Mus musculus	16-19
8397229-2	1993	Serum levels of EPO in ex-hypoxic polycythemic mice were significantly increased after injections of 200 micrograms/kg sodium nitroprusside for 4 d. One injection of NG-nitro-L-arginine methyl ester (L-NAME) produced a significant dose-related decrease in serum levels of EPO in ex-hypoxic polycythemic mice in response to hypoxia.	NG-Nitroarginine Methyl Ester	166-198	erythropoietin	Mus musculus	16-19
8397229-2	1993	Serum levels of EPO in ex-hypoxic polycythemic mice were significantly increased after injections of 200 micrograms/kg sodium nitroprusside for 4 d. One injection of NG-nitro-L-arginine methyl ester (L-NAME) produced a significant dose-related decrease in serum levels of EPO in ex-hypoxic polycythemic mice in response to hypoxia.	NG-Nitroarginine Methyl Ester	166-198	erythropoietin	Mus musculus	272-275
8397229-2	1993	Serum levels of EPO in ex-hypoxic polycythemic mice were significantly increased after injections of 200 micrograms/kg sodium nitroprusside for 4 d. One injection of NG-nitro-L-arginine methyl ester (L-NAME) produced a significant dose-related decrease in serum levels of EPO in ex-hypoxic polycythemic mice in response to hypoxia.	NG-Nitroarginine Methyl Ester	200-206	erythropoietin	Mus musculus	16-19
8330646-5	1993	Both hemin and butyrate caused a three- to five-fold increase in Epo secretion on a percell basis.	Hemin	5-10	erythropoietin	Mus musculus	65-68
8330646-5	1993	Both hemin and butyrate caused a three- to five-fold increase in Epo secretion on a percell basis.	Butyrates	15-23	erythropoietin	Mus musculus	65-68
8341708-11	1993	(vi) Anti-phosphotyrosine antiserum detected an EPO-dependent phosphorylation of the 78-kDa EPOR.	Phosphotyrosine	10-25	erythropoietin	Mus musculus	48-51
8353306-6	1993	These results suggest that EPO is expressed in an all-or-none fashion in peritubular interstitial cells and that the oxygen carrying capacity of blood is the major regulator of renal EPO production.	Oxygen	117-123	erythropoietin	Mus musculus	183-186
8391879-7	1993	The treatment of FVA cells with cycloheximide (CHX) 10 micrograms/mL, which in itself activates the expression of VL30 caused a superinduction of the Epo signal.	Cycloheximide	32-45	erythropoietin	Mus musculus	150-153
8464516-3	1993	Interleukin-3 and erythropoietin, however, induce transient tyrosine phosphorylation of a common set of proteins as a growth signal, and interleukin-2 induces phosphorylation of an overlapping but distinct set of proteins.	Tyrosine	60-68	erythropoietin	Mus musculus	18-32
7679009-11	1993	In contrast, cells growing in Epo (32D Epo or 32D Epo1.1) spend relatively less time in G0/G1 and correspondingly more time in S. These data were confirmed by the analysis of the tritiated thymidine (3H-TdR) suicide rate and of the expression of cell cycle-specific genes.	Tritiated thymidine	179-198	erythropoietin	Mus musculus	30-33
7679009-11	1993	In contrast, cells growing in Epo (32D Epo or 32D Epo1.1) spend relatively less time in G0/G1 and correspondingly more time in S. These data were confirmed by the analysis of the tritiated thymidine (3H-TdR) suicide rate and of the expression of cell cycle-specific genes.	Tritiated thymidine	179-198	erythropoietin	Mus musculus	50-56
7679009-11	1993	In contrast, cells growing in Epo (32D Epo or 32D Epo1.1) spend relatively less time in G0/G1 and correspondingly more time in S. These data were confirmed by the analysis of the tritiated thymidine (3H-TdR) suicide rate and of the expression of cell cycle-specific genes.	Tritium	200-202	erythropoietin	Mus musculus	30-33
7679009-11	1993	In contrast, cells growing in Epo (32D Epo or 32D Epo1.1) spend relatively less time in G0/G1 and correspondingly more time in S. These data were confirmed by the analysis of the tritiated thymidine (3H-TdR) suicide rate and of the expression of cell cycle-specific genes.	Tritium	200-202	erythropoietin	Mus musculus	50-56
1438344-1	1992	Thyroxine has been shown in vitro to stimulate erythropoiesis by two mechanisms: a direct, beta 2-adrenergic receptor-mediated stimulation of red cell precursors, and an indirect, erythropoietin-mediated mechanism.	Thyroxine	0-9	erythropoietin	Mus musculus	180-194
8485306-0	1993	In-vivo effect of interleukin 3 and erythropoietin, either alone or in combination, on the hematopoietic toxicity associated with zidovudine.	Zidovudine	130-140	erythropoietin	Mus musculus	36-50
8485306-6	1993	In general, use of EPO and IL-3 alone reduced zidovudine-induced toxicity, notably in erythropoiesis; however, combination EPO/IL-3 was associated with enhanced toxicity with an observed rebound only with the use of < 2.5 mg/ml drug; 2.5 mg/ml drug in the presence of combination EPO/IL-3 accelerated zidovudine-erythroid toxicity.	Zidovudine	46-56	erythropoietin	Mus musculus	19-22
8485306-6	1993	In general, use of EPO and IL-3 alone reduced zidovudine-induced toxicity, notably in erythropoiesis; however, combination EPO/IL-3 was associated with enhanced toxicity with an observed rebound only with the use of < 2.5 mg/ml drug; 2.5 mg/ml drug in the presence of combination EPO/IL-3 accelerated zidovudine-erythroid toxicity.	Zidovudine	304-314	erythropoietin	Mus musculus	123-126
8485306-6	1993	In general, use of EPO and IL-3 alone reduced zidovudine-induced toxicity, notably in erythropoiesis; however, combination EPO/IL-3 was associated with enhanced toxicity with an observed rebound only with the use of < 2.5 mg/ml drug; 2.5 mg/ml drug in the presence of combination EPO/IL-3 accelerated zidovudine-erythroid toxicity.	Zidovudine	304-314	erythropoietin	Mus musculus	123-126
8485306-9	1993	These studies demonstrate that use of EPO or IL-3, either alone or in combination may serve as an effective adjuvant therapy to modulate the erythroid toxicity associated with lower doses of zidovudine; however, this cytokine therapy was ineffective modulating zidovudine-induced myelosuppression when used in vivo.	Zidovudine	191-201	erythropoietin	Mus musculus	38-41
8485306-9	1993	These studies demonstrate that use of EPO or IL-3, either alone or in combination may serve as an effective adjuvant therapy to modulate the erythroid toxicity associated with lower doses of zidovudine; however, this cytokine therapy was ineffective modulating zidovudine-induced myelosuppression when used in vivo.	Zidovudine	261-271	erythropoietin	Mus musculus	38-41
1467516-2	1992	EPO binding induces tyrosine kinase activity and rapid tyrosine phosphorylation of several cellular substrates.	Tyrosine	20-28	erythropoietin	Mus musculus	0-3
1467516-5	1992	Stimulation with IL-3 or EPO of the Ba/F3 cells expressing the recombinant EPO-R (Ba/F3-EPO-R) resulted in tyrosine phosphorylation of the same p97 substrate.	Tyrosine	107-115	erythropoietin	Mus musculus	25-28
1467516-5	1992	Stimulation with IL-3 or EPO of the Ba/F3 cells expressing the recombinant EPO-R (Ba/F3-EPO-R) resulted in tyrosine phosphorylation of the same p97 substrate.	Tyrosine	107-115	erythropoietin	Mus musculus	75-78
1467516-8	1992	In CTLL-2-EPO-R cells, a T-lymphocyte line stably transfected with the EPO-R, the 97-Kd substrate was tyrosine-phosphorylated in response to IL-2 or EPO.	Tyrosine	102-110	erythropoietin	Mus musculus	10-13
1467516-8	1992	In CTLL-2-EPO-R cells, a T-lymphocyte line stably transfected with the EPO-R, the 97-Kd substrate was tyrosine-phosphorylated in response to IL-2 or EPO.	Tyrosine	102-110	erythropoietin	Mus musculus	71-74
8359151-3	1993	Cobalt dichloride was used to induce erythropoietin, a growth factor for erythropoiesis.	cobaltous chloride	0-17	erythropoietin	Mus musculus	37-51
1489179-5	1992	Concomitant administration of erythropoietin, vitamin E, or interleukin-3 to the AZT-treated pregnant mice caused a significant reversal in the AZT-induced toxicity to the fetus and to the mother"s bone marrow.	Zidovudine	81-84	erythropoietin	Mus musculus	30-44
1289180-0	1992	Higher erythropoietin secretion in response to cobaltous chloride in post-hypoxic than in hypertransfused polycythemic mice.	cobaltous chloride	47-65	erythropoietin	Mus musculus	7-21
1289180-2	1992	Since it has been demonstrated that cobalt (Co) treatment rises renal EPO-mRNA and increases plasma EPO levels, the present study was conducted to determine whether there is a difference between PH and HT mice in relation to the erythropoietic response to Co and whether the stimulatory effect of Co on EPO secretion can be blunted by polycythemia.	Cobalt	36-47	erythropoietin	Mus musculus	70-73
1289180-2	1992	Since it has been demonstrated that cobalt (Co) treatment rises renal EPO-mRNA and increases plasma EPO levels, the present study was conducted to determine whether there is a difference between PH and HT mice in relation to the erythropoietic response to Co and whether the stimulatory effect of Co on EPO secretion can be blunted by polycythemia.	Cobalt	36-47	erythropoietin	Mus musculus	100-103
1289180-2	1992	Since it has been demonstrated that cobalt (Co) treatment rises renal EPO-mRNA and increases plasma EPO levels, the present study was conducted to determine whether there is a difference between PH and HT mice in relation to the erythropoietic response to Co and whether the stimulatory effect of Co on EPO secretion can be blunted by polycythemia.	Cobalt	36-47	erythropoietin	Mus musculus	100-103
1489179-5	1992	Concomitant administration of erythropoietin, vitamin E, or interleukin-3 to the AZT-treated pregnant mice caused a significant reversal in the AZT-induced toxicity to the fetus and to the mother"s bone marrow.	Zidovudine	144-147	erythropoietin	Mus musculus	30-44
1489179-7	1992	The results suggest that AZT is toxic to the fetus in a dose-dependent manner and that treatment with erythropoietin, vitamin E, or interleukin-3 can ameliorate the AZT-induced fetal toxicity.	Zidovudine	165-168	erythropoietin	Mus musculus	102-116
1445329-4	1992	One N-glycosylation site exists in sEPO-R but the glycosylation did not affect the binding affinity to EPO.	Nitrogen	4-5	erythropoietin	Mus musculus	36-39
1445329-5	1992	A complex with a molecular size that corresponded to a 1:1 complex of EPO and sEPO-R was detected.	sepo-r	78-84	erythropoietin	Mus musculus	70-73
1382712-0	1992	Erythropoietin-induced tyrosine phosphorylations in a high erythropoietin receptor-expressing lymphoid cell line.	Tyrosine	23-31	erythropoietin	Mus musculus	0-14
1324920-0	1992	Interleukin 3, granulocyte-macrophage colony-stimulating factor, and transfected erythropoietin receptors mediate tyrosine phosphorylation of a common cytosolic protein (pp100) in FDC-ER cells.	Tyrosine	114-122	erythropoietin	Mus musculus	81-95
1378622-2	1992	Epo stimulation of Ba/F3 cells transfected with the Epo receptor resulted in increases in tyrosine phosphorylation of proteins of 97, 75, and 55 kDa.	Tyrosine	90-98	erythropoietin	Mus musculus	0-3
1378622-2	1992	Epo stimulation of Ba/F3 cells transfected with the Epo receptor resulted in increases in tyrosine phosphorylation of proteins of 97, 75, and 55 kDa.	Tyrosine	90-98	erythropoietin	Mus musculus	52-55
1378622-3	1992	Epo-induced increases in tyrosine phosphorylation of a 97-kDa protein were also detected within the Epo receptor complex, suggesting that a protein tyrosine kinase is associated with the Epo receptor.	Tyrosine	25-33	erythropoietin	Mus musculus	0-3
1378622-3	1992	Epo-induced increases in tyrosine phosphorylation of a 97-kDa protein were also detected within the Epo receptor complex, suggesting that a protein tyrosine kinase is associated with the Epo receptor.	Tyrosine	25-33	erythropoietin	Mus musculus	100-103
1378622-3	1992	Epo-induced increases in tyrosine phosphorylation of a 97-kDa protein were also detected within the Epo receptor complex, suggesting that a protein tyrosine kinase is associated with the Epo receptor.	Tyrosine	25-33	erythropoietin	Mus musculus	100-103
1378622-7	1992	An Epo receptor-associated protein of identical molecular mass was also found to bind ATP, a characteristic critical for protein kinases.	Adenosine Triphosphate	86-89	erythropoietin	Mus musculus	3-6
1560536-5	1992	In vitro, ME26 virus specifically induces Epo responsiveness in the interleukin-3-dependent myeloid cell line FDC-P2 by enhancing expression of the Epo receptor (EpoR).	fdc-p2	110-116	erythropoietin	Mus musculus	42-45
1587309-0	1992	Rapid protein tyrosine phosphorylation selectively induced in murine responsive ELM-I-1 cells by erythropoietin.	Tyrosine	14-22	erythropoietin	Mus musculus	97-111
1587309-1	1992	We investigated whether protein tyrosine phosphorylation was induced by erythropoietin (Epo) in two murine Epo-responsive cell lines (ELM-I-1, which proliferates autonomously and is induced to differentiate by Epo, and DA-1ER, which grows in a manner dependent on Epo or interleukin-3 (IL-3) without differentiation).	Tyrosine	32-40	erythropoietin	Mus musculus	72-86
1587309-1	1992	We investigated whether protein tyrosine phosphorylation was induced by erythropoietin (Epo) in two murine Epo-responsive cell lines (ELM-I-1, which proliferates autonomously and is induced to differentiate by Epo, and DA-1ER, which grows in a manner dependent on Epo or interleukin-3 (IL-3) without differentiation).	Tyrosine	32-40	erythropoietin	Mus musculus	88-91
1587309-2	1992	In ELM-I-1, Epo induced the tyrosine phosphorylation of a protein of about 80-85 kDa (py80) which appeared in the Triton-X soluble fraction of the cell lysate in a time- and concentration-dependent manner.	Tyrosine	28-36	erythropoietin	Mus musculus	12-15
1587309-2	1992	In ELM-I-1, Epo induced the tyrosine phosphorylation of a protein of about 80-85 kDa (py80) which appeared in the Triton-X soluble fraction of the cell lysate in a time- and concentration-dependent manner.	Octoxynol	114-122	erythropoietin	Mus musculus	12-15
1284250-8	1992	Increasing [Ca2+]i with the calcium ionophore 4-bromo-A23187 increased DNA cleavage; however, DNA fragments generated by high [Ca2+]i were much larger than those seen in the absence of EPO or presence of EGTA.	4-bromo-A-23187	46-60	erythropoietin	Mus musculus	185-188
1284250-11	1992	Cycloheximide inhibited DNA breakdown in a dose dependent manner in cultures lacking EPO, but two other protein synthesis inhibitors, pactamycin and puromycin, did not prevent DNA breakdown.	Cycloheximide	0-13	erythropoietin	Mus musculus	85-88
1314737-4	1992	Sodium orthovanadate (Na3VO4), a tyrosine phosphatase inhibitor, at 5 microM potentiated a subsaturating concentration of EPO.	Sodium orthovanadate	0-20	erythropoietin	Mus musculus	122-125
1314737-4	1992	Sodium orthovanadate (Na3VO4), a tyrosine phosphatase inhibitor, at 5 microM potentiated a subsaturating concentration of EPO.	Sodium orthovanadate	22-28	erythropoietin	Mus musculus	122-125
1314737-7	1992	Genistein, a tyrosine kinase inhibitor, blocked the effect of EPO at a concentration of 5 micrograms/ml.	Genistein	0-9	erythropoietin	Mus musculus	62-65
1284250-0	1992	Regulation of programmed death in erythroid progenitor cells by erythropoietin: effects of calcium and of protein and RNA syntheses.	Calcium	91-98	erythropoietin	Mus musculus	64-78
1309243-0	1992	Induction of erythropoietin responsiveness in murine hematopoietic cells by the gag-myb-ets-containing ME26 virus.	me26	103-107	erythropoietin	Mus musculus	13-27
1311145-5	1992	EPO stimulated the incorporation of 3H-leucine into TPA-treated L8057 cells, and the maximal effect of EPO was observed at the same order as the Kd value of high affinity sites.	DL-Leucine	36-46	erythropoietin	Mus musculus	0-3
1311145-5	1992	EPO stimulated the incorporation of 3H-leucine into TPA-treated L8057 cells, and the maximal effect of EPO was observed at the same order as the Kd value of high affinity sites.	DL-Leucine	36-46	erythropoietin	Mus musculus	103-106
1311145-5	1992	EPO stimulated the incorporation of 3H-leucine into TPA-treated L8057 cells, and the maximal effect of EPO was observed at the same order as the Kd value of high affinity sites.	Tetradecanoylphorbol Acetate	52-55	erythropoietin	Mus musculus	0-3
1311145-5	1992	EPO stimulated the incorporation of 3H-leucine into TPA-treated L8057 cells, and the maximal effect of EPO was observed at the same order as the Kd value of high affinity sites.	Tetradecanoylphorbol Acetate	52-55	erythropoietin	Mus musculus	103-106
1549625-0	1992	Suppression of murine hematopoiesis in vivo after chronic administration of zidovudine: evidence that zidovudine-induced anemia is the result of decreased bone marrow-derived, erythropoietin-responsive progenitor cells.	Zidovudine	76-86	erythropoietin	Mus musculus	176-190
1549625-0	1992	Suppression of murine hematopoiesis in vivo after chronic administration of zidovudine: evidence that zidovudine-induced anemia is the result of decreased bone marrow-derived, erythropoietin-responsive progenitor cells.	Zidovudine	102-112	erythropoietin	Mus musculus	176-190
1549625-12	1992	This study demonstrates that zidovudine-induced anemia results from: (i) inadequate numbers of bone marrow-derived, erythropoietin-dependent hematopoietic progenitors, i.e., CFU-E; and (ii) a shift in erythropoietin-responsive progenitors from bone marrow to spleen capable of responding to obligatory growth factors.	Zidovudine	29-39	erythropoietin	Mus musculus	116-130
1549625-12	1992	This study demonstrates that zidovudine-induced anemia results from: (i) inadequate numbers of bone marrow-derived, erythropoietin-dependent hematopoietic progenitors, i.e., CFU-E; and (ii) a shift in erythropoietin-responsive progenitors from bone marrow to spleen capable of responding to obligatory growth factors.	Zidovudine	29-39	erythropoietin	Mus musculus	201-215
1564955-2	1992	Multilineage colony formation from mice that had been treated with 150 mg/kg 5-fluorouracil was assayed in cultures containing interleukin-3, interleukin-6, and erythropoietin.	Fluorouracil	77-91	erythropoietin	Mus musculus	161-175
1739753-0	1992	Sensitivity of CFU-E to exogenous erythropoietin in benzene-treated mice.	Benzene	52-59	erythropoietin	Mus musculus	34-48
1728320-2	1992	Epo activation of c-myc in these cells requires protein kinase C. We now show the fidelity of this signaling pathway in normal erythroid cells isolated from the spleens of phenylhydrazine-treated mice.	phenylhydrazine	172-187	erythropoietin	Mus musculus	0-3
1728320-7	1992	Using a series of inhibitors with known specificities and established rank-orders of potency for different kinases, we determined that the c-myc response to Epo was blocked with the following rank order: staurosporine much greater than H7 greater than sangivamycin greater than H8.	Staurosporine	204-217	erythropoietin	Mus musculus	157-160
1728320-7	1992	Using a series of inhibitors with known specificities and established rank-orders of potency for different kinases, we determined that the c-myc response to Epo was blocked with the following rank order: staurosporine much greater than H7 greater than sangivamycin greater than H8.	sangivamycin	252-264	erythropoietin	Mus musculus	157-160
1309243-7	1992	Consistent with this idea, we are able to infect an interleukin-3-dependent myeloid cell line, FDC-P2, with ME26 virus and convert it to Epo dependence.	fdc-p2	95-101	erythropoietin	Mus musculus	137-140
1660472-3	1991	These antibodies precipitated erythropoietin-receptor complexes from Triton X-100-solubilized cells.	Octoxynol	69-81	erythropoietin	Mus musculus	30-44
1660472-4	1991	When the complexes were cross-linked by disuccinimidyl suberate, the 85- and 100-kDa erythropoietin-cross-linked proteins previously described were immunoprecipitated.	disuccinimidyl	40-54	erythropoietin	Mus musculus	85-99
1660472-6	1991	Using 1-ethyl 3-(3-dimethylaminopropyl)carbodiimide, we observed erythropoietin cross-linking with a protein of 66 kDa in addition to the 100- and 85-kDa proteins.	Ethyldimethylaminopropyl Carbodiimide	6-51	erythropoietin	Mus musculus	65-79
1660472-9	1991	We observed that reducing the length of molecules able to cross-link amino groups decreased the efficiency of cross-linking with the 100-kDa protein and only the 85-kDa protein was cross-linked with erythropoietin using 1,5-difluoro-2,4-dinitrobenzene.	1,5-difluoro-2,4-dinitrobenzene	220-251	erythropoietin	Mus musculus	199-213
1940611-6	1991	We report the results of further studies designed to investigate the ability of GM-CSF, erythropoietin, interleukin-1, and lithium to modulate AZT toxicity on murine hematopoietic granulocyte-macrophage (CFU-GM), megakaryocytic (CFU-Meg), and erythroid (BFU-E) progenitors cultured from bone marrow and spleen cells from mice infected with RLV.	Zidovudine	143-146	erythropoietin	Mus musculus	88-102
1722318-4	1991	EpoR mRNA (by RNase protection analysis) and EpoR protein (by specific antibody immunoprecipitation of metabolically labeled EpoR protein) were detectable not only in 32D and 32D Epo (an Epo-dependent subclone) but also in 32D GM, a subclone dependent for growth on granulocyte/macrophage colony-stimulating factor.	gm	227-229	erythropoietin	Mus musculus	0-3
1748684-9	1991	Erythropoietin treatment of Rauscher murine erythroleukemia cells previously labeled with [32P]orthophosphate results in a rapid increase in phosphorylation of two cytosolic proteins, designated pp96 and pp80, and a decrease in phosphorylation of another protein, designated pp90.	Phosphorus-32	91-94	erythropoietin	Mus musculus	0-14
1748684-9	1991	Erythropoietin treatment of Rauscher murine erythroleukemia cells previously labeled with [32P]orthophosphate results in a rapid increase in phosphorylation of two cytosolic proteins, designated pp96 and pp80, and a decrease in phosphorylation of another protein, designated pp90.	Phosphates	95-109	erythropoietin	Mus musculus	0-14
1748684-11	1991	Treatment of the cells with 12-O-tetradecanoylphorbol-13-acetate also increases pp80 but not pp96 phosphorylation, suggesting that erythropoietin triggers a protein kinase C-dependent pathway to pp80 and a protein kinase C-independent pathway to pp96.	Tetradecanoylphorbol Acetate	28-64	erythropoietin	Mus musculus	131-145
1748684-12	1991	The effect of erythropoietin on pp96 phosphorylation was also shown in nontransformed erythroid cells isolated from the spleens of phenylhydrazine-treated mice.	phenylhydrazine	131-146	erythropoietin	Mus musculus	14-28
1961720-0	1991	Functional analysis of an oxygen-regulated transcriptional enhancer lying 3" to the mouse erythropoietin gene.	Oxygen	26-32	erythropoietin	Mus musculus	90-104
1793828-3	1991	Activin alone had no effect in polycythemic BDF1 mice, but synergised with epo to significantly enhance 59Fe-incorporation into erythrocytes.	Iron-59	104-108	erythropoietin	Mus musculus	75-78
1961720-1	1991	Erythropoietin, the major hormone controlling red-cell production, is regulated in part through oxygen-dependent changes in the rate of transcription of its gene.	Oxygen	96-102	erythropoietin	Mus musculus	0-14
1884028-4	1991	Serum Epo levels measured in CsA-treated animals were then compared with the predicted levels, which had been calculated in a reference population of normal, either intact or anemic, mice.	Cyclosporine	29-32	erythropoietin	Mus musculus	6-9
1961720-5	1991	This enhancer operates in HepG2 and Hep3B cells, but not in Chinese hamster ovary cells or mouse erythroleukemia cells, and responds to cobalt but not to cyanide or 2-deoxyglucose, thus reflecting the physiological control of erythropoietin production accurately.	Cobalt	136-142	erythropoietin	Mus musculus	226-240
1656216-3	1991	By two-dimensional analysis of phosphotyrosine-containing proteins isolated with a monoclonal antibody (1G2) against phosphotyrosine, Epo and IL-3 were found to rapidly induce tyrosine phosphorylation of comparable substrates of 92, 70, and 56 kDa.	Tyrosine	38-46	erythropoietin	Mus musculus	134-137
1657247-7	1991	The half-life for EPO receptor mRNA was approximately 75 minutes, as determined using the transcriptional inhibitor actinomycin D.	Dactinomycin	116-129	erythropoietin	Mus musculus	18-21
1656216-2	1991	To extend these observations, we have examined the effects of erythropoietin (Epo) on tyrosine phosphorylation in an Epo-responsive cell that was obtained by transfecting the murine erythropoietin receptor (EpoR) into an interleukin-3 (IL-3)-dependent cell line.	Tyrosine	86-94	erythropoietin	Mus musculus	62-76
1656216-2	1991	To extend these observations, we have examined the effects of erythropoietin (Epo) on tyrosine phosphorylation in an Epo-responsive cell that was obtained by transfecting the murine erythropoietin receptor (EpoR) into an interleukin-3 (IL-3)-dependent cell line.	Tyrosine	86-94	erythropoietin	Mus musculus	78-81
1656216-3	1991	By two-dimensional analysis of phosphotyrosine-containing proteins isolated with a monoclonal antibody (1G2) against phosphotyrosine, Epo and IL-3 were found to rapidly induce tyrosine phosphorylation of comparable substrates of 92, 70, and 56 kDa.	Phosphotyrosine	31-46	erythropoietin	Mus musculus	134-137
1656216-3	1991	By two-dimensional analysis of phosphotyrosine-containing proteins isolated with a monoclonal antibody (1G2) against phosphotyrosine, Epo and IL-3 were found to rapidly induce tyrosine phosphorylation of comparable substrates of 92, 70, and 56 kDa.	Phosphotyrosine	117-132	erythropoietin	Mus musculus	134-137
1884028-5	1991	In CsA-treated, intact animals both hematocrit and serum Epo levels were not significantly different from controls.	Cyclosporine	3-6	erythropoietin	Mus musculus	57-60
1884028-6	1991	However, serum Epo levels in CsA-treated, anemic mice were significantly lower than those expected in a control population of untreated, anemic mice with similar degrees of anemia.	Cyclosporine	29-32	erythropoietin	Mus musculus	15-18
1884028-8	1991	Therefore, therapeutical doses of CsA appear to affect the production of Epo under conditions in which the demand of the hormone is increased, as in response to anemia.	Cyclosporine	34-37	erythropoietin	Mus musculus	73-76
1848708-0	1991	Erythropoietin receptors induced by dimethyl sulfoxide exhibit positive cooperativity associated with an amplified biologic response.	Dimethyl Sulfoxide	36-54	erythropoietin	Mus musculus	0-14
1939365-1	1991	The mechanism responsible for the accumulation of heme oxygenase and erythropoietin (epo) transcripts due to cobalt chloride (CoCl2) administration was investigated in rat kidney using a rat heme oxygenase and mouse epo probes.	cobaltous chloride	109-124	erythropoietin	Mus musculus	216-219
1939365-1	1991	The mechanism responsible for the accumulation of heme oxygenase and erythropoietin (epo) transcripts due to cobalt chloride (CoCl2) administration was investigated in rat kidney using a rat heme oxygenase and mouse epo probes.	cobaltous chloride	126-131	erythropoietin	Mus musculus	216-219
1747449-5	1991	In addition, TPF enhanced the acetylcholinesterase (Ach-E) activity of megakaryocytes induced by rh-Epo.	TPF	13-16	erythropoietin	Mus musculus	100-103
1889487-6	1991	Mean plasma erythropoietin (EPO) levels were increased by AZT in both groups in a dose-dependent manner and were inversely proportional to hematocrit values.	Zidovudine	58-61	erythropoietin	Mus musculus	12-26
1889487-6	1991	Mean plasma erythropoietin (EPO) levels were increased by AZT in both groups in a dose-dependent manner and were inversely proportional to hematocrit values.	Zidovudine	58-61	erythropoietin	Mus musculus	28-31
1711211-5	1991	In contrast, the deletion of 44 additional residues led to a dramatic loss (86.3% +/- 7.8%; mean +/- SD) in the ability of this receptor to mediate EPO-induced growth, thus indicating that residues between Gly-352 and Met-396 constitute a functionally critical cytosolic subdomain.	Glycine	206-209	erythropoietin	Mus musculus	148-151
1711211-5	1991	In contrast, the deletion of 44 additional residues led to a dramatic loss (86.3% +/- 7.8%; mean +/- SD) in the ability of this receptor to mediate EPO-induced growth, thus indicating that residues between Gly-352 and Met-396 constitute a functionally critical cytosolic subdomain.	Methionine	218-221	erythropoietin	Mus musculus	148-151
1848667-5	1991	A carboxy-terminal negative-control domain, a serine-rich region of approximately 40 amino acids, increased the EPO requirement for the Ba/F3 transfectants without altering EPO-R cell surface expression, affinity for EPO, receptor oligosaccharide processing, or receptor endocytosis.	Serine	46-52	erythropoietin	Mus musculus	112-115
2174776-9	1990	The minimal molecular mass value was significantly greater than those obtained by polyacrylamide gel electrophoresis under denaturing conditions, strongly suggesting that the erythropoietin receptors were present as multimeric complexes.	polyacrylamide	82-96	erythropoietin	Mus musculus	175-189
1934006-1	1991	Immunohistochemically detectable erythropoietin-like substance(Epo) in granular convoluted tubule(GCT) cells of submandibular glands (SMG"s) was examined in mice in which hemolytic anemia had been induced by phenylhydrazine (ph), and in mice subjected to hypoxia, nephrectomy, or testosterone (TP) injections.	phenylhydrazine	208-223	erythropoietin	Mus musculus	63-66
1934006-1	1991	Immunohistochemically detectable erythropoietin-like substance(Epo) in granular convoluted tubule(GCT) cells of submandibular glands (SMG"s) was examined in mice in which hemolytic anemia had been induced by phenylhydrazine (ph), and in mice subjected to hypoxia, nephrectomy, or testosterone (TP) injections.	Testosterone	280-292	erythropoietin	Mus musculus	63-66
1934006-1	1991	Immunohistochemically detectable erythropoietin-like substance(Epo) in granular convoluted tubule(GCT) cells of submandibular glands (SMG"s) was examined in mice in which hemolytic anemia had been induced by phenylhydrazine (ph), and in mice subjected to hypoxia, nephrectomy, or testosterone (TP) injections.	neotetrazolium	294-296	erythropoietin	Mus musculus	63-66
2175220-0	1990	Potentiation of the erythropoietin response by dimethyl sulfoxide priming of erythroleukemia cells: evidence for interaction of two signaling pathways.	Dimethyl Sulfoxide	47-65	erythropoietin	Mus musculus	20-34
2004015-0	1991	Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.	Zidovudine	66-80	erythropoietin	Mus musculus	48-62
2004015-6	1991	Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected, untreated mice.	Zidovudine	113-116	erythropoietin	Mus musculus	91-94
2004015-8	1991	The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.	Zidovudine	42-45	erythropoietin	Mus musculus	26-29
2004015-8	1991	The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.	phenylhydrazine	130-145	erythropoietin	Mus musculus	26-29
2004015-11	1991	AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.	Zidovudine	0-3	erythropoietin	Mus musculus	104-107
1985918-0	1991	Proliferative action of erythropoietin is associated with rapid protein tyrosine phosphorylation in responsive B6SUt.EP cells.	Tyrosine	72-80	erythropoietin	Mus musculus	24-38
1985918-3	1991	Presently it is shown in the responsive, factor-dependent murine cell line B6SUt.EP that erythropoietin induces the tyrosine phosphorylation of six plasma membrane-associated proteins in a time- and concentration-dependent fashion (i.e. phosphoproteins PY153, PY140, PY100, PY93, PY74, and PY54).	Tyrosine	116-124	erythropoietin	Mus musculus	89-103
1781737-9	1991	When CFU-E from benzene-exposed mice were cultured with varying concentrations of erythropoietin (EPO), the response at maximal EPO concentration was 66% of the response by control CFU-E.	Benzene	16-23	erythropoietin	Mus musculus	82-96
1781737-9	1991	When CFU-E from benzene-exposed mice were cultured with varying concentrations of erythropoietin (EPO), the response at maximal EPO concentration was 66% of the response by control CFU-E.	Benzene	16-23	erythropoietin	Mus musculus	98-101
1781737-9	1991	When CFU-E from benzene-exposed mice were cultured with varying concentrations of erythropoietin (EPO), the response at maximal EPO concentration was 66% of the response by control CFU-E.	Benzene	16-23	erythropoietin	Mus musculus	128-131
2175220-4	1990	Pretreatment of these cells for 1 day with DMSO followed by its removal and the addition of Epo resulted in a marked enhancement of the Epo specific hemoglobinization.	Dimethyl Sulfoxide	43-47	erythropoietin	Mus musculus	136-139
2175220-6	1990	This priming effect of DMSO on the Epo response was both time-dependent and DMSO concentration-dependent.	Dimethyl Sulfoxide	23-27	erythropoietin	Mus musculus	35-38
2175220-6	1990	This priming effect of DMSO on the Epo response was both time-dependent and DMSO concentration-dependent.	Dimethyl Sulfoxide	76-80	erythropoietin	Mus musculus	35-38
2175220-7	1990	DMSO priming potentiated the Epo response in three ways.	Dimethyl Sulfoxide	0-4	erythropoietin	Mus musculus	29-32
2175220-8	1990	Firstly, DMSO priming increased the total number of Epo responsive cells from 8% to 10% to 40% to 60%.	Dimethyl Sulfoxide	9-13	erythropoietin	Mus musculus	52-55
2175220-9	1990	Secondly, DMSO priming reduced the time required to reach the optimal Epo-induced response from 4 days to 2 days.	Dimethyl Sulfoxide	10-14	erythropoietin	Mus musculus	70-73
2175220-11	1990	DMSO priming was also associated with a marked increase in Epo receptor density characterized by an apparently new receptor population and by the appearance of positive cooperativity between receptors.	Dimethyl Sulfoxide	0-4	erythropoietin	Mus musculus	59-62
2175220-12	1990	Our results suggest that the DMSO priming effect is due to potentiation of the Epo signaling pathway, thus resulting in a much more rapid and dramatic Epo-induced hemoglobinization response.	Dimethyl Sulfoxide	29-33	erythropoietin	Mus musculus	79-82
2175220-12	1990	Our results suggest that the DMSO priming effect is due to potentiation of the Epo signaling pathway, thus resulting in a much more rapid and dramatic Epo-induced hemoglobinization response.	Dimethyl Sulfoxide	29-33	erythropoietin	Mus musculus	151-154
2285259-0	1990	The in vitro effect of recombinant erythropoietin on cisdiamminodichloroplatinum-induced inhibition of murine erythroid stem cells.	cisdiamminodichloroplatinum	53-80	erythropoietin	Mus musculus	35-49
2387842-7	1990	These results suggest that the ribonucleoprotein containing the down-regulated RNA species may be a negative transcriptional factor and that activation of the erythropoietin gene by cobalt salts may involve, in part, decreased binding of this factor, thus allowing transcription to proceed.	Cobalt	182-194	erythropoietin	Mus musculus	159-173
2171931-3	1990	cAMP-elevating agents, such as forskolin and 3-isobutyl-1-methyl-xanthine, caused spontaneous erythroid differentiation, and these agents showed the stimulatory effects on erythropoietin- or Me2SO-induced differentiation.	Cyclic AMP	0-4	erythropoietin	Mus musculus	172-186
2171931-3	1990	cAMP-elevating agents, such as forskolin and 3-isobutyl-1-methyl-xanthine, caused spontaneous erythroid differentiation, and these agents showed the stimulatory effects on erythropoietin- or Me2SO-induced differentiation.	Colforsin	31-40	erythropoietin	Mus musculus	172-186
2171931-3	1990	cAMP-elevating agents, such as forskolin and 3-isobutyl-1-methyl-xanthine, caused spontaneous erythroid differentiation, and these agents showed the stimulatory effects on erythropoietin- or Me2SO-induced differentiation.	1-Methyl-3-isobutylxanthine	45-73	erythropoietin	Mus musculus	172-186
2171931-4	1990	An adenylate cyclase inhibitor, 2",5"-dideoxyadenosine, blocked erythropoietin-induced differentiation.	2',5'-dideoxyadenosine	32-54	erythropoietin	Mus musculus	64-78
2171931-5	1990	The intracellular cAMP level was rapidly increased by addition of erythropoietin but not by Me2SO.	Cyclic AMP	18-22	erythropoietin	Mus musculus	66-80
2171931-6	1990	These observations suggest that erythroid differentiation induced by erythropoietin is mediated, at least in part, through the cAMP-dependent pathway.	Cyclic AMP	127-131	erythropoietin	Mus musculus	69-83
2171931-7	1990	When the effect of erythropoietin and Me2SO on the intracellular Ca2+ level was examined using fura 2, no acute change was observed.	Fura-2	95-101	erythropoietin	Mus musculus	19-33
2171931-8	1990	Measurements of the levels of inositol 1,4,5-trisphosphate and diacylglycerol following stimulation with erythropoietin or Me2SO showed that phosphatidylinositol turnover did not change significantly after erythropoietin stimulation but decreased gradually after Me2SO induction.	Inositol 1,4,5-Trisphosphate	30-58	erythropoietin	Mus musculus	105-119
2171931-8	1990	Measurements of the levels of inositol 1,4,5-trisphosphate and diacylglycerol following stimulation with erythropoietin or Me2SO showed that phosphatidylinositol turnover did not change significantly after erythropoietin stimulation but decreased gradually after Me2SO induction.	Diglycerides	63-77	erythropoietin	Mus musculus	105-119
2171931-8	1990	Measurements of the levels of inositol 1,4,5-trisphosphate and diacylglycerol following stimulation with erythropoietin or Me2SO showed that phosphatidylinositol turnover did not change significantly after erythropoietin stimulation but decreased gradually after Me2SO induction.	Phosphatidylinositols	141-161	erythropoietin	Mus musculus	105-119
1367500-4	1990	When calcium-free suspension culture media (Joklik, DME-S, McCoy 5A-S) were used, single cell suspension cultures were obtained and high Epo production observed.	Calcium	5-12	erythropoietin	Mus musculus	137-140
2161534-3	1990	In these cells, the EPO-R is synthesized as a minor 62-kDa unglycosylated form and a major 64-kDa form carrying one high-mannose N-linked oligosaccharide.	Mannose	121-128	erythropoietin	Mus musculus	20-23
2161534-3	1990	In these cells, the EPO-R is synthesized as a minor 62-kDa unglycosylated form and a major 64-kDa form carrying one high-mannose N-linked oligosaccharide.	n-linked oligosaccharide	129-153	erythropoietin	Mus musculus	20-23
2158283-3	1990	Upon chromatography on DEAE-Sephacel anion-exchange columns, two distinct Epo receptor peak fractions referred to as Peak I and Peak II were identified by 125I-Epo binding assays using the polyethylene glycol precipitation method.	deae-sephacel anion	23-42	erythropoietin	Mus musculus	74-77
2158283-3	1990	Upon chromatography on DEAE-Sephacel anion-exchange columns, two distinct Epo receptor peak fractions referred to as Peak I and Peak II were identified by 125I-Epo binding assays using the polyethylene glycol precipitation method.	Polyethylene Glycols	189-208	erythropoietin	Mus musculus	74-77
2316714-3	1990	We found that EPO formation in mice exposed to normobaric hypoxia (8% O2) or to carbon monoxide (0.1%) was reduced by 30 and 42% when animals were simultaneously exposed to hypercapnia (7% CO2), by 35 and 38% when subjected to metabolic acidosis (NH4Cl), and unchanged when subjected to metabolic alkalosis (NaHCO3).	Oxygen	70-72	erythropoietin	Mus musculus	14-17
2316714-3	1990	We found that EPO formation in mice exposed to normobaric hypoxia (8% O2) or to carbon monoxide (0.1%) was reduced by 30 and 42% when animals were simultaneously exposed to hypercapnia (7% CO2), by 35 and 38% when subjected to metabolic acidosis (NH4Cl), and unchanged when subjected to metabolic alkalosis (NaHCO3).	Carbon Monoxide	80-95	erythropoietin	Mus musculus	14-17
2316714-3	1990	We found that EPO formation in mice exposed to normobaric hypoxia (8% O2) or to carbon monoxide (0.1%) was reduced by 30 and 42% when animals were simultaneously exposed to hypercapnia (7% CO2), by 35 and 38% when subjected to metabolic acidosis (NH4Cl), and unchanged when subjected to metabolic alkalosis (NaHCO3).	Carbon Dioxide	189-192	erythropoietin	Mus musculus	14-17
2316714-3	1990	We found that EPO formation in mice exposed to normobaric hypoxia (8% O2) or to carbon monoxide (0.1%) was reduced by 30 and 42% when animals were simultaneously exposed to hypercapnia (7% CO2), by 35 and 38% when subjected to metabolic acidosis (NH4Cl), and unchanged when subjected to metabolic alkalosis (NaHCO3).	Ammonium Chloride	247-252	erythropoietin	Mus musculus	14-17
2316714-3	1990	We found that EPO formation in mice exposed to normobaric hypoxia (8% O2) or to carbon monoxide (0.1%) was reduced by 30 and 42% when animals were simultaneously exposed to hypercapnia (7% CO2), by 35 and 38% when subjected to metabolic acidosis (NH4Cl), and unchanged when subjected to metabolic alkalosis (NaHCO3).	Sodium Bicarbonate	308-314	erythropoietin	Mus musculus	14-17
2316714-5	1990	The results indicate that acidosis inhibits hypoxia-induced triggering of EPO formation independently of PCO2 and HCO3 levels.	pco2	105-109	erythropoietin	Mus musculus	74-77
2316714-5	1990	The results indicate that acidosis inhibits hypoxia-induced triggering of EPO formation independently of PCO2 and HCO3 levels.	Bicarbonates	114-118	erythropoietin	Mus musculus	74-77
2304468-2	1990	The single-copy EPO gene is normally expressed in liver and kidney, and increased transcription is induced by anemia or cobalt chloride administration.	cobaltous chloride	120-135	erythropoietin	Mus musculus	16-19
2304468-4	1990	tgEPO4 mice expressed the transgene in liver, where expression was inducible by anemia or cobalt chloride, kidney, where expression was not inducible, and other tissues that do not normally express EPO.	cobaltous chloride	90-105	erythropoietin	Mus musculus	2-5
34488438-4	2021	Erythropoietin levels were positively and linearly associated with blood pressure traits and inversely associated with cholesterol levels and red cell indices.	Cholesterol	119-130	erythropoietin	Mus musculus	0-14
33811103-4	2021	This study assessed the effects of EPO on DAH protection using an immune-mediated DAH murine model with macrophages as the major contributor.	dah	42-45	erythropoietin	Mus musculus	35-38
34891120-7	2022	The molar ratio of anti-PEG antibody to PEG-EPO that accelerates drug clearance in mice correlates with antibody binding avidity.	Polyethylene Glycols	24-27	erythropoietin	Mus musculus	44-47
34863041-8	2022	Since oxygen regulated stability of hypoxia-inducible transcription factors relevant for EPO expression is dependent on the activity of prolyl-4-hydroxylases (PHD) 2 and 3, this study aimed to determine the relevance of different PHD isoforms for the EPO expression in renin producing cells in vivo.	Oxygen	6-12	erythropoietin	Mus musculus	89-92
34863041-8	2022	Since oxygen regulated stability of hypoxia-inducible transcription factors relevant for EPO expression is dependent on the activity of prolyl-4-hydroxylases (PHD) 2 and 3, this study aimed to determine the relevance of different PHD isoforms for the EPO expression in renin producing cells in vivo.	Oxygen	6-12	erythropoietin	Mus musculus	251-254
34843656-1	2022	Chronic kidney disease (CKD) involves disturbances in iron metabolism including anemia caused by insufficient erythropoietin (EPO) production.	Iron	54-58	erythropoietin	Mus musculus	110-124
34843656-1	2022	Chronic kidney disease (CKD) involves disturbances in iron metabolism including anemia caused by insufficient erythropoietin (EPO) production.	Iron	54-58	erythropoietin	Mus musculus	126-129
34843656-3	2022	Using the unilateral ureteral obstruction (UUO) model in Irp1+/+ and Irp1-/- mice we asked if iron regulatory proteins (IRP), the central regulators of cellular iron metabolism and also suppressors of EPO production, contribute to the etiology of anemia in kidney failure.	Iron	94-98	erythropoietin	Mus musculus	201-204
34724959-10	2021	However, TGF-beta1 repressed HIF2alpha-encoding Epas1 promptly through activating activin receptor-like kinase-5 (ALK5), thereby decreasing Epo induction by hypoxia and prolyl hydroxylase domain inhibitor roxadustat.	roxadustat	205-215	erythropoietin	Mus musculus	140-143
34724959-11	2021	In mice with pro-fibrotic injury induced by ureteral obstruction, upregulation of Tgfb1 was accompanied with downregulation of Epas1 and Epo in injured kidneys and myofibroblasts, which were reversed by ALK5 inhibitor SB431542.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	218-226	erythropoietin	Mus musculus	137-140
2204123-1	1990	Some differences between erythropoietin biogenesis under the action of natural stimuli and that resulting from testosterone administration are commented.	Testosterone	111-123	erythropoietin	Mus musculus	25-39
33942716-5	2021	Mechanistically, EPO production is impaired in REPs in Fundc1-/- mice upon stresses, and the impairment is caused by the accumulation of damaged mitochondria, which consequently leads to the elevation of the reactive oxygen species (ROS) level and triggers inflammatory responses by up-regulating proinflammatory cytokines.	Reactive Oxygen Species	208-231	erythropoietin	Mus musculus	17-20
33942716-5	2021	Mechanistically, EPO production is impaired in REPs in Fundc1-/- mice upon stresses, and the impairment is caused by the accumulation of damaged mitochondria, which consequently leads to the elevation of the reactive oxygen species (ROS) level and triggers inflammatory responses by up-regulating proinflammatory cytokines.	Reactive Oxygen Species	233-236	erythropoietin	Mus musculus	17-20
33800732-7	2021	Treatment of iron-overloaded mask mice with erythropoietin increased hemoglobin and hematocrit, indicating that the response to erythropoietin is intact in mask mice.	Iron	13-17	erythropoietin	Mus musculus	44-58
33800732-7	2021	Treatment of iron-overloaded mask mice with erythropoietin increased hemoglobin and hematocrit, indicating that the response to erythropoietin is intact in mask mice.	Iron	13-17	erythropoietin	Mus musculus	128-142
34891120-7	2022	The molar ratio of anti-PEG antibody to PEG-EPO that accelerates drug clearance in mice correlates with antibody binding avidity.	Polyethylene Glycols	40-43	erythropoietin	Mus musculus	44-47
34478930-3	2021	Here, we describe a novel strategy to exert additive effects of a non-erythropoietic EPO derivative (ARA290), along with a free radical scavenger, superoxide dismutase (SOD), using a bioengineered nanoreactor (SOD@ARA290-HBc).	cibinetide	101-107	erythropoietin	Mus musculus	85-88
34332958-6	2021	Such changes were abolished in Cry-null mice and were independent from oxygen tension, oxygen saturation, or expression of hypoxia-inducible factor 2 alpha, indicating that circadian erythropoietin expression is transcriptionally regulated by CRY1 and CRY2.	Oxygen	71-77	erythropoietin	Mus musculus	183-197
34332958-6	2021	Such changes were abolished in Cry-null mice and were independent from oxygen tension, oxygen saturation, or expression of hypoxia-inducible factor 2 alpha, indicating that circadian erythropoietin expression is transcriptionally regulated by CRY1 and CRY2.	Oxygen	87-93	erythropoietin	Mus musculus	183-197
34603036-4	2021	Beyond erythropoiesis, EPO activity includes neuroprotection in brain ischemia and trauma, endothelial nitric oxide production and cardioprotection, skeletal muscle wound healing, and context dependent bone remodeling affecting bone repair or bone loss.	Nitric Oxide	103-115	erythropoietin	Mus musculus	23-26
34145754-4	2021	Thus, in 655 nm laser-triggered PDT process, An-NP generates abundant 1 O2 with extra 1 O2 being trapped via the conversion into EPO-NP; while in the subsequent 785 nm laser-driven PTT process, the converted EPO-NP undergoes thermolysis to liberate the captured 1 O2 and regenerates An-NP.	Oxygen	88-90	erythropoietin	Mus musculus	129-132
34502385-3	2021	In this study, we used the immortalized renal interstitial fibroblast cell line FAIK F3-5 to investigate the ability of the bioactive sphingolipid sphingosine 1-phosphate (S1P) to stimulate Epo production and to reveal the mechanism involved.	Sphingolipids	134-146	erythropoietin	Mus musculus	190-193
34502385-3	2021	In this study, we used the immortalized renal interstitial fibroblast cell line FAIK F3-5 to investigate the ability of the bioactive sphingolipid sphingosine 1-phosphate (S1P) to stimulate Epo production and to reveal the mechanism involved.	sphingosine 1-phosphate	147-170	erythropoietin	Mus musculus	190-193
34502385-4	2021	Stimulation of cells with exogenous S1P under normoxic conditions (21% O2) led to a dose-dependent increase in Epo mRNA and protein levels and subsequent release of Epo into the medium.	Oxygen	71-73	erythropoietin	Mus musculus	111-114
34502385-4	2021	Stimulation of cells with exogenous S1P under normoxic conditions (21% O2) led to a dose-dependent increase in Epo mRNA and protein levels and subsequent release of Epo into the medium.	Oxygen	71-73	erythropoietin	Mus musculus	165-168
34502385-7	2021	Furthermore, the approved S1P receptor modulator FTY720, and its active form FTY720-phosphate, both exerted a similar effect on Epo expression as S1P.	Fingolimod Hydrochloride	49-55	erythropoietin	Mus musculus	128-131
34502385-7	2021	Furthermore, the approved S1P receptor modulator FTY720, and its active form FTY720-phosphate, both exerted a similar effect on Epo expression as S1P.	FTY 720P	77-93	erythropoietin	Mus musculus	128-131
34502385-8	2021	The effect of S1P on Epo was antagonized by the selective S1P1 and S1P3 antagonists NIBR-0213 and TY-52156, but not by the S1P2 antagonist JTE-013.	NIBR-0213	84-93	erythropoietin	Mus musculus	21-24
34502385-8	2021	The effect of S1P on Epo was antagonized by the selective S1P1 and S1P3 antagonists NIBR-0213 and TY-52156, but not by the S1P2 antagonist JTE-013.	1-(4-chlorophenylhydrazono)-1-(4-chlorophenylamino)-3,3-dimethyl-2-butanone	98-106	erythropoietin	Mus musculus	21-24
34360974-1	2021	Erythropoietin (EPO) downregulates hepcidin expression to increase the availability of iron; the downregulation of hepcidin is mediated by erythroferrone (ERFE) secreted by erythroblasts.	Iron	87-91	erythropoietin	Mus musculus	0-14
34360974-1	2021	Erythropoietin (EPO) downregulates hepcidin expression to increase the availability of iron; the downregulation of hepcidin is mediated by erythroferrone (ERFE) secreted by erythroblasts.	Iron	87-91	erythropoietin	Mus musculus	16-19
34360974-1	2021	Erythropoietin (EPO) downregulates hepcidin expression to increase the availability of iron; the downregulation of hepcidin is mediated by erythroferrone (ERFE) secreted by erythroblasts.	erythroferrone	139-153	erythropoietin	Mus musculus	16-19
34449797-8	2021	Captopril significantly reduced radiation-induced expression of cytokines erythropoietin and granulocyte-macrophage colony-stimulating factor and suppressed radiation-induced acute-phase inflammatory response cytokine serum amyloid protein A.	Captopril	0-9	erythropoietin	Mus musculus	74-88
34145754-4	2021	Thus, in 655 nm laser-triggered PDT process, An-NP generates abundant 1 O2 with extra 1 O2 being trapped via the conversion into EPO-NP; while in the subsequent 785 nm laser-driven PTT process, the converted EPO-NP undergoes thermolysis to liberate the captured 1 O2 and regenerates An-NP.	Oxygen	264-266	erythropoietin	Mus musculus	208-211
34980719-6	2021	NaNO2 consumption and HFD feeding each resulted in increased splenic mRNAs for cell markers of neutrophils (Ngp, NE, Ly6g, Mpo) and eosinophils (Epo, Ear6), and an S100 family member (S100A8).	Sodium Nitrite	0-5	erythropoietin	Mus musculus	145-148
34725710-1	2021	Erythropoietin enhances oxygen delivery and reduces hypoxia-induced cell death, but its pro-thrombotic activity is problematic for use of erythropoietin in treating hypoxia.	Oxygen	24-30	erythropoietin	Mus musculus	0-14
34483444-9	2021	Malone dialdehyde level in EPO and orchidopexy group showed significant difference p = 0.01 and 0.009 when compared to undescended testis group.	Dialdehyde	7-17	erythropoietin	Mus musculus	27-30
34124083-17	2021	The cyclosporin A- and stanozolol-treated mice showed higher serum erythropoietin (corrected by hemoglobin level) and higher erythropoietin receptor levels in bone marrow mononuclear cells than the other groups (P < 0.05).	Cyclosporine	4-17	erythropoietin	Mus musculus	67-81
34124083-17	2021	The cyclosporin A- and stanozolol-treated mice showed higher serum erythropoietin (corrected by hemoglobin level) and higher erythropoietin receptor levels in bone marrow mononuclear cells than the other groups (P < 0.05).	Stanozolol	23-33	erythropoietin	Mus musculus	67-81
34124083-21	2021	Stanozolol could enhance the secretion of erythropoietin and expression of erythropoietin receptor in bone marrow mononuclear cells.	Stanozolol	0-10	erythropoietin	Mus musculus	42-56
35389892-6	2022	Together, the data support the conclusion that EPO promotes TREG-dependent murine cardiac allograft survival by crucially altering the phenotype and function of macrophages.	treg	60-64	erythropoietin	Mus musculus	47-50
35435001-5	2022	Examination of plasma samples demonstrated that PNx induced significant increases in systemic oxidant stress as assessed by protein carbonylation, plasma erythropoietin (EPO) concentration, and BUN.	Pentoxifylline	48-51	erythropoietin	Mus musculus	154-168
35435001-5	2022	Examination of plasma samples demonstrated that PNx induced significant increases in systemic oxidant stress as assessed by protein carbonylation, plasma erythropoietin (EPO) concentration, and BUN.	Pentoxifylline	48-51	erythropoietin	Mus musculus	170-173
35563527-0	2022	DOT1L Methyltransferase Regulates Calcium Influx in Erythroid Progenitor Cells in Response to Erythropoietin.	Calcium	34-41	erythropoietin	Mus musculus	94-108
35563527-2	2022	An important downstream response of EPO signaling is calcium (Ca2+) influx, which is regulated by transient receptor potential channel (TRPC) proteins, particularly TRPC2 and TRPC6.	Calcium	53-60	erythropoietin	Mus musculus	36-39
35193085-11	2022	CONCLUSIONS: Erythropoietin and GM1 have therapeutic effects on axonal regeneration in mice subjected to experimental spinal cord injury, and administration of GM1 alone had the highest scores on the BMS and MFS scales.	G(M1) Ganglioside	160-163	erythropoietin	Mus musculus	13-27
35514353-0	2022	In Transgenic Erythropoietin Deficient Mice, an Increase in Respiratory Response to Hypercapnia Parallels Abnormal Distribution of CO2/H+-Activated Cells in the Medulla Oblongata.	Carbon Dioxide	131-134	erythropoietin	Mus musculus	14-28
34982511-1	2022	AIM: Fibroblast-like renal erythropoietin (Epo) producing (REP) cells of the corticomedullary border region "sense" a decrease in blood oxygen content following anaemia or hypoxaemia.	Oxygen	136-142	erythropoietin	Mus musculus	27-41
34982511-1	2022	AIM: Fibroblast-like renal erythropoietin (Epo) producing (REP) cells of the corticomedullary border region "sense" a decrease in blood oxygen content following anaemia or hypoxaemia.	Oxygen	136-142	erythropoietin	Mus musculus	43-46
35491502-7	2022	RESULTS: In AN, molidustat-induced Epo transcripts were not found in areas of fibrosis and did not colocalize with interstitial cells that expressed alpha-smooth muscle actin, a marker of myofibroblast transdifferentiation.	molidustat	16-26	erythropoietin	Mus musculus	35-38
35487446-7	2022	The concentration of EPO and HIF-1alpha and the expression of HIF-1alpha protein in A549 cells was increased by 10 mumol/L BaP (P < 0.05); with HIF-1alpha inhibitors treated, HSP90alpha, HSC70, Lamp-2A mRNA and protein expression and the fluorescence intensity of HSP90alpha was decreased of A549 cells (P < 0.05).	benzylaminopurine	123-126	erythropoietin	Mus musculus	21-24
35385924-9	2022	Trp53floxWapCre mice are the first mouse model where EPO-resistant anemia is described and may serve as a disease model to test therapeutic approaches for a subpopulation of human cancer patients with normal or corrected iron levels that do not respond to EPO.	Iron	221-225	erythropoietin	Mus musculus	53-56
35114188-6	2022	In the kidneys and livers of mice, both of which are unique sites of EPO production, a majority of the methyl-esterified roxadustat was deesterified within 6 hours after drug administration.	roxadustat	121-131	erythropoietin	Mus musculus	69-72
35114188-8	2022	Additionally, we confirmed that methyl-esterified roxadustat activated erythropoiesis in mice by inducing EPO mRNA expression exclusively in renal interstitial cells, which have intrinsic EPO-producing potential.	roxadustat	50-60	erythropoietin	Mus musculus	106-109
35114188-8	2022	Additionally, we confirmed that methyl-esterified roxadustat activated erythropoiesis in mice by inducing EPO mRNA expression exclusively in renal interstitial cells, which have intrinsic EPO-producing potential.	roxadustat	50-60	erythropoietin	Mus musculus	188-191
35203399-0	2022	The HIFalpha-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1+ Cells.	roxadustat	30-40	erythropoietin	Mus musculus	71-74
35203399-1	2022	Inhibition of the prolyl-4-hydroxylase domain (PHD) enzymes, leading to the stabilization of hypoxia-inducible factor (HIF) alpha as well as to the stimulation of erythropoietin (Epo) synthesis, is the functional mechanism of the new anti-anemia drug roxadustat.	roxadustat	251-261	erythropoietin	Mus musculus	163-177
35203399-1	2022	Inhibition of the prolyl-4-hydroxylase domain (PHD) enzymes, leading to the stabilization of hypoxia-inducible factor (HIF) alpha as well as to the stimulation of erythropoietin (Epo) synthesis, is the functional mechanism of the new anti-anemia drug roxadustat.	roxadustat	251-261	erythropoietin	Mus musculus	179-182
35203399-8	2022	In summary, we have identified a Sca-1+ MSC-like cell population that is involved in renal Epo production and might contribute to the strong anti-anemic effect of the PHD inhibitor roxadustat.	roxadustat	181-191	erythropoietin	Mus musculus	91-94
2792225-0	1989	Calcium response to erythropoietin in erythroleukemia cells.	Calcium	0-7	erythropoietin	Mus musculus	20-34
2783129-4	1989	When mouse bone marrow cells were cultured in methylcellulose medium containing physiological concentrations of erythropoietin (0.048 units/ml), addition of ESA stimulated the growth of colony forming unit-erythroid (CFU-E) up to three-fold a in dose dependent manner.	methylcellulose medium	46-68	erythropoietin	Mus musculus	112-126
2792225-2	1989	The antigen-positive subpopulation of cells responded to EPO by transiently changing indo 1 fluorescence emissions, indicating a change in cytoplasmic calcium concentration.	Calcium	151-158	erythropoietin	Mus musculus	57-60
2792225-3	1989	EGTA blocked the EPO response, suggesting that Ca2+ influx may have followed EPO exposure in these cells.	Egtazic Acid	0-4	erythropoietin	Mus musculus	17-20
2792225-3	1989	EGTA blocked the EPO response, suggesting that Ca2+ influx may have followed EPO exposure in these cells.	Egtazic Acid	0-4	erythropoietin	Mus musculus	77-80
2752138-10	1989	These results suggest that following an acute blood loss and during the recovery from a blood loss, the capacity to deliver oxygen, as represented by hematocrit, is the major regulator of EP production.	Oxygen	124-130	erythropoietin	Mus musculus	188-190
2496770-0	1989	The effect of recombinant erythropoietin on intracellular free calcium in erythropoietin-responsive cells.	Calcium	63-70	erythropoietin	Mus musculus	26-40
2543671-2	1989	Using the cross-linking reagents disuccinimidyl suberate and dithiobissuccinimidyl propionate, we show that 125I-Epo can be specifically conjugated in a complex of 224kDa using mouse fetal liver cells, bone marrow cells, and Friend virus-induced splenic erythroblasts as demonstrated by electrophoresis on sodium dodecyl sulfate-polyacrylamide gels under nonreducing conditions.	dithiobis(succinimidylpropionate)	61-93	erythropoietin	Mus musculus	113-116
2543671-2	1989	Using the cross-linking reagents disuccinimidyl suberate and dithiobissuccinimidyl propionate, we show that 125I-Epo can be specifically conjugated in a complex of 224kDa using mouse fetal liver cells, bone marrow cells, and Friend virus-induced splenic erythroblasts as demonstrated by electrophoresis on sodium dodecyl sulfate-polyacrylamide gels under nonreducing conditions.	Iodine-125	108-112	erythropoietin	Mus musculus	113-116
2543671-2	1989	Using the cross-linking reagents disuccinimidyl suberate and dithiobissuccinimidyl propionate, we show that 125I-Epo can be specifically conjugated in a complex of 224kDa using mouse fetal liver cells, bone marrow cells, and Friend virus-induced splenic erythroblasts as demonstrated by electrophoresis on sodium dodecyl sulfate-polyacrylamide gels under nonreducing conditions.	Sodium Dodecyl Sulfate	306-328	erythropoietin	Mus musculus	113-116
2543671-2	1989	Using the cross-linking reagents disuccinimidyl suberate and dithiobissuccinimidyl propionate, we show that 125I-Epo can be specifically conjugated in a complex of 224kDa using mouse fetal liver cells, bone marrow cells, and Friend virus-induced splenic erythroblasts as demonstrated by electrophoresis on sodium dodecyl sulfate-polyacrylamide gels under nonreducing conditions.	polyacrylamide	329-343	erythropoietin	Mus musculus	113-116
2543671-5	1989	With increasing time of 125I-Epo binding to Friend virus erythroblasts in the presence of sodium azide to inhibit receptor internalization, the 136-kDa and 119-kDa bands seen under reducing conditions increased markedly in intensity, whereas the 224-kDa band seen under nonreducing conditions declined.	Sodium Azide	90-102	erythropoietin	Mus musculus	29-32
2543671-8	1989	It is concluded that the two disulfide-linked Epo-binding proteins which can be independently cross-linked to Epo form a single ligand binding site.	Disulfides	29-38	erythropoietin	Mus musculus	46-49
2543671-8	1989	It is concluded that the two disulfide-linked Epo-binding proteins which can be independently cross-linked to Epo form a single ligand binding site.	Disulfides	29-38	erythropoietin	Mus musculus	110-113
2714418-8	1989	As positive control, kidneys from anemic mice were hybridized with the biotin-labeled Epo DNA.	Biotin	71-77	erythropoietin	Mus musculus	86-89
2543671-2	1989	Using the cross-linking reagents disuccinimidyl suberate and dithiobissuccinimidyl propionate, we show that 125I-Epo can be specifically conjugated in a complex of 224kDa using mouse fetal liver cells, bone marrow cells, and Friend virus-induced splenic erythroblasts as demonstrated by electrophoresis on sodium dodecyl sulfate-polyacrylamide gels under nonreducing conditions.	disuccinimidyl	33-47	erythropoietin	Mus musculus	113-116
2719123-1	1989	Regulation of renal erythropoietin (EPO) production is based on an intrarenal oxygen sensor.	Oxygen	78-84	erythropoietin	Mus musculus	20-34
2719123-1	1989	Regulation of renal erythropoietin (EPO) production is based on an intrarenal oxygen sensor.	Oxygen	78-84	erythropoietin	Mus musculus	36-39
2719123-6	1989	Acetazolamide on the other hand, which is thought to act predominantly at the proximal tubular site, significantly reduced EPO formation in response to normobaric hypoxia (8 and 14% O2) and functional anemia (0.1% carbon monoxide).	Acetazolamide	0-13	erythropoietin	Mus musculus	123-126
2719123-6	1989	Acetazolamide on the other hand, which is thought to act predominantly at the proximal tubular site, significantly reduced EPO formation in response to normobaric hypoxia (8 and 14% O2) and functional anemia (0.1% carbon monoxide).	Oxygen	182-184	erythropoietin	Mus musculus	123-126
2496770-1	1989	We have investigated whether recombinant erythropoietin (r-Epo) elicits a change in intracellular free calcium (IFC) in purified Epo-responsive cells in spleens of mice treated with phenylhydrazine.	Calcium	103-110	erythropoietin	Mus musculus	41-55
2496770-1	1989	We have investigated whether recombinant erythropoietin (r-Epo) elicits a change in intracellular free calcium (IFC) in purified Epo-responsive cells in spleens of mice treated with phenylhydrazine.	Calcium	103-110	erythropoietin	Mus musculus	59-62
2496770-1	1989	We have investigated whether recombinant erythropoietin (r-Epo) elicits a change in intracellular free calcium (IFC) in purified Epo-responsive cells in spleens of mice treated with phenylhydrazine.	phenylhydrazine	182-197	erythropoietin	Mus musculus	41-55
2496770-0	1989	The effect of recombinant erythropoietin on intracellular free calcium in erythropoietin-responsive cells.	Calcium	63-70	erythropoietin	Mus musculus	74-88
2545067-0	1989	Tunicamycin modulates binding of 125I-erythropoietin to Friend erythroleukemia cells.	Tunicamycin	0-11	erythropoietin	Mus musculus	38-52
2651136-2	1989	In this assay, spleen (SP) cells from phenylhydrazine (PHZ)-treated mice (PHZ-SP), enriched for erythroid progenitor cells, respond to Epo in a dose-dependent manner.	phenylhydrazine	38-53	erythropoietin	Mus musculus	135-138
2651136-2	1989	In this assay, spleen (SP) cells from phenylhydrazine (PHZ)-treated mice (PHZ-SP), enriched for erythroid progenitor cells, respond to Epo in a dose-dependent manner.	phenylhydrazine	55-58	erythropoietin	Mus musculus	135-138
2651136-2	1989	In this assay, spleen (SP) cells from phenylhydrazine (PHZ)-treated mice (PHZ-SP), enriched for erythroid progenitor cells, respond to Epo in a dose-dependent manner.	phz-sp	74-80	erythropoietin	Mus musculus	135-138
2651136-4	1989	When SP or BM cells from malaria-infected mice were added to cultures of SP or BM cells from PHZ-treated mice the response to Epo of these cells was significantly inhibited.	phenylhydrazine	93-96	erythropoietin	Mus musculus	126-129
2651136-7	1989	Cell-free conditioned media (CM) prepared from SP cells of P. berghei- or P. vinckei-infected mice or from normal SP cells incubated with pRBC were also able to inhibit the response to Epo of SP cells from PHZ-treated mice.	prbc	138-142	erythropoietin	Mus musculus	185-188
2465166-6	1989	In initial experiments, cAMP levels in cells stimulated with either recombinant Epo or recombinant IL-3 were monitored.	Cyclic AMP	24-28	erythropoietin	Mus musculus	80-83
2465166-10	1989	The regulatory effects of cAMP on Epo- and IL-3-stimulated cell growth were next examined.	Cyclic AMP	26-30	erythropoietin	Mus musculus	34-37
2465166-11	1989	It was found that whereas Epo-stimulated growth was markedly inhibited by cAMP-enhancing agents, IL-3-stimulated growth was relatively resistant and inhibited only by high doses of these agents.	Cyclic AMP	74-78	erythropoietin	Mus musculus	26-29
2543389-1	1989	Functional erythropoietin (Ep) receptor (Ep-R) on transplantable mouse leukemic cells was solubilized by 3[(3-cholamidopropyl)dimethyl ammonio]-1-propanesulfate (CHAPS).	3[(3-cholamidopropyl)dimethyl ammonio]-1-propanesulfate	105-160	erythropoietin	Mus musculus	11-25
2543389-1	1989	Functional erythropoietin (Ep) receptor (Ep-R) on transplantable mouse leukemic cells was solubilized by 3[(3-cholamidopropyl)dimethyl ammonio]-1-propanesulfate (CHAPS).	3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate	162-167	erythropoietin	Mus musculus	11-25
2501036-1	1989	The murine erythroleukemia (MEL) cell line, TSA8, becomes responsive to erythropoietin after induction with dimethyl sulfoxide (DMSO).	Dimethyl Sulfoxide	108-126	erythropoietin	Mus musculus	72-86
2501036-1	1989	The murine erythroleukemia (MEL) cell line, TSA8, becomes responsive to erythropoietin after induction with dimethyl sulfoxide (DMSO).	Dimethyl Sulfoxide	128-132	erythropoietin	Mus musculus	72-86
2501036-3	1989	Amiloride, an inhibitor of the Na+/H+ antiporter, completely blocked the commitment of TSA8 cells to become responsive to erythropoietin at a concentration that did not affect cell proliferation, while it showed no effect on the differentiation or proliferation of the erythroid progenitor cells derived from TSA8 cells by erythropoietin.	Amiloride	0-9	erythropoietin	Mus musculus	122-136
2501036-3	1989	Amiloride, an inhibitor of the Na+/H+ antiporter, completely blocked the commitment of TSA8 cells to become responsive to erythropoietin at a concentration that did not affect cell proliferation, while it showed no effect on the differentiation or proliferation of the erythroid progenitor cells derived from TSA8 cells by erythropoietin.	Amiloride	0-9	erythropoietin	Mus musculus	323-337
2545067-2	1989	Neuraminidase treatment of B8 cells did not affect the specific binding of erythropoietin, but tunicamycin treatment caused a 2.5 to 4-fold increase in the amount of 125I-erythropoietin binding.	Tunicamycin	95-106	erythropoietin	Mus musculus	171-185
2545067-4	1989	These results suggest that N-linked sugars of the erythropoietin receptor protein are involved in the interaction of erythropoietin with the cell-surface receptors on B8 cells.	Nitrogen	27-28	erythropoietin	Mus musculus	50-64
2545067-4	1989	These results suggest that N-linked sugars of the erythropoietin receptor protein are involved in the interaction of erythropoietin with the cell-surface receptors on B8 cells.	Nitrogen	27-28	erythropoietin	Mus musculus	117-131
2545067-4	1989	These results suggest that N-linked sugars of the erythropoietin receptor protein are involved in the interaction of erythropoietin with the cell-surface receptors on B8 cells.	Sugars	36-42	erythropoietin	Mus musculus	50-64
2545067-4	1989	These results suggest that N-linked sugars of the erythropoietin receptor protein are involved in the interaction of erythropoietin with the cell-surface receptors on B8 cells.	Sugars	36-42	erythropoietin	Mus musculus	117-131
2649180-6	1989	Animal experiments using murine models have documented that several purified molecules including erythropoietin, multi-CSF and GM-CSF possess Mk-CSA.	mk-csa	142-148	erythropoietin	Mus musculus	97-111
2553385-3	1989	TSA8 cells become responsive to erythropoietin after induction with DMSO.	Dimethyl Sulfoxide	68-72	erythropoietin	Mus musculus	32-46
2914166-0	1989	[Determination of serum and plasma erythropoietin in mice with phenylhydrazine-induced anemia].	phenylhydrazine	63-78	erythropoietin	Mus musculus	35-49
2914166-1	1989	The simple, specific and sensitive erythropoietin bioassay in serum and plasma from phenylhydrazine treated mice is described, based on H3-thymidine incorporation into divided hemopoietic cells.	phenylhydrazine	84-99	erythropoietin	Mus musculus	35-49
2914166-1	1989	The simple, specific and sensitive erythropoietin bioassay in serum and plasma from phenylhydrazine treated mice is described, based on H3-thymidine incorporation into divided hemopoietic cells.	h3-thymidine	136-148	erythropoietin	Mus musculus	35-49
2553385-4	1989	Stimulatory effects on erythropoietin response are observed with the addition of compounds affecting the cAMP level such as forskolin, phosphodiesterase inhibitor and cholera toxin only in the presence of erythropoietin.	Cyclic AMP	105-109	erythropoietin	Mus musculus	23-37
2553385-4	1989	Stimulatory effects on erythropoietin response are observed with the addition of compounds affecting the cAMP level such as forskolin, phosphodiesterase inhibitor and cholera toxin only in the presence of erythropoietin.	Cyclic AMP	105-109	erythropoietin	Mus musculus	205-219
2553385-4	1989	Stimulatory effects on erythropoietin response are observed with the addition of compounds affecting the cAMP level such as forskolin, phosphodiesterase inhibitor and cholera toxin only in the presence of erythropoietin.	Colforsin	124-133	erythropoietin	Mus musculus	23-37
2553385-4	1989	Stimulatory effects on erythropoietin response are observed with the addition of compounds affecting the cAMP level such as forskolin, phosphodiesterase inhibitor and cholera toxin only in the presence of erythropoietin.	Colforsin	124-133	erythropoietin	Mus musculus	205-219
2553385-5	1989	cAMP analogues themselves show no stimulatory effect on TSA8 cells, nor does erythropoietin increase cAMP level in the cells.	Cyclic AMP	101-105	erythropoietin	Mus musculus	77-91
2553385-6	1989	Thus, it is suggested that cAMP does not act as a direct second messenger for signal transduction through erythropoietin receptors, but as a stimulator of the erythropoietin receptor pathway and/or as a second messenger in combination with the receptor pathway.	Cyclic AMP	27-31	erythropoietin	Mus musculus	106-120
2553385-6	1989	Thus, it is suggested that cAMP does not act as a direct second messenger for signal transduction through erythropoietin receptors, but as a stimulator of the erythropoietin receptor pathway and/or as a second messenger in combination with the receptor pathway.	Cyclic AMP	27-31	erythropoietin	Mus musculus	159-173
2840960-4	1988	Crosslinking of 125I-erythropoietin to its binding sites with disuccinimidyl suberate revealed the existence of a single binding protein with molecular mass of 63 kDa.	disuccinimidyl	62-76	erythropoietin	Mus musculus	21-35
2632899-6	1989	These results suggest that the renal Epo-producing tissue or its oxygen-sensing system is less hypoxic in cyanated mice than in normal mice under 350 Torr, and that the physiologically optimal oxygen affinity of blood is variable depending on hypoxic degrees.	Oxygen	193-199	erythropoietin	Mus musculus	37-40
2737182-3	1989	The highest frequency of micronucleated polychromatic erythrocytes (MPCE) and a dose-response relationship between erythropoietin doses and MPCE frequency were seen 30 hr after injection of 1,1-dimethylhydrazine (DMH) to mice administered 24 hr previously with erythropoietin.	dimazine	190-211	erythropoietin	Mus musculus	115-129
2737182-3	1989	The highest frequency of micronucleated polychromatic erythrocytes (MPCE) and a dose-response relationship between erythropoietin doses and MPCE frequency were seen 30 hr after injection of 1,1-dimethylhydrazine (DMH) to mice administered 24 hr previously with erythropoietin.	dimazine	190-211	erythropoietin	Mus musculus	261-275
2737182-3	1989	The highest frequency of micronucleated polychromatic erythrocytes (MPCE) and a dose-response relationship between erythropoietin doses and MPCE frequency were seen 30 hr after injection of 1,1-dimethylhydrazine (DMH) to mice administered 24 hr previously with erythropoietin.	dimazine	213-216	erythropoietin	Mus musculus	115-129
2737182-3	1989	The highest frequency of micronucleated polychromatic erythrocytes (MPCE) and a dose-response relationship between erythropoietin doses and MPCE frequency were seen 30 hr after injection of 1,1-dimethylhydrazine (DMH) to mice administered 24 hr previously with erythropoietin.	dimazine	213-216	erythropoietin	Mus musculus	261-275
2737182-4	1989	The effect of erythropoietin was maximal when erythropoietin was given 24 hr before DMH, indicating that accelerating the multiplication of erythroblasts will increase the frequency of micronuclei induced by mutagens.	dimazine	84-87	erythropoietin	Mus musculus	14-28
2737182-5	1989	Induction of MPCE in the bone marrow by four other compounds--benzo(a)pyrene, 2-naphthylamine, mitomycin C, and vincristine--was also increased by pretreatment with erythropoietin.	mpce	13-17	erythropoietin	Mus musculus	165-179
2737182-5	1989	Induction of MPCE in the bone marrow by four other compounds--benzo(a)pyrene, 2-naphthylamine, mitomycin C, and vincristine--was also increased by pretreatment with erythropoietin.	Benzo(a)pyrene	62-76	erythropoietin	Mus musculus	165-179
2737182-5	1989	Induction of MPCE in the bone marrow by four other compounds--benzo(a)pyrene, 2-naphthylamine, mitomycin C, and vincristine--was also increased by pretreatment with erythropoietin.	2-Naphthylamine	78-93	erythropoietin	Mus musculus	165-179
2737182-5	1989	Induction of MPCE in the bone marrow by four other compounds--benzo(a)pyrene, 2-naphthylamine, mitomycin C, and vincristine--was also increased by pretreatment with erythropoietin.	Mitomycin	95-106	erythropoietin	Mus musculus	165-179
2737182-5	1989	Induction of MPCE in the bone marrow by four other compounds--benzo(a)pyrene, 2-naphthylamine, mitomycin C, and vincristine--was also increased by pretreatment with erythropoietin.	Vincristine	112-123	erythropoietin	Mus musculus	165-179
2632899-6	1989	These results suggest that the renal Epo-producing tissue or its oxygen-sensing system is less hypoxic in cyanated mice than in normal mice under 350 Torr, and that the physiologically optimal oxygen affinity of blood is variable depending on hypoxic degrees.	Oxygen	65-71	erythropoietin	Mus musculus	37-40
2467647-1	1988	The signal for erythropoietin (epo) production is partial oxygen tension.	Oxygen	58-64	erythropoietin	Mus musculus	15-29
3402556-4	1988	When r-EPo was added to the culture system on day 3 after megakaryocytic colony formation with PWM-SCM, the serotonin content in megakaryocytes increased markedly but ATP content and Ach-E activity did not increase significantly.	Serotonin	108-117	erythropoietin	Mus musculus	7-10
2467647-1	1988	The signal for erythropoietin (epo) production is partial oxygen tension.	Oxygen	58-64	erythropoietin	Mus musculus	31-34
2467647-2	1988	Erythropoietin release from cultured macrophages, derived from unstimulated and unseparated mouse bone marrow cells, occurs in response to changing physiological oxygen concentrations.	Oxygen	162-168	erythropoietin	Mus musculus	0-14
2467647-3	1988	In situ hybridisation, using biotin-labelled epo DNA demonstrated epo gene expression in both in vitro-derived and in vivo macrophages.	Biotin	29-35	erythropoietin	Mus musculus	45-48
2467647-3	1988	In situ hybridisation, using biotin-labelled epo DNA demonstrated epo gene expression in both in vitro-derived and in vivo macrophages.	Biotin	29-35	erythropoietin	Mus musculus	66-69
3165492-3	1988	While cytosine arabinoside inhibited colony formation and terminal differentiation of the CFU-E cells responding to epo, herbimycin, which is a drug that inhibits src-related phosphorylation, inhibited colony formation only.	Cytarabine	6-26	erythropoietin	Mus musculus	116-119
2460423-7	1988	Studies on binding and cross-linking of 125I-erythropoietin showed that ELM-I-1 cells had erythropoietin receptors, and two major radiolabeled protein products with molecular weights of 120 kDa and 140 kDa were detected on sodium dodecyl sulfate/polyacrylamide gel electrophoresis under reducing conditions.	Sodium Dodecyl Sulfate	223-245	erythropoietin	Mus musculus	45-59
3240225-2	1988	Both EPO preparations have been characterized biologically: The proliferation of murine spleen cells in vitro after pretreatment with phenylhydrazine and the 59Fe incorporation into the heme of polycythemic mice have been determined.	Iron-59	158-162	erythropoietin	Mus musculus	5-8
3281726-1	1988	Marrow cells from 5-fluorouracil (5-FU)-treated mice formed few or no mixed erythroid colonies when plated in semisolid medium with interleukin 3 (IL 3) and erythropoietin (Ep) alone.	Fluorouracil	18-32	erythropoietin	Mus musculus	157-171
3216494-0	1988	[In vitro erythropoietin bioassay based on 3H-thymidine incorporation into spleen cells from phenylhydrazine-treated mice].	3h-thymidine	43-55	erythropoietin	Mus musculus	10-24
3216494-0	1988	[In vitro erythropoietin bioassay based on 3H-thymidine incorporation into spleen cells from phenylhydrazine-treated mice].	phenylhydrazine	93-108	erythropoietin	Mus musculus	10-24
3281726-1	1988	Marrow cells from 5-fluorouracil (5-FU)-treated mice formed few or no mixed erythroid colonies when plated in semisolid medium with interleukin 3 (IL 3) and erythropoietin (Ep) alone.	Fluorouracil	34-38	erythropoietin	Mus musculus	157-171
2832053-0	1988	Induction of the receptor for erythropoietin in murine erythroleukemia cells after dimethyl sulfoxide treatment.	Dimethyl Sulfoxide	83-101	erythropoietin	Mus musculus	30-44
2835222-1	1987	On addition of DMSO, the MEL cell line TSA8 becomes committed into erythroid progenitor cells (CFU-E) which can form differentiated colonies in the presence of erythropoietin.	Dimethyl Sulfoxide	15-19	erythropoietin	Mus musculus	160-174
2832053-3	1988	During erythroid differentiation by dimethyl sulfoxide, B8 cells displayed a rapid and marked increase in the amount of specific 125I-EPO binding before the appearance of hemoglobin-containing cells.	Dimethyl Sulfoxide	36-54	erythropoietin	Mus musculus	134-137
2832053-5	1988	In addition, the number of EPO receptors on B8 cells was increased twice by induction with DMSO for 1 day, but the binding affinity of EPO toward its receptors did not change significantly.	Dimethyl Sulfoxide	91-95	erythropoietin	Mus musculus	27-30
3265640-4	1988	Addition of anemic mouse spleen-conditioned medium (AMSCM) to the culture as a source of BPA resulted in the increase of BFUe and the reduction of CFUe under various concentrations of Epo.	bisphenol A	89-92	erythropoietin	Mus musculus	184-187
2822405-5	1987	Covalent binding of 125I-erythropoietin to its receptors with a cross-linking reagent, disuccinimidyl suberate or glutaraldehyde, resulted in the formation of two major radiolabeled products that migrated as 120-kDa and 140-kDa species on sodium dodecyl sulfate/polyacrylamide electrophoresis gels under reducing conditions.	disuccinimidyl	87-101	erythropoietin	Mus musculus	25-39
2822405-5	1987	Covalent binding of 125I-erythropoietin to its receptors with a cross-linking reagent, disuccinimidyl suberate or glutaraldehyde, resulted in the formation of two major radiolabeled products that migrated as 120-kDa and 140-kDa species on sodium dodecyl sulfate/polyacrylamide electrophoresis gels under reducing conditions.	Glutaral	114-128	erythropoietin	Mus musculus	25-39
2822405-5	1987	Covalent binding of 125I-erythropoietin to its receptors with a cross-linking reagent, disuccinimidyl suberate or glutaraldehyde, resulted in the formation of two major radiolabeled products that migrated as 120-kDa and 140-kDa species on sodium dodecyl sulfate/polyacrylamide electrophoresis gels under reducing conditions.	Sodium Dodecyl Sulfate	239-261	erythropoietin	Mus musculus	25-39
2822405-5	1987	Covalent binding of 125I-erythropoietin to its receptors with a cross-linking reagent, disuccinimidyl suberate or glutaraldehyde, resulted in the formation of two major radiolabeled products that migrated as 120-kDa and 140-kDa species on sodium dodecyl sulfate/polyacrylamide electrophoresis gels under reducing conditions.	polyacrylamide	262-276	erythropoietin	Mus musculus	25-39
3339134-4	1988	35S-labeled DNA fragments of the murine Epo gene were used as probes for in situ hybridization.	Sulfur-35	0-3	erythropoietin	Mus musculus	40-43
3273627-1	1988	The method here described is based on the property of erythropoietin to remain in water solution in the presence of up to 60% ethanol.	Water	82-87	erythropoietin	Mus musculus	54-68
3273627-1	1988	The method here described is based on the property of erythropoietin to remain in water solution in the presence of up to 60% ethanol.	Ethanol	126-133	erythropoietin	Mus musculus	54-68
3398696-1	1988	The effects of adenosine (ADE) and ADE agonists on erythropoietin (Ep) production were determined using percent (%) 59Fe incorporation in red cells of exhypoxic polycythemic mice.	Adenosine	26-29	erythropoietin	Mus musculus	51-65
3398696-1	1988	The effects of adenosine (ADE) and ADE agonists on erythropoietin (Ep) production were determined using percent (%) 59Fe incorporation in red cells of exhypoxic polycythemic mice.	Adenosine	35-38	erythropoietin	Mus musculus	51-65
3115260-1	1987	Erythroid progenitor cells synthesize 12-hydroxyeicosatetraenoic acid (12-HETE) and 15-hydroxyeicosatetraenoic acid (15-HETE) when stimulated by erythropoietin (Ep).	12-Hydroxy-5,8,10,14-eicosatetraenoic Acid	38-69	erythropoietin	Mus musculus	145-159
3115260-1	1987	Erythroid progenitor cells synthesize 12-hydroxyeicosatetraenoic acid (12-HETE) and 15-hydroxyeicosatetraenoic acid (15-HETE) when stimulated by erythropoietin (Ep).	12-Hydroxy-5,8,10,14-eicosatetraenoic Acid	71-78	erythropoietin	Mus musculus	145-159
3115260-1	1987	Erythroid progenitor cells synthesize 12-hydroxyeicosatetraenoic acid (12-HETE) and 15-hydroxyeicosatetraenoic acid (15-HETE) when stimulated by erythropoietin (Ep).	Eicosatetraenoic acid, 15-hydroxy-	84-115	erythropoietin	Mus musculus	145-159
3115260-1	1987	Erythroid progenitor cells synthesize 12-hydroxyeicosatetraenoic acid (12-HETE) and 15-hydroxyeicosatetraenoic acid (15-HETE) when stimulated by erythropoietin (Ep).	15-Hete	117-124	erythropoietin	Mus musculus	145-159
3035548-4	1987	The binding of 125I-labeled Epo (125I-Epo) to plasma membranes from these cells was studied in this investigation.	Iodine-125	15-19	erythropoietin	Mus musculus	28-31
3475040-6	1987	We demonstrated that a novel MEL cell line, TSA 8, could be induced to be committed to CFU-E, an erythropoietin-mediated progenitor cell, with the addition of DMSO.	trichostatin A	44-47	erythropoietin	Mus musculus	97-111
3035548-4	1987	The binding of 125I-labeled Epo (125I-Epo) to plasma membranes from these cells was studied in this investigation.	Iodine-125	15-19	erythropoietin	Mus musculus	38-41
3035548-5	1987	125I-Epo binding reached equilibrium within 20 min at 37 degrees C. Twenty percent of the receptors bound 125I-Epo with a Kd of 0.08 X 10(-9) M, while the remaining receptors bound the hormone with a Kd of 0.6 X 10(-9) M. In this study, a receptor for Epo was identified by cross-linking 125I-Epo to the receptor in intact cells and plasma membrane preparations using disuccinimidyl suberate.	disuccinimidyl	368-382	erythropoietin	Mus musculus	5-8
3035570-4	1987	Radioiodinated Epo bound specifically to SKT6 cells, and Scatchard analysis of the data showed a high affinity for 125I-Epo (Kd = 0.15 nM) but displayed only a small number of specific receptors (approximately equal to 470 per cell).	Iodine-125	115-119	erythropoietin	Mus musculus	15-18
3035570-4	1987	Radioiodinated Epo bound specifically to SKT6 cells, and Scatchard analysis of the data showed a high affinity for 125I-Epo (Kd = 0.15 nM) but displayed only a small number of specific receptors (approximately equal to 470 per cell).	Iodine-125	115-119	erythropoietin	Mus musculus	120-123
3035570-5	1987	Membrane components that specifically interact with 125I-Epo were identified by covalent crosslinking with disuccinimidyl suberate, and three receptor species with apparent Mr 63,000, 94,000, and 119,000 were found in membrane from SKT6 cells, suggesting the complex structure of the receptor molecules.	disuccinimidyl	107-121	erythropoietin	Mus musculus	57-60
3469202-2	1987	A virtually identical reduction of pp43 phosphorylation was seen when erythropoietin-responsive Rauscher murine erythroleukemia cell membranes were exposed to the hormone.	pp43	35-39	erythropoietin	Mus musculus	70-84
3567362-3	1987	We studied the interaction of this labeled recombinant EPO with erythroid precursor cells from mice made anemic with phenylhydrazine.	phenylhydrazine	117-132	erythropoietin	Mus musculus	55-58
3467981-3	1987	However, we show in this paper that both uncommitted and committed, benzidine-positive, cells bind iodinated erythropoietin.	benzidine	68-77	erythropoietin	Mus musculus	109-123
3790446-2	1986	In animals in which erythropoiesis had been stimulated by hypoxia, Fe3+ uptake by the duodenal fragments was enhanced due to an increase in Vappmax, However, when erythropoiesis was increased by injections of erythropoietin, intestinal Fe3+ uptake rates were unaffected.	ferric sulfate	67-71	erythropoietin	Mus musculus	209-223
3478108-3	1987	The results show that EP increases glucose uptake and the syntheses of RNA and protein in the first few hours after exposure of the erythroblasts to the hormone.	Glucose	35-42	erythropoietin	Mus musculus	22-24
3790446-2	1986	In animals in which erythropoiesis had been stimulated by hypoxia, Fe3+ uptake by the duodenal fragments was enhanced due to an increase in Vappmax, However, when erythropoiesis was increased by injections of erythropoietin, intestinal Fe3+ uptake rates were unaffected.	ferric sulfate	236-240	erythropoietin	Mus musculus	209-223
3772223-5	1986	Plasma clots per se were not essential for megakaryocytic colony formation, because recombinant erythropoietin also supported colony growth in soft agar containing 25% serum.	Agar	148-152	erythropoietin	Mus musculus	96-110
3772223-6	1986	However, little colony formation was observed in serum-free soft agar cultures containing erythropoietin.	Agar	65-69	erythropoietin	Mus musculus	90-104
3958510-11	1986	In cultures of 5-FU-bm already supplemented with HPCM + PMUE, the addition of Epo did not change total colony numbers but did induce erythroid differentiation in one third of the colonies present.	5-fu-bm	15-22	erythropoietin	Mus musculus	78-81
3091386-8	1986	The production of erythropoietin (epo), present in the culture supernatants, increased as the oxygen concentration increased from 2% to 3.5%, but then decreased as the oxygen concentration was increased further, from 3.5% to 5%.	Oxygen	94-100	erythropoietin	Mus musculus	18-32
3091386-8	1986	The production of erythropoietin (epo), present in the culture supernatants, increased as the oxygen concentration increased from 2% to 3.5%, but then decreased as the oxygen concentration was increased further, from 3.5% to 5%.	Oxygen	94-100	erythropoietin	Mus musculus	34-37
3091386-8	1986	The production of erythropoietin (epo), present in the culture supernatants, increased as the oxygen concentration increased from 2% to 3.5%, but then decreased as the oxygen concentration was increased further, from 3.5% to 5%.	Oxygen	168-174	erythropoietin	Mus musculus	18-32
3091386-8	1986	The production of erythropoietin (epo), present in the culture supernatants, increased as the oxygen concentration increased from 2% to 3.5%, but then decreased as the oxygen concentration was increased further, from 3.5% to 5%.	Oxygen	168-174	erythropoietin	Mus musculus	34-37
3738431-2	1986	Erythropoietin, indirectly determined by measuring 59Fe incorporation in polycythemic mouse bioassay, was not detected in serum and urine, but was found in cerebrospinal fluid.	Iron-59	51-55	erythropoietin	Mus musculus	0-14
3459916-7	1986	These results indicate that a proliferation assay based on the incorporation of [3H]dThd into spleen cells in response to Epo can be used as a quantitative means of assessing and comparing the effects of erythroleukemia-inducing retroviruses on the proliferation of their target cells.	Tritium	81-83	erythropoietin	Mus musculus	122-125
3958510-12	1986	These data suggest that multi-CSA and SA may be expressed by different factors and that 5-FU pre-treated marrow contains: a population of primitive multipotential progenitors which form large, mixed colonies in the presence of SCM + Epo, and a larger Epo-sensitive population which also requires HPCM + PMUE to form mixed colonies.	Fluorouracil	88-92	erythropoietin	Mus musculus	233-236
3958510-12	1986	These data suggest that multi-CSA and SA may be expressed by different factors and that 5-FU pre-treated marrow contains: a population of primitive multipotential progenitors which form large, mixed colonies in the presence of SCM + Epo, and a larger Epo-sensitive population which also requires HPCM + PMUE to form mixed colonies.	Fluorouracil	88-92	erythropoietin	Mus musculus	251-254
3840095-1	1985	Pretreatment of pregnant mice (CD-1) with intravenous dexamethasone phosphate (10(-3)-10(-7) g/mouse), a synthetic glucocorticoid, reduced the number of erythroid colonies that formed when 15-day-old fetal liver erythroid progenitor cells (3 X 10(4] were cultured for two days in plasma clots containing exogenous erythropoietin (Epo) (25 mU).	dexamethasone 21-phosphate	54-77	erythropoietin	Mus musculus	330-333
4054239-1	1985	The effect of transferrin from various sources and the degree of saturation with iron on the stimulation of DNA synthesis by erythropoietin (Epo) has been investigated.	Iron	81-85	erythropoietin	Mus musculus	125-139
4054239-1	1985	The effect of transferrin from various sources and the degree of saturation with iron on the stimulation of DNA synthesis by erythropoietin (Epo) has been investigated.	Iron	81-85	erythropoietin	Mus musculus	141-144
4054246-9	1985	Thus, either the iron-incorporating system of normal CFU-E was inducible by epo, or else epo permitted survival of the CFU-E so that the activity of a constitutive iron-incorporating system could be recognized.	Iron	17-21	erythropoietin	Mus musculus	76-79
4054251-1	1985	The uptake of 3H-thymidine by a suspension of spleen cells, obtained from mice made anemic by phenylhydrazine injections, is increased above the values obtained with native human or mouse erythropoietin (Ep) if the hormone is enzymatically asialylated.	3h-thymidine	14-26	erythropoietin	Mus musculus	188-202
3003119-2	1986	Analysis of conditioned media by high performance liquid chromatography (HPLC) on anion exchange, reverse phase, molecular size exclusion, and hydroxyapatite columns demonstrated that the erythropoietin-like activity (EpLA) has different biochemical characteristics to mouse Ep from anemic mouse serum.	Durapatite	143-157	erythropoietin	Mus musculus	188-202
4067362-2	1985	Five days after a single intraperitoneal injection of cDDP, hypoxia-induced Epo production was not decreased in mice and was increased significantly in rats in spite of severe multifocal tubular necrosis.	Cisplatin	54-58	erythropoietin	Mus musculus	76-79
3840095-1	1985	Pretreatment of pregnant mice (CD-1) with intravenous dexamethasone phosphate (10(-3)-10(-7) g/mouse), a synthetic glucocorticoid, reduced the number of erythroid colonies that formed when 15-day-old fetal liver erythroid progenitor cells (3 X 10(4] were cultured for two days in plasma clots containing exogenous erythropoietin (Epo) (25 mU).	dexamethasone 21-phosphate	54-77	erythropoietin	Mus musculus	314-328
3840095-4	1985	Concomitantly, the inhibitory effect of dexamethasone on erythroid colony formation by these fetal liver cells in response to exogenous Epo is reduced.	Dexamethasone	40-53	erythropoietin	Mus musculus	136-139
4045257-1	1985	The exogenous addition of dolichyl phosphate (Dol-P), an active form of dolichol (Dol) that carries oligosaccharide chains for protein-N-glycosylation, significantly enhanced colony formation of mouse bone marrow hematopoietic progenitors (CFU-e, BFU-e, and CFU-gm) was stimulated by erythropoietin (Epo) and colony-stimulating factor (CSF), but Dol enhanced colony formation of CFU-e only.	dolichol monophosphate	26-44	erythropoietin	Mus musculus	284-298
4045257-1	1985	The exogenous addition of dolichyl phosphate (Dol-P), an active form of dolichol (Dol) that carries oligosaccharide chains for protein-N-glycosylation, significantly enhanced colony formation of mouse bone marrow hematopoietic progenitors (CFU-e, BFU-e, and CFU-gm) was stimulated by erythropoietin (Epo) and colony-stimulating factor (CSF), but Dol enhanced colony formation of CFU-e only.	Dolichols	46-49	erythropoietin	Mus musculus	284-298
4045257-1	1985	The exogenous addition of dolichyl phosphate (Dol-P), an active form of dolichol (Dol) that carries oligosaccharide chains for protein-N-glycosylation, significantly enhanced colony formation of mouse bone marrow hematopoietic progenitors (CFU-e, BFU-e, and CFU-gm) was stimulated by erythropoietin (Epo) and colony-stimulating factor (CSF), but Dol enhanced colony formation of CFU-e only.	Dolichols	46-49	erythropoietin	Mus musculus	300-303
4045257-1	1985	The exogenous addition of dolichyl phosphate (Dol-P), an active form of dolichol (Dol) that carries oligosaccharide chains for protein-N-glycosylation, significantly enhanced colony formation of mouse bone marrow hematopoietic progenitors (CFU-e, BFU-e, and CFU-gm) was stimulated by erythropoietin (Epo) and colony-stimulating factor (CSF), but Dol enhanced colony formation of CFU-e only.	dolichol monophosphate	26-44	erythropoietin	Mus musculus	300-303
4045257-1	1985	The exogenous addition of dolichyl phosphate (Dol-P), an active form of dolichol (Dol) that carries oligosaccharide chains for protein-N-glycosylation, significantly enhanced colony formation of mouse bone marrow hematopoietic progenitors (CFU-e, BFU-e, and CFU-gm) was stimulated by erythropoietin (Epo) and colony-stimulating factor (CSF), but Dol enhanced colony formation of CFU-e only.	Dolichols	82-85	erythropoietin	Mus musculus	284-298
4045257-1	1985	The exogenous addition of dolichyl phosphate (Dol-P), an active form of dolichol (Dol) that carries oligosaccharide chains for protein-N-glycosylation, significantly enhanced colony formation of mouse bone marrow hematopoietic progenitors (CFU-e, BFU-e, and CFU-gm) was stimulated by erythropoietin (Epo) and colony-stimulating factor (CSF), but Dol enhanced colony formation of CFU-e only.	Dolichols	82-85	erythropoietin	Mus musculus	300-303
4045257-2	1985	The effects of Dol or Dol-P on these hematopoietic progenitors were fully dependent on stimulation by Epo or CSF.	Dolichols	15-18	erythropoietin	Mus musculus	102-105
4045257-1	1985	The exogenous addition of dolichyl phosphate (Dol-P), an active form of dolichol (Dol) that carries oligosaccharide chains for protein-N-glycosylation, significantly enhanced colony formation of mouse bone marrow hematopoietic progenitors (CFU-e, BFU-e, and CFU-gm) was stimulated by erythropoietin (Epo) and colony-stimulating factor (CSF), but Dol enhanced colony formation of CFU-e only.	dolichol monophosphate	46-51	erythropoietin	Mus musculus	284-298
4045257-1	1985	The exogenous addition of dolichyl phosphate (Dol-P), an active form of dolichol (Dol) that carries oligosaccharide chains for protein-N-glycosylation, significantly enhanced colony formation of mouse bone marrow hematopoietic progenitors (CFU-e, BFU-e, and CFU-gm) was stimulated by erythropoietin (Epo) and colony-stimulating factor (CSF), but Dol enhanced colony formation of CFU-e only.	dolichol monophosphate	46-51	erythropoietin	Mus musculus	300-303
4045257-2	1985	The effects of Dol or Dol-P on these hematopoietic progenitors were fully dependent on stimulation by Epo or CSF.	dolichol monophosphate	22-27	erythropoietin	Mus musculus	102-105
4045257-4	1985	These studies suggest that exogenous Dol-P enhances the frequency of differentiation of hematopoietic progenitors stimulated by Epo or CSF, and there may be a diversity in cellular response of these progenitors to Dol.	dolichol monophosphate	37-42	erythropoietin	Mus musculus	128-131
4045257-1	1985	The exogenous addition of dolichyl phosphate (Dol-P), an active form of dolichol (Dol) that carries oligosaccharide chains for protein-N-glycosylation, significantly enhanced colony formation of mouse bone marrow hematopoietic progenitors (CFU-e, BFU-e, and CFU-gm) was stimulated by erythropoietin (Epo) and colony-stimulating factor (CSF), but Dol enhanced colony formation of CFU-e only.	Dolichols	72-80	erythropoietin	Mus musculus	284-298
4045257-4	1985	These studies suggest that exogenous Dol-P enhances the frequency of differentiation of hematopoietic progenitors stimulated by Epo or CSF, and there may be a diversity in cellular response of these progenitors to Dol.	Dolichols	37-40	erythropoietin	Mus musculus	128-131
4045257-1	1985	The exogenous addition of dolichyl phosphate (Dol-P), an active form of dolichol (Dol) that carries oligosaccharide chains for protein-N-glycosylation, significantly enhanced colony formation of mouse bone marrow hematopoietic progenitors (CFU-e, BFU-e, and CFU-gm) was stimulated by erythropoietin (Epo) and colony-stimulating factor (CSF), but Dol enhanced colony formation of CFU-e only.	Dolichols	72-80	erythropoietin	Mus musculus	300-303
3996489-2	1985	At low doses the polyene antibiotic AmB has been shown to increase cell permeability to Na+ and K+ and we found that it potentiated erythropoietin (epo)-stimulated erythroid-colony (CFU-E) and burst (BFU-E) growth at concentrations ranging from 0.5-1.0 micrograms/ml.	Polyenes	17-24	erythropoietin	Mus musculus	132-146
3996489-2	1985	At low doses the polyene antibiotic AmB has been shown to increase cell permeability to Na+ and K+ and we found that it potentiated erythropoietin (epo)-stimulated erythroid-colony (CFU-E) and burst (BFU-E) growth at concentrations ranging from 0.5-1.0 micrograms/ml.	Polyenes	17-24	erythropoietin	Mus musculus	148-151
3996489-2	1985	At low doses the polyene antibiotic AmB has been shown to increase cell permeability to Na+ and K+ and we found that it potentiated erythropoietin (epo)-stimulated erythroid-colony (CFU-E) and burst (BFU-E) growth at concentrations ranging from 0.5-1.0 micrograms/ml.	Amphotericin B	36-39	erythropoietin	Mus musculus	132-146
3996489-2	1985	At low doses the polyene antibiotic AmB has been shown to increase cell permeability to Na+ and K+ and we found that it potentiated erythropoietin (epo)-stimulated erythroid-colony (CFU-E) and burst (BFU-E) growth at concentrations ranging from 0.5-1.0 micrograms/ml.	Amphotericin B	36-39	erythropoietin	Mus musculus	148-151
3996489-3	1985	Monensin, a sodium-specific ionophore, potentiated epo-stimulated erythroid growth at concentrations of 1-30 nM.	Sodium	12-18	erythropoietin	Mus musculus	51-54
3996489-4	1985	On the other hand, a potassium-specific ionophore, valinomycin, did not cause potentiation, but rather suppressed epo-dependent colony formation.	Potassium	21-30	erythropoietin	Mus musculus	114-117
3996489-4	1985	On the other hand, a potassium-specific ionophore, valinomycin, did not cause potentiation, but rather suppressed epo-dependent colony formation.	Valinomycin	51-62	erythropoietin	Mus musculus	114-117
6377952-0	1984	Effect of chronic ethanol administration on production of and response to erythropoietin in the mouse.	Ethanol	18-25	erythropoietin	Mus musculus	74-88
3996313-2	1985	Enzymic removal of most of the sugars results in aggregation of glycosidase-treated epo, loss of biological activity when assayed in mice, and retention of activity when assayed in marrow cell cultures or by RIA.	Sugars	31-37	erythropoietin	Mus musculus	84-87
3987874-1	1985	Pretreatment of pregnant mice with aminoglutethimide phosphate, an inhibitor of glucocorticoid synthesis, increases the content of fetal liver erythroid colony-forming cells (CFU-E), as assessed by the formation of erythroid colonies in vitro by fetal liver cells in plasma clots containing exogenous erythropoietin.	aminoglutethimide phosphate	35-62	erythropoietin	Mus musculus	301-315
3990509-0	1985	Effect of amines on erythropoietin-stimulated heme synthesis in fetal mouse liver cells.	Amines	10-16	erythropoietin	Mus musculus	20-34
3990509-0	1985	Effect of amines on erythropoietin-stimulated heme synthesis in fetal mouse liver cells.	Heme	46-50	erythropoietin	Mus musculus	20-34
3990509-1	1985	Amines, diamines and polyamines inhibit the erythropoietin-stimulated incorporation of 59Fe into newly-synthesized heme by fetal mouse liver cells in short-term culture.	Amines	0-6	erythropoietin	Mus musculus	44-58
3990509-1	1985	Amines, diamines and polyamines inhibit the erythropoietin-stimulated incorporation of 59Fe into newly-synthesized heme by fetal mouse liver cells in short-term culture.	Diamines	8-16	erythropoietin	Mus musculus	44-58
3990509-1	1985	Amines, diamines and polyamines inhibit the erythropoietin-stimulated incorporation of 59Fe into newly-synthesized heme by fetal mouse liver cells in short-term culture.	Polyamines	21-31	erythropoietin	Mus musculus	44-58
3990509-1	1985	Amines, diamines and polyamines inhibit the erythropoietin-stimulated incorporation of 59Fe into newly-synthesized heme by fetal mouse liver cells in short-term culture.	Iron-59	87-91	erythropoietin	Mus musculus	44-58
3990509-1	1985	Amines, diamines and polyamines inhibit the erythropoietin-stimulated incorporation of 59Fe into newly-synthesized heme by fetal mouse liver cells in short-term culture.	Heme	115-119	erythropoietin	Mus musculus	44-58
6334610-5	1984	On the other hand, in anemic mice treated with phenylhydrazine, this erythropoietic factor was not detected, although the serum level of erythropoietin was elevated.	phenylhydrazine	47-62	erythropoietin	Mus musculus	137-151
6377952-6	1984	When ethanol-treated and control mice, both made polycythemic by hypertransfusion to suppress their endogenous erythropoietin formation, were injected with doses of erythropoietin in the range of 0.2 to 3.2 IRP units, the derived dose-response curves were markedly different because of a reduced response to the hormone by the treated mice.	Ethanol	5-12	erythropoietin	Mus musculus	111-125
6377952-7	1984	This finding suggests that the number of "erythropoietin-responsive cells" may be reduced as the result of ethanol, or that their response to the hormone may be delayed or inhibited.	Ethanol	107-114	erythropoietin	Mus musculus	42-56
6377952-8	1984	Plasma erythropoietin concentration in alcohol- treated mice, as determined in the posthypoxic polycythemic mouse bioassay, was higher than normal in both normoxic and hypoxic conditions, probably as the result of the impaired responsiveness to the hormone mentioned above.	Alcohols	39-46	erythropoietin	Mus musculus	7-21
6831039-4	1983	The addition of EP initiates the final stages of erythroid differentiation, including heme synthesis in 70%-80% of these isolated cells.	Heme	86-90	erythropoietin	Mus musculus	16-18
6589018-6	1984	IW32 erythropoietic factor and murine plasma erythropoietin were similarly precipitated by ethanol and ammonium sulfate.	Ethanol	91-98	erythropoietin	Mus musculus	45-59
6589018-6	1984	IW32 erythropoietic factor and murine plasma erythropoietin were similarly precipitated by ethanol and ammonium sulfate.	Ammonium Sulfate	103-119	erythropoietin	Mus musculus	45-59
6641829-4	1983	When hypertransfused mice were exposed to hypoxia before transfusions, a linear increase in 59Fe uptake values in response to hypoxia was observed with exposures between 6 and 30 h. No further increase was observed for exposures of 46 to 216 h. These results suggest a sensitization of the erythropoietin-producing organ(s) by hypoxia.	Iron-59	92-96	erythropoietin	Mus musculus	290-304
6884442-1	1983	Studies are described which were designed to compare an erythropoietin (Ep) bioassay using the uptake of 125I-deoxyuridine (125-I-UdR) into whole cells cultured in micro-titer plates with an established method where the cells were cultured in 1 ml volumes using the incorporation of 59Fe into heme as the endpoint.	125i-deoxyuridine	105-122	erythropoietin	Mus musculus	56-70
6884443-0	1983	A simple microassay for erythropoietin based on 3H-thymidine incorporation into spleen cells from phenylhydrazine treated mice.	3h-thymidine	48-60	erythropoietin	Mus musculus	24-38
6884443-0	1983	A simple microassay for erythropoietin based on 3H-thymidine incorporation into spleen cells from phenylhydrazine treated mice.	phenylhydrazine	98-113	erythropoietin	Mus musculus	24-38
6884443-2	1983	More than 90% of these spleen cells are recognizable erythroid and form the basis of a new in vitro microassay for erythropoietin (Ep) which uses 3H-thymidine incorporation as an endpoint.	Tritium	146-148	erythropoietin	Mus musculus	115-129
6884443-2	1983	More than 90% of these spleen cells are recognizable erythroid and form the basis of a new in vitro microassay for erythropoietin (Ep) which uses 3H-thymidine incorporation as an endpoint.	Thymidine	149-158	erythropoietin	Mus musculus	115-129
6241781-0	1984	Suppressive effect of acetylsalicylic acid on erythropoietin-responsive cells in mice.	Aspirin	22-42	erythropoietin	Mus musculus	46-60
6241781-5	1984	Administration of ASA prior to administration of erythropoietin (Epo) into post-hypoxic polycythemic mice depresses the incorporation of 59Fe into erythrocytes.	Aspirin	18-21	erythropoietin	Mus musculus	65-68
6241781-5	1984	Administration of ASA prior to administration of erythropoietin (Epo) into post-hypoxic polycythemic mice depresses the incorporation of 59Fe into erythrocytes.	Iron-59	137-141	erythropoietin	Mus musculus	49-63
6241781-5	1984	Administration of ASA prior to administration of erythropoietin (Epo) into post-hypoxic polycythemic mice depresses the incorporation of 59Fe into erythrocytes.	Iron-59	137-141	erythropoietin	Mus musculus	65-68
6241781-6	1984	The depression of radioiron uptake is similar when ASA is given prior to or simultaneously with Epo.	radioiron	18-27	erythropoietin	Mus musculus	96-99
6241781-7	1984	When ASA is given 24 hr after injection of Epo, suppression is less marked.	Aspirin	5-8	erythropoietin	Mus musculus	43-46
6603986-2	1983	Erythropoietin at 400 mU/ml caused a 40-80 fold increase in the incorporation of the labeled nucleoside.	Nucleosides	93-103	erythropoietin	Mus musculus	0-14
6572760-6	1983	FVA-induced cells appeared to be hypersensitive to EPO, since small concentrations of the hormone produced marked increases in hemoglobin production--even when the hormone was added to the culture 3 days post infection.	fva	0-3	erythropoietin	Mus musculus	51-54
6291970-2	1982	We report here that digoxin and theophylline also enhance erythroid stem cell colony formation, in the presence of suboptimal concentrations of erythropoietin (Ep) (0.01 IU/ml) in methylcellulose culture.	Digoxin	20-27	erythropoietin	Mus musculus	144-158
6825158-5	1983	Burst formation in the presence of BFA-cell showed a high epo requirement whereas plateau numbers of bursts were evident at concentrations of 1 to 2 units of epo/ml in cultures containing BFA-mscm.	O(4)-benzylfolic acid	35-38	erythropoietin	Mus musculus	58-61
6825158-5	1983	Burst formation in the presence of BFA-cell showed a high epo requirement whereas plateau numbers of bursts were evident at concentrations of 1 to 2 units of epo/ml in cultures containing BFA-mscm.	O(4)-benzylfolic acid	188-191	erythropoietin	Mus musculus	158-161
6825158-6	1983	The epo-independent developmental activities (EIDA) of BFA-cell and BFA-mscm were examined in methylcellulose cultures to which the addition of epo was delayed for up to four days.	O(4)-benzylfolic acid	55-58	erythropoietin	Mus musculus	4-7
6825158-7	1983	Under all conditions examined, the number of bursts formed in the presence of BFA-cell declined with increasing delay of epo addition.	O(4)-benzylfolic acid	78-81	erythropoietin	Mus musculus	121-124
6288144-1	1982	Murine bone marrow and adherence-separated spleen cells cultured on hydrophobic, gas-permeable Teflon foils (petriperm dishes) can be shown to synthesize and secrete erythropoietin (Epo) and colony-stimulating activity (CSA) simultaneously into the surrounding medium.	Cyclosporine	220-223	erythropoietin	Mus musculus	182-185
6288144-3	1982	Use of the macrophage-specific cytotoxic agent, crystalline silica, as a tool to release residual Epo contained in these cells produces a similar time-Epo activity curve to that found in the primary supernatants.	Silicon Dioxide	60-66	erythropoietin	Mus musculus	98-101
6288144-3	1982	Use of the macrophage-specific cytotoxic agent, crystalline silica, as a tool to release residual Epo contained in these cells produces a similar time-Epo activity curve to that found in the primary supernatants.	Silicon Dioxide	60-66	erythropoietin	Mus musculus	151-154
6288144-8	1982	These results, together with the reversible inhibition of Epo and CSA production by cycloheximide, demonstrate that these molecules are synthesized by the macrophage.	Cycloheximide	84-97	erythropoietin	Mus musculus	58-61
6291970-2	1982	We report here that digoxin and theophylline also enhance erythroid stem cell colony formation, in the presence of suboptimal concentrations of erythropoietin (Ep) (0.01 IU/ml) in methylcellulose culture.	Theophylline	32-44	erythropoietin	Mus musculus	144-158
7097158-5	1982	Examination of the FV-P-induced cellular changes indicated that dramatic increase in erythropoietin (epo)-independent erythroid precursor (CFU-E*) cells was detected in the spleens and marrow of both strains of mice.	fv-p	19-23	erythropoietin	Mus musculus	85-99
7097158-5	1982	Examination of the FV-P-induced cellular changes indicated that dramatic increase in erythropoietin (epo)-independent erythroid precursor (CFU-E*) cells was detected in the spleens and marrow of both strains of mice.	fv-p	19-23	erythropoietin	Mus musculus	101-104
7327299-1	1981	Plethoric mice treated with pharmacological doses of estradiol have decreased concentration of erythropoietin-responsive cells (ERC) in the marrow.	Estradiol	53-62	erythropoietin	Mus musculus	95-109
7084423-0	1982	Erythropoietin formation during hypoxia in mice with impaired responsiveness to erythropoietin induced by irradiation or 5-fluorouracil injection.	Fluorouracil	121-135	erythropoietin	Mus musculus	0-14
7084423-0	1982	Erythropoietin formation during hypoxia in mice with impaired responsiveness to erythropoietin induced by irradiation or 5-fluorouracil injection.	Fluorouracil	121-135	erythropoietin	Mus musculus	80-94
7084423-1	1982	Plasma erythropoietin levels during continuous exposure to hypobaric hypoxia in mice with marrow aplasia induced by whole body X-irradiation of 5-fluorouracil injection were higher than in control mice similarly exposed.	Fluorouracil	144-158	erythropoietin	Mus musculus	7-21
6952215-6	1982	Those events of erythroid differentiation shown to be directed by EP were extrusion of the nucleus from the erythroblast, induction of uroporphyrinogen I synthetase activity, increased iron incorporation into protoporphyrin, synthesis of alpha- and beta-globin polypeptides due largely to increased mRNA production, and synthesis and incorporation of spectrin into the cell membrane.	Iron	185-189	erythropoietin	Mus musculus	66-68
6952215-6	1982	Those events of erythroid differentiation shown to be directed by EP were extrusion of the nucleus from the erythroblast, induction of uroporphyrinogen I synthetase activity, increased iron incorporation into protoporphyrin, synthesis of alpha- and beta-globin polypeptides due largely to increased mRNA production, and synthesis and incorporation of spectrin into the cell membrane.	protoporphyrin IX	209-223	erythropoietin	Mus musculus	66-68
7141069-4	1982	The addition of valinomycin (10(-11) to 10(-15) M) in the presence of ouabain and erythropoietin (Ep) did not alter the erythroid colony-forming stimulation which was characteristic of cultures in which only ouabain (10(-15) M) and Ep were added.	Valinomycin	16-27	erythropoietin	Mus musculus	82-96
7318980-2	1981	It is a well recognized problem that sample derived transferrin-bound iron (Tf-Fe) interferes with radio-iron incorporation into heme in the in vitro assay of erythropoietin (Ep) using fetal mouse liver cells (FMLC).	Iron	70-74	erythropoietin	Mus musculus	159-173
7318980-2	1981	It is a well recognized problem that sample derived transferrin-bound iron (Tf-Fe) interferes with radio-iron incorporation into heme in the in vitro assay of erythropoietin (Ep) using fetal mouse liver cells (FMLC).	Iron	105-109	erythropoietin	Mus musculus	159-173
7318980-2	1981	It is a well recognized problem that sample derived transferrin-bound iron (Tf-Fe) interferes with radio-iron incorporation into heme in the in vitro assay of erythropoietin (Ep) using fetal mouse liver cells (FMLC).	Heme	129-133	erythropoietin	Mus musculus	159-173
7452087-7	1981	In contrast, only material that was additive with epo was demonstrable in the WG column eluate, and this activity coeluted with epo on Sephadex G150.	sephadex	135-143	erythropoietin	Mus musculus	128-131
6945590-3	1981	Conversely, similar concentrations of tumor-promoting phorbol esters inhibit the formation of colonies (bursts) by early erythroid progenitor cells, even when the culture medium contains saturating amounts of burst-promoting activity and erythropoietin.	Phorbol Esters	54-68	erythropoietin	Mus musculus	238-252
7238657-0	1981	Inhibition by dexamethasone of erythropoietin-induced amplification of the erythropoietin-responsive cell compartment.	Dexamethasone	14-27	erythropoietin	Mus musculus	31-45
7238657-0	1981	Inhibition by dexamethasone of erythropoietin-induced amplification of the erythropoietin-responsive cell compartment.	Dexamethasone	14-27	erythropoietin	Mus musculus	75-89
7238657-1	1981	Erythropoietin-responsive cells (ERC) were reduced to very low levels in post-hypoxic polycythemic mice by intraperitoneal injection of 60 mg/kg-mouse of busulfan.	Busulfan	154-162	erythropoietin	Mus musculus	0-14
7238657-2	1981	Repeated injections of 5 units erythropoietin (Ep), 1, 2, and 3 days after busulfan repopulated the ERC compartment.	Busulfan	75-83	erythropoietin	Mus musculus	31-45
7459282-4	1981	The effect of erythropoietin, with or without transferrin-iron is blocked by pre-incubation of the erythropoietin with rabbit anti erythropoietin serum.	Iron	58-62	erythropoietin	Mus musculus	99-113
7459282-4	1981	The effect of erythropoietin, with or without transferrin-iron is blocked by pre-incubation of the erythropoietin with rabbit anti erythropoietin serum.	Iron	58-62	erythropoietin	Mus musculus	99-113
7459282-5	1981	Human sera contain factors in addition to erythropoietin and transferin-iron which may modify the stimulation of incorporation of 3H-thymidine into fetal mouse liver DNA induced by erythropoietin.	Iron	72-76	erythropoietin	Mus musculus	181-195
7459282-5	1981	Human sera contain factors in addition to erythropoietin and transferin-iron which may modify the stimulation of incorporation of 3H-thymidine into fetal mouse liver DNA induced by erythropoietin.	3h-thymidine	130-142	erythropoietin	Mus musculus	42-56
7459282-5	1981	Human sera contain factors in addition to erythropoietin and transferin-iron which may modify the stimulation of incorporation of 3H-thymidine into fetal mouse liver DNA induced by erythropoietin.	3h-thymidine	130-142	erythropoietin	Mus musculus	181-195
6794303-0	1981	Effect of erythropoietin on erythropoietin-responsive cell regeneration in polycythemic mice treated with cyclophosphamide.	Cyclophosphamide	106-122	erythropoietin	Mus musculus	28-42
7448425-0	1981	Further evidence of the in vivo role of erythropoietin or companion molecules induced by hypoxia on proliferation and continuing differentiation of BFU-e in PCDC.	pcdc	157-161	erythropoietin	Mus musculus	40-54
16398023-8	1980	On the contrary, injection of dexamethasone 1 h after erythropoietin reduces by 60% the effective erythropoiesis, which can be attributed to a decrease in differentiation of ERC into proerythroblasts.	Dexamethasone	30-43	erythropoietin	Mus musculus	54-68
7428682-6	1980	Testosterone or 5 beta-DHT added directly to Ta/Y marrow cultures caused an enhancement of CFU-E colony numbers compared with erythropoietin alone.	Testosterone	0-12	erythropoietin	Mus musculus	126-140
7428682-6	1980	Testosterone or 5 beta-DHT added directly to Ta/Y marrow cultures caused an enhancement of CFU-E colony numbers compared with erythropoietin alone.	beta-dht	18-26	erythropoietin	Mus musculus	126-140
7459981-0	1980	Erythropoietin-independent regeneration of erythroid progenitor cells following multiple injections of hydroxyurea.	Hydroxyurea	103-114	erythropoietin	Mus musculus	0-14
6254867-7	1980	The pluripotent stem cells from thiamphenicol-treated mice were in a low cycling state, despite a very high erythropoietin level.	Thiamphenicol	32-45	erythropoietin	Mus musculus	108-122
6940758-1	1981	An erythropoietin-independent virus-induced murine erythroleukemia (FVP) is used to compare the effects of an erythropoiesis inhibitory factor (EIF) isolated from human urine with the effects of prostaglandin F2 alpha.	Dinoprost	195-217	erythropoietin	Mus musculus	3-17
6100955-0	1981	Release of erythropoietin from macrophages by treatment with silica.	Silicon Dioxide	61-67	erythropoietin	Mus musculus	11-25
7448391-3	1980	It is known that inoculation of mice with low doses of actinomycin D (Act D) results in a specific suppression of erythropoiesis without impairing the endogenous erythropoietin production.	Dactinomycin	55-68	erythropoietin	Mus musculus	162-176
7202579-11	1980	In addition, enhanced release of erythropoietin from the kidney following the application of albuterol may contribute to beta 2-adrenergic stimulation of erythropoiesis.	Albuterol	93-102	erythropoietin	Mus musculus	33-47
6249431-0	1980	An erythropoietic stimulating factor similar to erythropoietin released by macrophages after treatment with silica.	Silicon Dioxide	108-114	erythropoietin	Mus musculus	48-62
7373218-1	1980	We investigated the effects of murine resident peritoneal macrophages on the in vitro proliferation of erythropoietin (Ep)-sensitive committed precursors colony-forming unit-erythroid (CFU-E) and burst-forming unit-erythroid (BFU-E) with a two-layer cloning system of methylcellulose and semisolid agar.	Methylcellulose	268-283	erythropoietin	Mus musculus	103-117
6988531-6	1980	Thus, at high levels of erythropoietin, the in vivo PCDC assay appears to be somewhat less sensitive than conventional in vitro assays.	pcdc	52-56	erythropoietin	Mus musculus	24-38
6988531-10	1980	However, phenylhydrazine treatment of donor mice leads to the transient development of a new subclass of BFU-E which gives rise to colonies relatively late in culture, suggesting that erythropoietin does have a direct effect on the physiological status of BFU-E in the bone marrow.	phenylhydrazine	9-24	erythropoietin	Mus musculus	184-198
7373218-1	1980	We investigated the effects of murine resident peritoneal macrophages on the in vitro proliferation of erythropoietin (Ep)-sensitive committed precursors colony-forming unit-erythroid (CFU-E) and burst-forming unit-erythroid (BFU-E) with a two-layer cloning system of methylcellulose and semisolid agar.	Agar	298-302	erythropoietin	Mus musculus	103-117
6761139-0	1980	Prostaglandins activation of erythropoietin production and erythroid progenitor cells.	Prostaglandins	0-14	erythropoietin	Mus musculus	29-43
7416158-5	1980	The effects of arsenic on erythropoietin-induced erythroid differentation revealed a significant inhibitory effect on young, proliferating marrow nucleated erythroid precursor cells.	Arsenic	15-22	erythropoietin	Mus musculus	26-40
6761139-1	1980	A model is presented postulating a role for prostaglandins E and prostacyclin in kidney generation of erythropoietin and the activation of the erythroid progenitor cell (CFU-E) compartment by erythropoietin (Ep).	Prostaglandins E	44-60	erythropoietin	Mus musculus	102-116
6761139-1	1980	A model is presented postulating a role for prostaglandins E and prostacyclin in kidney generation of erythropoietin and the activation of the erythroid progenitor cell (CFU-E) compartment by erythropoietin (Ep).	Epoprostenol	65-77	erythropoietin	Mus musculus	102-116
6761139-3	1980	These studies indicate that hypoxic stimulation of kidney production of erythropoietin may be related to the generation of prostacyclin (PGI2).	Epoprostenol	123-135	erythropoietin	Mus musculus	72-86
6761139-4	1980	On the other hand, albuterol and ischemic (reduction in renal blood flow) stimulation of kidney production of erythropoietin involves prostaglandins of the E type.	Albuterol	19-28	erythropoietin	Mus musculus	110-124
6761139-4	1980	On the other hand, albuterol and ischemic (reduction in renal blood flow) stimulation of kidney production of erythropoietin involves prostaglandins of the E type.	Prostaglandins	134-148	erythropoietin	Mus musculus	110-124
6761139-5	1980	In addition, E-type prostaglandins were found to enhance the effects of erythropoietin in activating erythroid progenitor cells (CFU-E) in the bone marrow.	Prostaglandins	20-34	erythropoietin	Mus musculus	72-86
6761139-6	1980	We postulate from our model that prostaglandins E and prostacyclins are involved in the mechanism of kidney production of erythropoietin as well as the activation of the Ep-responsive cell (ERC) compartment.	Prostaglandins E	33-49	erythropoietin	Mus musculus	122-136
115902-2	1979	The in vitro plasma clot technique was employed to examine the role of calcium during the interaction of erythropoietin and mouse erythroid progenitor cells.	Calcium	71-78	erythropoietin	Mus musculus	105-119
6761139-6	1980	We postulate from our model that prostaglandins E and prostacyclins are involved in the mechanism of kidney production of erythropoietin as well as the activation of the Ep-responsive cell (ERC) compartment.	Prostaglandins I	54-67	erythropoietin	Mus musculus	122-136
115902-3	1979	Erythropoietin-induced erythroid colony formation was increased 24% by the carboxylic ionophore A23187 (10 nM), whereas a 35% increase was produced by the carboxylic ionophore Ro 2-2985/1 (1 nM).	Calcimycin	96-102	erythropoietin	Mus musculus	0-14
115902-4	1979	EGTA (3 mM) inhibited erythropoietin-induced erythroid colony formation.	Egtazic Acid	0-4	erythropoietin	Mus musculus	22-36
519701-8	1979	BFA acts as an in vitro inducer of EP-responsiveness in BFUe.	O(4)-benzylfolic acid	0-3	erythropoietin	Mus musculus	35-37
115902-7	1979	EGTA substantially inhibited erythropoietin-induced erythroid colony formation even when the marrow cells were exposed to the hormone for up to 2 h before addition of the chelator.	Egtazic Acid	0-4	erythropoietin	Mus musculus	29-43
115902-8	1979	Marrow cells incubated first in calcium-free medium with erythropoietin and then cultured in the presence of calcium but not erythropoietin, failed to form erythroid colonies although colony formation occurred when erythropoietin was provided.	Calcium	32-39	erythropoietin	Mus musculus	57-71
115902-9	1979	Taken together, the data indicate that calcium is required for both extracellular and intracellular events during the interaction of erythropoietin with its target cells.	Calcium	39-46	erythropoietin	Mus musculus	133-147
444656-0	1979	In vitro assay for erythropoietin: erythroid colony formation in methyl cellulose used for the measurement of erythropoietin in plasma.	Methylcellulose	65-81	erythropoietin	Mus musculus	19-33
444655-5	1979	Daily injections of Epo promptly restored normal B-4 numbers and near-normal CFU-e numbers in BCNU-treated mice.	Carmustine	94-98	erythropoietin	Mus musculus	20-23
476265-0	1979	Further investigations about actinomycin D action on mouse erythropoietin responsive cell.	Dactinomycin	29-42	erythropoietin	Mus musculus	59-73
476265-3	1979	The same relation appeared in the action of various Actinomycin D doses on the response to erythropoietin in hypertransfused-mice.	Dactinomycin	52-65	erythropoietin	Mus musculus	91-105
435647-1	1979	We have demonstrated that the cyclohexanone method for the extraction of hematin can be used to measure hemoglobin synthesis induced by erythropoietin (epo) in mouse bone marrow cells cultured in medium containing methyl cellulose.	cyclohexanone	30-43	erythropoietin	Mus musculus	136-150
435647-1	1979	We have demonstrated that the cyclohexanone method for the extraction of hematin can be used to measure hemoglobin synthesis induced by erythropoietin (epo) in mouse bone marrow cells cultured in medium containing methyl cellulose.	cyclohexanone	30-43	erythropoietin	Mus musculus	152-155
435647-1	1979	We have demonstrated that the cyclohexanone method for the extraction of hematin can be used to measure hemoglobin synthesis induced by erythropoietin (epo) in mouse bone marrow cells cultured in medium containing methyl cellulose.	Hemin	73-80	erythropoietin	Mus musculus	136-150
435647-1	1979	We have demonstrated that the cyclohexanone method for the extraction of hematin can be used to measure hemoglobin synthesis induced by erythropoietin (epo) in mouse bone marrow cells cultured in medium containing methyl cellulose.	Hemin	73-80	erythropoietin	Mus musculus	152-155
435647-1	1979	We have demonstrated that the cyclohexanone method for the extraction of hematin can be used to measure hemoglobin synthesis induced by erythropoietin (epo) in mouse bone marrow cells cultured in medium containing methyl cellulose.	Methylcellulose	214-230	erythropoietin	Mus musculus	136-150
435647-1	1979	We have demonstrated that the cyclohexanone method for the extraction of hematin can be used to measure hemoglobin synthesis induced by erythropoietin (epo) in mouse bone marrow cells cultured in medium containing methyl cellulose.	Methylcellulose	214-230	erythropoietin	Mus musculus	152-155
444656-0	1979	In vitro assay for erythropoietin: erythroid colony formation in methyl cellulose used for the measurement of erythropoietin in plasma.	Methylcellulose	65-81	erythropoietin	Mus musculus	110-124
444656-1	1979	Erythroid colony formation in methyl cellulose has been used for the measurement of erythropoietin in plasma.	Methylcellulose	30-46	erythropoietin	Mus musculus	84-98
283282-0	1979	Hematopoietic stem cells in Friend murine leukemia virus-infected mice undergoing chemotherapy: remission and relapse of erythropoietin-independent erythropoiesis induced by hydroxyurea.	Hydroxyurea	174-185	erythropoietin	Mus musculus	121-135
429879-5	1979	In these experiments, bone marrow cells cultured in the presence of Epo (25 microU) and dexamethasone (2 X 10(-6)M to 2 X 10(-8)M) formed fewer erythroid colonies than cells cultured in the presence of Epo alone.	Dexamethasone	88-101	erythropoietin	Mus musculus	202-205
429879-7	1979	These studies show therefore that dexamethasone, either in vivo or in vitro, decreases the number and/or functional capacity of adult murine bone marrow cells capable of forming erythroid colonies in vitro in response to Epo, although the precise mechanism of this inhibition remains to be established.	Dexamethasone	34-47	erythropoietin	Mus musculus	221-224
698937-2	1978	Plethoric mice with busulphan-induced reductions in stem cell populations (characterized as colony-forming units) and stimulated erythropoietin-responsive cell compartments were given FV; control groups, not receiving erythropoietin, also received FV.	Busulfan	20-29	erythropoietin	Mus musculus	129-143
34369-0	1978	Effects of terbutaline, a synthetic beta adrenoceptor agonist, on in vivo erythropoietin production.	Terbutaline	11-22	erythropoietin	Mus musculus	74-88
712628-0	1978	The effects of arachidonic acid on erythropoietin production in exhypoxic polycythemic mice and the isolated perfused canine kidney.	Arachidonic Acid	15-31	erythropoietin	Mus musculus	35-49
678672-3	1978	Investigations on the mouse fetal liver cell bioassay for erythropoietin (ESF) have revealed that iron present in test sera significantly dilutes the radiolabel (59Fe) and thus decreases 59Fe incorporation into heme.	Iron	98-102	erythropoietin	Mus musculus	58-72
744202-6	1978	After EPO injections in such Myleran-treated recipients, with a consequent appreciable ERC repopulation, splenic colonies again occurred.	Busulfan	29-36	erythropoietin	Mus musculus	6-9
687808-1	1978	In 22 healthy newborns and in 31 newborns with transposition of the major arterial vessels (TMAV) erythropoietin and erythropoiesis inhibitor was studied on a model of polycythemic mice.	tmav	92-96	erythropoietin	Mus musculus	98-112
687808-3	1978	The newborns with TMAV displayed a rise of erythropoietin level up to the 14th day and its reduction during the period of from 14th to the 56th days.	tmav	18-22	erythropoietin	Mus musculus	43-57
678672-3	1978	Investigations on the mouse fetal liver cell bioassay for erythropoietin (ESF) have revealed that iron present in test sera significantly dilutes the radiolabel (59Fe) and thus decreases 59Fe incorporation into heme.	Heme	211-215	erythropoietin	Mus musculus	58-72
638088-0	1978	Transferrin-bound iron and its effect on erythropoietin as measured by mouse fetal liver cell assay.	Iron	18-22	erythropoietin	Mus musculus	41-55
647120-1	1978	Erythropoietin (Ep), insulin, and prostaglandins E1 and A1 (PGE1, PGA1) enhanced heme synthesis by mitochondria isolated from embryonic and adult mouse liver cells.	Alprostadil	60-64	erythropoietin	Mus musculus	0-14
647120-1	1978	Erythropoietin (Ep), insulin, and prostaglandins E1 and A1 (PGE1, PGA1) enhanced heme synthesis by mitochondria isolated from embryonic and adult mouse liver cells.	prostaglandin A1	66-70	erythropoietin	Mus musculus	0-14
647120-1	1978	Erythropoietin (Ep), insulin, and prostaglandins E1 and A1 (PGE1, PGA1) enhanced heme synthesis by mitochondria isolated from embryonic and adult mouse liver cells.	Heme	81-85	erythropoietin	Mus musculus	0-14
624335-3	1978	The similar regeneration of erythropoietin-responsive cells in normal and hypertransfused mice was shown by comparison of 55Fe labeling in the repopulating relative to the contralateral marrow; in each case, labeling in the repopulating marrow was about 20% of that in the intact contralateral marrow.	Iron-55	122-126	erythropoietin	Mus musculus	28-42
148364-2	1978	High concentrations of chondroitin sulphate A, B and C and heparitin sulphate partly or completely inhibited the response of CFU-E to erythropoietin stimulation whereas addition of heparin, hyalyronic acid and keratan sulphate II in concentrations up to 100 microgram/ml did not elicit an inhibition of erythrocytic colony formation.	Chondroitin Sulfates	23-45	erythropoietin	Mus musculus	134-148
148364-2	1978	High concentrations of chondroitin sulphate A, B and C and heparitin sulphate partly or completely inhibited the response of CFU-E to erythropoietin stimulation whereas addition of heparin, hyalyronic acid and keratan sulphate II in concentrations up to 100 microgram/ml did not elicit an inhibition of erythrocytic colony formation.	Heparitin Sulfate	59-77	erythropoietin	Mus musculus	134-148
213236-0	1978	A concept for the control of kidney production of erythropoietin involving prostaglandins and cyclic nucleotides.	Prostaglandins	75-89	erythropoietin	Mus musculus	50-64
213236-0	1978	A concept for the control of kidney production of erythropoietin involving prostaglandins and cyclic nucleotides.	Nucleotides, Cyclic	94-112	erythropoietin	Mus musculus	50-64
976389-1	1976	It has been shown that erythropoietin-mediated stimulation of heme synthesis in mouse fetal liver cells in vitro is correlated with hydroxyurea sensitivity.	Heme	62-66	erythropoietin	Mus musculus	23-37
714206-1	1978	Prostaglandin A2 (PGA2) is shown to stimulate RNA synthesis in 12-day embryonic mouse liver cells, thus expressing an erythropoietin-like effect.	prostaglandin A2	0-16	erythropoietin	Mus musculus	118-132
714206-1	1978	Prostaglandin A2 (PGA2) is shown to stimulate RNA synthesis in 12-day embryonic mouse liver cells, thus expressing an erythropoietin-like effect.	prostaglandin A2	18-22	erythropoietin	Mus musculus	118-132
332511-2	1977	Immunofluorescent and carbon particle ingestion techniques suggest that the erythropoietin was elaborated by macrophages or Kupffer cells of the hepatic reticuloendothelial system.	Carbon	22-28	erythropoietin	Mus musculus	76-90
590407-2	1977	This conclusion applied both when the cells were exposed to oxymetholone prior to culturing with erythropoietin and when the steroid was present in the cultures simultaneously with erythropoietin.	Oxymetholone	60-72	erythropoietin	Mus musculus	97-111
927031-0	1977	Erythroid colony formation and erythropoietin activity in mice treated with estradiol benzoate.	estradiol 3-benzoate	76-94	erythropoietin	Mus musculus	31-45
871411-0	1977	Effect of testosterone and oestradiol on erythropoietin production in vitro.	Testosterone	10-22	erythropoietin	Mus musculus	41-55
871411-0	1977	Effect of testosterone and oestradiol on erythropoietin production in vitro.	Estradiol	27-37	erythropoietin	Mus musculus	41-55
871411-1	1977	The effects of testosterone and oestradiol on erythropoietin production by mouse fetal liver in primary culture was studied.	Estradiol	32-42	erythropoietin	Mus musculus	46-60
871411-4	1977	Therefore, it is concluded that testosterone can exert a direct stimulatory effect on erythropoietin production by mouse fetal liver.	Testosterone	32-44	erythropoietin	Mus musculus	86-100
854648-0	1977	Influence of ambient temperature on erythropoietin production in carbon monoxide-intoxicated mice.	Carbon Monoxide	65-80	erythropoietin	Mus musculus	36-50
891662-2	1977	The erythropoietin production was stimulated by anemia (phenylhydrazine) and hypobaric hypoxia (0.4 atm).	phenylhydrazine	56-71	erythropoietin	Mus musculus	4-18
891665-6	1977	Both tritiated thymidine and iron incorporation were dependent on erythropoietin concentration.	Tritiated thymidine	5-24	erythropoietin	Mus musculus	66-80
891665-6	1977	Both tritiated thymidine and iron incorporation were dependent on erythropoietin concentration.	Iron	29-33	erythropoietin	Mus musculus	66-80
987043-1	1976	A time course study of the sequential appearance of erythropoietin-dependent colonies and bursts (derived from CFU-E and BFU-E, respectively) was performed on mouse hemopoietic cells cultured in methyl cellulose containing 2-mercaptoethanol.	Methylcellulose	195-211	erythropoietin	Mus musculus	52-66
987043-1	1976	A time course study of the sequential appearance of erythropoietin-dependent colonies and bursts (derived from CFU-E and BFU-E, respectively) was performed on mouse hemopoietic cells cultured in methyl cellulose containing 2-mercaptoethanol.	Mercaptoethanol	223-240	erythropoietin	Mus musculus	52-66
976389-1	1976	It has been shown that erythropoietin-mediated stimulation of heme synthesis in mouse fetal liver cells in vitro is correlated with hydroxyurea sensitivity.	Hydroxyurea	132-143	erythropoietin	Mus musculus	23-37
976389-2	1976	Assuming that OHU is specifically cytotoxic for cells in DNA synthesis this suggests that erythropoietin sensitivity may be related to this phase of the cell cycle.	ohu	14-17	erythropoietin	Mus musculus	90-104
173742-5	1976	Dexamethasone increased erythroid colony formation with peak stimulation at 10(-9) M. Dexamethasone potentiation was most marked in cultures containing less than maximally stimulating concentrations of erythropoietin.	Dexamethasone	0-13	erythropoietin	Mus musculus	202-216
935624-1	1976	The effects of the beta-adrenergic blocking agent (propranolol) on erythropoietin production in carbon monoxide intoxicated mice were studied.	Propranolol	51-62	erythropoietin	Mus musculus	67-81
935624-1	1976	The effects of the beta-adrenergic blocking agent (propranolol) on erythropoietin production in carbon monoxide intoxicated mice were studied.	Carbon Monoxide	96-111	erythropoietin	Mus musculus	67-81
935624-2	1976	The raise in plasma erythropoietin after a 4 hour intoxication with carbon monoxide was 47% less in the propranolol treated group.	Carbon Monoxide	68-83	erythropoietin	Mus musculus	20-34
935624-2	1976	The raise in plasma erythropoietin after a 4 hour intoxication with carbon monoxide was 47% less in the propranolol treated group.	Propranolol	104-115	erythropoietin	Mus musculus	20-34
1003522-7	1976	Furthermore, the increased numbers of this FVP target cell in the EP-stimulated, BU-treated mice with HT-induced polycythemia supported the model licating the target for this effect in the EP-responsive cell population.	Busulfan	81-83	erythropoietin	Mus musculus	66-68
1003522-7	1976	Furthermore, the increased numbers of this FVP target cell in the EP-stimulated, BU-treated mice with HT-induced polycythemia supported the model licating the target for this effect in the EP-responsive cell population.	Busulfan	81-83	erythropoietin	Mus musculus	189-191
1268909-0	1976	Study of the effect of hydroxyurea on the erythropoietin-sensitive cells.	Hydroxyurea	23-34	erythropoietin	Mus musculus	42-56
1268909-1	1976	The response of polycythaemic mice to a standard dose of erythropoietin has been measured at various time intervals after single or repeated injections of hydroxyurea.	Hydroxyurea	155-166	erythropoietin	Mus musculus	57-71
1268909-4	1976	Hydroxyurea given to polycythaemic mice at various time intervals after erythropoietin induced characteristic changes in the response.	Hydroxyurea	0-11	erythropoietin	Mus musculus	72-86
173742-5	1976	Dexamethasone increased erythroid colony formation with peak stimulation at 10(-9) M. Dexamethasone potentiation was most marked in cultures containing less than maximally stimulating concentrations of erythropoietin.	Dexamethasone	86-99	erythropoietin	Mus musculus	202-216
163577-0	1975	The role of renal adenosine 3",5"-monophosphate in the control of erythropoietin production.	Cyclic AMP	18-47	erythropoietin	Mus musculus	66-80
1206743-3	1975	RLV-infected mice, subjected to PHZ-induced hemolysis or phlebotomy, produced high levels of plasma erythropoietin (Ep); this suggested that Ep mediated the PHZ-induced differentiation.	phenylhydrazine	32-35	erythropoietin	Mus musculus	100-114
1174696-2	1975	The present studies were undertaken to assess the effects of isoniazid, an inhibitor of heme synthesis, on erythropoietin-induced erythroid maturation in hypertransfused mice.	Isoniazid	61-70	erythropoietin	Mus musculus	107-121
1168647-10	1975	Despite the different patterns observed for heme synthesis and hemoglobin synthesis, both synthetic activities were consistently higher in cells cultured with erythropoietin as compared to controls.	Heme	44-48	erythropoietin	Mus musculus	159-173
1121163-3	1975	Continuous exposure of mice to 8% O2 for 11 da resulted in a polycythemia of sufficient magnitude and duration to provide appropriate erythropoietic conditions for the erythropoietin assay.	Oxygen	34-36	erythropoietin	Mus musculus	168-182
4142788-1	1974	The tumorigenic EPO clonal cell line, derived from a methylcholanthrene-induced murine sarcoma, was exposed to increasing concentrations of actinomycin D and gave rise to a subline, resistant to 0.02 mug of actinomycin D per ml of medium, which was designated EPO/ADj.	Methylcholanthrene	53-71	erythropoietin	Mus musculus	16-19
4142788-1	1974	The tumorigenic EPO clonal cell line, derived from a methylcholanthrene-induced murine sarcoma, was exposed to increasing concentrations of actinomycin D and gave rise to a subline, resistant to 0.02 mug of actinomycin D per ml of medium, which was designated EPO/ADj.	Dactinomycin	140-153	erythropoietin	Mus musculus	16-19
4142788-5	1974	The morphology of cells changed with actinomycin-D-resistance: EPO/ADj cells were more spread and flattened and less overlapping than the original fibroblast-like EPO cells.	Dactinomycin	37-50	erythropoietin	Mus musculus	63-66
4142788-5	1974	The morphology of cells changed with actinomycin-D-resistance: EPO/ADj cells were more spread and flattened and less overlapping than the original fibroblast-like EPO cells.	Dactinomycin	37-50	erythropoietin	Mus musculus	163-166
164670-3	1975	These studies confirm earlier reports of the effects of cyclic AMP in increasing radioactive iron incorporation into red cells and further indicate that this change is associated with an absolute increase renal cyclic AMP concentrations probably stimulate erythropoiesis as a consequence of increased kidney production of erythropoietin.	Cyclic AMP	211-221	erythropoietin	Mus musculus	322-336
1234703-0	1975	Extraction of biologically active erythropoietin from kidneys of carbon monoxide intoxicated mice.	Carbon Monoxide	65-80	erythropoietin	Mus musculus	34-48
1234703-2	1975	From 2 to 4 hr after the start of carbon monoxide (CO)-hypoxemia large amounts of erythropoietin (ESF) are released in the plasma.	Carbon Monoxide	34-49	erythropoietin	Mus musculus	82-96
1234703-2	1975	From 2 to 4 hr after the start of carbon monoxide (CO)-hypoxemia large amounts of erythropoietin (ESF) are released in the plasma.	Carbon Monoxide	51-53	erythropoietin	Mus musculus	82-96
1157835-3	1975	Efficiency of colony formation observed after 2 days of culture was increased as much as 5-fold (to an average of 325 colonies/10-5 nucleated marrow cells) by the addition of thiol (either beta-mercaptoethanol or alphal-thioglycerol) at a final concentration of 10 minus 4 M. Optimum efficiency required 0.5 erythropoietin units/ml and was influenced by the purity of the preparation.	Sulfhydryl Compounds	175-180	erythropoietin	Mus musculus	308-322
1157835-4	1975	When cultures contained thiol and high doses (3 units/ml) of purified erythropoietin, a second population of erythroid colonies became apparent after 5 days of culture, and increased in size to macroscopic dimensions by the tenth day, when they contained as many as 10-4 cells.	Sulfhydryl Compounds	24-29	erythropoietin	Mus musculus	70-84
163577-2	1975	Studies in rates reveal a temporal relationship between renal cyclic AMP levels and plasma titers of erythropoietin.	Cyclic AMP	62-72	erythropoietin	Mus musculus	101-115
163577-3	1975	In addition, cobalt increases the activity of an erythropoietin-generating enzyme (renal erythropoietic factor) with maximal enzyme activity occurring after the rise in cyclic AMP levels but before the increase in erythropoietin titers.	Cobalt	13-19	erythropoietin	Mus musculus	49-63
163577-3	1975	In addition, cobalt increases the activity of an erythropoietin-generating enzyme (renal erythropoietic factor) with maximal enzyme activity occurring after the rise in cyclic AMP levels but before the increase in erythropoietin titers.	Cobalt	13-19	erythropoietin	Mus musculus	214-228
163577-3	1975	In addition, cobalt increases the activity of an erythropoietin-generating enzyme (renal erythropoietic factor) with maximal enzyme activity occurring after the rise in cyclic AMP levels but before the increase in erythropoietin titers.	Cyclic AMP	169-179	erythropoietin	Mus musculus	49-63
163577-9	1975	These results suggest that cyclic AMP plays a significant role in the renal production of erythropoietin following cobalt administration.	Cyclic AMP	27-37	erythropoietin	Mus musculus	90-104
163577-9	1975	These results suggest that cyclic AMP plays a significant role in the renal production of erythropoietin following cobalt administration.	Cobalt	115-121	erythropoietin	Mus musculus	90-104
163577-11	1975	Cyclic AMP then activates a protein kinase which subsequently stimulates renal erythropoietic factor to generate erythropoietin.	Cyclic AMP	0-10	erythropoietin	Mus musculus	113-127
5153058-0	1971	Erythropoietin-like activity of dexamethasone on the time-course of radioiron incorporation into red blood cells of erythremic mice.	Dexamethasone	32-45	erythropoietin	Mus musculus	0-14
4784627-0	1973	Erythropoiesis and erythropoietin in busulphan treated mice.	Busulfan	37-46	erythropoietin	Mus musculus	19-33
5152321-0	1971	[Effect of an increased and lowered production of erythropoietin in mice on the development in them of skin tumors induced by 20-methylcholanthrene].	Methylcholanthrene	126-147	erythropoietin	Mus musculus	50-64
4522297-2	1973	Within 1 hr, erythropoietin causes a 2- to 3-fold stimulation of uridine incorporation into RNA by these cells.	Uridine	65-72	erythropoietin	Mus musculus	13-27
5153058-0	1971	Erythropoietin-like activity of dexamethasone on the time-course of radioiron incorporation into red blood cells of erythremic mice.	radioiron	68-77	erythropoietin	Mus musculus	0-14
5668151-0	1968	Effect of erythropoietin on early recovery of erythropoiesis in mice after sublethal dose of 5-fluorouracil.	Fluorouracil	93-107	erythropoietin	Mus musculus	10-24
5312813-0	1970	Stimulation by serotonin of erythropoietin-dependent erythropoiesis in mice.	Serotonin	15-24	erythropoietin	Mus musculus	28-42
6024808-0	1967	Effects of erythropoietin on 14C-formate uptake by spleen and bone marrow nucleic acids of erythrocyte-transfused mice.	14c-formate	29-40	erythropoietin	Mus musculus	11-25
6054277-0	1967	Different [14C]formate and [6-14C]orotic acid incorporation patterns in the nucleic acids of spleen from normal and polycythemic mice treated with erythropoietin.	Carbon-14	11-14	erythropoietin	Mus musculus	147-161
6054277-0	1967	Different [14C]formate and [6-14C]orotic acid incorporation patterns in the nucleic acids of spleen from normal and polycythemic mice treated with erythropoietin.	Carbon-14	30-33	erythropoietin	Mus musculus	147-161
5240721-0	1968	Use of silicone rubber membrane enclosures for preparation of erythropoietin assay mice.	Silicones	7-15	erythropoietin	Mus musculus	62-76
5240754-0	1968	Preliminary purification of sheep and mouse erythropoietin by vertical flat bed discontinous electrophoresis in acrylamide gel.	Acrylamide	112-122	erythropoietin	Mus musculus	44-58
5980545-0	1966	Inhibition of erythropoietic stimulation by testosterone in polycythemic mice receiving anti-erythropoietin.	Testosterone	44-56	erythropoietin	Mus musculus	93-107
33512384-6	2021	MK-6482 treatment decreased EPO production and reversed polycythemia in all three mouse models.	Belzutifan	0-7	erythropoietin	Mus musculus	28-31
33822774-6	2021	The amelioration of responsiveness to erythropoietin resulted in reduced soluble erythroferrone, increased liver Hamp expression, and diminished liver iron overload.	erythroferrone	81-95	erythropoietin	Mus musculus	38-52
33822774-6	2021	The amelioration of responsiveness to erythropoietin resulted in reduced soluble erythroferrone, increased liver Hamp expression, and diminished liver iron overload.	Iron	151-155	erythropoietin	Mus musculus	38-52
14494235-0	1962	Erythropoietin assays using iron59 incorporation into blood and spleen of the polycythemic mouse.	Iron-59	28-34	erythropoietin	Mus musculus	0-14
33651336-3	2022	Here, we determined whether EPO-secreting KMSC-derived EVs (EPO(+)-EVs) can improve renal anemia in mouse models of chronic kidney disease (CKD).	kmsc	42-46	erythropoietin	Mus musculus	28-31
33928100-7	2021	The results showed that EPO significantly decreased serum creatinine, blood urea nitrogen, and cystatin C levels and alleviated renal histological changes in vivo.	Creatinine	58-68	erythropoietin	Mus musculus	24-27
33928100-7	2021	The results showed that EPO significantly decreased serum creatinine, blood urea nitrogen, and cystatin C levels and alleviated renal histological changes in vivo.	Urea	76-80	erythropoietin	Mus musculus	24-27
33928100-7	2021	The results showed that EPO significantly decreased serum creatinine, blood urea nitrogen, and cystatin C levels and alleviated renal histological changes in vivo.	Nitrogen	81-89	erythropoietin	Mus musculus	24-27
33611955-1	2021	The aim of this study was to explore the effects of ethanol extracts from Portulaca oleracea L. (ePO) on joint inflammation and to explain the underlying mechanisms.	Ethanol	52-59	erythropoietin	Mus musculus	97-100
33927725-6	2021	Moreover, EPO ameliorated inflammation and increased the actions of ciprofloxacin and vancomycin in resolution-delayed E. coli- and S. aureus-initiated infections.	Ciprofloxacin	68-81	erythropoietin	Mus musculus	10-13
33927725-6	2021	Moreover, EPO ameliorated inflammation and increased the actions of ciprofloxacin and vancomycin in resolution-delayed E. coli- and S. aureus-initiated infections.	Vancomycin	86-96	erythropoietin	Mus musculus	10-13
33186690-6	2021	To demonstrate the therapeutic potential of the technology, we injected mice with a TMP-responsive RNA replicon encoding erythropoietin (EPO) and successfully controlled the timing and magnitude of EPO production as well as changes in hematocrit.	Trimethoprim	84-87	erythropoietin	Mus musculus	121-135
33186690-6	2021	To demonstrate the therapeutic potential of the technology, we injected mice with a TMP-responsive RNA replicon encoding erythropoietin (EPO) and successfully controlled the timing and magnitude of EPO production as well as changes in hematocrit.	Trimethoprim	84-87	erythropoietin	Mus musculus	137-140
33186690-6	2021	To demonstrate the therapeutic potential of the technology, we injected mice with a TMP-responsive RNA replicon encoding erythropoietin (EPO) and successfully controlled the timing and magnitude of EPO production as well as changes in hematocrit.	Trimethoprim	84-87	erythropoietin	Mus musculus	198-201
33651336-7	2022	Furthermore, at two weeks post-injection of EPO(+)-KMSCs or EPO(+)-EVs into CKD mice with renal anemia, we observed significant increases in hemoglobin levels (11.7 +- 0.2 and 11.5 +- 0.2 vs. 10.1 +- 0.2 g/dL, respectively) and significantly lower serum creatinine levels at eight weeks in comparison to mice receiving vehicle control (0.30 +- 0.00 and 0.23 +- 0.03 vs. 0.43 +- 0.06 mg/dL, respectively).	Creatinine	254-264	erythropoietin	Mus musculus	44-47
33651336-7	2022	Furthermore, at two weeks post-injection of EPO(+)-KMSCs or EPO(+)-EVs into CKD mice with renal anemia, we observed significant increases in hemoglobin levels (11.7 +- 0.2 and 11.5 +- 0.2 vs. 10.1 +- 0.2 g/dL, respectively) and significantly lower serum creatinine levels at eight weeks in comparison to mice receiving vehicle control (0.30 +- 0.00 and 0.23 +- 0.03 vs. 0.43 +- 0.06 mg/dL, respectively).	Creatinine	254-264	erythropoietin	Mus musculus	60-63
33309599-3	2021	The decreased fat accumulation with EPO treatment during HFD in ovariectomized females was abrogated with estradiol supplementation, providing evidence for estrogen related gender specific EPO action in metabolic regulation.	Estradiol	106-115	erythropoietin	Mus musculus	36-39
33309599-3	2021	The decreased fat accumulation with EPO treatment during HFD in ovariectomized females was abrogated with estradiol supplementation, providing evidence for estrogen related gender specific EPO action in metabolic regulation.	Estradiol	106-115	erythropoietin	Mus musculus	189-192
32506750-11	2020	EPO also prevented LPS-induced increase in placental prostaglandin (PG)E2 and uterine inducible nitric oxide synthase (iNOS) production, while decreasing nuclear factor kappa-B (NF-kappabeta) activity in the myometrium.	Dinoprostone	53-73	erythropoietin	Mus musculus	0-3
33508746-10	2021	INTERPRETATION: Renal interstitial fibroblasts function as central controllers of systemic oxygen delivery by producing both renin and erythropoietin.	Oxygen	91-97	erythropoietin	Mus musculus	135-149
32193252-3	2021	Conversely, stimulation of erythropoiesis suppresses hepcidin expression via induction of the erythropoietin-responsive hormone erythroferrone.	erythroferrone	128-142	erythropoietin	Mus musculus	94-108
33255601-4	2020	Confocal microscopy confirmed EPO production in erythroblastic island (EBI)-associated macrophages, and analysis of mice depleted of EBI macrophages by clodronate liposomes revealed drops in EPO levels in bone marrow (BM) cell lysates, and decreased percentages of EPO-responsive erythroblasts in the BM.	Clodronic Acid	152-162	erythropoietin	Mus musculus	191-194
33255601-4	2020	Confocal microscopy confirmed EPO production in erythroblastic island (EBI)-associated macrophages, and analysis of mice depleted of EBI macrophages by clodronate liposomes revealed drops in EPO levels in bone marrow (BM) cell lysates, and decreased percentages of EPO-responsive erythroblasts in the BM.	Clodronic Acid	152-162	erythropoietin	Mus musculus	191-194
32712065-3	2020	The combination of evening primrose/hemp seed oil (EPO / HSO) has essential fatty acids (EFAs) for human optimal health due to the favorable ratio of omega-6 / omega-3 and antioxidant properties.	Fatty Acids, Essential	66-87	erythropoietin	Mus musculus	51-54
32712065-3	2020	The combination of evening primrose/hemp seed oil (EPO / HSO) has essential fatty acids (EFAs) for human optimal health due to the favorable ratio of omega-6 / omega-3 and antioxidant properties.	Fatty Acids, Essential	89-93	erythropoietin	Mus musculus	51-54
32712065-11	2020	RESULTS: Our findings indicated that EPO / HSO therapy significantly increased the percentage of essential fatty acids in cell membranes of the spleen and blood.	Fatty Acids, Essential	97-118	erythropoietin	Mus musculus	37-40
32759272-2	2020	A novel erythropoietin-derived cyclic helix B surface peptide (CHBP) protects kidneys against AKI subjected to different causes.	surface	46-53	erythropoietin	Mus musculus	8-22
33592127-3	2021	Anemia is a potent driver of FGF23 secretion; therefore, a HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitor) currently in clinical trials to elevate endogenous EPO to resolve anemia, was tested for effects on iron utilization and FGF23-related parameters in a CKD mouse model.	Iron	223-227	erythropoietin	Mus musculus	174-177
33467745-5	2021	Moreover, EPO promotes a rescue of mitochondrial respiration while markedly enhancing the glycolytic rate, as shown by the augmented extracellular acidification rate, contributing to elevated ATP levels in MPP+-challenged cells.	Adenosine Triphosphate	192-195	erythropoietin	Mus musculus	10-13
33467745-5	2021	Moreover, EPO promotes a rescue of mitochondrial respiration while markedly enhancing the glycolytic rate, as shown by the augmented extracellular acidification rate, contributing to elevated ATP levels in MPP+-challenged cells.	mangion-purified polysaccharide (Candida albicans)	206-210	erythropoietin	Mus musculus	10-13
33467745-9	2021	We report for the first time, that EPO-neuroprotection is exerted through restoring ATP levels by accelerating the glycolytic rate.	Adenosine Triphosphate	84-87	erythropoietin	Mus musculus	35-38
33231436-0	2020	Chemical Synthesis of an Erythropoietin Glycoform Having a Triantennary N-Glycan: Significant Change of Biological Activity of Glycoprotein by Addition of a Small Molecular Weight Trisaccharide.	n-glycan	72-80	erythropoietin	Mus musculus	25-39
33231436-0	2020	Chemical Synthesis of an Erythropoietin Glycoform Having a Triantennary N-Glycan: Significant Change of Biological Activity of Glycoprotein by Addition of a Small Molecular Weight Trisaccharide.	Trisaccharides	180-193	erythropoietin	Mus musculus	25-39
32556142-8	2020	To overcome this issue, we postulated that some level of iron restriction (by targeting Tmprss6) would improve the splenomegaly while preserving the beneficial effects on RBC production mediated by EPO or Tfr2 deletion.	Iron	57-61	erythropoietin	Mus musculus	198-201
32907997-7	2020	Moreover, we found that i.v.-injected ICs in Epo-treated mice were more rapidly removed from the circulation than in PBS-treated mice.	Lead	117-120	erythropoietin	Mus musculus	45-48
32621283-7	2020	RESULTS: EPO overexpression promoted cell viability and migration of BM-MSCs without inducing apoptosis, and EPO-MSC treatment significantly alleviated liver fibrosis in a carbon tetrachloride (CCl4) induced mouse liver fibrosis model.	Carbon Tetrachloride	172-192	erythropoietin	Mus musculus	109-112
32621283-7	2020	RESULTS: EPO overexpression promoted cell viability and migration of BM-MSCs without inducing apoptosis, and EPO-MSC treatment significantly alleviated liver fibrosis in a carbon tetrachloride (CCl4) induced mouse liver fibrosis model.	Carbon Tetrachloride	194-198	erythropoietin	Mus musculus	9-12
32621283-7	2020	RESULTS: EPO overexpression promoted cell viability and migration of BM-MSCs without inducing apoptosis, and EPO-MSC treatment significantly alleviated liver fibrosis in a carbon tetrachloride (CCl4) induced mouse liver fibrosis model.	Carbon Tetrachloride	194-198	erythropoietin	Mus musculus	109-112
32881928-5	2020	The mice were divided into four groups according to the type of drugs administered (control, erythropoietin, dexamethasone, and erythropoietin with dexamethasone).	Dexamethasone	148-161	erythropoietin	Mus musculus	128-142
32311143-6	2020	The erythroid response in wild-type mice following 5alpha-DHT treatment was associated with increased serum erythropoietin (EPO) and its downstream target erythroferrone, and hepcidin suppression.	Dihydrotestosterone	51-61	erythropoietin	Mus musculus	108-122
31562532-11	2020	Treatment with BMS309403: (1) reversed the effects induced by COCO in physiological conditions and in mouse models of diarrhea; (2) prevented the effects of EPO on BW, VMR to CRD and castor oil-induced diarrhea; (3) affected proliferation of preadipocytes; (4) changed the expression of Fabp4 in colonic and adipocyte samples from COCO and EPO.	2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid	15-24	erythropoietin	Mus musculus	157-160
31562532-11	2020	Treatment with BMS309403: (1) reversed the effects induced by COCO in physiological conditions and in mouse models of diarrhea; (2) prevented the effects of EPO on BW, VMR to CRD and castor oil-induced diarrhea; (3) affected proliferation of preadipocytes; (4) changed the expression of Fabp4 in colonic and adipocyte samples from COCO and EPO.	2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid	15-24	erythropoietin	Mus musculus	340-343
32667087-7	2020	In iron-deficient mice, erythropoietin levels were higher but erythropoietin-regulated genes were generally downregulated relative to iron-replete mice, suggesting erythropoietin resistance.	Iron	3-7	erythropoietin	Mus musculus	24-38
32667087-7	2020	In iron-deficient mice, erythropoietin levels were higher but erythropoietin-regulated genes were generally downregulated relative to iron-replete mice, suggesting erythropoietin resistance.	Iron	3-7	erythropoietin	Mus musculus	62-76
32667087-7	2020	In iron-deficient mice, erythropoietin levels were higher but erythropoietin-regulated genes were generally downregulated relative to iron-replete mice, suggesting erythropoietin resistance.	Iron	3-7	erythropoietin	Mus musculus	62-76
32667087-9	2020	However, testosterone worsens anemia in iron-deficient mice because of ineffective erythropoiesis possibly due to erythropoietin resistance associated with iron deficiency.	Testosterone	9-21	erythropoietin	Mus musculus	114-128
32311143-6	2020	The erythroid response in wild-type mice following 5alpha-DHT treatment was associated with increased serum erythropoietin (EPO) and its downstream target erythroferrone, and hepcidin suppression.	Dihydrotestosterone	51-61	erythropoietin	Mus musculus	124-127
32311143-8	2020	Paradoxically testosterone, but not 5alpha-DHT, suppressed EPO levels in AR ZF2 mice, suggesting testosterone following aromatization may oppose the erythroid-stimulating effects of androgens.	Testosterone	14-26	erythropoietin	Mus musculus	59-62
32579360-0	2020	Eliminating Fc N-linked glycosylation and its impact on dosing consideration for a transferrin receptor antibody-erythropoietin fusion protein in mice.	fc n	12-16	erythropoietin	Mus musculus	113-127
32579360-4	2020	To overcome this, we recently developed an effectorless TfRMAb-EPO fusion protein, designated TfRMAb-N292G-EPO, by eliminating the Fc N-linked glycosylation site at position 292 of the antibody heavy chain.	Nitrogen	101-102	erythropoietin	Mus musculus	56-66
32579360-4	2020	To overcome this, we recently developed an effectorless TfRMAb-EPO fusion protein, designated TfRMAb-N292G-EPO, by eliminating the Fc N-linked glycosylation site at position 292 of the antibody heavy chain.	Nitrogen	101-102	erythropoietin	Mus musculus	63-66
32579360-18	2020	No reticulocyte suppression was observed at the 3 mg/kg SQ dose of TfRMAb-N292G-EPO.	tfrmab-n292g	67-79	erythropoietin	Mus musculus	80-83
32221724-4	2020	Previous studies have shown that darbepoetin (DPO)-alpha, a long lasting analogue of erythropoietin, is capable of promoting angiogenesis.	darbepoetin (dpo)-alpha	33-56	erythropoietin	Mus musculus	85-99
32579360-20	2020	Overall, elimination of Fc N-linked glycosylation, to mitigate TfRMAb effector function side-effects, has a profound effect on the plasma exposure of TfRMAb-N292G-EPO at therapeutic as well as high doses (3-20 mg/kg).	Nitrogen	27-28	erythropoietin	Mus musculus	163-166
32708962-9	2020	Erythropoietin levels were increased in the serum of gemfibrozil-treated animals, and we also observed an increased expression of hypoxia-inducible factor-2 alpha (HIF-2alpha) and erythropoietin in renal tissue, while PPAR-alpha knockout mice treated with gemfibrozil did not present increased levels of serum erythropoietin or tissue HIF-2alpha and erythropoietin mRNA levels in the kidneys.	Gemfibrozil	53-64	erythropoietin	Mus musculus	0-14
32708962-9	2020	Erythropoietin levels were increased in the serum of gemfibrozil-treated animals, and we also observed an increased expression of hypoxia-inducible factor-2 alpha (HIF-2alpha) and erythropoietin in renal tissue, while PPAR-alpha knockout mice treated with gemfibrozil did not present increased levels of serum erythropoietin or tissue HIF-2alpha and erythropoietin mRNA levels in the kidneys.	Gemfibrozil	53-64	erythropoietin	Mus musculus	180-194
32708962-9	2020	Erythropoietin levels were increased in the serum of gemfibrozil-treated animals, and we also observed an increased expression of hypoxia-inducible factor-2 alpha (HIF-2alpha) and erythropoietin in renal tissue, while PPAR-alpha knockout mice treated with gemfibrozil did not present increased levels of serum erythropoietin or tissue HIF-2alpha and erythropoietin mRNA levels in the kidneys.	Gemfibrozil	53-64	erythropoietin	Mus musculus	310-324
32393787-9	2021	Mechanistically, Wt1 recruits Tet2 to the promoter of erythropoietin (Epo), which results in enhanced 5-hydroxymethylcytosine (5hmC) levels and the promotion of Epo expression.	5-hydroxymethylcytosine	102-125	erythropoietin	Mus musculus	54-68
32708962-9	2020	Erythropoietin levels were increased in the serum of gemfibrozil-treated animals, and we also observed an increased expression of hypoxia-inducible factor-2 alpha (HIF-2alpha) and erythropoietin in renal tissue, while PPAR-alpha knockout mice treated with gemfibrozil did not present increased levels of serum erythropoietin or tissue HIF-2alpha and erythropoietin mRNA levels in the kidneys.	Gemfibrozil	53-64	erythropoietin	Mus musculus	310-324
32708962-9	2020	Erythropoietin levels were increased in the serum of gemfibrozil-treated animals, and we also observed an increased expression of hypoxia-inducible factor-2 alpha (HIF-2alpha) and erythropoietin in renal tissue, while PPAR-alpha knockout mice treated with gemfibrozil did not present increased levels of serum erythropoietin or tissue HIF-2alpha and erythropoietin mRNA levels in the kidneys.	Gemfibrozil	256-267	erythropoietin	Mus musculus	0-14
32352602-8	2020	As shown by immunostaining of endothelial makers, renal vascular densities were decreased accompanied by increased HIF-1alpha and erythropoietin levels in the kidneys of KS-tg/OVE mice.	Potassium	170-172	erythropoietin	Mus musculus	130-144
32438631-6	2020	Cilastatin enhanced HIF-1alpha translation via the phosphorylation of Akt and mTOR was followed by the upregulation of erythropoietin (EPO) and vascular endothelial growth factor (VEGF).	Cilastatin	0-10	erythropoietin	Mus musculus	119-133
32438631-6	2020	Cilastatin enhanced HIF-1alpha translation via the phosphorylation of Akt and mTOR was followed by the upregulation of erythropoietin (EPO) and vascular endothelial growth factor (VEGF).	Cilastatin	0-10	erythropoietin	Mus musculus	135-138
32393787-9	2021	Mechanistically, Wt1 recruits Tet2 to the promoter of erythropoietin (Epo), which results in enhanced 5-hydroxymethylcytosine (5hmC) levels and the promotion of Epo expression.	5-hydroxymethylcytosine	102-125	erythropoietin	Mus musculus	70-73
32393787-9	2021	Mechanistically, Wt1 recruits Tet2 to the promoter of erythropoietin (Epo), which results in enhanced 5-hydroxymethylcytosine (5hmC) levels and the promotion of Epo expression.	5-hydroxymethylcytosine	127-131	erythropoietin	Mus musculus	54-68
32393787-9	2021	Mechanistically, Wt1 recruits Tet2 to the promoter of erythropoietin (Epo), which results in enhanced 5-hydroxymethylcytosine (5hmC) levels and the promotion of Epo expression.	5-hydroxymethylcytosine	127-131	erythropoietin	Mus musculus	70-73
31640478-2	2020	Daprodustat"s biological activity simulates components of the natural response to hypoxia; inhibition of PHDs results in HIF stabilization and modulation of HIF-controlled gene products, including erythropoietin.	GSK1278863	0-11	erythropoietin	Mus musculus	197-211
32143001-12	2020	The protein expression of IL-1beta, F4/80, CD31, NF-kappaB p65, NF-H, MPZ, and DHE (redox-sensitive probe) was also significantly modulated by EPO treatment.	Dihydroergotamine	79-82	erythropoietin	Mus musculus	143-146
31970695-9	2020	Erythropoietin treatment induced anti-apoptotic signaling via down-regulated Bax mRNA expression and abrogated phospho-Nf-kb p65.	phosphorylleucylphenylalanine	111-118	erythropoietin	Mus musculus	0-14
32092924-0	2020	Acai Extract Transiently Upregulates Erythropoietin by Inducing a Renal Hypoxic Condition in Mice.	acai extract	0-12	erythropoietin	Mus musculus	37-51
32092924-8	2020	Acai administration significantly increased the levels of the hematopoietic-related hormone erythropoietin in blood compared to controls and also transiently upregulated the gene expression of Epo in the kidney.	acai	0-4	erythropoietin	Mus musculus	92-106
32092924-8	2020	Acai administration significantly increased the levels of the hematopoietic-related hormone erythropoietin in blood compared to controls and also transiently upregulated the gene expression of Epo in the kidney.	acai	0-4	erythropoietin	Mus musculus	193-196
32092924-10	2020	These results demonstrated that acai increases the erythropoietin expression via hypoxic action in the kidney.	acai	32-36	erythropoietin	Mus musculus	51-65
31954768-2	2020	Thus, protective effects of erythropoietin(EPO) on myelinization of oligodendrocytes and schwann cells respectively in CNS and PNS following MS induced by cuprizone (CPZ) administration in young female mice.	Cuprizone	166-169	erythropoietin	Mus musculus	43-46
32038269-7	2019	Erythropoietin regulation of fat mass is masked in female mice due to estrogen production.	Estrogens	70-78	erythropoietin	Mus musculus	0-14
31954768-2	2020	Thus, protective effects of erythropoietin(EPO) on myelinization of oligodendrocytes and schwann cells respectively in CNS and PNS following MS induced by cuprizone (CPZ) administration in young female mice.	Cuprizone	155-164	erythropoietin	Mus musculus	43-46
31740386-8	2019	In contrast, in renal ischemia animal model, increased EPO triggered by hypoxia signaling activation, was accompanied by decreased triglyceride (TG) in serum.	Triglycerides	131-143	erythropoietin	Mus musculus	55-58
30744451-3	2019	The present study is designed to deliver the erythropoietin (EPO) into the N-methyl-N-nitrosourea (MNU) induced mice, a pharmacological retinopathy model via intranasal or intravenous route.	Methylnitrosourea	75-97	erythropoietin	Mus musculus	45-59
30744451-3	2019	The present study is designed to deliver the erythropoietin (EPO) into the N-methyl-N-nitrosourea (MNU) induced mice, a pharmacological retinopathy model via intranasal or intravenous route.	Methylnitrosourea	75-97	erythropoietin	Mus musculus	61-64
30744451-3	2019	The present study is designed to deliver the erythropoietin (EPO) into the N-methyl-N-nitrosourea (MNU) induced mice, a pharmacological retinopathy model via intranasal or intravenous route.	Methylnitrosourea	99-102	erythropoietin	Mus musculus	45-59
30744451-3	2019	The present study is designed to deliver the erythropoietin (EPO) into the N-methyl-N-nitrosourea (MNU) induced mice, a pharmacological retinopathy model via intranasal or intravenous route.	Methylnitrosourea	99-102	erythropoietin	Mus musculus	61-64
30744451-5	2019	Our results showed that the intranasal delivery of EPO is effective to alleviate the morphological disruptions in the MNU induced mice.	Methylnitrosourea	118-121	erythropoietin	Mus musculus	51-54
30744451-6	2019	The intranasal delivery of EPO also ameliorated the visual impairments in the MNU induced mice.	Methylnitrosourea	78-81	erythropoietin	Mus musculus	27-30
31740386-8	2019	In contrast, in renal ischemia animal model, increased EPO triggered by hypoxia signaling activation, was accompanied by decreased triglyceride (TG) in serum.	Triglycerides	145-147	erythropoietin	Mus musculus	55-58
31740386-10	2019	Delivering of recombinant EPO into both wild type and CKD mice suppressed TG in serum by accelerating lipid catabolism in adipose tissue.	Triglycerides	74-76	erythropoietin	Mus musculus	26-29
31211943-0	2019	EPO regulates neuroprotective Transmembrane BAX Inhibitor-1 Motif-containing (TMBIM) family members GRINA and FAIM2 after cerebral ischemia-reperfusion injury.	tmbim	78-83	erythropoietin	Mus musculus	0-3
31173165-6	2019	In addition, in palmitate-treated hepatocytes, small interfering RNA-mediated SIRT1 silencing suppressed the effects of EPO on lipid-induced ER stress.	Palmitates	16-25	erythropoietin	Mus musculus	120-123
31551766-10	2019	FRA, CAL, and CLG improved the content of EPO.	ferulic acid	0-3	erythropoietin	Mus musculus	42-45
31551766-10	2019	FRA, CAL, and CLG improved the content of EPO.	7,3'-dihydroxy-4'-methoxyisoflavone	5-8	erythropoietin	Mus musculus	42-45
31551766-10	2019	FRA, CAL, and CLG improved the content of EPO.	calycosin-7-O-beta-D-glucoside	14-17	erythropoietin	Mus musculus	42-45
31170519-2	2019	Evidence from our preclinical work in an umbilical cord blood (UCB) transplantation murine model suggests that treatment with hyperbaric oxygen (HBO) before UCB infusion improves UCB CD34+ cell engraftment by reducing erythropoietin levels.	Oxygen	137-143	erythropoietin	Mus musculus	218-232
31260338-8	2019	Serum erythropoietin (EPO) levels were increased significantly in young mice receiving low-oxygen SIHT treatments (10% and 15% oxygen).	Oxygen	91-97	erythropoietin	Mus musculus	6-20
31260338-8	2019	Serum erythropoietin (EPO) levels were increased significantly in young mice receiving low-oxygen SIHT treatments (10% and 15% oxygen).	Oxygen	91-97	erythropoietin	Mus musculus	22-25
31260338-8	2019	Serum erythropoietin (EPO) levels were increased significantly in young mice receiving low-oxygen SIHT treatments (10% and 15% oxygen).	Oxygen	127-133	erythropoietin	Mus musculus	6-20
31260338-8	2019	Serum erythropoietin (EPO) levels were increased significantly in young mice receiving low-oxygen SIHT treatments (10% and 15% oxygen).	Oxygen	127-133	erythropoietin	Mus musculus	22-25
30876881-0	2019	The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic.	cibinetide	103-113	erythropoietin	Mus musculus	135-149
31091718-6	2019	Further, inhibition of HIF2alpha with its specific inhibitor PT2385 significantly reduced erythropoietin levels in the mutant mice.	PT2385	61-67	erythropoietin	Mus musculus	90-104
31091718-7	2019	However, polycythemia persisted after PT2385 treatment, suggesting an alternative erythropoietin-independent mechanism of polycythemia.	PT2385	38-44	erythropoietin	Mus musculus	82-96
31308217-7	2019	Anemia was present in adenine-fed mice, while PBI-4050 blunted these effects and led to significantly higher plasma erythropoietin (EPO) levels.	pbi	46-49	erythropoietin	Mus musculus	116-130
31308217-7	2019	Anemia was present in adenine-fed mice, while PBI-4050 blunted these effects and led to significantly higher plasma erythropoietin (EPO) levels.	pbi	46-49	erythropoietin	Mus musculus	132-135
30876881-4	2019	Based on recent findings that ARA290 (cibinetide), a peptide based on the Helix-B domain of erythropoietin (EPO), is anti-inflammatory and tissue-protective, the effect of this peptide on ECFC-mediated vascular regeneration was studied in the ischemic retina.	cibinetide	30-36	erythropoietin	Mus musculus	92-106
30876881-4	2019	Based on recent findings that ARA290 (cibinetide), a peptide based on the Helix-B domain of erythropoietin (EPO), is anti-inflammatory and tissue-protective, the effect of this peptide on ECFC-mediated vascular regeneration was studied in the ischemic retina.	cibinetide	30-36	erythropoietin	Mus musculus	108-111
30876881-4	2019	Based on recent findings that ARA290 (cibinetide), a peptide based on the Helix-B domain of erythropoietin (EPO), is anti-inflammatory and tissue-protective, the effect of this peptide on ECFC-mediated vascular regeneration was studied in the ischemic retina.	cibinetide	38-48	erythropoietin	Mus musculus	92-106
30876881-4	2019	Based on recent findings that ARA290 (cibinetide), a peptide based on the Helix-B domain of erythropoietin (EPO), is anti-inflammatory and tissue-protective, the effect of this peptide on ECFC-mediated vascular regeneration was studied in the ischemic retina.	cibinetide	38-48	erythropoietin	Mus musculus	108-111
31179408-1	2019	A combination of structure-based drug design and medicinal chemistry efforts led us from benzimidazole-2-carboxamide with modestly active hypoxia-inducible factor prolyl hydroxylase 2 inhibition to certain benzimidazole-2-pyrazole carboxylic acids that were more potent as well as orally efficacious stimulators of erythropoietin secretion in our in vivo mouse model.	1H-Benzo[d]imidazole-2-carboxamide	89-116	erythropoietin	Mus musculus	315-329
31179408-1	2019	A combination of structure-based drug design and medicinal chemistry efforts led us from benzimidazole-2-carboxamide with modestly active hypoxia-inducible factor prolyl hydroxylase 2 inhibition to certain benzimidazole-2-pyrazole carboxylic acids that were more potent as well as orally efficacious stimulators of erythropoietin secretion in our in vivo mouse model.	benzimidazole-2-pyrazole carboxylic acids	206-247	erythropoietin	Mus musculus	315-329
30918303-4	2019	Single subcutaneous administration of sustained-release prostacyclin analog ONO-1301-MS to mSOD1G93A mice abrogated the expression of HIF-1alpha in their spinal cords, as well as erythropoietin (EPO) and vascular endothelial growth factor (VEGF), both of which are downstream to HIF-1alpha.	Epoprostenol	56-68	erythropoietin	Mus musculus	179-193
31013255-5	2019	In a murine model of TH17-dependent aristolochic acid (ArA)-induced, interstitial kidney disease associated with reduced renal EPO production, we demonstrate that transgenic EPO overexpression or recombinant EPO (rEPO) administration limits TH17 formation and clinical/histological disease expression.	aristolochic acid I	36-53	erythropoietin	Mus musculus	174-177
31013255-5	2019	In a murine model of TH17-dependent aristolochic acid (ArA)-induced, interstitial kidney disease associated with reduced renal EPO production, we demonstrate that transgenic EPO overexpression or recombinant EPO (rEPO) administration limits TH17 formation and clinical/histological disease expression.	aristolochic acid I	36-53	erythropoietin	Mus musculus	174-177
31013255-5	2019	In a murine model of TH17-dependent aristolochic acid (ArA)-induced, interstitial kidney disease associated with reduced renal EPO production, we demonstrate that transgenic EPO overexpression or recombinant EPO (rEPO) administration limits TH17 formation and clinical/histological disease expression.	aristolochic acid I	55-58	erythropoietin	Mus musculus	174-177
31013255-5	2019	In a murine model of TH17-dependent aristolochic acid (ArA)-induced, interstitial kidney disease associated with reduced renal EPO production, we demonstrate that transgenic EPO overexpression or recombinant EPO (rEPO) administration limits TH17 formation and clinical/histological disease expression.	aristolochic acid I	55-58	erythropoietin	Mus musculus	174-177
31013255-6	2019	EPO/EPO-R ligations on CD4+ T cells abrogate, while absence of T cell-expressed EPO-R augments, TH17 induction and clinical/histological expression of pristane-induced glomerulonephritis (associated with decreased intrarenal EPO).	pristane	151-159	erythropoietin	Mus musculus	0-3
31013255-6	2019	EPO/EPO-R ligations on CD4+ T cells abrogate, while absence of T cell-expressed EPO-R augments, TH17 induction and clinical/histological expression of pristane-induced glomerulonephritis (associated with decreased intrarenal EPO).	pristane	151-159	erythropoietin	Mus musculus	4-7
30958854-4	2019	Administration of iron increased liver phosphorylated SMAD protein content and hepcidin mRNA content; subsequent administration of erythropoietin significantly decreased both the iron-induced phosphorylated SMAD proteins and hepcidin mRNA.	Iron	179-183	erythropoietin	Mus musculus	131-145
30958854-6	2019	Administration of erythropoietin substantially increased the amount of erythroferrone and transferrin receptor 2 proteins in the spleen; pretreatment with iron did not influence the erythropoietin-induced content of these proteins.	erythroferrone	71-85	erythropoietin	Mus musculus	18-32
30958854-7	2019	Erythropoietin-treated iron-deficient mice displayed smaller spleen size in comparison with erythropoietin-treated mice kept on a control diet.	Iron	23-27	erythropoietin	Mus musculus	0-14
30733080-14	2019	Tissue pre- and postconditioning with low doses of EPO protects the critically perfused musculocutaneous tissue by maintaining capillary perfusion because of increased arteriolar blood flow mediated by nitric oxide (NO) expression.	Nitric Oxide	202-214	erythropoietin	Mus musculus	51-54
30918303-4	2019	Single subcutaneous administration of sustained-release prostacyclin analog ONO-1301-MS to mSOD1G93A mice abrogated the expression of HIF-1alpha in their spinal cords, as well as erythropoietin (EPO) and vascular endothelial growth factor (VEGF), both of which are downstream to HIF-1alpha.	Epoprostenol	56-68	erythropoietin	Mus musculus	195-198
30918303-4	2019	Single subcutaneous administration of sustained-release prostacyclin analog ONO-1301-MS to mSOD1G93A mice abrogated the expression of HIF-1alpha in their spinal cords, as well as erythropoietin (EPO) and vascular endothelial growth factor (VEGF), both of which are downstream to HIF-1alpha.	ONO 1301	76-84	erythropoietin	Mus musculus	179-193
30918303-4	2019	Single subcutaneous administration of sustained-release prostacyclin analog ONO-1301-MS to mSOD1G93A mice abrogated the expression of HIF-1alpha in their spinal cords, as well as erythropoietin (EPO) and vascular endothelial growth factor (VEGF), both of which are downstream to HIF-1alpha.	ONO 1301	76-84	erythropoietin	Mus musculus	195-198
30893233-7	2019	Mice treated with 4-AP or EPO during the compression phase had significantly smaller declines in nerve conduction velocity and increased plateau nerve conduction velocities compared with untreated controls (animals that received saline solution).	Sodium Chloride	229-235	erythropoietin	Mus musculus	26-29
30778109-7	2019	Captopril reduced radiation-induced cytokines EPO, G-CSF, and SAA in the plasma.	Captopril	0-9	erythropoietin	Mus musculus	46-49
30266734-0	2019	Transient decrease of serum iron after acute erythropoietin treatment contributes to hepcidin inhibition by ERFE in mice.	Iron	28-32	erythropoietin	Mus musculus	45-59
30252956-2	2019	We present here data indicating that Fyn, a Src-family-kinase, participates in the EPO signaling-pathway, since Fyn-/- mice exhibit reduced Tyr-phosphorylation of EPO-R and decreased STAT5-activity.	Tyrosine	140-143	erythropoietin	Mus musculus	83-86
30292638-3	2019	In zymosan-induced acute peritonitis, in line with the delayed resolution of inflammation, the induction of macrophage EPO signaling was significantly reduced in obese mice relative to normal mice.	Zymosan	3-10	erythropoietin	Mus musculus	119-122
30382305-2	2019	We have demonstrated that pre-treating irradiated immune-deficient mice with hyperbaric oxygen (HBO) prior to UCB CD34+ cell transplantation lowered host systemic erythropoietin (EPO) and improved UCB CD34+ cell homing and engraftment.	Oxygen	88-94	erythropoietin	Mus musculus	163-177
30382305-2	2019	We have demonstrated that pre-treating irradiated immune-deficient mice with hyperbaric oxygen (HBO) prior to UCB CD34+ cell transplantation lowered host systemic erythropoietin (EPO) and improved UCB CD34+ cell homing and engraftment.	Oxygen	88-94	erythropoietin	Mus musculus	179-182
30535439-4	2019	Using the canonical mouse model of chronic alcohol exposure designed to mimic the repeated cycles of heavy abuse typical of chronic alcoholism, it was found that EPO delivered via intranasal route effectively restored the alcohol-impaired motor cooperation in rotarod and beam walk tests, reversed alcoholic cognitive and emotional alterations in the novel location recognition task and open-filed test, and rescued alcohol-disrupted nervous conduction in the somatosensory-evoked potential (SSEP) test.	Alcohols	43-50	erythropoietin	Mus musculus	162-165
30535439-4	2019	Using the canonical mouse model of chronic alcohol exposure designed to mimic the repeated cycles of heavy abuse typical of chronic alcoholism, it was found that EPO delivered via intranasal route effectively restored the alcohol-impaired motor cooperation in rotarod and beam walk tests, reversed alcoholic cognitive and emotional alterations in the novel location recognition task and open-filed test, and rescued alcohol-disrupted nervous conduction in the somatosensory-evoked potential (SSEP) test.	Alcohols	132-139	erythropoietin	Mus musculus	162-165
30535439-4	2019	Using the canonical mouse model of chronic alcohol exposure designed to mimic the repeated cycles of heavy abuse typical of chronic alcoholism, it was found that EPO delivered via intranasal route effectively restored the alcohol-impaired motor cooperation in rotarod and beam walk tests, reversed alcoholic cognitive and emotional alterations in the novel location recognition task and open-filed test, and rescued alcohol-disrupted nervous conduction in the somatosensory-evoked potential (SSEP) test.	Alcohols	132-139	erythropoietin	Mus musculus	162-165
30535439-5	2019	Consistently, the intranasally administered EPO promoted the remyelination and synapse formation in chronic alcohol-affected neocortex and hippocampus as evidenced by immunofluorescence staining and transmission electron microscopy.	Alcohols	108-115	erythropoietin	Mus musculus	44-47
30535439-7	2019	Furthermore, the intranasal EPO-exerted neuroprotection was almost abolished when the specific Nrf2 antagonist ATRA was administered intraperitoneally prior to intranasal EPO treatment.	Tretinoin	111-115	erythropoietin	Mus musculus	28-31
30501635-5	2018	We recently demonstrated that erythropoietin-releasing neural precursors cells (Er-NPCs) administered to MPTP-intoxicated animals survive after transplantation in the recipient"s damaged brain, differentiate, and rescue degenerating striatal dopaminergic neurons.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	105-109	erythropoietin	Mus musculus	30-44
30502238-2	2019	We previously reported that diazoxide (DZ), enhances the neuroprotective efficacy of erythropoietin (EPO).	Diazoxide	28-37	erythropoietin	Mus musculus	85-99
30502238-2	2019	We previously reported that diazoxide (DZ), enhances the neuroprotective efficacy of erythropoietin (EPO).	Diazoxide	28-37	erythropoietin	Mus musculus	101-104
30502238-2	2019	We previously reported that diazoxide (DZ), enhances the neuroprotective efficacy of erythropoietin (EPO).	Diazoxide	39-41	erythropoietin	Mus musculus	85-99
30502238-2	2019	We previously reported that diazoxide (DZ), enhances the neuroprotective efficacy of erythropoietin (EPO).	Diazoxide	39-41	erythropoietin	Mus musculus	101-104
30366982-0	2018	FAM210B is an erythropoietin target and regulates erythroid heme synthesis by controlling mitochondrial iron import and ferrochelatase activity.	Heme	60-64	erythropoietin	Mus musculus	14-28
30366982-0	2018	FAM210B is an erythropoietin target and regulates erythroid heme synthesis by controlling mitochondrial iron import and ferrochelatase activity.	Iron	104-108	erythropoietin	Mus musculus	14-28
30366982-2	2018	Despite the centrality of iron metabolism to erythropoiesis, the mechanisms by which EPO regulates iron status are not well-understood.	Iron	99-103	erythropoietin	Mus musculus	85-88
30366982-3	2018	To this end, here we profiled gene expression in EPO-treated 32D pro-B cells and developing fetal liver erythroid cells to identify additional iron regulatory genes.	Iron	143-147	erythropoietin	Mus musculus	49-52
30366982-10	2018	Collectively, our results reveal a critical mechanism by which EPO signaling regulates terminal erythropoiesis and iron metabolism.	Iron	115-119	erythropoietin	Mus musculus	63-66
30193997-12	2018	Mice treated with DZ+EPO had significantly fewer terminal deoxynucleotide transferase-mediated deoxy uridine triphosphate nick-end labeling-positive cells than other groups.	deoxyuridine triphosphate	95-121	erythropoietin	Mus musculus	21-24
30472982-5	2018	METHODS: We postulated that H2S might be a primary mediator of EPO synthesis during hypoxia, which was tested using an in vivo murine model of whole-body hypoxia and in clinical samples obtained from CKD patients.	Hydrogen Sulfide	28-31	erythropoietin	Mus musculus	63-66
30472982-8	2018	CONCLUSIONS: Together, our results confirm an interplay between the actions of H2S during hypoxia and EPO production.	Hydrogen Sulfide	79-82	erythropoietin	Mus musculus	102-105
30209118-5	2018	We generated a murine model of thalassemia intermedia specifically lacking BM Tfr2: because their erythroid cells are more susceptible to EPO stimulation, mice show improved erythropoiesis and red blood cell morphology as well as partial correction of anemia and iron overload.	Iron	263-267	erythropoietin	Mus musculus	138-141
30245128-0	2018	Iron attenuates erythropoietin production by decreasing hypoxia-inducible transcription factor 2alpha concentrations in renal interstitial fibroblasts.	Iron	0-4	erythropoietin	Mus musculus	16-30
30424786-3	2018	Hypoxia-inducible factors (HIFs) regulate gene transcription under conditions of low oxygen, and HIF target genes EPO and VEGF have been associated with muscle protection and repair.	Oxygen	85-91	erythropoietin	Mus musculus	114-117
30348300-2	2018	analyzed a mouse model of erythropoietin-deficient anemia to show that during iron overload renal interstitial fibroblasts accumulate iron, and this impairs the hypoxia-driven transcription of the erythropoietin gene.	Iron	78-82	erythropoietin	Mus musculus	26-40
30245128-2	2018	Because iron is primarily used in red blood cells, defective erythropoiesis caused by loss of the erythroid growth factor erythropoietin (Epo) elevates iron storage levels in serum and tissues.	Iron	8-12	erythropoietin	Mus musculus	122-136
30348300-2	2018	analyzed a mouse model of erythropoietin-deficient anemia to show that during iron overload renal interstitial fibroblasts accumulate iron, and this impairs the hypoxia-driven transcription of the erythropoietin gene.	Iron	78-82	erythropoietin	Mus musculus	197-211
30245128-2	2018	Because iron is primarily used in red blood cells, defective erythropoiesis caused by loss of the erythroid growth factor erythropoietin (Epo) elevates iron storage levels in serum and tissues.	Iron	8-12	erythropoietin	Mus musculus	138-141
30348300-2	2018	analyzed a mouse model of erythropoietin-deficient anemia to show that during iron overload renal interstitial fibroblasts accumulate iron, and this impairs the hypoxia-driven transcription of the erythropoietin gene.	Iron	134-138	erythropoietin	Mus musculus	26-40
30348300-2	2018	analyzed a mouse model of erythropoietin-deficient anemia to show that during iron overload renal interstitial fibroblasts accumulate iron, and this impairs the hypoxia-driven transcription of the erythropoietin gene.	Iron	134-138	erythropoietin	Mus musculus	197-211
30245128-2	2018	Because iron is primarily used in red blood cells, defective erythropoiesis caused by loss of the erythroid growth factor erythropoietin (Epo) elevates iron storage levels in serum and tissues.	Iron	152-156	erythropoietin	Mus musculus	122-136
30348300-3	2018	The authors show that excess iron decreases levels of hypoxia-inducible transcription factor 2alpha (HIF2alpha), the main driver of erythropoietin production in hypoxia and anemia.	Iron	29-33	erythropoietin	Mus musculus	132-146
30245128-2	2018	Because iron is primarily used in red blood cells, defective erythropoiesis caused by loss of the erythroid growth factor erythropoietin (Epo) elevates iron storage levels in serum and tissues.	Iron	152-156	erythropoietin	Mus musculus	138-141
30245128-4	2018	We found that intraperitoneal injection of iron-dextran caused severe iron deposition in renal interstitial fibroblasts, the site of Epo production.	Iron-Dextran Complex	43-55	erythropoietin	Mus musculus	133-136
30245128-4	2018	We found that intraperitoneal injection of iron-dextran caused severe iron deposition in renal interstitial fibroblasts, the site of Epo production.	Iron	43-47	erythropoietin	Mus musculus	133-136
30245128-5	2018	Iron overload induced by either intraperitoneal injection or feeding decreased activity of endogenous Epo gene expression by reducing levels of hypoxia-inducible transcription factor 2alpha (HIF2alpha), the major transcriptional activator of the Epo gene.	Iron	0-4	erythropoietin	Mus musculus	102-105
30245128-5	2018	Iron overload induced by either intraperitoneal injection or feeding decreased activity of endogenous Epo gene expression by reducing levels of hypoxia-inducible transcription factor 2alpha (HIF2alpha), the major transcriptional activator of the Epo gene.	Iron	0-4	erythropoietin	Mus musculus	246-249
30245128-6	2018	Administration of an iron-deficient diet to the anemic mice reduced serum iron to normal concentration and enhanced the ability of renal Epo production.	Iron	21-25	erythropoietin	Mus musculus	137-140
30245128-7	2018	These results demonstrate that iron overload due to Epo deficiency attenuates endogenous Epo gene expression in the kidneys.	Iron	31-35	erythropoietin	Mus musculus	52-55
30245128-7	2018	These results demonstrate that iron overload due to Epo deficiency attenuates endogenous Epo gene expression in the kidneys.	Iron	31-35	erythropoietin	Mus musculus	89-92
30245128-8	2018	Thus, iron suppresses Epo production by reducing HIF2alpha concentration in renal interstitial fibroblasts.	Iron	6-10	erythropoietin	Mus musculus	22-25
29903760-2	2018	As this molecule influences the production of the iron regulatory hormone hepcidin, we hypothesized that erythropoiesis-driven changes in diferric transferrin levels could contribute to the decrease in hepcidin observed following the administration of erythropoietin.	Iron	50-54	erythropoietin	Mus musculus	252-266
29903760-7	2018	Increasing diferric transferrin levels via intravenous iron injection prevented the inhibition of Hamp1 expression by erythropoietin without altering hepatic iron concentration or the expression of Erfe, the gene encoding erythroferrone.	Iron	55-59	erythropoietin	Mus musculus	118-132
30048878-5	2018	The current work aimed to explore the dynamics of calcium transport across Spalax nonhematopoietic cells" membrane compared to above ground rat and mouse, and the role of the erythropoietin receptor of Spalax in the regulation of calcium influx under hypoxia.	Calcium	230-237	erythropoietin	Mus musculus	175-189
30042411-11	2018	Lastly, differences in iron-related parameters between PV patients and mice with JAK2 V617F and JAK2 exon 12 mutations suggest that specific regions in JAK2 may influence iron metabolism by nuanced changes of erythropoietin receptor signaling.	Iron	23-27	erythropoietin	Mus musculus	209-223
30042411-11	2018	Lastly, differences in iron-related parameters between PV patients and mice with JAK2 V617F and JAK2 exon 12 mutations suggest that specific regions in JAK2 may influence iron metabolism by nuanced changes of erythropoietin receptor signaling.	Iron	171-175	erythropoietin	Mus musculus	209-223
30130550-0	2018	Upregulation of klotho and erythropoietin contributes to the neuroprotection induced by curcumin-loaded nanoparticles in experimental model of chronic epilepsy.	Curcumin	88-96	erythropoietin	Mus musculus	27-41
30130550-2	2018	The present study is an attempt to examine the potential role of klotho and EPO in therapeutic effect of curcumin-loaded nanoparticles (NPs) in pentylenetetrazol (PTZ)-induced kindling model.	Curcumin	105-113	erythropoietin	Mus musculus	76-79
30130550-10	2018	Curcumin-loaded NPs effectively upregulated the levels of EPO and klotho in PTZ receiving animals.	Curcumin	0-8	erythropoietin	Mus musculus	58-61
30130550-10	2018	Curcumin-loaded NPs effectively upregulated the levels of EPO and klotho in PTZ receiving animals.	Pentylenetetrazole	76-79	erythropoietin	Mus musculus	58-61
30130550-12	2018	Overall, the results of this study suggest that downregulation of TNF-alpha and consequent upregulation of klotho and EPO might contribute to the neuroprotective effect of curcumin-loaded NPs in experimental model of epilepsy.	Curcumin	172-180	erythropoietin	Mus musculus	118-121
29498007-5	2018	We also found that the neuronal mitochondrial metabolite N-acetylaspartate (NAA), a marker of neuronal mitochondrial activity, was increased with EPO treatment.	N-acetylaspartate	57-74	erythropoietin	Mus musculus	146-149
29498007-5	2018	We also found that the neuronal mitochondrial metabolite N-acetylaspartate (NAA), a marker of neuronal mitochondrial activity, was increased with EPO treatment.	N-acetylaspartate	76-79	erythropoietin	Mus musculus	146-149
29498007-6	2018	Further, we measured the effects of EPO on preventing mitochondrial deficits in the cuprizone toxic demyelinating mouse model of MS. We found that EPO prevented cuprizone-mediated decreases in Hbb, complex III, and NAA.	Cuprizone	84-93	erythropoietin	Mus musculus	147-150
29498007-6	2018	Further, we measured the effects of EPO on preventing mitochondrial deficits in the cuprizone toxic demyelinating mouse model of MS. We found that EPO prevented cuprizone-mediated decreases in Hbb, complex III, and NAA.	Cuprizone	161-170	erythropoietin	Mus musculus	36-39
29498007-6	2018	Further, we measured the effects of EPO on preventing mitochondrial deficits in the cuprizone toxic demyelinating mouse model of MS. We found that EPO prevented cuprizone-mediated decreases in Hbb, complex III, and NAA.	Cuprizone	161-170	erythropoietin	Mus musculus	147-150
29498007-6	2018	Further, we measured the effects of EPO on preventing mitochondrial deficits in the cuprizone toxic demyelinating mouse model of MS. We found that EPO prevented cuprizone-mediated decreases in Hbb, complex III, and NAA.	N-acetylaspartate	215-218	erythropoietin	Mus musculus	147-150
29887316-0	2018	Palmitate deranges erythropoietin production via transcription factor ATF4 activation of unfolded protein response.	Palmitates	0-9	erythropoietin	Mus musculus	19-33
29887316-3	2018	Since renal anemia is caused by derangement of EPO production in REP cells, we evaluated the effect of palmitate, a representative long-chain saturated fatty acid, on EPO production and the endoplasmic reticulum stress pathway.	Palmitates	103-112	erythropoietin	Mus musculus	167-170
29887316-6	2018	ATF4 knockdown by siRNA significantly attenuated the suppressive effect of palmitate on EPO production.	Palmitates	75-84	erythropoietin	Mus musculus	88-91
29887316-4	2018	EPO production was suppressed by palmitate (palmitate-conjugated bovine serum albumin [BSA]) or a high palmitate diet, but not oleic acid-conjugated BSA or a high oleic acid diet, especially under cobalt-induced pseudo-hypoxia both in vitro and in vivo.	Palmitates	33-42	erythropoietin	Mus musculus	0-3
29887316-7	2018	Studies utilizing inherited super-anemic mice (ISAM) mated with EPO-Cre mice (ISAM-REC mice) for lineage-labeling of REP cells showed that ATF4 activation by palmitate suppressed EPO production in REP cells.	Palmitates	158-167	erythropoietin	Mus musculus	64-67
29887316-7	2018	Studies utilizing inherited super-anemic mice (ISAM) mated with EPO-Cre mice (ISAM-REC mice) for lineage-labeling of REP cells showed that ATF4 activation by palmitate suppressed EPO production in REP cells.	Palmitates	158-167	erythropoietin	Mus musculus	179-182
29887316-4	2018	EPO production was suppressed by palmitate (palmitate-conjugated bovine serum albumin [BSA]) or a high palmitate diet, but not oleic acid-conjugated BSA or a high oleic acid diet, especially under cobalt-induced pseudo-hypoxia both in vitro and in vivo.	Palmitates	44-53	erythropoietin	Mus musculus	0-3
29887316-9	2018	Thus, endoplasmic reticulum stress induced by palmitate suppressed EPO expression by REP cells in a manner independent of HIF activation.	Palmitates	46-55	erythropoietin	Mus musculus	67-70
29887316-4	2018	EPO production was suppressed by palmitate (palmitate-conjugated bovine serum albumin [BSA]) or a high palmitate diet, but not oleic acid-conjugated BSA or a high oleic acid diet, especially under cobalt-induced pseudo-hypoxia both in vitro and in vivo.	Palmitates	44-53	erythropoietin	Mus musculus	0-3
29887316-4	2018	EPO production was suppressed by palmitate (palmitate-conjugated bovine serum albumin [BSA]) or a high palmitate diet, but not oleic acid-conjugated BSA or a high oleic acid diet, especially under cobalt-induced pseudo-hypoxia both in vitro and in vivo.	Cobalt	197-203	erythropoietin	Mus musculus	0-3
30007232-15	2018	In contrast, AZD1480, a JAK2 inhibitor, abolished this SN-EPO effect.	AZD 1480	13-20	erythropoietin	Mus musculus	55-61
29697839-1	2018	Study Objectives: Based on the fact that erythropoietin (Epo) administration in rodents protects against spatial learning and cognitive deficits induced by chronic intermittent hypoxia (CIH)-mediated oxidative damage, here we tested the hypothesis that Epo in the brain protects against cardiorespiratory disorders and oxidative stress induced by CIH in adult mice.	cih	186-189	erythropoietin	Mus musculus	41-55
29787432-9	2018	In addition, BBT-059 inhibited the induction of radiation-induced hematopoietic biomarkers, thrombopoietin, erythropoietin, and Flt-3 ligand.	bbt-059	13-20	erythropoietin	Mus musculus	108-122
30315639-2	2018	Along with this canonical role, EPO is also reported to modulate energy metabolism, resulting in improved glucose tolerance and insulin sensitivity.	Glucose	106-113	erythropoietin	Mus musculus	32-35
30315639-3	2018	EPO also stimulates the production of the hormone erythroferrone (ERFE) which acts to suppress hepcidin production, thus increasing dietary iron absorption and mobilizing stored iron for use in erythropoiesis.	erythroferrone	50-64	erythropoietin	Mus musculus	0-3
30315639-3	2018	EPO also stimulates the production of the hormone erythroferrone (ERFE) which acts to suppress hepcidin production, thus increasing dietary iron absorption and mobilizing stored iron for use in erythropoiesis.	Iron	140-144	erythropoietin	Mus musculus	0-3
30315639-3	2018	EPO also stimulates the production of the hormone erythroferrone (ERFE) which acts to suppress hepcidin production, thus increasing dietary iron absorption and mobilizing stored iron for use in erythropoiesis.	Iron	178-182	erythropoietin	Mus musculus	0-3
30315639-5	2018	As increased levels of circulating NEFA blunt insulin sensitivity and impair glucose tolerance, ERFE-induced clearance of NEFA after EPO administration would have a beneficial effect on glucose metabolism.	Glucose	186-193	erythropoietin	Mus musculus	133-136
30315639-9	2018	These findings suggest that the known beneficial effects of EPO on glucose metabolism are not attributable to an accompanying increase in ERFE production, and that Erfe is dispensable for normal glucose homeostasis.	Glucose	67-74	erythropoietin	Mus musculus	60-63
29697839-1	2018	Study Objectives: Based on the fact that erythropoietin (Epo) administration in rodents protects against spatial learning and cognitive deficits induced by chronic intermittent hypoxia (CIH)-mediated oxidative damage, here we tested the hypothesis that Epo in the brain protects against cardiorespiratory disorders and oxidative stress induced by CIH in adult mice.	cih	186-189	erythropoietin	Mus musculus	57-60
29697839-1	2018	Study Objectives: Based on the fact that erythropoietin (Epo) administration in rodents protects against spatial learning and cognitive deficits induced by chronic intermittent hypoxia (CIH)-mediated oxidative damage, here we tested the hypothesis that Epo in the brain protects against cardiorespiratory disorders and oxidative stress induced by CIH in adult mice.	cih	347-350	erythropoietin	Mus musculus	41-55
29697839-1	2018	Study Objectives: Based on the fact that erythropoietin (Epo) administration in rodents protects against spatial learning and cognitive deficits induced by chronic intermittent hypoxia (CIH)-mediated oxidative damage, here we tested the hypothesis that Epo in the brain protects against cardiorespiratory disorders and oxidative stress induced by CIH in adult mice.	cih	347-350	erythropoietin	Mus musculus	57-60
29697839-8	2018	Conclusions: We conclude that the neuroprotective effect of Epo prevents oxidative damage in the brain and cardiorespiratory disorders induced by CIH.	cih	146-149	erythropoietin	Mus musculus	60-63
29480820-4	2018	Here, we fed VhlR200W mice supplemented with Tempol, a small, stable nitroxide molecule and observed that Tempol decreased erythropoietin production, corrected splenomegaly, normalized hematocrit levels, and increased the lifespans of these mice.	tempol	45-51	erythropoietin	Mus musculus	123-137
29523405-3	2018	We hypothesized that the betacR can be induced by diazoxide (DZ), amplifying the neuroprotective effects of EPO in spinal cord ischemia-reperfusion injury.	betacr	25-31	erythropoietin	Mus musculus	108-111
29523405-3	2018	We hypothesized that the betacR can be induced by diazoxide (DZ), amplifying the neuroprotective effects of EPO in spinal cord ischemia-reperfusion injury.	Diazoxide	50-59	erythropoietin	Mus musculus	108-111
29523405-3	2018	We hypothesized that the betacR can be induced by diazoxide (DZ), amplifying the neuroprotective effects of EPO in spinal cord ischemia-reperfusion injury.	Diazoxide	61-63	erythropoietin	Mus musculus	108-111
29939494-0	2018	Activation of the beta-common receptor by erythropoietin impairs acetylcholine-mediated vasodilation in mouse mesenteric arterioles.	Acetylcholine	65-78	erythropoietin	Mus musculus	42-56
29654830-0	2018	Neuronal erythropoietin overexpression is protective against kanamycin-induced hearing loss in mice.	Kanamycin	61-70	erythropoietin	Mus musculus	9-23
29654830-3	2018	In vitro data suggests that the pleiotropic growth factor erythropoietin (EPO) is neuroprotective against aminoglycoside-induced hair cell loss.	Aminoglycosides	106-120	erythropoietin	Mus musculus	58-72
29654830-3	2018	In vitro data suggests that the pleiotropic growth factor erythropoietin (EPO) is neuroprotective against aminoglycoside-induced hair cell loss.	Aminoglycosides	106-120	erythropoietin	Mus musculus	74-77
29654830-4	2018	Here, we use a mouse model with EPO-overexpression in neuronal tissue to evaluate whether EPO could also in vivo protect from aminoglycoside-induced hearing loss.	Aminoglycosides	126-140	erythropoietin	Mus musculus	90-93
29654830-5	2018	Auditory brainstem response (ABR) thresholds were measured in 12-weeks-old mice before and after treatment with kanamycin for 15 days, which resulted in both C57BL/6 and EPO-transgenic animals in a high-frequency hearing loss.	Kanamycin	112-121	erythropoietin	Mus musculus	170-173
29654830-8	2018	In conclusion, neuronal overexpression of EPO is protective against aminoglycoside-induce hearing loss, which is in accordance with its known neuroprotective effects in other organs, such as the eye or the brain.	Aminoglycosides	68-82	erythropoietin	Mus musculus	42-45
29632923-5	2018	The results showed that the red blood cell count, the hemoglobin amount and the hematocrit of mice in the ginsenoside groups could be restored to normal values in a short time, and the effects of both Rk3 and Rh4 are obviously better than those of EPO.	Ginsenosides	106-117	erythropoietin	Mus musculus	248-251
30788934-4	2018	CONCLUSIONS: EPO could promote differentiation of brown adipose tissue by increase in the express ion of PRDM16, and decrease the blood glucose level, ameliorate glucose metabolism in obses mice.	Glucose	136-143	erythropoietin	Mus musculus	13-16
30788934-4	2018	CONCLUSIONS: EPO could promote differentiation of brown adipose tissue by increase in the express ion of PRDM16, and decrease the blood glucose level, ameliorate glucose metabolism in obses mice.	Glucose	162-169	erythropoietin	Mus musculus	13-16
29480820-4	2018	Here, we fed VhlR200W mice supplemented with Tempol, a small, stable nitroxide molecule and observed that Tempol decreased erythropoietin production, corrected splenomegaly, normalized hematocrit levels, and increased the lifespans of these mice.	tempol	106-112	erythropoietin	Mus musculus	123-137
29419424-0	2018	Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease.	erythroferrone	48-62	erythropoietin	Mus musculus	14-28
28859237-5	2018	A major cause of the systemic iron overload is the reduced iron usage due to suppressed erythropoiesis, which is consistent with an increase in interleukin-6 and reduced expression of erythropoietin.	Iron	30-34	erythropoietin	Mus musculus	184-198
29535446-5	2018	This report shows that the cause of insufficient EPO production in AOP is elevated renal oxygen levels due to poor oxygen consumption by immature tubules.	Oxygen	89-95	erythropoietin	Mus musculus	49-52
29535446-5	2018	This report shows that the cause of insufficient EPO production in AOP is elevated renal oxygen levels due to poor oxygen consumption by immature tubules.	Oxygen	115-121	erythropoietin	Mus musculus	49-52
29535446-10	2018	These data suggest that tubular maturation with increased oxygen consumption is required for renal EPO production.	Oxygen	58-64	erythropoietin	Mus musculus	99-102
29438490-1	2018	Roxadustat (FG-4592, Rox) is a stabilizer for hypoxia-inducible transcription factors (HIFs), which induce production of the erythroid growth factor erythropoietin, and has been listed by the World Anti-Doping Agency as a prohibited substance for athletes since 2011.	roxadustat	0-10	erythropoietin	Mus musculus	149-163
29282252-5	2018	Our results reveal that iron restriction limits surface display of Epo receptor in primary progenitors and that mice with enforced surface retention of the receptor fail to develop anemia with iron deprivation.	Iron	24-28	erythropoietin	Mus musculus	67-70
29180398-8	2018	SnPP administration led to a decrease in erythropoietin and increase in hepcidin serum levels, changes that were accompanied by an alleviation of ineffective erythropoiesis in Th3/+ mice.	S-Nitroso-N-propionyl-D,L-penicillamine	0-4	erythropoietin	Mus musculus	41-55
29051279-6	2018	We also generated inducible EPO-mediated secondary erythrocytosis models using Alb-Cre, Rosa26-loxP-stop-loxP-rtTA, and doxycycline inducible EPAS1-double point mutant (DPM) alleles (Alb-Cre;DPM mice).	Doxycycline	120-131	erythropoietin	Mus musculus	28-31
29415057-6	2018	In contrast, 50 mg/kg of adenine daily for 28 days showed severe renal dysfunction (plasma creatinine 1.9 +- 0.10 mg/dL) and anemia (hematocrit 36.5 +- 1.0% and EPO 28 +- 2.4 pg/mL) as compared with vehicle-treated mice (0.4 +- 0.02 mg/dL, 49.6 +- 1.6% and 61 +- 4.0 pg/mL, respectively).	Adenine	25-32	erythropoietin	Mus musculus	161-164
28859237-5	2018	A major cause of the systemic iron overload is the reduced iron usage due to suppressed erythropoiesis, which is consistent with an increase in interleukin-6 and reduced expression of erythropoietin.	Iron	59-63	erythropoietin	Mus musculus	184-198
28891332-9	2017	The SD-OCT and histological examination suggested the morphological devastations in MNU-administered mice were alleviated after EPO treatment.	Methylnitrosourea	84-87	erythropoietin	Mus musculus	128-131
29100648-13	2017	RESULTS: EPO preserved neuronal viability after oxygen-glucose deprivation (0.82 +- 0.04 versus 0.61 +- 0.01; p &lt; 0.01).	oxygen-glucose	48-62	erythropoietin	Mus musculus	9-12
29100648-16	2017	CONCLUSIONS: EPO attenuates neuronal loss after oxygen-glucose deprivation in a betacR-dependent fashion.	oxygen-glucose	48-62	erythropoietin	Mus musculus	13-16
28847650-4	2017	In the adult kidney, PHD oxygen sensors are differentially expressed in a cell type-dependent manner and control the production of erythropoietin in interstitial cells.	Oxygen	25-31	erythropoietin	Mus musculus	131-145
28891332-0	2017	Subretinal delivery of erythropoietin alleviates the N-methyl-N-nitrosourea-induced photoreceptor degeneration and visual functional impairments: an in vivo and ex vivo study.	Methylnitrosourea	53-75	erythropoietin	Mus musculus	23-37
28891332-2	2017	The present study sought to explore the therapeutic effects of erythropoietin (EPO) on the N-methyl-N-nitrosourea (MNU)-induced photoreceptor degeneration.	Methylnitrosourea	91-113	erythropoietin	Mus musculus	63-77
28928122-8	2017	In normal mice, a single dose of GSK1278863 induced significant increases in circulating plasma EPO but only minimal increases in plasma vascular endothelial growth factor (VEGF-A) concentrations.	GSK1278863	33-43	erythropoietin	Mus musculus	96-99
28891332-11	2017	Moreover, the EPO treatment rectified the apoptotic abnormalities in MNU-administered mice, and enhanced the expression level of Foxo3, a critical mediator of autophagy.	Methylnitrosourea	69-72	erythropoietin	Mus musculus	14-17
28891332-2	2017	The present study sought to explore the therapeutic effects of erythropoietin (EPO) on the N-methyl-N-nitrosourea (MNU)-induced photoreceptor degeneration.	Methylnitrosourea	91-113	erythropoietin	Mus musculus	79-82
28891332-2	2017	The present study sought to explore the therapeutic effects of erythropoietin (EPO) on the N-methyl-N-nitrosourea (MNU)-induced photoreceptor degeneration.	Methylnitrosourea	115-118	erythropoietin	Mus musculus	63-77
28891332-12	2017	The EPO treatment also mitigated the MDA concentration and enhanced the retinal SOD activity, thereby counteracting the retinal oxidative stress in MNU administered mice.	Methylnitrosourea	148-151	erythropoietin	Mus musculus	4-7
28891332-2	2017	The present study sought to explore the therapeutic effects of erythropoietin (EPO) on the N-methyl-N-nitrosourea (MNU)-induced photoreceptor degeneration.	Methylnitrosourea	115-118	erythropoietin	Mus musculus	79-82
28891332-3	2017	The MNU-administered mouse or normal control received a subretinal injection of EPO (at the dose of 10U).	Methylnitrosourea	4-7	erythropoietin	Mus musculus	80-83
29044949-8	2017	The mitoxantrone-induced aberrant transcripts contribute to the reporter protein production in epithelial cells that carry the reporter gene in the proper reading frame of mouse Epo gene.	Mitoxantrone	4-16	erythropoietin	Mus musculus	178-181
28891332-7	2017	The subretinal injection of EPO up-regulated the retinal EPO level in the retinas of MNU-administered mice.	Methylnitrosourea	85-88	erythropoietin	Mus musculus	28-31
28891332-7	2017	The subretinal injection of EPO up-regulated the retinal EPO level in the retinas of MNU-administered mice.	Methylnitrosourea	85-88	erythropoietin	Mus musculus	57-60
28891332-8	2017	The optokinetic tests and ERG examination suggested the visual functional impairments in MNU-administered mice were ameliorated after EPO treatment.	Methylnitrosourea	89-92	erythropoietin	Mus musculus	134-137
29044949-5	2017	Here, mitoxantrone and its analogues, identified as GATA factor inhibitors through high-throughput chemical library screenings, markedly induce EPO/Epo gene expression in epithelium-derived cell lines and mice regardless of oxygen levels.	Mitoxantrone	6-18	erythropoietin	Mus musculus	144-147
29044949-5	2017	Here, mitoxantrone and its analogues, identified as GATA factor inhibitors through high-throughput chemical library screenings, markedly induce EPO/Epo gene expression in epithelium-derived cell lines and mice regardless of oxygen levels.	Mitoxantrone	6-18	erythropoietin	Mus musculus	148-151
28452907-6	2017	In the delayed treatment group, combination Fe + EPO therapy did increase Hgb and reticulocyte production in WT mice (mean DeltaHgb in WT saline group -9.2 g/dL vs. Fe/EPO -5.5 g/dL; P &lt; 0.001).	Sodium Chloride	138-144	erythropoietin	Mus musculus	49-52
29026145-7	2017	Correspondingly, DSS-exposed mice treated with cibinetide or EPO displayed preserved tissue integrity due to reduced infiltration of myeloid cells and diminished production of pro-inflammatory disease mediators including cytokines, chemokines and nitric oxide synthase-2.	dss	17-20	erythropoietin	Mus musculus	61-64
28472013-6	2017	Reoxygenation with 100% oxygen significantly increased TNF-alpha (2.5 h after hypoxia), IL-1beta (5 h after hypoxia), caspase-3 (8 h after hypoxia) mRNA levels in the whole brain compared with 21% oxygen, and significantly decreased erythropoietin mRNA expression compared with 21% oxygen 9 h after reoxygenation.	Oxygen	2-8	erythropoietin	Mus musculus	233-247
28472013-6	2017	Reoxygenation with 100% oxygen significantly increased TNF-alpha (2.5 h after hypoxia), IL-1beta (5 h after hypoxia), caspase-3 (8 h after hypoxia) mRNA levels in the whole brain compared with 21% oxygen, and significantly decreased erythropoietin mRNA expression compared with 21% oxygen 9 h after reoxygenation.	Oxygen	24-30	erythropoietin	Mus musculus	233-247
28472013-6	2017	Reoxygenation with 100% oxygen significantly increased TNF-alpha (2.5 h after hypoxia), IL-1beta (5 h after hypoxia), caspase-3 (8 h after hypoxia) mRNA levels in the whole brain compared with 21% oxygen, and significantly decreased erythropoietin mRNA expression compared with 21% oxygen 9 h after reoxygenation.	Oxygen	24-30	erythropoietin	Mus musculus	233-247
29073189-0	2017	Effect of erythropoietin administration on proteins participating in iron homeostasis in Tmprss6-mutated mask mice.	Iron	69-73	erythropoietin	Mus musculus	10-24
29073189-2	2017	The aim of the study was to determine the effect of erythropoietin administration on proteins participating in the control of iron homeostasis in the liver and spleen in C57BL/6 and mask mice.	Iron	126-130	erythropoietin	Mus musculus	52-66
29073189-7	2017	At the protein level, erythropoietin increased the amount of splenic erythroferrone and transferrin receptor 2 both in C57BL/6 and mask mice.	erythroferrone	69-83	erythropoietin	Mus musculus	22-36
29104499-4	2017	Systemic use of EPO improved glucose profiles in type 2 diabetic mice after 4 and 8 weeks treatment.	Glucose	29-36	erythropoietin	Mus musculus	16-19
29201540-8	2017	EPO treatment also significantly increased Tregs level in spleen and injured brain tissue as well as significantly reduced the infiltration and activation of immune/inflammatory cells (neutrophils, CD3+T cells, and microglia) in the injured hemisphere compared to Saline-treated control animals (p &lt; .05).	Sodium Chloride	264-270	erythropoietin	Mus musculus	0-3
28954928-6	2017	Furthermore, transplantation of hiPSC-EPO cells into mice with CKD induced by adenine treatment improved renal anemia.	Adenine	78-85	erythropoietin	Mus musculus	38-41
28600471-7	2017	Additionally, wild-type Nx mice, but not DDAH-1 Tg Nx mice, had reduced splenic gene expression of erythropoietin receptor and erythroferrone, which regulates iron metabolism in response to erythropoietin.	erythroferrone	127-141	erythropoietin	Mus musculus	190-204
28600471-7	2017	Additionally, wild-type Nx mice, but not DDAH-1 Tg Nx mice, had reduced splenic gene expression of erythropoietin receptor and erythroferrone, which regulates iron metabolism in response to erythropoietin.	Iron	159-163	erythropoietin	Mus musculus	99-113
28600471-7	2017	Additionally, wild-type Nx mice, but not DDAH-1 Tg Nx mice, had reduced splenic gene expression of erythropoietin receptor and erythroferrone, which regulates iron metabolism in response to erythropoietin.	Iron	159-163	erythropoietin	Mus musculus	190-204
28302753-9	2017	Together, our findings delineate the protolerogenic properties of EPO in inhibiting conventional T cells while simultaneously promoting Treg induction, and suggest that manipulating the EPO/EPO receptor signaling axis could be exploited to prevent and/or treat T cell-mediated pathologies, including transplant rejection.	treg	136-140	erythropoietin	Mus musculus	66-69
28817120-10	2017	Furthermore, MK-X and EPO induced similar changes in the gene expression patterns under glutamate-induced excitotoxicity.	Glutamic Acid	88-97	erythropoietin	Mus musculus	22-25
29085580-0	2017	Protective effects of erythropoietin against cuprizone-induced oxidative stress and demyelination in the mouse corpus callosum.	Cuprizone	45-54	erythropoietin	Mus musculus	22-36
29085580-2	2017	The aim of the present work is to investigate the protective effects of erythropoietin against cuprizone-induced oxidative stress.	Cuprizone	95-104	erythropoietin	Mus musculus	72-86
28396201-0	2017	Pharmacological, but not genetic, alteration of neural Epo modifies the CO2/H+ central chemosensitivity in postnatal mice.	N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide	72-75	erythropoietin	Mus musculus	55-58
29085580-7	2017	Biochemical analysis showed that oxidative stress induced by cuprizone was regulated by erythropoietin.	Cuprizone	61-70	erythropoietin	Mus musculus	88-102
29085580-8	2017	Similarly, erythropoietin induced the expression of subunits of the respiratory chain complex over normal control values reflecting a mechanism to compensate cuprizone-mediated down-regulation of these genes.	Cuprizone	158-167	erythropoietin	Mus musculus	11-25
29085580-9	2017	CONCLUSION: The data implicate that erythropoietin abolishes destructive cuprizone effects in the corpus callosum by decreasing oxidative stress and restoring mitochondrial respiratory enzyme activity.	Cuprizone	73-82	erythropoietin	Mus musculus	36-50
28396201-5	2017	Accordingly, in this study we wanted to test the hypothesis that cerebral Epo is involved in the breathing stimulation induced by the activation of central CO2/H+ chemoreceptors at earlier postnatal ages.	N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide	156-159	erythropoietin	Mus musculus	74-77
28396201-11	2017	Our data suggest that variation of the Epo/sEpoR ratio is central to breathing modulation during CO2 challenges, and calls attention to clinical perspectives based on the use of Epo drugs at birth in hypoventilation cases.	N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide	97-100	erythropoietin	Mus musculus	39-42
28396201-11	2017	Our data suggest that variation of the Epo/sEpoR ratio is central to breathing modulation during CO2 challenges, and calls attention to clinical perspectives based on the use of Epo drugs at birth in hypoventilation cases.	N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide	97-100	erythropoietin	Mus musculus	44-47
28438754-9	2017	Epoetin alfa (EPO) robustly induced bone marrow erythroferrone (Fam132b) mRNA in control and Smad1fl/fl;Smad5fl/fl;Cre+ mice but suppressed hepcidin only in control mice.	erythroferrone	48-62	erythropoietin	Mus musculus	14-17
28373075-2	2017	This study shows that EPO, whether ectopically administered or released by neural precursors, does reverse MPTP-induced parkinsonism in mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	107-111	erythropoietin	Mus musculus	22-25
28283542-3	2017	Although EPO treatment increased hematocrit and improved glucose tolerance in male and female mice, we observed a gender difference in EPO effects in weight control.	Glucose	57-64	erythropoietin	Mus musculus	9-12
28283542-4	2017	EPO treatment reduced diet-induced weight gain from 9.6 +- 1.5 to 4.2 +- 1.4 g in male mice (P &lt; 0.001), while the weight gain in female mice was similar (4.7 +- 2.0 g with PBS treatment and 3.3 +- 2.1 g with EPO treatment).	Lead	176-179	erythropoietin	Mus musculus	0-3
28283542-5	2017	EPO treatment also reduced weight gain in ovariectomized female mice, while the effect was abrogated with estradiol supplementation, suggesting that the sex-differential response to EPO was associated with estrogen.	Estradiol	106-115	erythropoietin	Mus musculus	182-185
28283542-6	2017	Furthermore, mice with targeted deletion of EPO receptor in white adipose tissue exhibited sex-differential phenotype in weight control and glucose sensitivity, and EPO receptor gene expression was reduced in wild-type female mice, suggesting that white adipose tissue plays an integral role in mediating the metabolic effects of EPO.	Glucose	140-147	erythropoietin	Mus musculus	44-47
28298334-8	2017	The MEK inhibitor U0126 significantly inhibited EPO-induced Sox17 expression.	U 0126	18-23	erythropoietin	Mus musculus	48-51
28263291-3	2017	However, excess iron causes oxidative stress via the Fenton reaction, and iron supplementation might damage remnant renal function including erythropoietin (EPO) production in CKD.	Iron	74-78	erythropoietin	Mus musculus	141-155
28263291-0	2017	Iron suppresses erythropoietin expression via oxidative stress-dependent hypoxia-inducible factor-2 alpha inactivation.	Iron	0-4	erythropoietin	Mus musculus	16-30
28263291-3	2017	However, excess iron causes oxidative stress via the Fenton reaction, and iron supplementation might damage remnant renal function including erythropoietin (EPO) production in CKD.	Iron	74-78	erythropoietin	Mus musculus	157-160
28263291-4	2017	EPO gene expression was suppressed in mice following direct iron treatment.	Iron	60-64	erythropoietin	Mus musculus	0-3
28263291-5	2017	Hypoxia-inducible factor-2 alpha (HIF-2alpha), a positive regulator of the EPO gene, was also diminished in the kidney of mice following iron treatment.	Iron	137-141	erythropoietin	Mus musculus	75-78
28263291-6	2017	Anemia-induced increase in renal EPO and HIF-2alpha expression was inhibited by iron treatment.	Iron	80-84	erythropoietin	Mus musculus	33-36
28263291-8	2017	Moreover, iron treatment augmented oxidative stress, and iron-induced reduction of EPO and HIF-2alpha expression was restored by tempol, an antioxidant compound.	Iron	57-61	erythropoietin	Mus musculus	83-86
28263291-9	2017	HIF-2alpha interaction with the Epo promoter was inhibited by iron treatment, and was restored by tempol.	Iron	62-66	erythropoietin	Mus musculus	32-35
28263291-10	2017	These findings suggested that iron supplementation reduced EPO gene expression via an oxidative stress-HIF-2alpha-dependent signaling pathway.	Iron	30-34	erythropoietin	Mus musculus	59-62
28288167-6	2017	HOMA-IR (insulin resistance index) and glucose levels during intraperitoneal glucose tolerance test (IPGTT) were significantly lower in HFD-EPO mice than in HFD-Con mice.	Glucose	39-46	erythropoietin	Mus musculus	140-143
28288167-6	2017	HOMA-IR (insulin resistance index) and glucose levels during intraperitoneal glucose tolerance test (IPGTT) were significantly lower in HFD-EPO mice than in HFD-Con mice.	Glucose	77-84	erythropoietin	Mus musculus	140-143
28288167-7	2017	EPO-injected mice also showed increased oxygen consumption, indicative of metabolic rate, and skin temperature around iBAT tissue masses.	Oxygen	40-46	erythropoietin	Mus musculus	0-3
27579991-3	2017	The main objective of this study was to evaluate the effect of erythropoietin in the TNBS-induced colitis model in mice with a normal intestinal flora.	Trinitrobenzenesulfonic Acid	85-89	erythropoietin	Mus musculus	63-77
27232578-4	2017	In addition, EPO-induced nitrite oxide (NO) production, phosphorylation of eNOS, Akt and AMP-activated protein kinase (AMPK) and the formation of TRPV1-Akt-AMPK-eNOS complex as well as tube formation were diminished by the pharmacological inhibition of TRPV1 in BAECs.	nitrite oxide	25-38	erythropoietin	Mus musculus	13-16
27232578-8	2017	Matrigel plug assay showed that EPO-induced angiogenesis was abrogated in TRPV1 antagonist capsazepine-treated WT mice and TRPV1-/- mice.	capsazepine	91-102	erythropoietin	Mus musculus	32-35
28230720-5	2017	RA signaling appears to be essential for expression of genes involved in developmental hematopoiesis, regulating the endothelial/blood cells balance in the yolk sac, promoting the hemogenic program in the aorta-gonad-mesonephros area and stimulating eryrthropoiesis in fetal liver by activating the expression of erythropoietin.	Tretinoin	0-2	erythropoietin	Mus musculus	313-327
27579991-6	2017	The anti-inflammatory properties of erythropoietin in the TNBS-induced colitis were confirmed by suppression of pro-inflammatory mediators, such as TNF-alpha, IL-1beta and MPO, as well as a significant increase in the anti-inflammatory cytokine, IL-10, was promoted.	Trinitrobenzenesulfonic Acid	58-62	erythropoietin	Mus musculus	36-50
27579991-7	2017	These treated mice also presented a reduction in haemoglobin faecal and ALP, suggesting a beneficial effect of erythropoietin in the haemorrhagic focus and destruction of the enterocyte associated with the colon injury induced by TNBS, respectively.	Trinitrobenzenesulfonic Acid	230-234	erythropoietin	Mus musculus	111-125
27281679-11	2017	Systemic treatment with EPO or EPO-R76E beginning before or soon after trauma may exacerbate protective effects of EPO within the retina as a result of increased iron levels from erythropoiesis and, thus, increased oxidative stress within the retina.	Iron	162-166	erythropoietin	Mus musculus	24-27
28445874-4	2017	We hypothesized that exogenous EPO would limit injury from excess H2O2 seen in SOD1-overexpressing mice, and thus enhance recovery after HI.	Hydrogen Peroxide	66-70	erythropoietin	Mus musculus	31-34
28511187-6	2017	We found that Epo protects Ast from H2O2 injury (p &lt; 0.05) and increases secreted nitric oxide levels in these cells (p &lt; 0.05) while suppressing intracellular reactive oxygen species (p &lt; 0.05) and superoxide ion (p &lt; 0.05) levels only in Mg.	Nitric Oxide	85-97	erythropoietin	Mus musculus	14-17
28511187-6	2017	We found that Epo protects Ast from H2O2 injury (p &lt; 0.05) and increases secreted nitric oxide levels in these cells (p &lt; 0.05) while suppressing intracellular reactive oxygen species (p &lt; 0.05) and superoxide ion (p &lt; 0.05) levels only in Mg.	Reactive Oxygen Species	166-189	erythropoietin	Mus musculus	14-17
28511187-6	2017	We found that Epo protects Ast from H2O2 injury (p &lt; 0.05) and increases secreted nitric oxide levels in these cells (p &lt; 0.05) while suppressing intracellular reactive oxygen species (p &lt; 0.05) and superoxide ion (p &lt; 0.05) levels only in Mg.	Superoxides	208-218	erythropoietin	Mus musculus	14-17
27662300-6	2017	The deficits in spontaneous alternation, place learning in the water-maze, and novel object recognition observed in APPSwe mice were alleviated by the low dose of Neuro-EPO.	Water	63-68	erythropoietin	Mus musculus	169-172
27281679-11	2017	Systemic treatment with EPO or EPO-R76E beginning before or soon after trauma may exacerbate protective effects of EPO within the retina as a result of increased iron levels from erythropoiesis and, thus, increased oxidative stress within the retina.	Iron	162-166	erythropoietin	Mus musculus	31-34
27281679-11	2017	Systemic treatment with EPO or EPO-R76E beginning before or soon after trauma may exacerbate protective effects of EPO within the retina as a result of increased iron levels from erythropoiesis and, thus, increased oxidative stress within the retina.	Iron	162-166	erythropoietin	Mus musculus	31-34
27477940-16	2016	Injection of mice with an oligonucleotide antagonist of MIR122 increased blood levels of EPO, reticulocytes, and hemoglobin.	Oligonucleotides	26-41	erythropoietin	Mus musculus	89-92
30854158-0	2017	Direct Current Helium Plasma for In vivo Delivery of Plasmid DNA Encoding Erythropoietin to Murine Skin.	Helium	15-21	erythropoietin	Mus musculus	74-88
27760758-8	2016	Moreover, systemic reduction in EPO levels by hyperbaric oxygen (HBO) used in a preclinical mouse model and in a pilot clinical trial promoted homing of transplanted UCB CD34+ HSPC to BM.	Oxygen	57-63	erythropoietin	Mus musculus	32-35
26809838-7	2016	After feeding a 15N-leucine diet, we used nanoscopic secondary ion mass spectrometry, and found that in EPO-treated mice, an equivalent number of neurons was defined by elevated 15N-leucine incorporation.	15n-leucine	16-27	erythropoietin	Mus musculus	104-107
26809838-7	2016	After feeding a 15N-leucine diet, we used nanoscopic secondary ion mass spectrometry, and found that in EPO-treated mice, an equivalent number of neurons was defined by elevated 15N-leucine incorporation.	15n	16-19	erythropoietin	Mus musculus	104-107
26809838-7	2016	After feeding a 15N-leucine diet, we used nanoscopic secondary ion mass spectrometry, and found that in EPO-treated mice, an equivalent number of neurons was defined by elevated 15N-leucine incorporation.	Leucine	20-27	erythropoietin	Mus musculus	104-107
27683416-6	2016	We furthermore determined that Epo transcription in brain pericytes was HIF-2 dependent and cocontrolled by PHD2 and PHD3, oxygen- and 2-oxoglutarate-dependent prolyl-4-hydroxylases that regulate HIF activity.	Oxygen	123-129	erythropoietin	Mus musculus	31-34
27593486-8	2016	In vitro, EPO treatment promoted myelin formation and protected myelin from the effects of nitric oxide exposure in co-cultures of Schwann cells and dorsal root ganglion neurons.	Nitric Oxide	91-103	erythropoietin	Mus musculus	10-13
27789613-0	2016	Grafted Neural Precursors Integrate Into Mouse Striatum, Differentiate and Promote Recovery of Function Through Release of Erythropoietin in MPTP-Treated Mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	141-145	erythropoietin	Mus musculus	123-137
26706855-7	2016	Our study demonstrates the in vivo effect of excessive EPO/EPOR signaling on developmental erythropoiesis switch and describes that fetal polycythemia in this PFCP model is followed by transient correction of polycythemia in perinatal life associated with low Epo levels and increased exposure of erythrocytes" phosphatidylserine.	pfcp	159-163	erythropoietin	Mus musculus	55-58
27172159-0	2016	ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors" Angiogenic Potential and Homing Ability.	cibinetide	0-6	erythropoietin	Mus musculus	30-44
27283485-0	2016	Bi-functional prodrugs of 5-aminolevulinic acid and butyric acid increase erythropoiesis in anemic mice in an erythropoietin-independent manner.	5-amino levulinic acid	26-47	erythropoietin	Mus musculus	110-124
27283485-0	2016	Bi-functional prodrugs of 5-aminolevulinic acid and butyric acid increase erythropoiesis in anemic mice in an erythropoietin-independent manner.	Butyric Acid	52-64	erythropoietin	Mus musculus	110-124
26936784-4	2016	In a first attempt to answer this question, we tested the hypothesis that Epo alters the ventilatory response to increased CO2 levels.	N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide	123-126	erythropoietin	Mus musculus	74-77
27317882-0	2016	Carbamylated erythropoietin enhances mice ventilatory responses to changes in O2 but not CO2 levels.	Oxygen	78-80	erythropoietin	Mus musculus	13-27
27803781-7	2016	MATERIALS AND METHODS: EPO antibody was covalently crosslinked to protein A/G agarose.	Sepharose	78-85	erythropoietin	Mus musculus	23-26
26755707-1	2016	Hepcidin, the main regulator of iron homeostasis, is repressed when erythropoiesis is acutely stimulated by erythropoietin (EPO) to favor iron supply to maturing erythroblasts.	Iron	32-36	erythropoietin	Mus musculus	108-122
26755707-1	2016	Hepcidin, the main regulator of iron homeostasis, is repressed when erythropoiesis is acutely stimulated by erythropoietin (EPO) to favor iron supply to maturing erythroblasts.	Iron	32-36	erythropoietin	Mus musculus	124-127
26755707-1	2016	Hepcidin, the main regulator of iron homeostasis, is repressed when erythropoiesis is acutely stimulated by erythropoietin (EPO) to favor iron supply to maturing erythroblasts.	Iron	138-142	erythropoietin	Mus musculus	108-122
26755707-1	2016	Hepcidin, the main regulator of iron homeostasis, is repressed when erythropoiesis is acutely stimulated by erythropoietin (EPO) to favor iron supply to maturing erythroblasts.	Iron	138-142	erythropoietin	Mus musculus	124-127
27067488-0	2016	EPO-dependent induction of erythroferrone drives hepcidin suppression and systematic iron absorption under phenylhydrazine-induced hemolytic anemia.	erythroferrone	27-41	erythropoietin	Mus musculus	0-3
27067488-0	2016	EPO-dependent induction of erythroferrone drives hepcidin suppression and systematic iron absorption under phenylhydrazine-induced hemolytic anemia.	Iron	85-89	erythropoietin	Mus musculus	0-3
27067488-0	2016	EPO-dependent induction of erythroferrone drives hepcidin suppression and systematic iron absorption under phenylhydrazine-induced hemolytic anemia.	phenylhydrazine	107-122	erythropoietin	Mus musculus	0-3
27067488-4	2016	Mirrored with serum EPO concentration, the mRNA expression of erythroferrone (ERFE) was rapidly increased in the bone marrow and spleen 3days after injection of PHZ, and then gradually decreased but was still higher than baseline on day 6.	erythroferrone	62-76	erythropoietin	Mus musculus	20-23
27067488-8	2016	Thus, our data unearthed EPO-dependent ERFE expression acts as an erythropoiesis-driven regulator of iron metabolism under PHZ-induced hemolytic anemia.	Iron	101-105	erythropoietin	Mus musculus	25-28
27087140-5	2016	When mouse bone marrow cells were induced with erythropoietin to differentiate into erythroid cells, the synthesis of bilirubin increased.	Bilirubin	118-127	erythropoietin	Mus musculus	47-61
26706855-7	2016	Our study demonstrates the in vivo effect of excessive EPO/EPOR signaling on developmental erythropoiesis switch and describes that fetal polycythemia in this PFCP model is followed by transient correction of polycythemia in perinatal life associated with low Epo levels and increased exposure of erythrocytes" phosphatidylserine.	pfcp	159-163	erythropoietin	Mus musculus	260-263
26727632-3	2016	These polymers were capable of significant delivery of siRNA against FVII and mRNA-encoding erythropoietin (EPO) in mice.	Polymers	6-14	erythropoietin	Mus musculus	92-106
27800506-5	2016	Our original model of Epo-deficient (Epo-TAgh) mice allowed us to improve our knowledge of the possible role of Epo in O2 homeostasis.	Oxygen	119-121	erythropoietin	Mus musculus	22-25
27800506-5	2016	Our original model of Epo-deficient (Epo-TAgh) mice allowed us to improve our knowledge of the possible role of Epo in O2 homeostasis.	Oxygen	119-121	erythropoietin	Mus musculus	37-40
27800506-5	2016	Our original model of Epo-deficient (Epo-TAgh) mice allowed us to improve our knowledge of the possible role of Epo in O2 homeostasis.	Oxygen	119-121	erythropoietin	Mus musculus	37-40
26927670-2	2016	Decreases of renal pO2 promote hypoxia-inducible factor 2-mediated (HIF-2-mediated) induction of EPO in peritubular interstitial fibroblast-like cells, which serve as the cellular site of EPO synthesis in the kidney.	PO-2	19-22	erythropoietin	Mus musculus	97-100
26927670-2	2016	Decreases of renal pO2 promote hypoxia-inducible factor 2-mediated (HIF-2-mediated) induction of EPO in peritubular interstitial fibroblast-like cells, which serve as the cellular site of EPO synthesis in the kidney.	PO-2	19-22	erythropoietin	Mus musculus	188-191
26927670-6	2016	Moreover, suppression of renal EPO production was associated with increased glucose uptake, enhanced glycolysis, reduced mitochondrial mass, diminished O2 consumption, and elevated renal tissue pO2.	Glucose	76-83	erythropoietin	Mus musculus	31-34
26872696-3	2016	Here we found that find-me signal sphingosine 1-phosphate (S1P) activated macrophage erythropoietin (EPO) signaling promoted apoptotic cell clearance and immune tolerance.	sphingosine 1-phosphate	34-57	erythropoietin	Mus musculus	85-99
26872696-3	2016	Here we found that find-me signal sphingosine 1-phosphate (S1P) activated macrophage erythropoietin (EPO) signaling promoted apoptotic cell clearance and immune tolerance.	sphingosine 1-phosphate	34-57	erythropoietin	Mus musculus	101-104
26845567-5	2016	Feeding of iron-deficient diet as well as erythropoietin treatment increased TMPRSS6 protein content in rats and mice by a posttranscriptional mechanism; the increase in TMPRSS6 protein by erythropoietin was also observed in Bmp6-mutant mice.	Iron	11-15	erythropoietin	Mus musculus	189-203
26927670-6	2016	Moreover, suppression of renal EPO production was associated with increased glucose uptake, enhanced glycolysis, reduced mitochondrial mass, diminished O2 consumption, and elevated renal tissue pO2.	Oxygen	152-154	erythropoietin	Mus musculus	31-34
26927670-6	2016	Moreover, suppression of renal EPO production was associated with increased glucose uptake, enhanced glycolysis, reduced mitochondrial mass, diminished O2 consumption, and elevated renal tissue pO2.	PO-2	194-197	erythropoietin	Mus musculus	31-34
26915320-8	2016	The results showed that LPS/D-gal induced the enhanced expression of TF, elevation of NF-kappaB p65 nuclear translocation, up-regulation of HIF-1alpha and EPO expressions, and increased LA level.	Galactosamine	28-33	erythropoietin	Mus musculus	155-158
26727632-3	2016	These polymers were capable of significant delivery of siRNA against FVII and mRNA-encoding erythropoietin (EPO) in mice.	Polymers	6-14	erythropoietin	Mus musculus	108-111
26731474-5	2016	Exposure of myofibroblasts to nanomolar concentrations of the demethylating agent 5-azacytidine increased basal expression and hypoxic induction of erythropoietin.	Azacitidine	82-95	erythropoietin	Mus musculus	148-162
26054543-1	2016	Erythropoietin (Epo) is produced by renal Epo-producing cells (REPs) in a hypoxia-inducible manner.	reps	63-67	erythropoietin	Mus musculus	0-14
26054543-1	2016	Erythropoietin (Epo) is produced by renal Epo-producing cells (REPs) in a hypoxia-inducible manner.	reps	63-67	erythropoietin	Mus musculus	16-19
26054543-1	2016	Erythropoietin (Epo) is produced by renal Epo-producing cells (REPs) in a hypoxia-inducible manner.	reps	63-67	erythropoietin	Mus musculus	42-45
26054543-5	2016	Live imaging of REPs in transgenic mice expressing green fluorescent protein from a modified Epo-gene locus revealed that healthy REPs tightly associated with endothelium by wrapping processes around capillaries.	reps	16-20	erythropoietin	Mus musculus	93-96
26731474-6	2016	Mechanistically, the profibrotic factor TGF-beta1 induced hypermethylation and repression of erythropoietin in pericytes; these effects were prevented by 5-azacytidine treatment.	Azacitidine	154-167	erythropoietin	Mus musculus	93-107
26731474-7	2016	These findings shed light on the molecular mechanisms underlying erythropoietin repression in kidney myofibroblasts and demonstrate that clinically relevant, nontoxic doses of 5-azacytidine can restore erythropoietin production and ameliorate anemia in the setting of kidney fibrosis in mice.	Azacitidine	176-189	erythropoietin	Mus musculus	65-79
26469975-6	2016	The protective effect of EPO on mouse TBM was inhibited by miR-144 antagomir.	metsulfuron methyl	38-41	erythropoietin	Mus musculus	25-28
26776506-4	2016	Under an iron-deprived diet (2-3 mg/kg), mice failed to release iron from ferritin storage and developed severe microcytic hypochromic anemia and ineffective erythropoiesis associated with increased erythropoietin levels.	Iron	9-13	erythropoietin	Mus musculus	199-213
26824070-4	2016	In an in vivo erythropoiesis assay in mice, all of the EPO glycoforms displayed biological activity, in particular the EPO bearing three sialyloligosaccharides, which exhibited the highest activity.	sialooligosaccharides	137-159	erythropoietin	Mus musculus	55-58
26824070-4	2016	In an in vivo erythropoiesis assay in mice, all of the EPO glycoforms displayed biological activity, in particular the EPO bearing three sialyloligosaccharides, which exhibited the highest activity.	sialooligosaccharides	137-159	erythropoietin	Mus musculus	119-122
26469975-8	2016	In conclusion, our study provides the first evidence that EPO protects mouse renal TBM through promoting bone marrow cells to generate and secrete miR-144, which, in turn, is efficiently delivered into the mouse kidney via EVs to inhibit the activation of the tPA/MMP9-mediated proteolytic network.	metsulfuron methyl	83-86	erythropoietin	Mus musculus	58-61
26678394-1	2016	BACKGROUND: The glycoprotein hormone erythropoietin and its analogue darbepoetin-alpha (DPO) have been shown to reduce the risk of acute liver failure after major hepatectomy.	darbepoetin-alpha	69-86	erythropoietin	Mus musculus	37-51
26603720-5	2016	Serum erythropoietin (EPO) levels were similar in treated versus control mice, indicating that isocitrate increased sensitivity to EPO.	isocitric acid	95-105	erythropoietin	Mus musculus	131-134
26678394-1	2016	BACKGROUND: The glycoprotein hormone erythropoietin and its analogue darbepoetin-alpha (DPO) have been shown to reduce the risk of acute liver failure after major hepatectomy.	dpo	88-91	erythropoietin	Mus musculus	37-51
26025460-0	2016	Erythropoietin Reverses Sepsis-Induced Vasoplegia to Norepinephrine Through Preservation of alpha1D-Adrenoceptor mRNA Expression and Inhibition of GRK2-Mediated Desensitization in Mouse Aorta.	Norepinephrine	53-67	erythropoietin	Mus musculus	0-14
26025460-10	2016	Erythropoietin treatment attenuated iNOS mRNA expression and iNOS-induced overproduction of NO, but improved endothelium-dependent relaxation to ACh associated with increased eNOS mRNA expression.	Acetylcholine	145-148	erythropoietin	Mus musculus	0-14
26452589-0	2016	Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis.	Oxygen	83-89	erythropoietin	Mus musculus	15-29
27236808-8	2016	Due to the small volume of the withdrawn blood the hematocrit remains the same for mice injected with control mRNA, whereas significant hematocrit increase is measured between day 4 and 20 postinjection for those injected with pseudouridine-modified EPO mRNA.	Pseudouridine	227-240	erythropoietin	Mus musculus	250-253
26452589-2	2016	The erythroid growth factor erythropoietin (Epo) triggers the erythropoietic induction through the activation of erythroid genes related to cell survival, differentiation, and iron metabolism.	Iron	176-180	erythropoietin	Mus musculus	28-42
26452589-2	2016	The erythroid growth factor erythropoietin (Epo) triggers the erythropoietic induction through the activation of erythroid genes related to cell survival, differentiation, and iron metabolism.	Iron	176-180	erythropoietin	Mus musculus	44-47
26643367-4	2015	Here, we report that EPO administration promoted phosphatidylinositol 3-kinase (PI3K)/AKT pathway activation in palmitic acid (PA)-treated HepG2 cells and in the liver of high-fat diet (HFD)-fed mice, whereas adenovirus-mediated silencing of the erythropoietin receptor (EPOR) blocked EPO-induced AKT signalling in HepG2 cells.	Palmitic Acid	112-125	erythropoietin	Mus musculus	271-274
26643367-4	2015	Here, we report that EPO administration promoted phosphatidylinositol 3-kinase (PI3K)/AKT pathway activation in palmitic acid (PA)-treated HepG2 cells and in the liver of high-fat diet (HFD)-fed mice, whereas adenovirus-mediated silencing of the erythropoietin receptor (EPOR) blocked EPO-induced AKT signalling in HepG2 cells.	Palmitic Acid	127-129	erythropoietin	Mus musculus	271-274
26472708-6	2015	In this study we tested the hypothesis that endogenous brain Epo also modulates the respiratory stimulation induced by the activation of central CO2 chemoreceptors.	N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide	145-148	erythropoietin	Mus musculus	61-64
26647839-8	2015	Pre-treatment with EPO and sodium selenite significantly decreased serum expression levels of BUN and malonaldehyde, and increased the expression levels of superoxide dismutase, glutathione peroxidase and nitric oxide (NO), compared with the model group.	Malondialdehyde	102-115	erythropoietin	Mus musculus	19-22
26647839-8	2015	Pre-treatment with EPO and sodium selenite significantly decreased serum expression levels of BUN and malonaldehyde, and increased the expression levels of superoxide dismutase, glutathione peroxidase and nitric oxide (NO), compared with the model group.	Nitric Oxide	205-217	erythropoietin	Mus musculus	19-22
26072265-9	2015	The improved memory by EPO was blocked after IH 5-AZA.	Decitabine	48-53	erythropoietin	Mus musculus	23-26
26177968-0	2015	Activating mitochondrial function and haemoglobin expression with EH-201, an inducer of erythropoietin in neuronal cells, reverses memory impairment.	2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside	66-72	erythropoietin	Mus musculus	88-102
26177968-8	2015	In the hippocampus of mice given EH-201 in their diet, levels of erythropoietin, PGC-1alpha and haemoglobin were increased CONCLUSIONS AND IMPLICATIONS: The induction of endogenous erythropoietin in neuronal cells by inducers such as EH-201 might be a therapeutic strategy for memory impairment in neurodegenerative disease, physiological ageing or traumatic brain injury.	2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside	33-39	erythropoietin	Mus musculus	65-79
26177968-8	2015	In the hippocampus of mice given EH-201 in their diet, levels of erythropoietin, PGC-1alpha and haemoglobin were increased CONCLUSIONS AND IMPLICATIONS: The induction of endogenous erythropoietin in neuronal cells by inducers such as EH-201 might be a therapeutic strategy for memory impairment in neurodegenerative disease, physiological ageing or traumatic brain injury.	2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside	33-39	erythropoietin	Mus musculus	181-195
26357589-5	2015	After G418 selection, a stable EPO-overexpressing cell line, EPO-3T3-EGFP, was established.	antibiotic G 418	6-10	erythropoietin	Mus musculus	31-34
25809081-0	2015	Dual Delivery of EPO and BMP2 from a Novel Modular Poly-e-Caprolactone Construct to Increase the Bone Formation in Prefabricated Bone Flaps.	poly-e-caprolactone	51-70	erythropoietin	Mus musculus	17-20
25809081-8	2015	Increased endothelial cell proliferation on EPO-adsorbed PCL discs indicated protein bioactivity.	pcl	57-60	erythropoietin	Mus musculus	44-47
26047733-16	2015	CONCLUSION: We conclude that MB protects the hippocampus-derived neuronal cells against OGD-reoxygenation injury by enhancing energy metabolism and increasing HIF-1alpha protein content accompanied by an activation of the EPO signaling pathway.	Methylene Blue	29-31	erythropoietin	Mus musculus	222-225
26316120-3	2015	We report a solution NMR study of the mouse erythropoietin receptor (mEpoR) comprising the TMD and the JM regions reconstituted in dodecylphosphocholine (DPC) micelles.	dodecylphosphocholine	131-152	erythropoietin	Mus musculus	44-58
26316120-3	2015	We report a solution NMR study of the mouse erythropoietin receptor (mEpoR) comprising the TMD and the JM regions reconstituted in dodecylphosphocholine (DPC) micelles.	dodecylphosphocholine	154-157	erythropoietin	Mus musculus	44-58
26001375-0	2015	Midazolam inhibits the hypoxia-induced up-regulation of erythropoietin in the central nervous system.	Midazolam	0-9	erythropoietin	Mus musculus	56-70
26001375-3	2015	In the present study, we investigated the effect of midazolam on EPO expression in primary cultured astrocytes and the mouse brain.	Midazolam	52-61	erythropoietin	Mus musculus	65-68
26001375-8	2015	Midazolam significantly reduced the hypoxia-induced up-regulation of EPO in BALB/c mice brains and primary cultured astrocytes and suppressed EPO expression in the fetal brain.	Midazolam	0-9	erythropoietin	Mus musculus	69-72
26001375-8	2015	Midazolam significantly reduced the hypoxia-induced up-regulation of EPO in BALB/c mice brains and primary cultured astrocytes and suppressed EPO expression in the fetal brain.	Midazolam	0-9	erythropoietin	Mus musculus	142-145
26001375-10	2015	These results demonstrated the suppressive effects of midazolam on the hypoxia-induced up-regulation of EPO both in vivo and in vitro.	Midazolam	54-63	erythropoietin	Mus musculus	104-107
26125905-3	2015	Different concentrations of EPO were added to the cells and observed by Oil Red O staining on the 20th day to quantitatively analyze the degree of cell differentiation.	oil red O	72-81	erythropoietin	Mus musculus	28-31
26012551-1	2015	Erythropoietin (Epo) is produced in the kidney and liver in a hypoxia-inducible manner via the activation of hypoxia-inducible transcription factors (HIFs) to maintain oxygen homeostasis.	Oxygen	168-174	erythropoietin	Mus musculus	0-14
26012551-1	2015	Erythropoietin (Epo) is produced in the kidney and liver in a hypoxia-inducible manner via the activation of hypoxia-inducible transcription factors (HIFs) to maintain oxygen homeostasis.	Oxygen	168-174	erythropoietin	Mus musculus	16-19
26161863-5	2015	A significant increase in the erythropoietin levels in plasma was seen in mice exposed to 1000 ppm cadmium.	Cadmium	99-106	erythropoietin	Mus musculus	30-44
26125905-5	2015	EPO significantly inhibited adipogenic differentiation of MSCs after 20 days and reduced absorbance values by Oil Red O staining without affecting proliferation activity.	oil red O	110-119	erythropoietin	Mus musculus	0-3
25765155-10	2015	Moreover, Epo reduced the basal intracellular calcium (Ca(2+)) levels, suggesting an effect in the Ca(2+)-signaling pathway.	Calcium	46-53	erythropoietin	Mus musculus	10-13
25792712-10	2015	Because sex-specific effects are different in newborn male and female, sex steroids secreted at different ages mice appear to modulate the effects of Epo on respiratory regulation in normoxia and in response to hypoxia.	Steroids	75-83	erythropoietin	Mus musculus	150-153
25715089-8	2015	RESULTS: Dietary iron restriction gradually induced anemia, Epo secretion, and cardiac hypertrophy in wild-type mice.	Iron	17-21	erythropoietin	Mus musculus	60-63
25708005-7	2015	Although almost no differences among the studied cryoprotectant solutions were observed on the differentiation potential of encapsulated mesenchymal stem cells, the penetrating cryoprotectant DMSO at a concentration of 10% displayed the best viability and erythropoietin secretion profile compared to the other cryoprotectant solutions.	Dimethyl Sulfoxide	192-196	erythropoietin	Mus musculus	256-270
25519735-1	2015	Under conditions of accelerated erythropoiesis, elevated erythropoietin (Epo) levels are associated with inhibition of hepcidin synthesis, a response that ultimately increases iron availability to meet the enhanced iron needs of erythropoietic cells.	Iron	176-180	erythropoietin	Mus musculus	57-71
25500291-0	2015	Erythropoietin activates the phosporylated cAMP [adenosine 3"5" cyclic monophosphate] response element-binding protein pathway and attenuates delayed paraplegia after ischemia-reperfusion injury.	Cyclic AMP	43-47	erythropoietin	Mus musculus	0-14
25500291-0	2015	Erythropoietin activates the phosporylated cAMP [adenosine 3"5" cyclic monophosphate] response element-binding protein pathway and attenuates delayed paraplegia after ischemia-reperfusion injury.	Cyclic AMP	49-84	erythropoietin	Mus musculus	0-14
25500291-3	2015	We hypothesized that EPO induces the CREB (cAMP [adenosine 3"5" cyclic monophosphate] response element-binding protein) pathway and neurotrophin production in the murine spinal cord, attenuating functional and cellular injury.	Cyclic AMP	43-47	erythropoietin	Mus musculus	21-24
25500291-3	2015	We hypothesized that EPO induces the CREB (cAMP [adenosine 3"5" cyclic monophosphate] response element-binding protein) pathway and neurotrophin production in the murine spinal cord, attenuating functional and cellular injury.	Cyclic AMP	49-84	erythropoietin	Mus musculus	21-24
25519735-1	2015	Under conditions of accelerated erythropoiesis, elevated erythropoietin (Epo) levels are associated with inhibition of hepcidin synthesis, a response that ultimately increases iron availability to meet the enhanced iron needs of erythropoietic cells.	Iron	176-180	erythropoietin	Mus musculus	73-76
25519735-1	2015	Under conditions of accelerated erythropoiesis, elevated erythropoietin (Epo) levels are associated with inhibition of hepcidin synthesis, a response that ultimately increases iron availability to meet the enhanced iron needs of erythropoietic cells.	Iron	215-219	erythropoietin	Mus musculus	57-71
25519735-1	2015	Under conditions of accelerated erythropoiesis, elevated erythropoietin (Epo) levels are associated with inhibition of hepcidin synthesis, a response that ultimately increases iron availability to meet the enhanced iron needs of erythropoietic cells.	Iron	215-219	erythropoietin	Mus musculus	73-76
25519735-4	2015	We found that prolonged administration of high doses of Epo in mice leads to great inhibition of liver hepcidin mRNA levels, and concomitant induction of the hepcidin inhibitor erythroferrone (ERFE).	erythroferrone	177-191	erythropoietin	Mus musculus	56-59
25519735-5	2015	Epo treatment also resulted in liver iron mobilization, mediated by increased ferroportin activity and accompanied by reduced ferritin levels and increased TfR1 expression.	Iron	37-41	erythropoietin	Mus musculus	0-3
25499454-9	2015	We suggest that Tfr2 is a component of a novel iron-sensing mechanism that adjusts erythrocyte production according to iron availability, likely by modulating the erythroblast Epo sensitivity.	Iron	47-51	erythropoietin	Mus musculus	176-179
26227001-8	2015	RESULTS: Vitamin D treatment decreased mean corpuscular volume, reticulocyte count, and plasma erythropoietin levels.	Vitamin D	9-18	erythropoietin	Mus musculus	95-109
25786542-2	2015	To maintain oxygen homeostasis in adult mammals, when the kidney senses hypoxia, it secretes an erythroid growth factor, erythropoietin (Epo), which stimulates erythropoiesis in the bone marrow.	Oxygen	12-18	erythropoietin	Mus musculus	121-135
25786542-2	2015	To maintain oxygen homeostasis in adult mammals, when the kidney senses hypoxia, it secretes an erythroid growth factor, erythropoietin (Epo), which stimulates erythropoiesis in the bone marrow.	Oxygen	12-18	erythropoietin	Mus musculus	137-140
25236856-6	2015	Bone marrow erythroid progenitors from erythropoietin-treated mice exhibited iron-restricted erythropoiesis, as indicated by increased median fluorescence intensity of transferrin receptor immunostaining by flow cytometry.	Iron	77-81	erythropoietin	Mus musculus	39-53
25790933-10	2015	CEPO but not EPO significantly increased gene expression of dopamine receptors 1 and 2, and adenosine receptor 2a, and significantly down-regulated adrenergic receptor 1D and gastrin releasing peptide.	Adenosine	92-101	erythropoietin	Mus musculus	1-4
26101463-3	2015	In the current study, we investigated the role of betaCR in EPO-mediated protection in macrophages against oxidized low-density lipoprotein- (oxLDL-) induced deregulation of lipid metabolism and inflammation.	betacr	50-56	erythropoietin	Mus musculus	60-63
26101463-7	2015	Furthermore, EPO-promoted cholesterol efflux and upregulation of ATP-binding cassette (ABC) transporters ABCA1 and ABCG1 were prevented by pretreatment with betaCR neutralizing antibody or betaCR siRNA.	Cholesterol	26-37	erythropoietin	Mus musculus	13-16
25442789-3	2014	Because EPO is a known neuroprotectant, we hypothesized that infusion of HEK cells or HEK-conditioned medium (HEK-CM) may provide neuroprotection against kainic acid (KA)-induced hippocampal damage in mice.	Kainic Acid	154-165	erythropoietin	Mus musculus	8-11
26538835-5	2015	Pretreatment with EPO diminished mononuclear cell numbers, increased the recruitment of F4/80(+)/CD80(+) and F4/80(+)/CD86(+) cells to the bronchoalveolar space, induced higher production of IFN-gamma, IL-6, MIP-1alpha, MCP-1, and LTB4, reduced PGE2 concentration, and did not affect fungal burden.	Dinoprostone	245-249	erythropoietin	Mus musculus	18-21
25490417-5	2014	EPO also significantly decreased production of hydrogen peroxide and improved endothelium-dependent relaxations in aortas of hph1 mice.	Hydrogen Peroxide	47-64	erythropoietin	Mus musculus	0-3
25164531-11	2014	CONCLUSIONS AND IMPLICATIONS: Chronic treatment of mice with an EPO derivative, devoid of haematopoietic effects, improved metabolic abnormalities induced by a high-fat high-sucrose diet, by affecting several levels of the insulin signalling and inflammatory cascades within skeletal muscle, while enhancing mitochondrial biogenesis.	Sucrose	174-181	erythropoietin	Mus musculus	64-67
25490417-8	2014	Increased vascular expressions of antioxidants seem to be an important molecular mechanism underlying vascular protection by EPO during chronic BH4 deficiency.	sapropterin	144-147	erythropoietin	Mus musculus	125-128
25352847-11	2014	Our results provide the first evidence that EPO improved the outcome of mice presenting with disseminated aspergillosis when combined with amphotericin B.	Amphotericin B	139-153	erythropoietin	Mus musculus	44-47
25041251-0	2014	Erythropoietin increases bioavailability of tetrahydrobiopterin and protects cerebral microvasculature against oxidative stress induced by eNOS uncoupling.	sapropterin	44-63	erythropoietin	Mus musculus	0-14
25041251-4	2014	Treatment of hph1 mice with EPO attenuated the levels of 7,8-dihydrobiopterin, the oxidized product of BH4, and significantly increased the ratio of BH4 to 7,8-dihydrobiopterin.	7,8-dihydrobiopterin	57-77	erythropoietin	Mus musculus	28-31
25041251-4	2014	Treatment of hph1 mice with EPO attenuated the levels of 7,8-dihydrobiopterin, the oxidized product of BH4, and significantly increased the ratio of BH4 to 7,8-dihydrobiopterin.	sapropterin	103-106	erythropoietin	Mus musculus	28-31
25041251-4	2014	Treatment of hph1 mice with EPO attenuated the levels of 7,8-dihydrobiopterin, the oxidized product of BH4, and significantly increased the ratio of BH4 to 7,8-dihydrobiopterin.	sapropterin	149-152	erythropoietin	Mus musculus	28-31
25041251-4	2014	Treatment of hph1 mice with EPO attenuated the levels of 7,8-dihydrobiopterin, the oxidized product of BH4, and significantly increased the ratio of BH4 to 7,8-dihydrobiopterin.	7,8-dihydrobiopterin	156-176	erythropoietin	Mus musculus	28-31
25041251-5	2014	Moreover, EPO decreased the levels of superoxide anions and increased NO bioavailability in cerebral microvessels of hph1 mice.	Superoxides	38-55	erythropoietin	Mus musculus	10-13
25041251-8	2014	Our results suggest that EPO might protect the neurovascular unit against oxidative stress by restoring bioavailability of BH4 and endothelial NO in the cerebral microvascular endothelium.	sapropterin	123-126	erythropoietin	Mus musculus	25-28
25041251-10	2014	Our results suggest that EPO might protect the neurovascular unit against oxidative stress by restoring bioavailability of tetrahydrobiopterin (BH4) and endothelial nitric oxide.	sapropterin	123-142	erythropoietin	Mus musculus	25-28
25041251-10	2014	Our results suggest that EPO might protect the neurovascular unit against oxidative stress by restoring bioavailability of tetrahydrobiopterin (BH4) and endothelial nitric oxide.	sapropterin	144-147	erythropoietin	Mus musculus	25-28
25041251-10	2014	Our results suggest that EPO might protect the neurovascular unit against oxidative stress by restoring bioavailability of tetrahydrobiopterin (BH4) and endothelial nitric oxide.	Nitric Oxide	165-177	erythropoietin	Mus musculus	25-28
25346735-1	2014	BACKGROUND: Erythropoietin (Epo) improves post-traumatic cerebral blood flow (CBF), pressure autoregulation, and vascular reactivity to l-arginine.	Arginine	136-146	erythropoietin	Mus musculus	12-26
25346735-1	2014	BACKGROUND: Erythropoietin (Epo) improves post-traumatic cerebral blood flow (CBF), pressure autoregulation, and vascular reactivity to l-arginine.	Arginine	136-146	erythropoietin	Mus musculus	28-31
25346735-2	2014	This study examines the dependence of these cerebral hemodynamic effects of Epo on nitric oxide generated by endothelial nitric oxide synthase (eNOS).	Nitric Oxide	83-95	erythropoietin	Mus musculus	76-79
25346735-5	2014	Epo administration resulted in significantly higher CBF in the peri-contusional sites in the WT mice [70.2 +- 3.35% in Epo-treated compared to 53 +- 3.3% of baseline in saline-treated mice (p &lt; 0.0001)], but no effect was seen in the eNOS-deficient mice.	Sodium Chloride	169-175	erythropoietin	Mus musculus	0-3
25108527-6	2014	Moreover, in acquired and inherited chronic anemia mouse models, acetate supplementation increases EPO expression and the resting hematocrit.	Acetates	65-72	erythropoietin	Mus musculus	99-102
25052430-4	2014	Our Western blot data demonstrated that a dose of 40 mg/kg BW of CoCl2 was able to generate hypoxia like condition in mice in which Hif-1alpha and its immediate responsive genes-glutamate transporter-1 (Slc2a1) and erythropoietin (Epo) expression were up regulated.	cobaltous chloride	65-70	erythropoietin	Mus musculus	215-229
25052430-4	2014	Our Western blot data demonstrated that a dose of 40 mg/kg BW of CoCl2 was able to generate hypoxia like condition in mice in which Hif-1alpha and its immediate responsive genes-glutamate transporter-1 (Slc2a1) and erythropoietin (Epo) expression were up regulated.	cobaltous chloride	65-70	erythropoietin	Mus musculus	231-234
25052430-5	2014	Our in-gel assay data indicated that SOD and CAT activities significantly declined and it was associated with significant down regulation of Sod1 and Epo expression as evident from our semi quantitative RT-PCR and Western blot data, which might be correlated with up regulation of Hif-1alpha expression in the cerebral cortex of the CoCl2-treated hypoxic mice.	cobaltous chloride	333-338	erythropoietin	Mus musculus	150-153
24927405-8	2014	The data suggest that oligodendrocyte damage may explain the increased vulnerability of the juvenile brain to vanadium and support a potential for erythropoietin as a protective agent against vanadium-toxicity during perinatal brain development and maturation.	Vanadium	192-200	erythropoietin	Mus musculus	147-161
24647735-3	2014	Using comprehensive in vivo and in vitro analyses in mice, EPO treatment inhibited WAT inflammation, normalized insulin sensitivity, and reduced glucose intolerance.	Glucose	145-152	erythropoietin	Mus musculus	59-62
24704457-6	2014	The chronic treatment of MAP6 KO mice with Epo D strongly increased Mn(2+) propagation within both mono- and polysynaptic connections.	Manganese(2+)	68-74	erythropoietin	Mus musculus	43-46
24680923-0	2014	The volatile anesthetic isoflurane differentially suppresses the induction of erythropoietin synthesis elicited by acute anemia and systemic hypoxemia in mice in an hypoxia-inducible factor-2-dependent manner.	Isoflurane	24-34	erythropoietin	Mus musculus	78-92
24746751-4	2014	Intranasal curcumin (5mg/kg) was administered from days 21 to 55, an hour before every nebulization and inflammatory cells recruitment, levels of IgE, EPO, IL-4 and IL-5 were found suppressed in bronchoalveolar lavage fluid (BALF).	Curcumin	11-19	erythropoietin	Mus musculus	151-154
24788561-0	2014	Hepatoprotective effects of erythropoietin on D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice.	Galactosamine	46-61	erythropoietin	Mus musculus	28-42
24788561-8	2014	Compared with the D-GalN/LPS group, pretreatment with EPO significantly decreased the levels of aspartate aminotransferase, alanine aminotransferase and MDA, and increased the activities of SOD and GSH-Px.	gsh-px	198-204	erythropoietin	Mus musculus	54-57
24945310-5	2014	Our results demonstrated that the tolerance of mice to hypoxia, the changes of HIF-1alpha protein level and HIF-1 DNA binding activity in mice hippocampus, the mRNA level of erythropoietin (EPO) and vascular endothelial growth factor (VEGF), and the disappearance time of population spikes of hippocampal slices were substantially different between the control group and the CoCl2 group.	cobaltous chloride	375-380	erythropoietin	Mus musculus	174-188
24680923-7	2014	Plasma EPO concentration was induced as early as 3h following acute anemic and hypoxemic hypoxia and suppressed by clinically relevant doses of isoflurane in a dose-dependent manner.	Tritium	49-51	erythropoietin	Mus musculus	7-10
24680923-7	2014	Plasma EPO concentration was induced as early as 3h following acute anemic and hypoxemic hypoxia and suppressed by clinically relevant doses of isoflurane in a dose-dependent manner.	Isoflurane	144-154	erythropoietin	Mus musculus	7-10
24680923-9	2014	In the kidney, isoflurane inhibited EPO induction caused by anemia but not that caused by hypoxemia.	Isoflurane	15-25	erythropoietin	Mus musculus	36-39
24680923-10	2014	On the other hand, in the brain hypoxemia-induced EPO production was suppressed by isoflurane.	Isoflurane	83-93	erythropoietin	Mus musculus	50-53
24680923-11	2014	Finally, qRT-PCR studies demonstrate that isoflurane differentially inhibit HIF-1alpha and HIF-2alpha mRNA expression in brain and kidney, indicating the involvement of HIF-2 in the hypoxia-induced EPO expression and inhibition of the induction by isoflurane.	Isoflurane	42-52	erythropoietin	Mus musculus	198-201
24680923-11	2014	Finally, qRT-PCR studies demonstrate that isoflurane differentially inhibit HIF-1alpha and HIF-2alpha mRNA expression in brain and kidney, indicating the involvement of HIF-2 in the hypoxia-induced EPO expression and inhibition of the induction by isoflurane.	Isoflurane	248-258	erythropoietin	Mus musculus	198-201
24587369-6	2014	CI induced erythropoietin (EPO) mRNA in kidney and protein in kidney and serum; CIP stimulated EPO mRNA expression.	morin	0-2	erythropoietin	Mus musculus	11-25
24463938-8	2014	RESULTS: Erythropoietin increased SBP by 24  mmHg (P &lt; 0.05) and decreased by 25% vasodilatory responses to acetylcholine (P &lt; 0.01) in eET-1 mice.	Acetylcholine	111-124	erythropoietin	Mus musculus	9-23
24587369-6	2014	CI induced erythropoietin (EPO) mRNA in kidney and protein in kidney and serum; CIP stimulated EPO mRNA expression.	morin	0-2	erythropoietin	Mus musculus	27-30
24337294-2	2013	As administrated clinically, erythropoietin has a polypeptide backbone with complex dishomogeneity in its carbohydrate domains.	Carbohydrates	106-118	erythropoietin	Mus musculus	29-43
24435306-7	2014	The results showed that the combination therapy with EPO and G-CSF in the acute phase significantly improved rotarod performance and forelimb-use symmetry compared to the other groups, while subacute EPO and G-CSF therapy exhibited a modest improvement compared with the chronic saline controls.	Sodium Chloride	279-285	erythropoietin	Mus musculus	53-56
24756702-6	2014	The major demonstrated functions of TRPC2 are regulation of pheromone-evoked signaling in the rodent VNO, regulation of erythropoietin-stimulated calcium influx in murine erythroid cells, and ZP3-evoked calcium influx into sperm.	Calcium	146-153	erythropoietin	Mus musculus	120-134
24744892-0	2014	Catalyzing role of erythropoietin on the nitric oxide central pathway during the ventilatory responses to hypoxia.	Nitric Oxide	41-53	erythropoietin	Mus musculus	19-33
24744892-6	2014	At rest, Epo-TAg(h) mice displayed normal ventilatory parameters at 21% O2 but did not respond to acute hypoxia despite a larger expression of NMDA receptors and nNOS in the medulla.	Oxygen	72-74	erythropoietin	Mus musculus	9-12
24744892-10	2014	Ventilatory response to acute hypoxia was modified by MK-801 injection in WT and Epo-TAg(h) mice.	Dizocilpine Maleate	54-60	erythropoietin	Mus musculus	81-84
24744892-12	2014	Furthermore, erythropoietin plays a potential catalyzing role in the NMDA-NO central pathway during the ventilatory response and acclimatization to hypoxia.	N-Methylaspartate	69-73	erythropoietin	Mus musculus	13-27
29805869-17	2013	Conclusion: The erythropoietic activity of nano-encapsulated forms of erythropoietin was observed in the 0.05% and 0.005% pectin samples in the cyclophosphamide immunosuppression model setting.	Cyclophosphamide	144-160	erythropoietin	Mus musculus	70-84
24337294-3	2013	Here we describe the total synthesis of homogeneous erythropoietin with consensus carbohydrate domains incorporated at all of the native glycosylation sites.	Carbohydrates	82-94	erythropoietin	Mus musculus	52-66
24337294-6	2013	This homogeneous erythropoietin glycosylated at the three wild-type aspartates with N-linked high-mannose sialic acid-containing oligosaccharides and O-linked glycophorin exhibits Procrit-level in vivo activity in mice.	Aspartic Acid	68-78	erythropoietin	Mus musculus	17-31
24337294-6	2013	This homogeneous erythropoietin glycosylated at the three wild-type aspartates with N-linked high-mannose sialic acid-containing oligosaccharides and O-linked glycophorin exhibits Procrit-level in vivo activity in mice.	n-linked high-mannose	84-105	erythropoietin	Mus musculus	17-31
24337294-6	2013	This homogeneous erythropoietin glycosylated at the three wild-type aspartates with N-linked high-mannose sialic acid-containing oligosaccharides and O-linked glycophorin exhibits Procrit-level in vivo activity in mice.	N-Acetylneuraminic Acid	106-117	erythropoietin	Mus musculus	17-31
24337294-6	2013	This homogeneous erythropoietin glycosylated at the three wild-type aspartates with N-linked high-mannose sialic acid-containing oligosaccharides and O-linked glycophorin exhibits Procrit-level in vivo activity in mice.	Oligosaccharides	129-145	erythropoietin	Mus musculus	17-31
24337294-6	2013	This homogeneous erythropoietin glycosylated at the three wild-type aspartates with N-linked high-mannose sialic acid-containing oligosaccharides and O-linked glycophorin exhibits Procrit-level in vivo activity in mice.	o-linked glycophorin	150-170	erythropoietin	Mus musculus	17-31
24124607-3	2013	EPO increased the Glu uptake by astrocytes under both NC and especially upon HC in culture-aged APC (by 60%).	Glutamic Acid	18-21	erythropoietin	Mus musculus	0-3
23990359-4	2013	Moreover, EPO increased oxidative metabolism, fatty acid oxidation, and key metabolic genes in adipocytes and in white adipose tissue from diet-induced obese wild-type mice.	Fatty Acids	46-56	erythropoietin	Mus musculus	10-13
23990359-7	2013	PPARalpha also cooperates with Sirt1 activated by EPO through modulating the NAD+ level to regulate metabolic activity.	NAD	77-81	erythropoietin	Mus musculus	50-53
24124607-5	2013	EPO alleviated the Glu- and hypoxia-induced LDH release from astrocytes.	Glutamic Acid	19-22	erythropoietin	Mus musculus	0-3
24124607-10	2013	Here we show for the first time the direct correlation between the extent of differentiation (age) of astrocytes and the efficacy of EPO in balancing extracellular glutamate clearance and metabolism in an in-vitro model of hypoxia and Glu-induced astroglial injury.	Glutamic Acid	164-173	erythropoietin	Mus musculus	133-136
24124607-10	2013	Here we show for the first time the direct correlation between the extent of differentiation (age) of astrocytes and the efficacy of EPO in balancing extracellular glutamate clearance and metabolism in an in-vitro model of hypoxia and Glu-induced astroglial injury.	Glutamic Acid	235-238	erythropoietin	Mus musculus	133-136
23936499-4	2013	Recent study has shown that the novel 11-amino acid peptide erythropoietin derivative ARA290 produces a similar, long-lasting relief of NP.	cibinetide	86-92	erythropoietin	Mus musculus	60-74
23530756-10	2013	EH-201 also stimulated mitochondrial biogenesis and enhanced the expression of Hb by a mechanism dependent on EPO-mediated signalling.	2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside	0-6	erythropoietin	Mus musculus	110-113
23530756-11	2013	In mechanistic studies, using EPO and EPO receptor-neutralizing antibodies, we confirmed that EH-201 enhances EPO-EPOR autocrine activity.	2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside	94-100	erythropoietin	Mus musculus	30-33
23530756-11	2013	In mechanistic studies, using EPO and EPO receptor-neutralizing antibodies, we confirmed that EH-201 enhances EPO-EPOR autocrine activity.	2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside	94-100	erythropoietin	Mus musculus	38-41
23530756-11	2013	In mechanistic studies, using EPO and EPO receptor-neutralizing antibodies, we confirmed that EH-201 enhances EPO-EPOR autocrine activity.	2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside	94-100	erythropoietin	Mus musculus	38-41
23891710-3	2013	The serum [EPO] response was blunted in all RA groups compared to IA but the resulting reticulocyte response was similar in all experimental groups.	Radium	44-46	erythropoietin	Mus musculus	11-14
23523698-7	2013	In vitro erythropoietin treatment of primary skeletal myoblasts increased mitochondrial biogenesis gene expression including PGC-1alpha by 2.6-fold, CytC by 2-fold, oxygen consumption rate by 2-fold, and citrate synthase activity by 58%.	Oxygen	165-171	erythropoietin	Mus musculus	9-23
23567781-9	2013	CONCLUSIONS: The measurements of iron, whether in acute (dextran sodium sulfate) or chronic (T-cell transfer) models of colitis, were generally consistent with iron-deficient anemia, with large increases in erythropoietin indicative of tissue hypoxia.	Iron	33-37	erythropoietin	Mus musculus	207-221
23717580-2	2013	Here, we demonstrate that phosphorylation of GATA-1 at serine26 is also transiently induced in cells of the erythroid lineage (primary erythroblasts and erythrocyte-committed progenitors [EPs]) by erythropoietin (EPO), the principal cytokine regulating erythropoiesis.	serine26	55-63	erythropoietin	Mus musculus	197-211
23717580-2	2013	Here, we demonstrate that phosphorylation of GATA-1 at serine26 is also transiently induced in cells of the erythroid lineage (primary erythroblasts and erythrocyte-committed progenitors [EPs]) by erythropoietin (EPO), the principal cytokine regulating erythropoiesis.	serine26	55-63	erythropoietin	Mus musculus	213-216
23717580-9	2013	Taken together, these results suggest that EPO-induced transient phosphorylation of GATA-1 at serine26 is dispensable for erythropoiesis.	serine26	94-102	erythropoietin	Mus musculus	43-46
23524097-0	2013	Erythropoietin protects polychlorinated biphenyl (Aroclor 1254) induced neurotoxicity in mice.	Polychlorinated Biphenyls	24-48	erythropoietin	Mus musculus	0-14
23524097-0	2013	Erythropoietin protects polychlorinated biphenyl (Aroclor 1254) induced neurotoxicity in mice.	Chlorodiphenyl (54% Chlorine)	50-62	erythropoietin	Mus musculus	0-14
23524097-2	2013	The present study was designed to evaluate the neuroprotective role of erythropoietin in Aroclor 1254 induced oxidative stress in mice.	Chlorodiphenyl (54% Chlorine)	89-101	erythropoietin	Mus musculus	71-85
23524097-8	2013	Both doses of erythropoietin (500 and 1000 IU/kg) pretreatment and co-treatment, (i) significantly increased the habituation memory and percentage alteration which are indicative of the cognitive improvement, (ii) attenuated the Aroclor 1254 induced rise in acetylcholinesterase activity, corticosterone, triglycerides and total cholesterol, (iii) increased the glutamate and antioxidant enzyme levels.	Chlorodiphenyl (54% Chlorine)	229-241	erythropoietin	Mus musculus	14-28
23524097-8	2013	Both doses of erythropoietin (500 and 1000 IU/kg) pretreatment and co-treatment, (i) significantly increased the habituation memory and percentage alteration which are indicative of the cognitive improvement, (ii) attenuated the Aroclor 1254 induced rise in acetylcholinesterase activity, corticosterone, triglycerides and total cholesterol, (iii) increased the glutamate and antioxidant enzyme levels.	Corticosterone	289-303	erythropoietin	Mus musculus	14-28
23524097-8	2013	Both doses of erythropoietin (500 and 1000 IU/kg) pretreatment and co-treatment, (i) significantly increased the habituation memory and percentage alteration which are indicative of the cognitive improvement, (ii) attenuated the Aroclor 1254 induced rise in acetylcholinesterase activity, corticosterone, triglycerides and total cholesterol, (iii) increased the glutamate and antioxidant enzyme levels.	Triglycerides	305-318	erythropoietin	Mus musculus	14-28
23524097-8	2013	Both doses of erythropoietin (500 and 1000 IU/kg) pretreatment and co-treatment, (i) significantly increased the habituation memory and percentage alteration which are indicative of the cognitive improvement, (ii) attenuated the Aroclor 1254 induced rise in acetylcholinesterase activity, corticosterone, triglycerides and total cholesterol, (iii) increased the glutamate and antioxidant enzyme levels.	Cholesterol	329-340	erythropoietin	Mus musculus	14-28
23524097-8	2013	Both doses of erythropoietin (500 and 1000 IU/kg) pretreatment and co-treatment, (i) significantly increased the habituation memory and percentage alteration which are indicative of the cognitive improvement, (ii) attenuated the Aroclor 1254 induced rise in acetylcholinesterase activity, corticosterone, triglycerides and total cholesterol, (iii) increased the glutamate and antioxidant enzyme levels.	Glutamic Acid	362-371	erythropoietin	Mus musculus	14-28
23524097-9	2013	These results indicate that erythropoietin protects against Aroclor 1254 induced neurotoxicity and improves the cognitive function and that this cytokine could be a promising therapeutic agent for stress induced neurodegeneration.	Chlorodiphenyl (54% Chlorine)	60-72	erythropoietin	Mus musculus	28-42
23528251-4	2013	Phenobarbital (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a.	Phenobarbital	0-13	erythropoietin	Mus musculus	128-142
23528251-4	2013	Phenobarbital (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a.	Phenobarbital	15-17	erythropoietin	Mus musculus	128-142
22972668-0	2013	Treatment of adriamycin-induced nephropathy with erythropoietin and G-CSF.	Doxorubicin	13-23	erythropoietin	Mus musculus	49-63
23384249-6	2013	Even though pre-treatment with Epo did not prevent nitrite production, inducible nitric oxide synthase protein expression or tumor necrosis factor-alpha secretion, it prevented the oxidative stress induced by CoCl2 as well as cell proliferation.	cobaltous chloride	209-214	erythropoietin	Mus musculus	31-34
23399021-5	2013	Testosterone downregulated hepatic hepcidin mRNA expression, upregulated renal erythropoietin mRNA expression, and increased erythropoietin levels.	Testosterone	0-12	erythropoietin	Mus musculus	79-93
23399021-5	2013	Testosterone downregulated hepatic hepcidin mRNA expression, upregulated renal erythropoietin mRNA expression, and increased erythropoietin levels.	Testosterone	0-12	erythropoietin	Mus musculus	125-139
23333855-7	2013	In CHx Epo-TAg(h) mice, LV hypertrophy, CO and O2T decreased.	[2-[3-[(4-Azanyl-2-Methyl-Pyrimidin-5-Yl)methyl]-4-Methyl-2-[1,1,2-Tris(Oxidanyl)-2-Oxidanylidene-Ethyl]-1,3-Thiazol-3-Ium-5-Yl]ethoxy-Oxidanyl-Phosphoryl]hydrogen Phosphate	47-50	erythropoietin	Mus musculus	7-10
23314760-10	2013	AEPO, but not EPO, expressed heparin affinity in vitro.	Heparin	29-36	erythropoietin	Mus musculus	1-4
23174140-7	2013	In vivo, ten days of GCV treatment was enough to restore the increased hematocrit levels of mice implanted with encapsulated TGL-expressing and EPO-secreting cells.	Ganciclovir	21-24	erythropoietin	Mus musculus	144-147
23585722-0	2013	Effects of serotonin on erythropoietin expression in mouse hippocampus.	Serotonin	11-20	erythropoietin	Mus musculus	24-38
23190369-0	2013	A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	89-93	erythropoietin	Mus musculus	57-71
23190369-12	2013	These results show that systemically administered rAAV-generated non-erythropoietic Epo may protect against MPTP-induced parkinsonism by a combination of neuroprotection and enhanced axonal sprouting.	raav	50-54	erythropoietin	Mus musculus	84-87
23190369-12	2013	These results show that systemically administered rAAV-generated non-erythropoietic Epo may protect against MPTP-induced parkinsonism by a combination of neuroprotection and enhanced axonal sprouting.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	108-112	erythropoietin	Mus musculus	84-87
23328620-12	2013	Captopril alone and genistein plus captopril, but not genistein alone, suppressed radiation-induced erythropoietin production.	Captopril	0-9	erythropoietin	Mus musculus	100-114
23328620-12	2013	Captopril alone and genistein plus captopril, but not genistein alone, suppressed radiation-induced erythropoietin production.	Genistein	20-29	erythropoietin	Mus musculus	100-114
23328620-12	2013	Captopril alone and genistein plus captopril, but not genistein alone, suppressed radiation-induced erythropoietin production.	Captopril	35-44	erythropoietin	Mus musculus	100-114
22879008-2	2013	The hormone erythropoietin (EPO) is essential for maintenance of tissue oxygen supply by stimulating red blood cell production and promoting their survival.	Oxygen	72-78	erythropoietin	Mus musculus	12-26
22879008-2	2013	The hormone erythropoietin (EPO) is essential for maintenance of tissue oxygen supply by stimulating red blood cell production and promoting their survival.	Oxygen	72-78	erythropoietin	Mus musculus	28-31
23616999-0	2013	Retraction notice to "Erythropoietin as a possible mechanism for the effects of intermittent hypoxia on bodyweight, serum glucose and leptin in mice" [Regul.	Glucose	122-129	erythropoietin	Mus musculus	22-36
22984011-7	2012	Administration of S104I-EPO significantly inhibited N-methyl-d-aspartate-induced neuronal death in primary cultures and protected against cerebral infarction and neurological deficits with an efficacy similar to that of wild-type EPO.	N-Methylaspartate	52-72	erythropoietin	Mus musculus	24-27
23456860-1	2013	The hematopoietic growth factor erythropoietin (Epo) circulates in plasma and controls the oxygen carrying capacity of the blood (Fisher.	Oxygen	91-97	erythropoietin	Mus musculus	48-51
23456860-19	2013	Epo has been shown to regulate a variety of cell functions such as calcium flux (Korbel et al.	Calcium	67-74	erythropoietin	Mus musculus	0-3
22089494-1	2012	We previously reported regulated expression of erythropoietin (EPO) over 4 weeks in the peripheral nerve in vivo, using a herpes simplex virus (HSV)-based vector containing a Tet-on regulatable gene expression cassette.	tetramethylenedisulfotetramine	175-178	erythropoietin	Mus musculus	47-61
22089494-1	2012	We previously reported regulated expression of erythropoietin (EPO) over 4 weeks in the peripheral nerve in vivo, using a herpes simplex virus (HSV)-based vector containing a Tet-on regulatable gene expression cassette.	tetramethylenedisulfotetramine	175-178	erythropoietin	Mus musculus	63-66
22089494-3	2012	EPO expression from the vector was tightly controlled by administration of doxycycline (DOX) in vitro.	Doxycycline	75-86	erythropoietin	Mus musculus	0-3
22089494-3	2012	EPO expression from the vector was tightly controlled by administration of doxycycline (DOX) in vitro.	Doxycycline	88-91	erythropoietin	Mus musculus	0-3
22089494-4	2012	One month after inoculation of the vector to transduce dorsal root ganglion (DRG) in vivo, administration of DOX-containing chow-induced expression of EPO.	Doxycycline	109-112	erythropoietin	Mus musculus	151-154
23074165-7	2013	Phosphorylated AKT was colabeled with ChAT(+) neurons and coexpressed in bromodeoxyuridine-positive cells, suggesting that the PI3K/AKT pathway may play a pivotal role in CEPO/EPO-cholinergic neuron generation.	Bromodeoxyuridine	73-90	erythropoietin	Mus musculus	172-175
23326455-0	2013	Erythropoietin inhibits gluconeogenesis and inflammation in the liver and improves glucose intolerance in high-fat diet-fed mice.	Glucose	83-90	erythropoietin	Mus musculus	0-14
23326455-1	2013	Erythropoietin (EPO) has multiple biological functions, including the modulation of glucose metabolism.	Glucose	84-91	erythropoietin	Mus musculus	0-14
23326455-1	2013	Erythropoietin (EPO) has multiple biological functions, including the modulation of glucose metabolism.	Glucose	84-91	erythropoietin	Mus musculus	16-19
23326455-3	2013	This study is aimed at investigating the potential mechanisms by which EPO improves glucose tolerance in an animal model of type 2 diabetes.	Glucose	84-91	erythropoietin	Mus musculus	71-74
23326455-7	2013	EPO treatment significantly reduced the body weights and the levels of fasting blood glucose and serum insulin and improved the HFD-induced glucose intolerance in mice.	Glucose	85-92	erythropoietin	Mus musculus	0-3
23326455-7	2013	EPO treatment significantly reduced the body weights and the levels of fasting blood glucose and serum insulin and improved the HFD-induced glucose intolerance in mice.	Glucose	140-147	erythropoietin	Mus musculus	0-3
23326455-10	2013	Therefore, our data indicated that EPO treatment improved glucose intolerance by inhibiting gluconeogenesis and inflammation in the livers of HFD-fed mice.	Glucose	58-65	erythropoietin	Mus musculus	35-38
22704605-13	2012	Our data demonstrate that repetitive systemic EPO treatment reverses microvascular dysfunction during wound healing in hypercholesterolaemic mice by inducing new vessel formation and by providing the wound with more oxygen.	Oxygen	216-222	erythropoietin	Mus musculus	46-49
22932188-0	2012	Erythropoietin decreases carbon tetrachloride-induced hepatic fibrosis by inhibiting transforming growth factor-beta.	Carbon Tetrachloride	25-45	erythropoietin	Mus musculus	0-14
22403284-0	2012	Gene therapy with an erythropoietin enhancer-mediated, hypoxia-inducible gene expression system in the corpus cavernosum of mice with high-cholesterol diet-induced erectile dysfunction.	Cholesterol	139-150	erythropoietin	Mus musculus	21-35
22145921-13	2012	CD34(+)  cells in the lumbar spinal cord of erythropoietin-treated mice were more abundant at day 2 than those of saline-treated mice.	Sodium Chloride	114-120	erythropoietin	Mus musculus	44-58
22610607-9	2012	In addition, gene expression levels of C/ebpalpha were significantly reduced, and Epo mRNA expression levels were significantly increased after APAP intoxication.	Acetaminophen	144-148	erythropoietin	Mus musculus	82-85
22021095-3	2012	Inhibition of AMPK activation by compound C or dominant-negative AMPK mutant abrogated the EPO-induced increase in the phosphorylation of AMPK, ACC, and eNOS, as well as nitric oxide (NO) production.	Nitric Oxide	170-182	erythropoietin	Mus musculus	91-94
22738133-10	2012	EPO priming also increased ECFC resistance to H2 O2-induced apoptosis and survival in vivo.	Hydrogen Peroxide	46-51	erythropoietin	Mus musculus	0-3
22490927-6	2012	Skeletal muscle myoblasts also produced endogenous erythropoietin that increased at low O(2).	o(2)	88-92	erythropoietin	Mus musculus	51-65
22915994-4	2012	Proliferation assays demonstrated that EPO treatment increased the density of bromodeoxyuridine (BrdU)-labeled cells in the subgranular zone (SGZ) compared to that in vehicle-treated controls.	Bromodeoxyuridine	78-95	erythropoietin	Mus musculus	39-42
22915994-4	2012	Proliferation assays demonstrated that EPO treatment increased the density of bromodeoxyuridine (BrdU)-labeled cells in the subgranular zone (SGZ) compared to that in vehicle-treated controls.	Bromodeoxyuridine	97-101	erythropoietin	Mus musculus	39-42
22669948-2	2012	Structural-functional and murine knock-in experiments have suggested that EPO-R Tyr-343 is important in EPO-mediated mitogenesis.	Tyrosine	80-83	erythropoietin	Mus musculus	74-77
22669948-3	2012	Although Stat5 binds to EPO-R phosphotyrosine 343, the initial Stat5-deficient mice did not have profound erythroid abnormalities suggesting that additional Src homology 2 (SH2) domain-containing effectors may bind to EPO-R Tyr-343 and couple to downstream signaling pathways.	r phosphotyrosine	28-45	erythropoietin	Mus musculus	24-27
22669948-8	2012	We also demonstrate that SH2B1 is responsive to EPO stimulation and becomes phosphorylated, most likely on serines/threonines, in an EPO dose- and time-dependent manner.	Serine	107-114	erythropoietin	Mus musculus	48-51
22669948-8	2012	We also demonstrate that SH2B1 is responsive to EPO stimulation and becomes phosphorylated, most likely on serines/threonines, in an EPO dose- and time-dependent manner.	Serine	107-114	erythropoietin	Mus musculus	133-136
22669948-8	2012	We also demonstrate that SH2B1 is responsive to EPO stimulation and becomes phosphorylated, most likely on serines/threonines, in an EPO dose- and time-dependent manner.	Threonine	115-125	erythropoietin	Mus musculus	48-51
22669948-8	2012	We also demonstrate that SH2B1 is responsive to EPO stimulation and becomes phosphorylated, most likely on serines/threonines, in an EPO dose- and time-dependent manner.	Threonine	115-125	erythropoietin	Mus musculus	133-136
22396019-8	2012	Likewise, ventricular enlargement after cuprizone, as documented by MRI, was less pronounced upon EPO.	Cuprizone	40-49	erythropoietin	Mus musculus	98-101
22748015-1	2012	BACKGROUND: Erythropoietin (EPO) is known to improve exercise performance by increasing oxygen blood transport and thus inducing a higher maximum oxygen uptake (VO2max).	Oxygen	88-94	erythropoietin	Mus musculus	12-26
22748015-1	2012	BACKGROUND: Erythropoietin (EPO) is known to improve exercise performance by increasing oxygen blood transport and thus inducing a higher maximum oxygen uptake (VO2max).	Oxygen	88-94	erythropoietin	Mus musculus	28-31
22748015-1	2012	BACKGROUND: Erythropoietin (EPO) is known to improve exercise performance by increasing oxygen blood transport and thus inducing a higher maximum oxygen uptake (VO2max).	Oxygen	146-152	erythropoietin	Mus musculus	12-26
22748015-1	2012	BACKGROUND: Erythropoietin (EPO) is known to improve exercise performance by increasing oxygen blood transport and thus inducing a higher maximum oxygen uptake (VO2max).	Oxygen	146-152	erythropoietin	Mus musculus	28-31
22396019-10	2012	Histological analysis of the corpus callosum revealed attenuation by EPO of the cuprizone-induced increase in microglial numbers and amyloid precursor protein accumulations as a readout of inflammation and axonal degeneration.	Cuprizone	80-89	erythropoietin	Mus musculus	69-72
22396019-11	2012	To conclude, EPO ameliorates neurological symptoms in the cuprizone model of demyelination, possibly by reduction of inflammation-associated axonal degeneration in white matter tracts.	Cuprizone	58-67	erythropoietin	Mus musculus	13-16
21543202-0	2012	Ethanol extract of Portulaca oleracea L. protects against hypoxia-induced neuro damage through modulating endogenous erythropoietin expression.	Ethanol	0-7	erythropoietin	Mus musculus	117-131
22334017-0	2012	Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.	Pseudouridine	74-87	erythropoietin	Mus musculus	113-127
22334017-6	2012	In comparison, mRNA containing uridine produced 10-100-fold lower levels of EPO lasting only 1 day.	Uridine	31-38	erythropoietin	Mus musculus	76-79
22334017-7	2012	EPO translated from pseudouridine-mRNA was functional and caused a significant increase of both reticulocyte counts and hematocrits.	Pseudouridine	20-33	erythropoietin	Mus musculus	0-3
21543202-3	2012	We have found that ethanol extract of Portulaca oleracea L. (EEPO) could increase erythropoietin expression in hypoxic mouse brain in our previous study.	Ethanol	19-26	erythropoietin	Mus musculus	82-96
22306016-5	2012	To decrease this potentially lethal effect, we generated and tested a modified form that contains a single arginine to glutamate mutation at the 76th position (EPO-R76E).	Arginine	107-115	erythropoietin	Mus musculus	160-163
21620551-9	2012	RESULTS: All histological parameters of asthma in the group treated with a high dose of EPO (Group III) were significantly ameliorated when compared with the group treated with saline (Group I).	Sodium Chloride	177-183	erythropoietin	Mus musculus	88-91
22126194-3	2012	METHODS: Erythropoietin was injected in the peritoneal space of ICR mice after ischemia/reperfusion injury and its effect was assessed by measuring blood urea nitrogen and creatinine, and by histological analysis.	Urea	154-158	erythropoietin	Mus musculus	9-23
22306016-5	2012	To decrease this potentially lethal effect, we generated and tested a modified form that contains a single arginine to glutamate mutation at the 76th position (EPO-R76E).	Glutamic Acid	119-128	erythropoietin	Mus musculus	160-163
22126194-3	2012	METHODS: Erythropoietin was injected in the peritoneal space of ICR mice after ischemia/reperfusion injury and its effect was assessed by measuring blood urea nitrogen and creatinine, and by histological analysis.	Nitrogen	159-167	erythropoietin	Mus musculus	9-23
22126194-3	2012	METHODS: Erythropoietin was injected in the peritoneal space of ICR mice after ischemia/reperfusion injury and its effect was assessed by measuring blood urea nitrogen and creatinine, and by histological analysis.	Creatinine	172-182	erythropoietin	Mus musculus	9-23
22442357-6	2012	Neopterin treatment induced a decrease in serum erythropoietin concentrations in young mice but not in aged mice.	Neopterin	0-9	erythropoietin	Mus musculus	48-62
21362129-10	2012	EPO-treated animals revealed an enhanced mobilization of BMCs into peripheral blood.	bmcs	57-61	erythropoietin	Mus musculus	0-3
22126194-6	2012	RESULTS: Erythropoietin administration significantly inhibited the increase in blood urea nitrogen and creatinine after ischemia/reperfusion injury compared with control mice.	Urea	85-89	erythropoietin	Mus musculus	9-23
22126194-6	2012	RESULTS: Erythropoietin administration significantly inhibited the increase in blood urea nitrogen and creatinine after ischemia/reperfusion injury compared with control mice.	Nitrogen	90-98	erythropoietin	Mus musculus	9-23
22126194-6	2012	RESULTS: Erythropoietin administration significantly inhibited the increase in blood urea nitrogen and creatinine after ischemia/reperfusion injury compared with control mice.	Creatinine	103-113	erythropoietin	Mus musculus	9-23
21924222-1	2012	Transient receptor potential (TRP) channels Trpc2 and Trpc3 are expressed on normal murine erythroid precursors, and erythropoietin stimulates an increase in intracellular calcium ([Ca(2+)](i)) through TRPC2 and TRPC3.	Calcium	172-179	erythropoietin	Mus musculus	117-131
21924222-9	2012	Although erythropoietin-induced calcium influx through TRPC2 or TRPC3 is not critical for erythroid production, these data demonstrate that TRPC2 plays an important role in oxidative stress-induced hemolysis, which may be related to reduced calcium entry in red cells in the presence of Trpc2 depletion.	Calcium	32-39	erythropoietin	Mus musculus	9-23
21924222-9	2012	Although erythropoietin-induced calcium influx through TRPC2 or TRPC3 is not critical for erythroid production, these data demonstrate that TRPC2 plays an important role in oxidative stress-induced hemolysis, which may be related to reduced calcium entry in red cells in the presence of Trpc2 depletion.	Calcium	241-248	erythropoietin	Mus musculus	9-23
21362129-15	2012	Our study shows that EPO treatment after MI enhances the migration capacity of BMCs into ischaemic tissue, which may attribute to an improved perfusion and reduced size of infarction, respectively.	bmcs	79-83	erythropoietin	Mus musculus	21-24
22383962-7	2012	HemaMax also increased plasma erythropoietin, IL-15, IL-18, and neopterin levels.	hemamax	0-7	erythropoietin	Mus musculus	30-44
22623993-2	2012	We describe the properties of MRLB-11055, a highly potent inhibitor of both the WT and V617F forms of JAK2, that has therapeutic efficacy in erythropoietin (EPO)-driven and JAK2V617F-driven mouse models of PV.	mrlb-11055	30-40	erythropoietin	Mus musculus	141-155
22623993-2	2012	We describe the properties of MRLB-11055, a highly potent inhibitor of both the WT and V617F forms of JAK2, that has therapeutic efficacy in erythropoietin (EPO)-driven and JAK2V617F-driven mouse models of PV.	mrlb-11055	30-40	erythropoietin	Mus musculus	157-160
22623993-4	2012	MRLB-11055 effectively prevented EPO-induced STAT5 activation in the peripheral blood of acutely dosed mice, and could prevent EPO-induced splenomegaly and erythrocytosis in chronically dosed mice.	mrlb-11055	0-10	erythropoietin	Mus musculus	33-36
22623993-4	2012	MRLB-11055 effectively prevented EPO-induced STAT5 activation in the peripheral blood of acutely dosed mice, and could prevent EPO-induced splenomegaly and erythrocytosis in chronically dosed mice.	mrlb-11055	0-10	erythropoietin	Mus musculus	127-130
22138754-6	2011	Our findings suggest that PDGF-BB-induced EPO promotes tumor growth through two mechanisms: first, paracrine stimulation of tumor angiogenesis by direct induction of endothelial cell proliferation, migration, sprouting and tube formation, and second, endocrine stimulation of extramedullary hematopoiesis leading to increased oxygen perfusion and protection against tumor-associated anemia.	Oxygen	326-332	erythropoietin	Mus musculus	42-45
22291977-8	2012	In contrast, cSN50-treated mice receiving ciprofloxacin demonstrated a restored innate immune responsiveness and reduced EPO level.	Ciprofloxacin	42-55	erythropoietin	Mus musculus	121-124
22080867-2	2011	Control of physiologic and pathologic erythropoiesis is dependent predominantly on erythropoietin (EPO), the expression of which is regulated by hypoxia-inducible factor (HIF) activity in response to low oxygen tension.	Oxygen	204-210	erythropoietin	Mus musculus	83-97
22080867-2	2011	Control of physiologic and pathologic erythropoiesis is dependent predominantly on erythropoietin (EPO), the expression of which is regulated by hypoxia-inducible factor (HIF) activity in response to low oxygen tension.	Oxygen	204-210	erythropoietin	Mus musculus	99-102
21816364-4	2011	EPO binds to CPCs and seems to be responsible for maintaining an active CCL2/CCR2 system.	cpcs	13-17	erythropoietin	Mus musculus	0-3
21771175-0	2011	Erythropoietin attenuates isoflurane-induced neurodegeneration and learning deficits in the developing mouse brain.	Isoflurane	26-36	erythropoietin	Mus musculus	0-14
21771175-1	2011	OBJECTIVES: To examine whether recombinant erythropoietin (rEPO) attenuates neurodegeneration and the learning disability induced by isoflurane with the postnatal day 7 (P7) mice.	Isoflurane	133-143	erythropoietin	Mus musculus	43-57
21847101-0	2011	Erythropoietin gene-enhanced marrow mesenchymal stromal cells decrease cisplatin-induced kidney injury and improve survival of allogeneic mice.	Cisplatin	71-80	erythropoietin	Mus musculus	0-14
21847101-6	2011	Also, Epo-MSCs led to significantly better kidney function as shown by lower levels of blood urea nitrogen (72 +- 9.5 mg/dl versus 131 +- 9.20 mg/dl) and creatinine (74 +- 17 micromol/l versus 148+-19.4 micromol/l).	Urea	93-97	erythropoietin	Mus musculus	6-9
21847101-6	2011	Also, Epo-MSCs led to significantly better kidney function as shown by lower levels of blood urea nitrogen (72 +- 9.5 mg/dl versus 131 +- 9.20 mg/dl) and creatinine (74 +- 17 micromol/l versus 148+-19.4 micromol/l).	Nitrogen	98-106	erythropoietin	Mus musculus	6-9
21847101-6	2011	Also, Epo-MSCs led to significantly better kidney function as shown by lower levels of blood urea nitrogen (72 +- 9.5 mg/dl versus 131 +- 9.20 mg/dl) and creatinine (74 +- 17 micromol/l versus 148+-19.4 micromol/l).	Creatinine	154-164	erythropoietin	Mus musculus	6-9
21911936-6	2011	We further demonstrated that attenuated erythropoietin production in transdifferentiated myofibroblasts was restored by the administration of neuroprotective agents, such as dexamethasone and neurotrophins.	Dexamethasone	174-187	erythropoietin	Mus musculus	40-54
21911936-7	2011	Moreover, the in vivo administration of tamoxifen, a selective estrogen receptor modulator, restored attenuated erythropoietin production as well as fibrosis in a mouse model of kidney fibrosis.	Tamoxifen	40-49	erythropoietin	Mus musculus	112-126
21803333-8	2011	In EPO-perfused slices significant bigger responses were obtained (1Hz, 101.12+-5.69%, 10Hz, 123.24+-2.68, and 100Hz, 216.41+-20.1) when compared to the control slices.	1HZ	67-70	erythropoietin	Mus musculus	3-6
21803333-9	2011	These results suggest that erythropoietin decreases the excitatory neurotransmitter release probability and may in this way protect the synapses from toxic levels of glutamate.	Glutamic Acid	166-175	erythropoietin	Mus musculus	27-41
21755458-4	2011	The results showed that the protein level of HIF-1a and the expression of its targets inducible nitric oxide synthase (iNOS), erythropoietin, and heme oxygenase-1 were obviously increased after administration of DMOG.	oxalylglycine	212-216	erythropoietin	Mus musculus	126-140
21816364-5	2011	Supplementation with the EPO derivative CERA in a hematocrit-inactive low dose was sufficient to upregulate CCL2, restore endothelial differentiation of CPCs, and preserve the cardiac microvasculature and cardiac function in both mouse models.	cpcs	153-157	erythropoietin	Mus musculus	25-28
21516061-0	2011	Erythropoietin increases survival and attenuates fulminant hepatic failure injury induced by D-galactosamine/lipopolysaccharide in mice.	Galactosamine	93-108	erythropoietin	Mus musculus	0-14
21421837-7	2011	Inhibition of the osteoclast activity with bisphosphonate therapy blocked the Epo-induced bone loss.	Diphosphonates	43-57	erythropoietin	Mus musculus	78-81
21565202-6	2011	KEY FINDINGS: Survival rate and the expression of HIF-1 alpha and erythropoietin were significantly increased while apoptosis, renal tubule score, blood plasma creatinine and urea were decreased by isoflurane preconditioning.	Isoflurane	198-208	erythropoietin	Mus musculus	66-80
21498508-2	2011	Erythropoietin, a kidney-derived hormone, and iron are critical for the production of oxygen-carrying mature RBCs.	Oxygen	86-92	erythropoietin	Mus musculus	0-14
21421837-8	2011	Intriguingly, bisphosphonate treatment also reduced the magnitude of the erythroid response to Epo.	Diphosphonates	14-28	erythropoietin	Mus musculus	95-98
21255641-0	2011	Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.	Tyrosine	73-81	erythropoietin	Mus musculus	46-60
21347618-3	2011	Epo stimulation of coronary artery endothelial cells upregulated endothelial nitric oxide synthase (eNOS) activity in vitro and in vivo, and enhanced nitric oxide (NO) production that was determined directly by real-time measurements of gaseous NO release.	Nitric Oxide	77-89	erythropoietin	Mus musculus	0-3
21383158-0	2011	Nitric oxide prevents axonal degeneration by inducing HIF-1-dependent expression of erythropoietin.	Nitric Oxide	0-12	erythropoietin	Mus musculus	84-98
21880207-1	2011	The main object of this study is to examine the effect of Klamin , a nutraceutical containing phenylethylamine, phycocyanins, mycosporine-like aminoacids and aphanizomenon flos aquae-phytochrome on the learning and memory ability, the oxidative status and cerebral erythropoietin and its receptor EPO/EPOR system in prematurely senescent (PS) mice.	klamin	58-64	erythropoietin	Mus musculus	265-279
21880207-1	2011	The main object of this study is to examine the effect of Klamin , a nutraceutical containing phenylethylamine, phycocyanins, mycosporine-like aminoacids and aphanizomenon flos aquae-phytochrome on the learning and memory ability, the oxidative status and cerebral erythropoietin and its receptor EPO/EPOR system in prematurely senescent (PS) mice.	klamin	58-64	erythropoietin	Mus musculus	297-300
20969477-5	2011	A significant increase in the expression of erythropoietin, a downstream target of HIF1alpha, and expansion of stress erythroid progenitors (burst forming units-erythroid) were seen in the Se-deficient mice.	Selenium	189-191	erythropoietin	Mus musculus	44-58
21383158-6	2011	Transduction of Schwann cells with adenovirus AdCA5 encoding a constitutively active form of HIF-1alpha results in amelioration of acrylamide-induced axonal degeneration in an EPO-dependent manner.	Acrylamide	131-141	erythropoietin	Mus musculus	176-179
20669261-6	2011	Moreover, BJBDT increased the level of EPO at mRNA in kidney and plasma, and the numbers of erythroid-specific antigen Ter-119(+) erythroid cells in mice with aplastic anemia induced by 20% benzene.	bjbdt	10-15	erythropoietin	Mus musculus	39-42
21095239-7	2011	Furthermore, Epo-activated JNK1 phosphorylated Bad at threonine 201, thereby inhibiting the association of Bad with the anti-apoptotic molecule B-cell lymphoma-extra large (Bcl-X(L)).	Threonine	54-63	erythropoietin	Mus musculus	13-16
21146580-0	2011	Captopril modulates hypoxia-inducible factors and erythropoietin responses in a murine model of total body irradiation.	Captopril	0-9	erythropoietin	Mus musculus	50-64
21146580-3	2011	Here we investigate captopril and radiation regulation of erythropoietin (EPO) and thrombopoietin (TPO), key effectors of erythroid progenitor proliferation and differentiation.	Captopril	20-29	erythropoietin	Mus musculus	58-72
21146580-3	2011	Here we investigate captopril and radiation regulation of erythropoietin (EPO) and thrombopoietin (TPO), key effectors of erythroid progenitor proliferation and differentiation.	Captopril	20-29	erythropoietin	Mus musculus	74-77
21146580-9	2011	EPO plasma levels and gene expression were reduced below detectable limits after 2 days of captopril treatment, but recovered within 7 days.	Captopril	91-100	erythropoietin	Mus musculus	0-3
21146580-12	2011	Captopril treatment postirradiation suppressed radiation-induced HIF activation and EPO expression.	Captopril	0-9	erythropoietin	Mus musculus	84-87
21146580-13	2011	In contrast, captopril administration for 7 days before TBI resulted in earlier EPO induction and activation.	Captopril	13-22	erythropoietin	Mus musculus	80-83
21146580-15	2011	CONCLUSIONS: In nonirradiated mice, captopril biphasically regulates EPO via HIF activation.	Captopril	36-45	erythropoietin	Mus musculus	69-72
21146580-16	2011	TBI ablates erythroid progenitors, resulting in hypoxia, HIF activation, and increased EPO expression that are modulated by captopril treatment.	Captopril	124-133	erythropoietin	Mus musculus	87-90
20924361-3	2011	Primary DRG neurons in culture infected with vHrtEPO express and release EPO in response to exposure to doxycycline (DOX).	Doxycycline	104-115	erythropoietin	Mus musculus	49-52
21094617-7	2011	Butyrate initially delays EPO-mediated suppression of p38 phosphorylation, but p38 phosphorylation thereafter, at 30 minutes to 48 hours, is equivalent and at low levels in EPO-treated FL EryD, with or without butyrate.	Butyrates	0-8	erythropoietin	Mus musculus	26-29
21462262-4	2011	Mice were treated with erythropoietin starting before (early erythropoietin) and after (late erythropoietin) intoxication with 3-nitropropionic acid.	3-nitropropionic acid	127-148	erythropoietin	Mus musculus	23-37
21462262-8	2011	Animals receiving erythropoietin before and after 3-nitropropionic acid intoxication scored significantly lower on the motor behavior scale and they performed better in the pole test than controls with no significant difference between early and late erythropoietin administration.	3-nitropropionic acid	50-71	erythropoietin	Mus musculus	18-32
21462262-10	2011	Immunohistochemistry revealed significant attenuation of 3-nitropropionic acid-induced loss of tyrosine hydroxylase and DARPP-32 positive neurons in substantia nigra pars compacta and striatum, respectively, in both erythropoietin-treated groups without significant group difference in the substantia nigra.	3-nitropropionic acid	57-78	erythropoietin	Mus musculus	216-230
21462262-12	2011	In the combined (proteolipid protein)-alpha-synuclein 3-nitropropionic acid multiple system atrophy mouse model, erythropoietin appears to rescue dopaminergic and striatal gabaergic projection neurons.	3-nitropropionic acid	54-75	erythropoietin	Mus musculus	113-127
20924361-3	2011	Primary DRG neurons in culture infected with vHrtEPO express and release EPO in response to exposure to doxycycline (DOX).	Doxycycline	117-120	erythropoietin	Mus musculus	49-52
20924361-4	2011	Animals infected with vHrtEPO by footpad inoculation demonstrated regulated expression of EPO in DRG under the control of DOX administered by gavage.	Doxycycline	122-125	erythropoietin	Mus musculus	26-29
21887333-2	2011	In this process, iron acts as a critical cofactor, with iron deficiency blunting EPO-responsiveness of erythroid progenitors.	Iron	17-21	erythropoietin	Mus musculus	81-84
21138976-7	2011	Chromatin immunoprecipitation studies support Epo as a direct target of RA signaling in embryonic liver.	Tretinoin	72-74	erythropoietin	Mus musculus	46-49
21138976-11	2011	We propose a new model for the mechanism of RA-mediated myocardial expansion in which RA directly induces hepatic Epo resulting in activation of epicardial Igf2 that stimulates compact zone growth.	Tretinoin	44-46	erythropoietin	Mus musculus	114-117
21138976-11	2011	We propose a new model for the mechanism of RA-mediated myocardial expansion in which RA directly induces hepatic Epo resulting in activation of epicardial Igf2 that stimulates compact zone growth.	Tretinoin	86-88	erythropoietin	Mus musculus	114-117
22087308-4	2011	Etoposide or doxorubicin dose-dependently decreased the expression level of Jak2 in UT7 or 32D cells expressing EpoR in the absence of Epo and that of exogenously expressed Jak2-V617F in UT7 cells when cotreated with the Jak2 inhibitor JakI-1 or AG490.	Etoposide	0-9	erythropoietin	Mus musculus	112-115
22087308-4	2011	Etoposide or doxorubicin dose-dependently decreased the expression level of Jak2 in UT7 or 32D cells expressing EpoR in the absence of Epo and that of exogenously expressed Jak2-V617F in UT7 cells when cotreated with the Jak2 inhibitor JakI-1 or AG490.	Doxorubicin	13-24	erythropoietin	Mus musculus	112-115
20844235-2	2010	The aim of this work was to compare spleen stress erythropoiesis and bone marrow erythropoiesis in a mouse model of zymosan-induced generalized inflammation, which induces long-lasting anemia and to evaluate the ability of erythropoietin (Epo) injections to correct anemia in this setting.	Zymosan	116-123	erythropoietin	Mus musculus	239-242
20844235-5	2010	On the contrary, a robust erythropoietic response takes place in the spleen after Epo injections in both control and zymosan-induced generalized inflammation mice.	Zymosan	117-124	erythropoietin	Mus musculus	82-85
21138976-0	2011	Retinoic acid stimulates myocardial expansion by induction of hepatic erythropoietin which activates epicardial Igf2.	Tretinoin	0-13	erythropoietin	Mus musculus	70-84
22216265-7	2011	Hypoxia-induced EPO mRNA expression in the brain was significantly suppressed by isoflurane in a concentration-dependent manner.	Isoflurane	81-91	erythropoietin	Mus musculus	16-19
22216265-10	2011	In the experiments using primary cultured astrocytes, isoflurane, pentobarbital, and ketamine suppressed hypoxia-inducible expression of HIF-2alpha protein and EPO mRNA.	Isoflurane	54-64	erythropoietin	Mus musculus	160-163
22216265-10	2011	In the experiments using primary cultured astrocytes, isoflurane, pentobarbital, and ketamine suppressed hypoxia-inducible expression of HIF-2alpha protein and EPO mRNA.	Pentobarbital	66-79	erythropoietin	Mus musculus	160-163
22216265-10	2011	In the experiments using primary cultured astrocytes, isoflurane, pentobarbital, and ketamine suppressed hypoxia-inducible expression of HIF-2alpha protein and EPO mRNA.	Ketamine	85-93	erythropoietin	Mus musculus	160-163
21811636-7	2011	Indeed, primary cardiomyocytes and HL-1 cardiac cells both induce Epo gene expression when exposed to low O(2) tension in a HIF-dependent manner.	Oxygen	106-110	erythropoietin	Mus musculus	66-69
21811636-8	2011	Thus, as well as demonstrating the potential of dietary tamoxifen administration for gene inactivation studies in UBC-Cre-ER(T2) mouse lines, this data provides evidence of a cardiac oxygen-sensing VHL/HIF/EPO pathway in adult mice.	Tamoxifen	56-65	erythropoietin	Mus musculus	206-209
21811636-8	2011	Thus, as well as demonstrating the potential of dietary tamoxifen administration for gene inactivation studies in UBC-Cre-ER(T2) mouse lines, this data provides evidence of a cardiac oxygen-sensing VHL/HIF/EPO pathway in adult mice.	Oxygen	183-189	erythropoietin	Mus musculus	206-209
21760888-8	2011	Mutant mice had a higher hematocrit, lower serum Epo, and an increased number of splenic erythroid progenitors, suggesting that Fas negatively regulates erythropoiesis at the level of the whole animal.	ammonium ferrous sulfate	128-131	erythropoietin	Mus musculus	49-52
21887333-12	2011	We propose a model in which aconitase functions as a licensing factor in ERK-dependent proliferation and differentiation, thereby providing a regulatory input for iron in EPO-dependent erythropoiesis.	Iron	163-167	erythropoietin	Mus musculus	171-174
20628150-5	2010	Furthermore, we provide evidence that hepatocyte-derived Hif-2 is involved in the regulation of iron metabolism genes, supporting a role for HIF-2 in the coordination of EPO synthesis with iron homeostasis.	Iron	96-100	erythropoietin	Mus musculus	170-173
20655957-0	2010	Erythropoietin as a possible mechanism for the effects of intermittent hypoxia on bodyweight, serum glucose and leptin in mice.	Glucose	100-107	erythropoietin	Mus musculus	0-14
20861276-1	2010	Apart from enhancing the production of red blood cells, erythropoietin (Epo) alters the ventilatory response when oxygen supply is reduced.	Oxygen	114-120	erythropoietin	Mus musculus	56-70
20861276-1	2010	Apart from enhancing the production of red blood cells, erythropoietin (Epo) alters the ventilatory response when oxygen supply is reduced.	Oxygen	114-120	erythropoietin	Mus musculus	72-75
20577577-7	2010	In vitro experiments showed that this EPO fusion protein retained all its protective properties against neuronal death elicited by oxygen-glucose deprivation and NMDA insults.	oxygen-glucose	131-145	erythropoietin	Mus musculus	38-41
20670846-9	2010	Both EPO groups had significantly more capillaries and arterioles at the BZ.	3-quinuclidinyl 4-fluoromethylbenzilate	73-75	erythropoietin	Mus musculus	5-8
20657614-11	2010	CONCLUSION: Erythropoietin can significantly ameliorate the cisplatin-induced visceral hyperplasia and DRG nuclear membrane structure damage in mice, indicating a neuroprotective role of erythropoietin.	Cisplatin	60-69	erythropoietin	Mus musculus	12-26
20657614-11	2010	CONCLUSION: Erythropoietin can significantly ameliorate the cisplatin-induced visceral hyperplasia and DRG nuclear membrane structure damage in mice, indicating a neuroprotective role of erythropoietin.	Cisplatin	60-69	erythropoietin	Mus musculus	187-201
20499015-8	2010	AP20187 administration significantly reduced hematocrit and plasma Epo levels in 30% of the animals belonging to group 2.	AP20187	0-7	erythropoietin	Mus musculus	67-70
20499015-10	2010	Doxycycline administration was efficient in controlling Epo secretion in both groups.	Doxycycline	0-11	erythropoietin	Mus musculus	56-59
20219824-0	2010	Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells.	Oxygen	10-16	erythropoietin	Mus musculus	59-73
20219824-1	2010	The kidney is a major site of systemic oxygen sensing, regulating blood erythrocyte and hence oxygen content by hypoxia-inducible erythropoietin (Epo) expression.	Oxygen	39-45	erythropoietin	Mus musculus	130-144
20219824-1	2010	The kidney is a major site of systemic oxygen sensing, regulating blood erythrocyte and hence oxygen content by hypoxia-inducible erythropoietin (Epo) expression.	Oxygen	39-45	erythropoietin	Mus musculus	146-149
20219824-2	2010	A constant ratio between blood perfusion and oxygen consumption, a stable corticomedullary oxygen gradient, and a relatively low tissue Po(2) are the prerequisites for the function of renal Epo-producing and oxygen-sensing (REPOS) cells, which are located in the juxtamedullary cortex.	Oxygen	45-51	erythropoietin	Mus musculus	190-193
20219824-2	2010	A constant ratio between blood perfusion and oxygen consumption, a stable corticomedullary oxygen gradient, and a relatively low tissue Po(2) are the prerequisites for the function of renal Epo-producing and oxygen-sensing (REPOS) cells, which are located in the juxtamedullary cortex.	Oxygen	91-97	erythropoietin	Mus musculus	190-193
20219824-2	2010	A constant ratio between blood perfusion and oxygen consumption, a stable corticomedullary oxygen gradient, and a relatively low tissue Po(2) are the prerequisites for the function of renal Epo-producing and oxygen-sensing (REPOS) cells, which are located in the juxtamedullary cortex.	Oxygen	91-97	erythropoietin	Mus musculus	190-193
20219824-4	2010	The molecular principles of cellular oxygen sensing have been elucidated in the last few years, and genetically altered mouse models as well as hereditary diseases causing erythrocytosis have clarified the oxygen-signaling cascade leading to increased Epo expression in REPOS cells.	Oxygen	206-212	erythropoietin	Mus musculus	252-255
20554434-7	2010	Agarose beads containing EPO were implanted into dorsal skin of C57BL/6 mice to examine effects of EPO on hair growth in vivo.	Sepharose	0-7	erythropoietin	Mus musculus	25-28
20353770-7	2010	This study suggests that EPO receptor recovery is necessary for the subsequent bone marrow ability to accomplish the erythroid program through the modulation of apoptotic and survival events after a single paclitaxel insult.	Paclitaxel	206-216	erythropoietin	Mus musculus	25-28
20395592-8	2010	CONCLUSIONS: These findings support a new physiological and protective role for EPO, acting through its cell surface receptor and eNOS-Akt1 signal transduction, in matching cardiac mitochondrial mass to the convective O(2) transport capacity as erythrocyte mass expands.	o(2)	218-222	erythropoietin	Mus musculus	80-83
20577577-7	2010	In vitro experiments showed that this EPO fusion protein retained all its protective properties against neuronal death elicited by oxygen-glucose deprivation and NMDA insults.	N-Methylaspartate	162-166	erythropoietin	Mus musculus	38-41
20061512-0	2010	Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models.	Glucose	48-55	erythropoietin	Mus musculus	0-14
20385932-5	2010	Furthermore, erythropoietin markedly attenuated lipid accumulation in oxidized low-density lipoprotein-treated macrophages, a result that was due to an increase in cholesterol efflux.	Cholesterol	164-175	erythropoietin	Mus musculus	13-27
20219396-8	2010	Pretreatment of C57BL/6 mice with iron (5mg/mouse) almost completely inhibited the EPO-induced decrease of Hamp mRNA.	Iron	34-38	erythropoietin	Mus musculus	83-86
20061512-6	2010	The data presented herein demonstrate EPO-mediated decrease in blood glucose levels in all mice models tested.	Glucose	69-76	erythropoietin	Mus musculus	38-41
20414335-1	2010	Erythropoietin (Epo) and vascular growth factor (VEGF) are known to be involved in the regulation of cellular activity when oxygen transport is reduced as in anaemia or hypoxic conditions.	Oxygen	124-130	erythropoietin	Mus musculus	16-19
20194292-3	2010	In the present study, we hypothesized that EPO stimulates expression and activity of copper- and zinc-containing superoxide dismutase (SOD1), thus protecting vascular tissue from oxidative stress induced by excessive concentrations of superoxide anions.	Copper	85-91	erythropoietin	Mus musculus	43-46
20194292-3	2010	In the present study, we hypothesized that EPO stimulates expression and activity of copper- and zinc-containing superoxide dismutase (SOD1), thus protecting vascular tissue from oxidative stress induced by excessive concentrations of superoxide anions.	Superoxides	235-252	erythropoietin	Mus musculus	43-46
20194292-6	2010	The ability of EPO to reduce vascular production of superoxide anions was abolished in SOD1-deficient mice.	Superoxides	52-69	erythropoietin	Mus musculus	15-18
19900484-3	2010	HIFs are transcription factors involved in the cellular response to low oxygen, including upregulation of transcripts like vascular endothelial growth factor (VEGF) and EPO.	Oxygen	72-78	erythropoietin	Mus musculus	169-172
19819285-7	2010	Adding EPO in human lymphocyte cultures in vitro and in P388 leukemia bearing mice in vivo in the presence of CPT-11 decreased SCEs levels and increased PRIs and MIs were observed compared with cells treated either in vitro or in vivo with CPT-11 alone, which shows that EPO protected cells from the toxic action of CPT-11.	Irinotecan	110-116	erythropoietin	Mus musculus	271-274
20102705-4	2010	In this study we hypothesized that Epo may confer neuroprotection by enhancing cellular redox defense brought about by cellular glutathione (GSH).	Glutathione	128-139	erythropoietin	Mus musculus	35-38
20102705-4	2010	In this study we hypothesized that Epo may confer neuroprotection by enhancing cellular redox defense brought about by cellular glutathione (GSH).	Glutathione	141-144	erythropoietin	Mus musculus	35-38
20102705-6	2010	Our data shows that Epo causes a time- and dose-dependent increase in expression and activity of system Xc(-), the transporter responsible for uptake of cystine for the production of glutathione.	Cystine	153-160	erythropoietin	Mus musculus	20-23
20102705-6	2010	Our data shows that Epo causes a time- and dose-dependent increase in expression and activity of system Xc(-), the transporter responsible for uptake of cystine for the production of glutathione.	Glutathione	183-194	erythropoietin	Mus musculus	20-23
20102705-7	2010	Cystine uptake increases 3-5 fold in differentiated neural stem cells and B104 cells treated with Epo.	Cystine	0-7	erythropoietin	Mus musculus	98-101
20102705-8	2010	Exposure of cells to 100 microM kainate suppressed cellular GSH and caused excitotoxicity, but GSH levels and cell viability were completely restored by Epo in the continued presence of kainate.	Glutathione	95-98	erythropoietin	Mus musculus	153-156
20102705-8	2010	Exposure of cells to 100 microM kainate suppressed cellular GSH and caused excitotoxicity, but GSH levels and cell viability were completely restored by Epo in the continued presence of kainate.	Kainic Acid	186-193	erythropoietin	Mus musculus	153-156
19966291-1	2010	Erythropoietin (Epo) treatment increases hematocrit (Htc) and, consequently, arterial O(2) content.	o(2)	86-90	erythropoietin	Mus musculus	0-14
19966291-1	2010	Erythropoietin (Epo) treatment increases hematocrit (Htc) and, consequently, arterial O(2) content.	o(2)	86-90	erythropoietin	Mus musculus	16-19
19537929-0	2010	Increased expression of erythropoietin receptor in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinsonian model.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	51-98	erythropoietin	Mus musculus	24-38
19602048-5	2009	Moreover, LY294002 that is a specific inhibitor of phosphatidylinositol 3-kinase (PI3K) significantly reduced the enhanced expression of HIF-1alpha, EPO and 136p-Bad induced by GB and IP.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	10-18	erythropoietin	Mus musculus	149-152
19901910-9	2010	In contrast, coadministration of L-Name abolished EPO-mediated tissue protection by abrogating the dilatory effect resulting in reduced FCD and tissue survival, without counteracting angiogenesis and apoptotic cell death, whereas additional administration of bevacizumab did not influence the beneficial effect of EPO on flap survival despite abrogating angiogenesis.	NG-Nitroarginine Methyl Ester	33-39	erythropoietin	Mus musculus	50-53
19901910-9	2010	In contrast, coadministration of L-Name abolished EPO-mediated tissue protection by abrogating the dilatory effect resulting in reduced FCD and tissue survival, without counteracting angiogenesis and apoptotic cell death, whereas additional administration of bevacizumab did not influence the beneficial effect of EPO on flap survival despite abrogating angiogenesis.	NG-Nitroarginine Methyl Ester	33-39	erythropoietin	Mus musculus	314-317
19602048-4	2009	GB and IP significantly increased cell viability, expression of hypoxia-inducible factor-1 alpha (HIF-1alpha), erythropoietin (EPO), phosphorylated Bad at serine 136 (136p-Bad) and phosphorylated glycogen synthase kinase- 3beta at serine 9 (p-GSK-3beta), and decreased the percentage of apoptotic cells and the level of active caspase-3 in severely ischaemic neurons.	ginkgolide B	0-2	erythropoietin	Mus musculus	111-125
19602048-5	2009	Moreover, LY294002 that is a specific inhibitor of phosphatidylinositol 3-kinase (PI3K) significantly reduced the enhanced expression of HIF-1alpha, EPO and 136p-Bad induced by GB and IP.	ginkgolide B	177-179	erythropoietin	Mus musculus	149-152
19602048-4	2009	GB and IP significantly increased cell viability, expression of hypoxia-inducible factor-1 alpha (HIF-1alpha), erythropoietin (EPO), phosphorylated Bad at serine 136 (136p-Bad) and phosphorylated glycogen synthase kinase- 3beta at serine 9 (p-GSK-3beta), and decreased the percentage of apoptotic cells and the level of active caspase-3 in severely ischaemic neurons.	ginkgolide B	0-2	erythropoietin	Mus musculus	127-130
19575748-5	2009	Our recent studies showed that 2-OX reduces HIF-1alpha, erythropoietin, and vascular endothelial growth factor (VEGF) expression in the hepatoma cell line Hep3B when under hypoxic conditions in vitro.	Ketoglutaric Acids	31-35	erythropoietin	Mus musculus	56-70
19887744-0	2009	Amelioration of anemia in the ICGN mouse, a renal anemia model, with a subcutaneous bolus injection of erythropoietin adsorbed to hydroxyapatite matrix.	Durapatite	130-144	erythropoietin	Mus musculus	103-117
19845617-1	2009	Using mice, we demonstrated that when oxygen supply is lowered, erythropoietin (Epo), the main regulator of red blood cell production, modulates the ventilatory response by interacting with central (brainstem) and peripheral (carotid bodies) respiratory centers.	Oxygen	38-44	erythropoietin	Mus musculus	64-78
19845617-1	2009	Using mice, we demonstrated that when oxygen supply is lowered, erythropoietin (Epo), the main regulator of red blood cell production, modulates the ventilatory response by interacting with central (brainstem) and peripheral (carotid bodies) respiratory centers.	Oxygen	38-44	erythropoietin	Mus musculus	80-83
19679834-9	2009	In cultured EPCs from WT but not Nox2(y/-) mice, EPO induced ROS production, migration, and proliferation.	Reactive Oxygen Species	61-64	erythropoietin	Mus musculus	49-52
21155236-5	2009	Besides ginkgolide B and hypoxic preconditioning could both up-regulate the expression of RTP801mRNA and EPO.	ginkgolide B	8-20	erythropoietin	Mus musculus	105-108
19515903-2	2009	It was suggested that some of Epo cytoprotective properties are due to its regulation of nitric oxide (NO) production.	Nitric Oxide	89-101	erythropoietin	Mus musculus	30-33
19602296-0	2009	Erythropoietin overrides the triggering effect of DNA platination products in a mouse model of cisplatin-induced neuropathy.	Cisplatin	95-104	erythropoietin	Mus musculus	0-14
19602296-3	2009	We investigated in a mouse model by which mechanism recombinant erythropoietin (rhEPO) protects the peripheral nervous system from structural and functional damage caused by cisplatin treatment with special emphasis on DNA damage burden.	Cisplatin	174-183	erythropoietin	Mus musculus	64-78
19602296-4	2009	RESULTS: A cumulative dose of 16 mg cisplatin/kg resulted in clear electrophysiological signs of neuropathy, which were significantly attenuated by concomitant erythropoietin (cisplatin 32,48 m/s +/- 1,68 m/s; cisplatin + rhEPO 49,66 m/s +/- 1,26 m/s; control 55,01 m/s +/- 1,88 m/s; p &lt; 0,001).	Cisplatin	36-45	erythropoietin	Mus musculus	160-174
19602296-4	2009	RESULTS: A cumulative dose of 16 mg cisplatin/kg resulted in clear electrophysiological signs of neuropathy, which were significantly attenuated by concomitant erythropoietin (cisplatin 32,48 m/s +/- 1,68 m/s; cisplatin + rhEPO 49,66 m/s +/- 1,26 m/s; control 55,01 m/s +/- 1,88 m/s; p &lt; 0,001).	Cisplatin	176-185	erythropoietin	Mus musculus	160-174
19602296-4	2009	RESULTS: A cumulative dose of 16 mg cisplatin/kg resulted in clear electrophysiological signs of neuropathy, which were significantly attenuated by concomitant erythropoietin (cisplatin 32,48 m/s +/- 1,68 m/s; cisplatin + rhEPO 49,66 m/s +/- 1,26 m/s; control 55,01 m/s +/- 1,88 m/s; p &lt; 0,001).	Cisplatin	176-185	erythropoietin	Mus musculus	160-174
19413997-12	2009	Surprisingly, Epo rapidly (&lt;1h) induces mobilization of activated erythroid precursors into the blood, thus allowing drug-response relationships to guide discovery.	Hydrogen	31-33	erythropoietin	Mus musculus	14-17
19327822-2	2009	In the present paper, alginate-poly-l-lysine-alginate (APA) microcapsules containing erythropoietin (Epo)-secreting C(2)C(12) myoblasts were elaborated, characterized and tested both in vitro and in vivo.	Alginates	22-30	erythropoietin	Mus musculus	85-99
19327822-2	2009	In the present paper, alginate-poly-l-lysine-alginate (APA) microcapsules containing erythropoietin (Epo)-secreting C(2)C(12) myoblasts were elaborated, characterized and tested both in vitro and in vivo.	Alginates	22-30	erythropoietin	Mus musculus	101-104
19327822-2	2009	In the present paper, alginate-poly-l-lysine-alginate (APA) microcapsules containing erythropoietin (Epo)-secreting C(2)C(12) myoblasts were elaborated, characterized and tested both in vitro and in vivo.	alginate-polylysine-alginate	31-53	erythropoietin	Mus musculus	85-99
19327822-2	2009	In the present paper, alginate-poly-l-lysine-alginate (APA) microcapsules containing erythropoietin (Epo)-secreting C(2)C(12) myoblasts were elaborated, characterized and tested both in vitro and in vivo.	apa	55-58	erythropoietin	Mus musculus	85-99
19327822-2	2009	In the present paper, alginate-poly-l-lysine-alginate (APA) microcapsules containing erythropoietin (Epo)-secreting C(2)C(12) myoblasts were elaborated, characterized and tested both in vitro and in vivo.	apa	55-58	erythropoietin	Mus musculus	101-104
19521513-8	2009	In addition, muscular fat oxidation was increased 1.8-fold in both the EPO transfected and contralateral muscles.In conclusion, we have shown that EPO when expressed in supra-physiological levels has substantial metabolic effects including protection against diet-induced obesity and normalisation of glucose sensitivity associated with a shift to increased fat metabolism in the muscles.	Glucose	301-308	erythropoietin	Mus musculus	147-150
19284235-3	2009	The authors have previously shown that EPO and IGF-I, when administered together, provide acute and prolonged neuroprotection in cerebrocortical cultures against N-methyl-D-aspartate-induced apoptosis.	N-Methylaspartate	162-182	erythropoietin	Mus musculus	39-42
19307451-5	2009	Cotreatment with the phosphatidylinositol 3 (PI3)-kinase inhibitor, LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride], or treatment of cardiomyocytes infected with a dominant negative adenovirus targeted to Akt1 (ADV-dnAkt1) blocked the effects of EPO on nNOS expression, suggesting that EPO regulates nNOS expression via PI3-kinase and Akt.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	68-76	erythropoietin	Mus musculus	273-276
19307451-5	2009	Cotreatment with the phosphatidylinositol 3 (PI3)-kinase inhibitor, LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride], or treatment of cardiomyocytes infected with a dominant negative adenovirus targeted to Akt1 (ADV-dnAkt1) blocked the effects of EPO on nNOS expression, suggesting that EPO regulates nNOS expression via PI3-kinase and Akt.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	68-76	erythropoietin	Mus musculus	313-316
19307451-5	2009	Cotreatment with the phosphatidylinositol 3 (PI3)-kinase inhibitor, LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride], or treatment of cardiomyocytes infected with a dominant negative adenovirus targeted to Akt1 (ADV-dnAkt1) blocked the effects of EPO on nNOS expression, suggesting that EPO regulates nNOS expression via PI3-kinase and Akt.	2-(4-morpholinyl	78-94	erythropoietin	Mus musculus	273-276
19307451-5	2009	Cotreatment with the phosphatidylinositol 3 (PI3)-kinase inhibitor, LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride], or treatment of cardiomyocytes infected with a dominant negative adenovirus targeted to Akt1 (ADV-dnAkt1) blocked the effects of EPO on nNOS expression, suggesting that EPO regulates nNOS expression via PI3-kinase and Akt.	2-(4-morpholinyl	78-94	erythropoietin	Mus musculus	313-316
19578280-0	2009	Sustained efficacy of erythropoietin with a hydroxyapatite carrier administered in mice.	Durapatite	44-58	erythropoietin	Mus musculus	22-36
19578280-2	2009	In the present study, we examined the efficiency of hydroxyapatite (HAp) as a drug delivery carrier for the sustained release of erythropoietin (EPO) to reduce the frequency of administration.	Durapatite	52-66	erythropoietin	Mus musculus	129-143
19578280-2	2009	In the present study, we examined the efficiency of hydroxyapatite (HAp) as a drug delivery carrier for the sustained release of erythropoietin (EPO) to reduce the frequency of administration.	Durapatite	52-66	erythropoietin	Mus musculus	145-148
19578280-3	2009	Spray-dried HAp microparticles, formed from zinc-containing HAp (Zn-HAp) and Zn-HAp calcined at 400 degrees C, were used as carriers of EPO, and five Zn-HAp formulation samples incorporating EPO were prepared; no formulation, poly-L-lactic acid (PLA) formulation, zinc (Zn) formulation, Zn/PLA formulation, and calcined/Zn/PLA formulation.	Durapatite	12-15	erythropoietin	Mus musculus	136-139
19307451-9	2009	Furthermore, EPO treatment after ischemia significantly reduced the threshold dose of cesium chloride (CsCl) to induce VT. We conclude that EPO via nNOS protects the heart from spontaneous and CsCl-induced ventricular arrhythmia during myocardial I/R.	cesium chloride	86-101	erythropoietin	Mus musculus	13-16
19307451-9	2009	Furthermore, EPO treatment after ischemia significantly reduced the threshold dose of cesium chloride (CsCl) to induce VT. We conclude that EPO via nNOS protects the heart from spontaneous and CsCl-induced ventricular arrhythmia during myocardial I/R.	cesium chloride	86-101	erythropoietin	Mus musculus	140-143
19307451-9	2009	Furthermore, EPO treatment after ischemia significantly reduced the threshold dose of cesium chloride (CsCl) to induce VT. We conclude that EPO via nNOS protects the heart from spontaneous and CsCl-induced ventricular arrhythmia during myocardial I/R.	cesium chloride	103-107	erythropoietin	Mus musculus	13-16
19307451-9	2009	Furthermore, EPO treatment after ischemia significantly reduced the threshold dose of cesium chloride (CsCl) to induce VT. We conclude that EPO via nNOS protects the heart from spontaneous and CsCl-induced ventricular arrhythmia during myocardial I/R.	cesium chloride	103-107	erythropoietin	Mus musculus	140-143
19307451-9	2009	Furthermore, EPO treatment after ischemia significantly reduced the threshold dose of cesium chloride (CsCl) to induce VT. We conclude that EPO via nNOS protects the heart from spontaneous and CsCl-induced ventricular arrhythmia during myocardial I/R.	cesium chloride	193-197	erythropoietin	Mus musculus	13-16
19307451-9	2009	Furthermore, EPO treatment after ischemia significantly reduced the threshold dose of cesium chloride (CsCl) to induce VT. We conclude that EPO via nNOS protects the heart from spontaneous and CsCl-induced ventricular arrhythmia during myocardial I/R.	cesium chloride	193-197	erythropoietin	Mus musculus	140-143
19244253-3	2009	DHEPO expressed and released erythropoietin from primary dorsal root ganglion neurons in vitro, and following subcutaneous inoculation in the foot, expressed erythropoietin in dorsal root ganglion neurons in vivo.	dhepo	0-5	erythropoietin	Mus musculus	29-43
18672303-5	2009	TTC staining showed that the infarct size in EPO-treated mice was significantly reduced compared with untreated I/R mice (P&lt;0.05).	6-thiotheophylline	0-3	erythropoietin	Mus musculus	45-48
18672303-10	2009	More significantly, blocking GATA-4 by transfection of a dominant-negative form of GATA-4 (dnGATA-4) abolished EPO-induced cardioprotective effects.	dngata-4	91-99	erythropoietin	Mus musculus	111-114
19244253-3	2009	DHEPO expressed and released erythropoietin from primary dorsal root ganglion neurons in vitro, and following subcutaneous inoculation in the foot, expressed erythropoietin in dorsal root ganglion neurons in vivo.	dhepo	0-5	erythropoietin	Mus musculus	158-172
19244253-4	2009	At 2 weeks after induction of diabetes, subcutaneous inoculation of erythropoietin prevented the reduction in sensory nerve amplitude characteristic of diabetic neuropathy measured 4 weeks later, preserved autonomic function measured by pilocarpine-induced sweating, and prevented the loss of nerve fibres in the skin and reduction of neuropeptide calcitonin gene-related peptide in the dorsal horn of spinal cord of the diabetic mice.	Pilocarpine	237-248	erythropoietin	Mus musculus	68-82
19187767-4	2009	A truncated receptor with only one cytosolic tyrosine (Y343) is sufficient for signaling in response to erythropoietin, regardless of the monomer on which it is located.	Tyrosine	45-53	erythropoietin	Mus musculus	104-118
19471548-3	2009	The EPO- and untreated differentiated cells were labeled with 5-bromo-2 deoxyuridine (BrdU) before transplantation and analyzed using flow cytometry and reverse transcription-PCR methods.	Bromodeoxyuridine	62-84	erythropoietin	Mus musculus	4-7
19164545-0	2009	Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection.	Water	39-44	erythropoietin	Mus musculus	0-14
19164545-4	2009	Here we report that erythropoietin (EPO), which in recent years has emerged as a potent neuro-protective agent, antagonizes the effect of a group I mGluR agonist on astrocyte water permeability.	Water	175-180	erythropoietin	Mus musculus	20-34
19164545-4	2009	Here we report that erythropoietin (EPO), which in recent years has emerged as a potent neuro-protective agent, antagonizes the effect of a group I mGluR agonist on astrocyte water permeability.	Water	175-180	erythropoietin	Mus musculus	36-39
19164545-5	2009	Activation of group I mGluRs triggers fast and highly regular intracellular calcium oscillations and we show that EPO interferes with this signaling event by altering the frequency of the oscillations.	Calcium	76-83	erythropoietin	Mus musculus	114-117
19164545-8	2009	In support of this conclusion we found that EPO reduced the neurological symptoms in a mouse model of primary brain edema known to depend upon AQP4 water transport.	Water	148-153	erythropoietin	Mus musculus	44-47
19100675-7	2009	EPO treatment resulted in rapid phosphorylation of BIM at Serine 65 and phosphorylation correlated with degradation of BIM.	Serine	58-64	erythropoietin	Mus musculus	0-3
19144758-2	2009	Here, we show that preconditioning with the anesthetic gas xenon activates hypoxia-inducible factor 1alpha (HIF-1alpha) and its downstream effectors erythropoietin and vascular endothelial growth factor in a time-dependent manner in the kidneys of adult mice.	Xenon	59-64	erythropoietin	Mus musculus	149-163
19237893-12	2009	Erythropoietin also reduced inducible nitric oxide synthase expression, nitric oxide production, peroxynitrite formation, and tissue hypoxia.	Nitric Oxide	38-50	erythropoietin	Mus musculus	0-14
19237893-12	2009	Erythropoietin also reduced inducible nitric oxide synthase expression, nitric oxide production, peroxynitrite formation, and tissue hypoxia.	Peroxynitrous Acid	97-110	erythropoietin	Mus musculus	0-14
19237893-14	2009	CONCLUSIONS: The results of the study demonstrate that administration of a large dose of erythropoietin after induction of experimental endotoxemia improved survival and that the beneficial effects of erythropoietin were associated with inhibition of apoptosis, nitric oxide production, and tissue hypoxia, without alterations in inflammatory responses.	Nitric Oxide	262-274	erythropoietin	Mus musculus	89-103
19237893-14	2009	CONCLUSIONS: The results of the study demonstrate that administration of a large dose of erythropoietin after induction of experimental endotoxemia improved survival and that the beneficial effects of erythropoietin were associated with inhibition of apoptosis, nitric oxide production, and tissue hypoxia, without alterations in inflammatory responses.	Nitric Oxide	262-274	erythropoietin	Mus musculus	201-215
19027957-9	2009	EPO stimulation of the BM-DCs led to Tyr-phosphorylation of STAT3.	Tyrosine	37-40	erythropoietin	Mus musculus	0-3
19187767-4	2009	A truncated receptor with only one cytosolic tyrosine (Y343) is sufficient for signaling in response to erythropoietin, regardless of the monomer on which it is located.	y343	55-59	erythropoietin	Mus musculus	104-118
18854306-8	2008	In short term transplant experiments, DYRK3-/- progenitors also supported enhanced erythroblast formation, and erythropoietic advantages due to DYRK3-deficiency also were observed in 5-fluorouracil-treated mice expressing a compromised erythropoietin receptor EPOR-HM allele.	Fluorouracil	183-197	erythropoietin	Mus musculus	236-250
18996987-6	2009	Selective inhibition of HO-1 using chromium mesoporphyrin (CrMP) significantly diminished the ability of EPO to inhibit apoptosis.	chromium mesoporphyrin	35-57	erythropoietin	Mus musculus	105-108
18996987-6	2009	Selective inhibition of HO-1 using chromium mesoporphyrin (CrMP) significantly diminished the ability of EPO to inhibit apoptosis.	chromium mesoporphyrin	59-63	erythropoietin	Mus musculus	105-108
18996987-7	2009	Cotreatment of EPO with SB-202190, an inhibitor of p38 activation, blocked the EPO-mediated HO-1 expression and antiapoptotic effects, suggesting a p38-dependent mechanism.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	24-33	erythropoietin	Mus musculus	15-18
18996987-7	2009	Cotreatment of EPO with SB-202190, an inhibitor of p38 activation, blocked the EPO-mediated HO-1 expression and antiapoptotic effects, suggesting a p38-dependent mechanism.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	24-33	erythropoietin	Mus musculus	79-82
18996987-11	2009	Furthermore, EPO given during ischemia reduced infarct size in mice subjected to I/R, and this effect was blocked by CrMP treatment in wild-type mice.	chromium mesoporphyrin	117-121	erythropoietin	Mus musculus	13-16
19407475-9	2009	RESULTS: Among the 3 designed siRNAs (named siEPO1-3), siEPO2 is the most efficient in inhibiting EPO expression.	siepo2	55-61	erythropoietin	Mus musculus	46-49
19407475-12	2009	Furthermore, the expression of EPO in the retinas injected with siEPO2 was dramatically decreased.	siepo2	64-70	erythropoietin	Mus musculus	31-34
18664788-0	2008	Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia.	Iron	64-68	erythropoietin	Mus musculus	16-30
18653480-5	2008	Consistent with previous reports, the administration of EPO diminished the decline in renal function associated with cisplatin administration.	Cisplatin	117-126	erythropoietin	Mus musculus	56-59
18653480-6	2008	This effect was partially reproduced by intraperitoneal injection of cultured EPO-mobilized cells in cisplatin-treated mice.	Cisplatin	101-110	erythropoietin	Mus musculus	78-81
18620011-1	2008	We report a simple method to microencapsulate erythropoietin (EPO, a protein easily denatured and antigenized by contact with water-organic solvent interfaces) into poly(lactic-co-glycolic acid) (PLGA) microspheres with minimal aggregation.	Water	126-131	erythropoietin	Mus musculus	46-60
18620011-1	2008	We report a simple method to microencapsulate erythropoietin (EPO, a protein easily denatured and antigenized by contact with water-organic solvent interfaces) into poly(lactic-co-glycolic acid) (PLGA) microspheres with minimal aggregation.	Water	126-131	erythropoietin	Mus musculus	62-65
18620011-1	2008	We report a simple method to microencapsulate erythropoietin (EPO, a protein easily denatured and antigenized by contact with water-organic solvent interfaces) into poly(lactic-co-glycolic acid) (PLGA) microspheres with minimal aggregation.	Polylactic Acid-Polyglycolic Acid Copolymer	165-194	erythropoietin	Mus musculus	46-60
18620011-1	2008	We report a simple method to microencapsulate erythropoietin (EPO, a protein easily denatured and antigenized by contact with water-organic solvent interfaces) into poly(lactic-co-glycolic acid) (PLGA) microspheres with minimal aggregation.	Polylactic Acid-Polyglycolic Acid Copolymer	165-194	erythropoietin	Mus musculus	62-65
18620011-3	2008	EPO was first dissolved in water together with dextran (MW=70,000) and polyethylene glycol (MW=8000), followed by a freezing process during which dextran separated out as the dispersed phase with EPO partitioned in preferentially.	Water	27-32	erythropoietin	Mus musculus	0-3
18620011-3	2008	EPO was first dissolved in water together with dextran (MW=70,000) and polyethylene glycol (MW=8000), followed by a freezing process during which dextran separated out as the dispersed phase with EPO partitioned in preferentially.	Dextrans	47-54	erythropoietin	Mus musculus	0-3
18620011-3	2008	EPO was first dissolved in water together with dextran (MW=70,000) and polyethylene glycol (MW=8000), followed by a freezing process during which dextran separated out as the dispersed phase with EPO partitioned in preferentially.	Polyethylene Glycols	71-90	erythropoietin	Mus musculus	0-3
18620011-3	2008	EPO was first dissolved in water together with dextran (MW=70,000) and polyethylene glycol (MW=8000), followed by a freezing process during which dextran separated out as the dispersed phase with EPO partitioned in preferentially.	Dextrans	146-153	erythropoietin	Mus musculus	0-3
18620011-5	2008	Once loaded in the polysaccharide particles, 1-4 microm in diameter, EPO gained resistance to organic solvents and was encapsulated into PLGA microspheres without significant aggregation (&lt;2%).	Polysaccharides	19-33	erythropoietin	Mus musculus	69-72
18714393-6	2008	Erythropoietin induced the proliferation of HMVECs and protected them from H2O2-induced cell death.	Hydrogen Peroxide	75-79	erythropoietin	Mus musculus	0-14
18713087-7	2008	Expression of phosphorylated Akt and Erk, which are thought to mediate the survival signalling pathway induced by EPO, tended to be increased in lung tissues from mice treated with EPO compared with those from mice treated with saline after bleomycin instillation.	Bleomycin	241-250	erythropoietin	Mus musculus	114-117
18713087-7	2008	Expression of phosphorylated Akt and Erk, which are thought to mediate the survival signalling pathway induced by EPO, tended to be increased in lung tissues from mice treated with EPO compared with those from mice treated with saline after bleomycin instillation.	Bleomycin	241-250	erythropoietin	Mus musculus	181-184
18664788-13	2008	Stimulation of erythropoiesis by erythropoietin injections also led to a decrease in hepcidin mRNA in zymosan-treated mice.	Zymosan	102-109	erythropoietin	Mus musculus	33-47
18621143-3	2008	The blood plasma erythropoietin level increased after the injection of N6-2-O-dibutyladenosine-3",5"-cyclic monophosphate into adenosine 3",5"-cyclic monophosphate (cAMP) at a dose of 500 mg/kg.	n6-2-o-dibutyladenosine-3",5"-cyclic monophosphate	71-121	erythropoietin	Mus musculus	17-31
18621143-3	2008	The blood plasma erythropoietin level increased after the injection of N6-2-O-dibutyladenosine-3",5"-cyclic monophosphate into adenosine 3",5"-cyclic monophosphate (cAMP) at a dose of 500 mg/kg.	Cyclic AMP	127-163	erythropoietin	Mus musculus	17-31
18621143-3	2008	The blood plasma erythropoietin level increased after the injection of N6-2-O-dibutyladenosine-3",5"-cyclic monophosphate into adenosine 3",5"-cyclic monophosphate (cAMP) at a dose of 500 mg/kg.	Cyclic AMP	165-169	erythropoietin	Mus musculus	17-31
18621143-4	2008	A peak of erythropoietin induction was observed 3 h after the injection of cAMP.	Cyclic AMP	75-79	erythropoietin	Mus musculus	10-24